Chronic Disease Management — MCQs

During a practice audit of patients over 75 years taking 10 or more regular medications, you identify several patients who would benefit from structured medication reviews. You are prioritising which patients to review first based on risk stratification. According to best practice guidance on medication reviews in primary care, which patient characteristic indicates HIGHEST priority for urgent structured medication review?

A 75-year-old man with COPD (post-bronchodilator FEV1 42% predicted), ischaemic heart disease, atrial fibrillation, and type 2 diabetes attends for medication review. He is on multiple inhalers: tiotropium, salmeterol/fluticasone 25/250 twice daily, and salbutamol as needed. Other medications include apixaban, bisoprolol, ramipril, atorvastatin, and metformin. He has had two exacerbations requiring oral steroids in the past year, the last one being 8 months ago. His current COPD symptoms are well-controlled with no exacerbations recently. Sputum cultures from his last exacerbation grew Pseudomonas aeruginosa. Which change to his inhaler therapy is MOST appropriate?

You are conducting a structured medication review for an 80-year-old man with heart failure (NYHA class II), type 2 diabetes, chronic kidney disease stage 3b (eGFR 38 ml/min/1.73m²), and benign prostatic hyperplasia. He lives alone and manages his medications independently using a dosette box filled by his daughter. He takes 13 different medications at various times throughout the day. He mentions he sometimes forgets his evening doses and finds the regimen 'complicated'. Which approach BEST addresses medication adherence in this context according to principles of medicines optimisation?

A 70-year-old woman with rheumatoid arthritis, osteoporosis, hypertension, and gastro-oesophageal reflux disease attends for review. She takes: methotrexate 15mg weekly, folic acid 5mg weekly (taken day after methotrexate), prednisolone 5mg daily, alendronic acid 70mg weekly, omeprazole 20mg daily, amlodipine 10mg daily, and calcium/vitamin D daily. Blood tests show: Hb 102 g/L (MCV 88 fL), WCC 3.8 × 10⁹/L, platelets 156 × 10⁹/L, ALT 68 U/L (previously 32), eGFR 58 ml/min/1.73m². Which aspect of her medication regimen requires MOST urgent attention?

A practice pharmacist is conducting a quality improvement project on anticholinergic burden in elderly patients with multimorbidity. She identifies a 73-year-old man taking 12 medications with a total Anticholinergic Cognitive Burden (ACB) score of 6. His medications include amitriptyline 50mg nocte for neuropathic pain, tolterodine 4mg for overactive bladder, lansoprazole 30mg, co-codamol 30/500, atorvastatin, ramipril, bisoprolol, aspirin, and metformin. He reports feeling 'foggy-headed' and has had two falls. Which intervention would have the GREATEST impact on reducing anticholinergic burden?

A 76-year-old woman with dementia (MMSE 18/30), Parkinson's disease, type 2 diabetes, and recurrent falls is brought by her daughter for medication review. Current medications include: co-careldopa 25/100 three times daily, ropinirole 8mg three times daily, quetiapine 25mg twice daily, metformin 500mg twice daily, gliclazide 40mg twice daily, alendronic acid 70mg weekly, calcium/vitamin D, and PRN paracetamol. She has had three falls in the past two months. Her daughter reports increasing confusion and hallucinations. Blood glucose monitoring shows values between 4.8-8.2 mmol/L. Which medication intervention should be prioritised?

A 68-year-old man with ischaemic heart disease, permanent atrial fibrillation, type 2 diabetes, and osteoarthritis takes: aspirin 75mg, apixaban 5mg twice daily, bisoprolol 5mg, atorvastatin 80mg, metformin 1g twice daily, gliclazide 80mg twice daily, and paracetamol as required. He has no history of stenting or acute coronary syndrome in the past 12 months. His most recent echocardiogram shows LVEF 55% with no wall motion abnormalities. His CHA₂DS₂-VASc score is 5. Which medication change is MOST appropriate?

During a structured medication review using the STOPP/START criteria for a 71-year-old woman, you identify she takes co-codamol 30/500 four times daily for chronic lower back pain, alongside atorvastatin, ramipril, and bisoprolol. She mentions she has been constipated for several weeks and also takes senna tablets daily. She has no history of major surgery or inflammatory spinal disease, and her back pain has been present for 18 months. Her renal function and liver function are normal. Which action represents BEST practice according to deprescribing principles?

A 74-year-old man attends for medication review. He has heart failure (LVEF 32%), atrial fibrillation, type 2 diabetes, stage 3b CKD (eGFR 36 ml/min/1.73m²), and benign prostatic hyperplasia. Current medications: bisoprolol 10mg, ramipril 10mg, furosemide 40mg, spironolactone 25mg, apixaban 5mg twice daily, metformin 1g twice daily, empagliflozin 10mg, finasteride 5mg, tamsulosin 400mcg, atorvastatin 80mg. Blood tests show potassium 5.4 mmol/L, sodium 134 mmol/L, urea 12.8 mmol/L, creatinine 168 μmol/L (stable). He reports good symptom control but occasional dizziness on standing. Which represents the BEST management approach?

Q10

According to the Beers Criteria for potentially inappropriate medication use in older adults, which of the following medications should be avoided in elderly patients regardless of diagnosis or condition?

Chronic Disease Management UK Medical PG Practice Questions and MCQs

Question 1: During a practice audit of patients over 75 years taking 10 or more regular medications, you identify several patients who would benefit from structured medication reviews. You are prioritising which patients to review first based on risk stratification. According to best practice guidance on medication reviews in primary care, which patient characteristic indicates HIGHEST priority for urgent structured medication review?

A. A patient taking 15 medications who has been stable on the same regimen for 3 years with no recent adverse events
B. A patient recently discharged from hospital with five new medications added to their existing regimen (Correct Answer)
C. A patient taking multiple high-risk medications including warfarin, methotrexate, and lithium who attends regular monitoring
D. A patient who has reached the age of 75 and is now eligible for routine medication review under the Quality and Outcomes Framework
E. A patient with declining renal function (eGFR decreased from 68 to 54 over 12 months) taking eight regular medications

Explanation: ***A patient recently discharged from hospital with five new medications added to their existing regimen*** - **Hospital discharge** is a high-risk transition point where medication errors, **therapeutic duplication**, and communication gaps between primary and secondary care frequently occur. - National guidelines (NICE and NHS England) prioritize patients with recent **regimen changes** for urgent review to ensure **medication reconciliation** and prevent adverse drug events. *A patient taking 15 medications who has been stable on the same regimen for 3 years with no recent adverse events* - While **polypharmacy** (taking 10+ medications) is a risk factor, clinical **stability** over three years suggests the regimen is currently tolerated and less urgent than an acute transition. - This patient requires a review to reduce **pill burden**, but they do not meet the criteria for "highest priority" compared to a post-discharge patient. *A patient taking multiple high-risk medications including warfarin, methotrexate, and lithium who attends regular monitoring* - Patients on **narrow therapeutic index** drugs require careful supervision, but the fact they are attending **regular monitoring** indicates their risk is already being managed systematically. - Urgent intervention is typically reserved for those with **unmonitored** high-risk drugs or those experiencing active complications. *A patient who has reached the age of 75 and is now eligible for routine medication review under the Quality and Outcomes Framework* - Routine eligibility based on age or **QOF requirements** is a preventative and administrative trigger rather than an urgent clinical risk stratification. - This represents a **scheduled review** rather than an urgent need driven by clinical instability or a high-risk event like hospitalization. *A patient with declining renal function (eGFR decreased from 68 to 54 over 12 months) taking eight regular medications* - A gradual decline in **eGFR** over a year requires dose adjustments for renally cleared drugs, but the **12-month timeline** makes it less acute than a post-hospital change. - This scenario necessitates a review to prevent **nephrotoxicity**, but it does not represent the immediate high-risk window associated with discharge reconciliation.

Question 2: A 75-year-old man with COPD (post-bronchodilator FEV1 42% predicted), ischaemic heart disease, atrial fibrillation, and type 2 diabetes attends for medication review. He is on multiple inhalers: tiotropium, salmeterol/fluticasone 25/250 twice daily, and salbutamol as needed. Other medications include apixaban, bisoprolol, ramipril, atorvastatin, and metformin. He has had two exacerbations requiring oral steroids in the past year, the last one being 8 months ago. His current COPD symptoms are well-controlled with no exacerbations recently. Sputum cultures from his last exacerbation grew Pseudomonas aeruginosa. Which change to his inhaler therapy is MOST appropriate?

A. Add a regular azithromycin prophylaxis regimen due to previous Pseudomonas infection
B. Switch from salmeterol/fluticasone to a triple therapy inhaler (LABA/LAMA/ICS combination) (Correct Answer)
C. Stop inhaled corticosteroids and continue bronchodilators only, given limited recent exacerbations
D. Reduce fluticasone dose to minimise steroid-related adverse effects including pneumonia risk
E. Add regular nebulised colistin for Pseudomonas suppression in COPD

Explanation: ***Switch from salmeterol/fluticasone to a triple therapy inhaler (LABA/LAMA/ICS combination)***- The patient is already on **triple therapy** (LAMA, LABA, ICS) using separate devices. Combining these into a single **LABA/LAMA/ICS** inhaler simplifies the regimen and improves **medication adherence**.- For patients with severe COPD (FEV1 42%) and frequent exacerbations (two in the past year), **triple therapy** is indicated to reduce exacerbation rates, and using a single device is preferred.*Add a regular azithromycin prophylaxis regimen due to previous Pseudomonas infection*- **Azithromycin prophylaxis** is typically considered for frequent exacerbators despite **optimal inhaled therapy**, often after ensuring the current inhaler regimen is maximally effective and simplified.- While the patient has a history of exacerbations, the initial step should be to optimize and streamline their primary inhaled maintenance therapy before adding prophylactic antibiotics, which carry risks of **antibiotic resistance** and side effects.*Stop inhaled corticosteroids and continue bronchodilators only, given limited recent exacerbations*- Stopping **inhaled corticosteroids (ICS)** is inappropriate in this patient due to a history of **frequent exacerbations** (two in the past year) and severe airflow limitation.- Discontinuing ICS in patients with a history of frequent exacerbations is associated with an increased risk of **future exacerbations** and worsening lung function.*Reduce fluticasone dose to minimise steroid-related adverse effects including pneumonia risk*- While **pneumonia risk** is a known concern with ICS, this patient's history of two exacerbations in the past year indicates a need for continued, effective anti-inflammatory therapy.- Reducing the **fluticasone dose** would be a step-down approach, which is not recommended for a patient who is a frequent exacerbator and has severe COPD.*Add regular nebulised colistin for Pseudomonas suppression in COPD*- **Nebulised colistin** is primarily used for chronic suppression of **Pseudomonas aeruginosa** in conditions like **bronchiectasis** or **cystic fibrosis**.- Its routine use for Pseudomonas suppression in COPD, especially without co-existing bronchiectasis, is not a standard recommendation in current guidelines and lacks strong evidence.

Question 3: You are conducting a structured medication review for an 80-year-old man with heart failure (NYHA class II), type 2 diabetes, chronic kidney disease stage 3b (eGFR 38 ml/min/1.73m²), and benign prostatic hyperplasia. He lives alone and manages his medications independently using a dosette box filled by his daughter. He takes 13 different medications at various times throughout the day. He mentions he sometimes forgets his evening doses and finds the regimen 'complicated'. Which approach BEST addresses medication adherence in this context according to principles of medicines optimisation?

A. Simplify the regimen by switching to once-daily preparations where possible and aligning administration times (Correct Answer)
B. Arrange for a district nurse to visit twice daily to supervise medication administration
C. Provide detailed written instructions about each medication and the importance of adherence
D. Reduce the total number of medications by stopping those not providing immediate symptom relief
E. Arrange urgent assessment of his cognitive function as non-adherence suggests early dementia

Explanation: ***Simplify the regimen by switching to once-daily preparations where possible and aligning administration times***- Medicines optimisation principles prioritise reducing **regimen complexity** and dosing frequency to improve **treatment adherence**, especially in elderly patients with polypharmacy.- Aligning schedules and using **once-daily formulations** addresses the patient's specific struggle with evening doses and his perception that the regimen is too 'complicated'.*Arrange for a district nurse to visit twice daily to supervise medication administration*- This is an overly restrictive and **paternalistic intervention** that undermines the patient's independence while he is still largely capable of self-care.- Resource-heavy interventions like **supervised administration** are typically reserved for patients with severe cognitive or physical impairments who cannot use aids independently.*Provide detailed written instructions about each medication and the importance of adherence*- While education is helpful, it does not solve the **structural complexity** of a 13-medication regimen with multiple dosing times throughout the day.- Information alone is often insufficient to overcome **unintentional non-adherence** caused by a burdensome and confusing schedule.*Reduce the total number of medications by stopping those not providing immediate symptom relief*- Arbitrarily stopping medications based only on immediate symptoms ignores **preventative treatments** (like those for CKD or heart failure) that reduce long-term morbidity.- While **deprescribing** is a key part of review, it must be based on a clinical risk-benefit analysis rather than simply the absence of immediate symptoms.*Arrange urgent assessment of his cognitive function as non-adherence suggests early dementia*- Forgetting parts of an exceptionally complex **13-medication regimen** is frequently a result of the system's burden rather than an indicator of **cognitive impairment**.- Formal cognitive assessment may be considered later, but the immediate priority should be the **optimisation** of a demonstrably difficult medication schedule.

Question 4: A 70-year-old woman with rheumatoid arthritis, osteoporosis, hypertension, and gastro-oesophageal reflux disease attends for review. She takes: methotrexate 15mg weekly, folic acid 5mg weekly (taken day after methotrexate), prednisolone 5mg daily, alendronic acid 70mg weekly, omeprazole 20mg daily, amlodipine 10mg daily, and calcium/vitamin D daily. Blood tests show: Hb 102 g/L (MCV 88 fL), WCC 3.8 × 10⁹/L, platelets 156 × 10⁹/L, ALT 68 U/L (previously 32), eGFR 58 ml/min/1.73m². Which aspect of her medication regimen requires MOST urgent attention?

A. The alendronic acid and omeprazole combination reducing bisphosphonate absorption
B. The low haemoglobin suggesting methotrexate-induced bone marrow suppression requiring urgent cessation
C. The elevated ALT indicating methotrexate hepatotoxicity requiring dose reduction or cessation (Correct Answer)
D. The combination of prednisolone and alendronic acid requiring additional osteoporosis monitoring
E. The declining renal function requiring methotrexate dose adjustment or alternative DMARD

Explanation: ***The elevated ALT indicating methotrexate hepatotoxicity requiring dose reduction or cessation***- The patient's **ALT** has doubled from baseline (32 to 68 U/L), which is a significant signal for **methotrexate hepatotoxicity** according to clinical monitoring guidelines.- Immediate action is required to withhold the medication and re-test **liver function** within 1-2 weeks to prevent progressive hepatic damage.*The alendronic acid and omeprazole combination reducing bisphosphonate absorption*- While some PPIs may theoretically affect mineral absorption, this combination is common and not an **urgent clinical concern** compared to organ toxicity.- The patient is already being treated for osteoporosis, and the **GORD** management is a higher symptomatic priority than minor absorption variances.*The low haemoglobin suggesting methotrexate-induced bone marrow suppression requiring urgent cessation*- The **Hb of 102 g/L** with a normal **MCV of 88 fL** (normocytic) often reflects **anaemia of chronic disease** in a patient with rheumatoid arthritis.- Although **bone marrow suppression** is a risk, the WCC and platelets remain within relatively safe ranges, making this less urgent than the liver function abnormalities.*The combination of prednisolone and alendronic acid requiring additional osteoporosis monitoring*- The patient is already appropriately prescribed **alendronic acid** and **calcium/vitamin D** to mitigate the bone loss risk associated with **prednisolone**.- While monitoring via **DEXA scans** is necessary in the long term, it does not constitute an "urgent" priority in the context of acute lab changes.*The declining renal function requiring methotrexate dose adjustment or alternative DMARD*- An **eGFR of 58 ml/min/1.73m²** indicates mild renal impairment but is still above the critical threshold (usually 30 ml/min) for absolute cessation.- While renal function affects **methotrexate clearance**, the current level does not require immediate discontinuation as urgently as the rising **ALT** levels do.

Question 5: A practice pharmacist is conducting a quality improvement project on anticholinergic burden in elderly patients with multimorbidity. She identifies a 73-year-old man taking 12 medications with a total Anticholinergic Cognitive Burden (ACB) score of 6. His medications include amitriptyline 50mg nocte for neuropathic pain, tolterodine 4mg for overactive bladder, lansoprazole 30mg, co-codamol 30/500, atorvastatin, ramipril, bisoprolol, aspirin, and metformin. He reports feeling 'foggy-headed' and has had two falls. Which intervention would have the GREATEST impact on reducing anticholinergic burden?

A. Switch tolterodine to mirabegron, a beta-3 agonist with no anticholinergic activity
B. Replace amitriptyline with duloxetine for neuropathic pain management
C. Stop lansoprazole as proton pump inhibitors contribute to cognitive impairment
D. Address both amitriptyline and tolterodine simultaneously by switching to alternatives (Correct Answer)
E. Reduce co-codamol dose as opioids can contribute to cognitive impairment

Explanation: ***Address both amitriptyline and tolterodine simultaneously by switching to alternatives*** - **Amitriptyline** and **tolterodine** are both high-burden drugs (ACB score of 3 each); replacing both is the most effective way to reduce the total **Anticholinergic Cognitive Burden (ACB)** score from 6 to near zero. - Addressing both medications directly targets the patient's symptoms of **cognitive impairment ('foggy-headed')** and **falls**, which are classic adverse effects of high anticholinergic exposure in the elderly. *Switch tolterodine to mirabegron, a beta-3 agonist with no anticholinergic activity* - Switching **tolterodine** alone would only reduce the ACB score by 3, leaving the patient with a still-significant burden from the **amitriptyline**. - While **mirabegron** is an excellent alternative for **overactive bladder** without anticholinergic effects, it does not address the neuropathic pain medication's contribution to the score. *Replace amitriptyline with duloxetine for neuropathic pain management* - Replacing **amitriptyline** with **duloxetine** (which has minimal to no anticholinergic activity) reduces the score by 3 but ignores the impact of **tolterodine**. - Although this is a clinically sound step for **neuropathic pain**, a singular drug change is less impactful than a comprehensive review of all high-ACB agents. *Stop lansoprazole as proton pump inhibitors contribute to cognitive impairment* - **Lansoprazole** (a proton pump inhibitor) does not contribute to the **Anticholinergic Cognitive Burden** score, so stopping it would not improve the ACB metrics. - While PPIs have other long-term risks, they are not the primary cause of **anticholinergic-mediated** delirium or falls in this scenario. *Reduce co-codamol dose as opioids can contribute to cognitive impairment* - **Co-codamol** (codeine/paracetamol) can cause sedation and falls due to its **opioid** component, but it does not carry a weight on the **ACB scale**. - Reducing the dose may help general alertness but will not lower the **anticholinergic-specific** burden that this quality improvement project aims to address.

Question 6: A 76-year-old woman with dementia (MMSE 18/30), Parkinson's disease, type 2 diabetes, and recurrent falls is brought by her daughter for medication review. Current medications include: co-careldopa 25/100 three times daily, ropinirole 8mg three times daily, quetiapine 25mg twice daily, metformin 500mg twice daily, gliclazide 40mg twice daily, alendronic acid 70mg weekly, calcium/vitamin D, and PRN paracetamol. She has had three falls in the past two months. Her daughter reports increasing confusion and hallucinations. Blood glucose monitoring shows values between 4.8-8.2 mmol/L. Which medication intervention should be prioritised?

A. Reduce co-careldopa dose as dopaminergic medications contribute to hallucinations and falls
B. Stop quetiapine immediately as antipsychotics worsen Parkinson's disease motor symptoms
C. Review and rationalise diabetes medications given risk of hypoglycaemia contributing to falls
D. Stop alendronic acid as bisphosphonates increase fall risk in elderly patients
E. Reduce ropinirole as dopamine agonists cause hallucinations and should be withdrawn first (Correct Answer)

Explanation: ***Reduce ropinirole as dopamine agonists cause hallucinations and should be withdrawn first*** - **Dopamine agonists** like ropinirole carry a much higher risk of inducing **visual hallucinations** and confusion compared to levodopa, especially in patients with cognitive impairment. - Management guidelines for Parkinson’s psychosis prioritize the **gradual withdrawal** of dopamine agonists before altering levodopa therapy to minimize neuropsychiatric side effects while preserving motor function. *Reduce co-careldopa dose as dopaminergic medications contribute to hallucinations and falls* - While levodopa can contribute to hallucinations, it is the **gold standard** for motor control and is less frequently the primary cause of psychosis than dopamine agonists. - Reducing **co-careldopa** before reducing ropinirole might severely compromise the patient's mobility and increase the risk of **motor fluctuations**. *Stop quetiapine immediately as antipsychotics worsen Parkinson's disease motor symptoms* - **Quetiapine** is one of the few antipsychotics used in Parkinson's because it has a low affinity for **D2 receptors**, making it less likely to worsen motor symptoms. - Abruptly stopping it may cause a rebound of psychiatric symptoms; the priority is to remove the **precipitating factor** (ropinirole) rather than the treatment for the symptoms. *Review and rationalise diabetes medications given risk of hypoglycaemia contributing to falls* - The patient's blood glucose readings (4.8-8.2 mmol/L) indicate **tight control**, but she is not currently experiencing clinical **hypoglycemia** that would explain acute hallucinations. - While preventing hypoglycemia is important for fall prevention, it does not address the primary complaint of **visual hallucinations** and increasing confusion. *Stop alendronic acid as bisphosphonates increase fall risk in elderly patients* - **Alendronic acid** is used to prevent fractures and does not have a known association with an increased **risk of falls** or hallucinations. - It is generally continued in elderly patients with high fracture risk unless there are specific contraindications like **esophageal disorders** or severe renal impairment.

Question 7: A 68-year-old man with ischaemic heart disease, permanent atrial fibrillation, type 2 diabetes, and osteoarthritis takes: aspirin 75mg, apixaban 5mg twice daily, bisoprolol 5mg, atorvastatin 80mg, metformin 1g twice daily, gliclazide 80mg twice daily, and paracetamol as required. He has no history of stenting or acute coronary syndrome in the past 12 months. His most recent echocardiogram shows LVEF 55% with no wall motion abnormalities. His CHA₂DS₂-VASc score is 5. Which medication change is MOST appropriate?

A. Stop apixaban and continue aspirin alone for cardiovascular protection
B. Stop aspirin as dual antiplatelet and anticoagulation increases bleeding risk without additional benefit (Correct Answer)
C. Continue both medications as dual therapy is indicated in atrial fibrillation with ischaemic heart disease
D. Stop both aspirin and apixaban and commence warfarin for better control
E. Reduce apixaban to 2.5mg twice daily when used in combination with aspirin

Explanation: ***Stop aspirin as dual antiplatelet and anticoagulation increases bleeding risk without additional benefit***- In patients with stable **ischaemic heart disease** (beyond 12 months from an ACS event or stenting) and **atrial fibrillation**, monotherapy with an **oral anticoagulant** is sufficient and preferred.- The addition of **aspirin** to a **DOAC** like apixaban significantly increases the risk of **major bleeding** and intracranial haemorrhage without providing additional cardiovascular protection.*Stop apixaban and continue aspirin alone for cardiovascular protection*- This patient has a **CHA₂DS₂-VASc score of 5**, indicating a high risk of thromboembolic stroke that requires formal **anticoagulation**.- Aspirin is inferior to **apixaban** for stroke prevention in atrial fibrillation and would leave the patient inadequately protected.*Continue both medications as dual therapy is indicated in atrial fibrillation with ischaemic heart disease*- Dual therapy is only indicated for a limited period (usually **12 months**) following **Acute Coronary Syndrome (ACS)** or **stenting**.- Chronic dual therapy is avoided in stable disease because the **bleeding risk** outweighs the benefits of combined antiplatelet and anticoagulant action.*Stop both aspirin and apixaban and commence warfarin for better control*- There is no clinical indication to switch to **warfarin**, as **DOACs** like apixaban are generally preferred due to better safety profiles and no requirement for **INR monitoring**.- Stopping both medications would leave the patient at an unacceptably high risk of both **myocardial infarction** and **ischaemic stroke**.*Reduce apixaban to 2.5mg twice daily when used in combination with aspirin*- Dose reduction of **apixaban** is based on specific criteria (age ≥80, weight ≤60kg, or creatinine ≥133 μmol/L), not on the concurrent use of **antiplatelets**.- Using a sub-therapeutic dose of an anticoagulant increases the risk of **thromboembolism** while still carrying a bleeding risk when combined with aspirin.

Question 8: During a structured medication review using the STOPP/START criteria for a 71-year-old woman, you identify she takes co-codamol 30/500 four times daily for chronic lower back pain, alongside atorvastatin, ramipril, and bisoprolol. She mentions she has been constipated for several weeks and also takes senna tablets daily. She has no history of major surgery or inflammatory spinal disease, and her back pain has been present for 18 months. Her renal function and liver function are normal. Which action represents BEST practice according to deprescribing principles?

A. Switch co-codamol to tramadol to reduce constipation while maintaining analgesia
B. Add a stimulant laxative such as sodium picosulfate to manage opioid-induced constipation
C. Gradually reduce and stop codeine while optimising non-opioid analgesia and addressing pain holistically (Correct Answer)
D. Continue current regimen but refer for specialist pain management assessment
E. Switch to modified-release morphine for more consistent pain control

Explanation: ***Gradually reduce and stop codeine while optimising non-opioid analgesia and addressing pain holistically*** - The **STOPP criteria** highlight long-term **opioid use** for chronic non-cancer pain as potentially inappropriate, given its limited long-term efficacy and significant side effects, like constipation, especially in elderly patients.- Best practice involves a **gradual taper** of the opioid to prevent withdrawal, while transitioning to **non-pharmacological interventions** (e.g., exercise, physiotherapy) and optimizing **non-opioid analgesia**. *Switch co-codamol to tramadol to reduce constipation while maintaining analgesia*- **Tramadol** is also an **opioid** with a similar risk profile for **constipation**, dependence, and cognitive impairment, particularly in the elderly.- This option represents an **opioid rotation**, which does not address the core issue of potentially **inappropriate long-term opioid prescribing** for chronic primary pain. *Add a stimulant laxative such as sodium picosulfate to manage opioid-induced constipation*- This is an example of a **prescribing cascade**, where a new medication is introduced to manage the side effect of an existing, potentially unnecessary drug.- While providing symptomatic relief, it fails to address the underlying problem of the **opioid-induced constipation** and the continued use of an opioid identified as inappropriate by the **STOPP criteria**. *Continue current regimen but refer for specialist pain management assessment*- Maintaining a regimen with **potentially inappropriate medication** (long-term high-dose opioid) delays crucial clinical action to reduce harm, which can often be initiated in primary care.- The **STOPP/START criteria** aim to empower clinicians to take immediate action on deprescribing opportunities to mitigate **adverse drug events**. *Switch to modified-release morphine for more consistent pain control*- Upgrading to a **stronger, long-acting opioid** like morphine for chronic non-cancer pain is contrary to current guidelines and significantly increases the risk of **opioid toxicity** and dependence, especially in an elderly patient.- Modified-release strong opioids are not recommended for routine management of **chronic lower back pain** without clear structural pathology and should be avoided in deprescribing.

Question 9: A 74-year-old man attends for medication review. He has heart failure (LVEF 32%), atrial fibrillation, type 2 diabetes, stage 3b CKD (eGFR 36 ml/min/1.73m²), and benign prostatic hyperplasia. Current medications: bisoprolol 10mg, ramipril 10mg, furosemide 40mg, spironolactone 25mg, apixaban 5mg twice daily, metformin 1g twice daily, empagliflozin 10mg, finasteride 5mg, tamsulosin 400mcg, atorvastatin 80mg. Blood tests show potassium 5.4 mmol/L, sodium 134 mmol/L, urea 12.8 mmol/L, creatinine 168 μmol/L (stable). He reports good symptom control but occasional dizziness on standing. Which represents the BEST management approach?

A. Stop spironolactone due to hyperkalaemia risk and continue other heart failure medications
B. Reduce ramipril to 5mg daily to decrease potassium and improve renal function
C. Stop empagliflozin as it may be contributing to hyperkalaemia and renal impairment
D. Continue current regimen with close monitoring as benefits outweigh risks (Correct Answer)
E. Stop tamsulosin as it may be causing orthostatic hypotension and reduce polypharmacy

Explanation: ***Continue current regimen with close monitoring as benefits outweigh risks*** - The patient is receiving the **'quadruple therapy'** for heart failure with reduced ejection fraction (HFrEF), which significantly reduces **mortality** and hospitalizations. - A potassium of 5.4 mmol/L is acceptable for transition to long-term monitoring as it remains **below 5.5 mmol/L**, and his creatinine/eGFR values are stable and within an acceptable range for these medications. *Stop spironolactone due to hyperkalaemia risk and continue other heart failure medications* - Guidance suggests keeping mineralocorticoid receptor antagonists (MRAs) unless potassium consistently **exceeds 5.5 mmol/L**, as they provide a crucial **survival benefit**. - Routine cessation for mild elevations prevents the patient from receiving life-prolonging **aldosterone blockade**. *Reduce ramipril to 5mg daily to decrease potassium and improve renal function* - Reducing the **ACE inhibitor** dose for a stable eGFR of 36 ml/min/1.73m² and mild hyperkalemia would result in sub-optimal **neurohormonal blockade**. - Stable renal impairment (Stage 3b CKD) is not an indication for dose reduction if the serum **creatinine rise** from baseline is less than 30%. *Stop empagliflozin as it may be contributing to hyperkalaemia and renal impairment* - **SGLT2 inhibitors** like empagliflozin actually provide **renoprotective** benefits and reduce the risk of more severe hyperkalemia when used with MRAs. - There is no clinical indication to stop this medication as it is indicated for both **HFrEF** and **type 2 diabetes** with CKD. *Stop tamsulosin as it may be causing orthostatic hypotension and reduce polypharmacy* - While **tamsulosin** can cause orthostatic hypotension, the patient's dizziness is occasional, and his overall symptom control is good. - Stopping an effective medication for **benign prostatic hyperplasia** (BPH) without a clear, overriding reason may worsen urinary symptoms, and dizziness could also stem from other cardiovascular medications.

Question 10: According to the Beers Criteria for potentially inappropriate medication use in older adults, which of the following medications should be avoided in elderly patients regardless of diagnosis or condition?

A. Long-acting benzodiazepines such as diazepam and chlordiazepoxide (Correct Answer)
B. Non-selective beta-blockers in patients with peripheral vascular disease
C. First-generation antihistamines in patients with cognitive impairment
D. Proton pump inhibitors when used for longer than 8 weeks
E. Thiazide diuretics in patients with a history of gout

Explanation: ***Long-acting benzodiazepines such as diazepam and chlordiazepoxide*** - The **Beers Criteria** recommends avoiding these medications in all older adults due to their **long half-lives**, which lead to accumulation and prolonged effects. - Usage significantly increases the risk of **falls, fractures, cognitive impairment**, and motor vehicle accidents in the elderly population. *Non-selective beta-blockers in patients with peripheral vascular disease* - This is a **condition-specific** precaution rather than a general category for avoidance in all older adults regardless of diagnosis. - While they can theoretically worsen claudication, they are not listed as **potentially inappropriate medications** for all geriatric patients in the primary Beers list. *First-generation antihistamines in patients with cognitive impairment* - While these are generally avoided due to **anticholinergic effects**, the option specifies a condition (cognitive impairment) rather than a universal avoidance. - The Beers Criteria actually recommends avoiding all highly anticholinergic **first-generation antihistamines** for most older adults, but the long-acting benzodiazepine choice is the most definitive answer for universal avoidance in this context. *Proton pump inhibitors when used for longer than 8 weeks* - PPIs are listed under the Beers Criteria to be avoided beyond **8 weeks** of use due to risks of **Clostridioides difficile** infection and bone loss. - This is a **duration-specific** recommendation rather than a medication that must be avoided entirely regardless of the clinical situation or time frame. *Thiazide diuretics in patients with a history of gout* - This represents a **disease-drug interaction** where the medication may exacerbate a specific pre-existing condition by increasing **uric acid** levels. - Thiazides are not on the list of medications to be avoided in all elderly patients; they remain first-line therapy for **hypertension** in many older adults.

Question 11: A 69-year-old woman attends for annual review with type 2 diabetes, hypertension, osteoarthritis affecting both knees and hands, and recurrent urinary tract infections. She takes metformin, ramipril, amlodipine, paracetamol, ibuprofen 400mg three times daily, and recently completed a course of trimethoprim. She reports good glycaemic control but mentions her blood pressure readings at home are occasionally elevated. Her recent blood results show: eGFR 52 ml/min/1.73m² (previously 68 six months ago), potassium 5.2 mmol/L, HbA1c 52 mmol/mol. Which medication interaction represents the GREATEST current risk?

A. The combination of metformin and trimethoprim increasing lactic acidosis risk
B. The interaction between ramipril and ibuprofen affecting renal function (Correct Answer)
C. The combination of amlodipine and ibuprofen reducing antihypertensive efficacy
D. The interaction between ramipril and amlodipine causing excessive hypotension
E. The combination of paracetamol and ibuprofen increasing hepatotoxicity risk

Explanation: ***The interaction between ramipril and ibuprofen affecting renal function*** - Combining an **ACE inhibitor** (ramipril) with an **NSAID** (ibuprofen) significantly impairs renal autoregulation by causing **efferent arteriolar vasodilation** (ramipril) and **afferent arteriolar vasoconstriction** (ibuprofen). - This

Question 12: A 72-year-old man with chronic kidney disease stage 4 (eGFR 24 ml/min/1.73m²), type 2 diabetes, hypertension, and gout presents for medication review. His current medications include: metformin 1g twice daily, gliclazide 80mg twice daily, ramipril 10mg once daily, amlodipine 10mg once daily, aspirin 75mg once daily, atorvastatin 80mg once daily, allopurinol 100mg once daily, and omeprazole 20mg once daily. His HbA1c is 58 mmol/mol, and he reports intermittent episodes of feeling 'shaky and sweaty'. Which medication requires MOST urgent modification?

A. Allopurinol should be increased to 300mg daily for adequate urate control
B. Metformin should be stopped immediately due to risk of lactic acidosis (Correct Answer)
C. Ramipril should be reduced due to advanced chronic kidney disease
D. Gliclazide should be reviewed and reduced due to hypoglycaemia risk
E. Aspirin should be stopped as cardiovascular protection is inadequate at this dose

Explanation: ***Metformin should be stopped immediately due to risk of lactic acidosis***- **Metformin** is primarily cleared by the kidneys and is **contraindicated** when the **eGFR falls below 30 ml/min/1.73m²** (CKD Stage 4). The patient's eGFR is 24.- Continued use in this setting significantly increases the risk of **metformin-associated lactic acidosis (MALA)**, a severe and life-threatening metabolic emergency requiring urgent discontinuation.*Allopurinol should be increased to 300mg daily for adequate urate control*- Increasing **allopurinol** to 300mg in a patient with an **eGFR of 24 ml/min/1.73m²** is inappropriate and risky, as it can lead to severe toxicity, including **allopurinol hypersensitivity syndrome**.- The current dose of **100mg daily** is generally considered the maximum safe dose for patients with this level of **renal impairment**.*Ramipril should be reduced due to advanced chronic kidney disease*- **ACE inhibitors** like **ramipril** are often beneficial in CKD for **renoprotection** and blood pressure control, provided there is no acute kidney injury or severe hyperkalemia.- While renal function and electrolytes require close monitoring, discontinuing metformin due to the immediate and severe risk of **lactic acidosis** takes precedence.*Gliclazide should be reviewed and reduced due to hypoglycaemia risk*- The patient's symptoms of feeling "shaky and sweaty" are classic for **hypoglycaemia**, likely exacerbated by **gliclazide** accumulation due to reduced renal clearance.- While adjusting **gliclazide** is crucial to prevent further hypoglycaemic episodes, the immediate risk of **metformin-associated lactic acidosis** is a higher priority.*Aspirin should be stopped as cardiovascular protection is inadequate at this dose*- **Aspirin 75mg daily** is the standard and effective dose for **secondary prevention** of cardiovascular events, especially in patients with multiple risk factors like this gentleman.- There is no clinical indication to stop aspirin based on its efficacy at this dose, and doing so would remove a crucial component of his cardiovascular protection.

Question 13: A 67-year-old woman with multimorbidity attends for a comprehensive medication review. She has six chronic conditions: heart failure, atrial fibrillation, type 2 diabetes, hypothyroidism, osteoporosis, and depression. She takes 11 regular medications. According to NICE guidance on multimorbidity (NG56), which approach is MOST important when prioritising her care during this consultation?

A. Focus on achieving optimal disease-specific targets for each individual condition
B. Establish the patient's priorities for treatment and quality of life outcomes (Correct Answer)
C. Systematically review medications starting with those prescribed most recently
D. Concentrate on reducing the total number of medications to fewer than 10
E. Prioritise management of conditions with the highest mortality risk first

Explanation: ***Establish the patient's priorities for treatment and quality of life outcomes***- According to **NICE NG56**, the core of multimorbidity management is a **patient-centered approach** that identifies personal goals, values, and desired outcomes.- Shared decision-making ensures that care focuses on improving **quality of life** and reducing **treatment burden**, rather than just following clinical guidelines.*Focus on achieving optimal disease-specific targets for each individual condition*- Managing multiple conditions solely through **single-disease guidelines** often leads to **polypharmacy** and increased risk of adverse drug interactions.- Strict adherence to multiple guidelines may ignore the patient's overall wellbeing and can be practically unfeasible for those with many comorbidities.*Systematically review medications starting with those prescribed most recently*- Medication reviews should focus on assessing **clinical benefit**, **safety**, and **adherence** rather than being dictated by the chronological order of prescription.- The goal is to identify medications that are no longer effective or are causing harm, which may include long-standing prescriptions.*Concentrate on reducing the total number of medications to fewer than 10*- While **deprescribing** is a key goal, there is no evidence-based **arbitrary threshold** (like fewer than 10) for what constitutes an appropriate number of drugs.- Focus should be on the **appropriateness of polypharmacy** and ensuring each medication provides more benefit than harm for that specific patient.*Prioritise management of conditions with the highest mortality risk first*- Focusing only on **mortality risk** (like heart failure) can overlook conditions that significantly impact **functional status** and daily life, such as depression or osteoporosis.- A holistic approach balances survival with the patient's own concerns regarding **symptom control** and daily living activities.

Question 14: A practice pharmacist is developing a protocol for identifying patients who would benefit from structured medication reviews. According to the NHS England Structured Medication Review and Medicines Optimisation guidance, which of the following criteria would indicate the highest priority for a structured medication review?

A. A 58-year-old woman with well-controlled asthma on two inhalers and no recent exacerbations
B. A 72-year-old man taking 15 regular medications for six long-term conditions with recent unplanned hospital admission (Correct Answer)
C. A 65-year-old woman with type 2 diabetes on metformin alone with stable HbA1c for 3 years
D. A 70-year-old man with hypertension on amlodipine with good blood pressure control
E. A 68-year-old woman taking warfarin for atrial fibrillation with stable INR attending anticoagulation clinic regularly

Explanation: ***A 72-year-old man taking 15 regular medications for six long-term conditions with recent unplanned hospital admission***- This patient satisfies critical **NHS England criteria** for high-priority reviews due to **severe polypharmacy** (defined as 10+ medications) and **multimorbidity** (multiple long-term conditions).- A recent **unplanned hospital admission** is a significant indicator of potential **medication-related harm**, adverse drug reactions, or suboptimal disease control, necessitating urgent medication optimization.*A 58-year-old woman with well-controlled asthma on two inhalers and no recent exacerbations*- This patient has a **low medication burden** and is considered clinically stable, which places her at a lower priority for a **Structured Medication Review (SMR)**.- SMRs are primarily focused on patients with complex medication regimens or clinical instability, not routine management of stable, well-controlled conditions.*A 65-year-old woman with type 2 diabetes on metformin alone with stable HbA1c for 3 years*- While diabetes is a chronic condition, **monotherapy** with stable, long-term outcomes does not meet the high-priority criteria for an SMR.- The absence of **polypharmacy**, recent clinical deterioration, or complex medication challenges makes her a lower priority.*A 70-year-old man with hypertension on amlodipine with good blood pressure control*- Single-medication regimens for **hypertension** with achieved target clinical goals are typically managed through routine annual reviews rather than a high-priority SMR.- High priority is reserved for patients with **complex medication needs** where the risk of interactions, adverse effects, or therapeutic failure is higher.*A 68-year-old woman taking warfarin for atrial fibrillation with stable INR attending anticoagulation clinic regularly*- Although warfarin is a **high-risk medication**, this patient is already receiving **specialist oversight** and regular monitoring through a dedicated anticoagulation clinic.- Since her therapy is **stable** and well-managed by a specialized service, she is not the primary target for an urgent primary care SMR compared to a patient with uncontrolled polypharmacy.

Question 15: You are reviewing prescribing data for your practice as part of a medication safety initiative. You identify a 69-year-old man with heart failure (LVEF 38%), type 2 diabetes, CKD stage 3b (eGFR 36 ml/min/1.73m²), and gout who has been prescribed allopurinol 300mg daily, ramipril 10mg daily, spironolactone 25mg daily, and furosemide 40mg daily. His most recent blood results show: sodium 138 mmol/L, potassium 5.8 mmol/L, urea 12.4 mmol/L, creatinine 165 µmol/L (baseline 158 µmol/L). He is asymptomatic. What is the most appropriate immediate management?

A. Stop spironolactone immediately and recheck potassium in 3-5 days (Correct Answer)
B. Reduce ramipril to 5mg daily and recheck electrolytes in 1 week
C. Stop allopurinol temporarily until renal function improves
D. Prescribe calcium resonium 15g three times daily and continue all medications
E. Increase furosemide to 80mg daily to enhance potassium excretion

Explanation: ***Stop spironolactone immediately and recheck potassium in 3-5 days*** - The patient has significant **hyperkalaemia (5.8 mmol/L)** while taking both an **ACE inhibitor (ramipril)** and a **mineralocorticoid receptor antagonist (spironolactone)**, a combination that significantly increases the risk of potassium retention in **CKD stage 3b**. - Guidelines generally mandate stopping or withholding **spironolactone** if potassium exceeds **5.5 mmol/L** to prevent life-threatening arrhythmias, followed by close monitoring of electrolytes. *Reduce ramipril to 5mg daily and recheck electrolytes in 1 week* - While **ACE inhibitors** contribute to hyperkalaemia, **spironolactone** is usually the first medication to be discontinued as it is more likely to cause severe potassium elevation in the setting of renal impairment. - Maintaining the ACE inhibitor is prioritised for **prognostic benefit** in heart failure unless potassium levels cannot be managed by stopping the aldosterone antagonist alone. *Stop allopurinol temporarily until renal function improves* - **Allopurinol** does not directly affect serum **potassium levels**, and its discontinuation would not address the acute risk of hyperkalaemia. - Stopping allopurinol unnecessarily could trigger an acute **gout flare**, which is undesirable given the patient's existing comorbidities. *Prescribe calcium resonium 15g three times daily and continue all medications* - **Calcium resonium** is a potassium-binding resin typically reserved for more severe or refractory hyperkalaemia and does not address the **underlying cause** of the elevation. - Continuing the offending medications while using an ion-exchange resin is inappropriate management for a patient with a **K+ of 5.8 mmol/L** and significant renal impairment. *Increase furosemide to 80mg daily to enhance potassium excretion* - Although **loop diuretics** increase potassium excretion, this is not an appropriate primary treatment for ACEi/MRA-induced hyperkalaemia. - Increasing the dose of **furosemide** in a patient with **CKD stage 3b** risks further volume depletion and potential worsening of **acute kidney injury**.

Question 16: A 74-year-old woman with moderate Alzheimer's dementia (MMSE 16/30), type 2 diabetes, hypertension, and atrial fibrillation lives alone with support from carers visiting twice daily. Her daughter reports that her mother has become increasingly confused and is now missing medication doses. Current medications include donepezil, memantine, metformin, gliclazide, amlodipine, ramipril, apixaban, and atorvastatin. The daughter asks whether her mother's medications could be simplified. Which medication would it be most appropriate to consider stopping first?

A. Donepezil, as the patient has progressed to moderate dementia
B. Atorvastatin, as the cardiovascular benefit diminishes with advanced age and limited life expectancy
C. Memantine, as combination therapy with donepezil shows limited additional benefit
D. Gliclazide, due to the high risk of hypoglycaemia in a patient with cognitive impairment (Correct Answer)
E. Ramipril, as blood pressure targets can be relaxed in elderly patients with dementia

Explanation: ***Gliclazide, due to the high risk of hypoglycaemia in a patient with cognitive impairment***- **Sulfonylureas** like gliclazide carry a high risk of **hypoglycaemia**, which can worsen **confusion** and increase the risk of **falls** in elderly patients with dementia.- In patients with cognitive impairment who have **irregular eating patterns** or poor medication adherence, the safety risk of hypoglycemia often outweighs the benefits of strict glycemic control. It is a priority for **deprescribing** due to immediate safety concerns.*Donepezil, as the patient has progressed to moderate dementia*- **Donepezil**, a **cholinesterase inhibitor**, is indicated for **mild-to-moderate Alzheimer's disease** and can help maintain cognitive and functional abilities (MMSE 16/30 falls within this range).- Guidelines often recommend continuing **cholinesterase inhibitors** until the late stages of dementia or when the symptomatic benefits are no longer evident, to prevent further decline.*Atorvastatin, as the cardiovascular benefit diminishes with advanced age and limited life expectancy*- While **statin therapy** for **primary prevention** may be reviewed in very frail or elderly patients with limited life expectancy, this patient has multiple cardiovascular risk factors (diabetes, hypertension, AF) implying a need for secondary prevention or significant risk.- Stopping atorvastatin provides a **long-term reduction in cardiovascular protection**, but does not pose the immediate risk of acute harm that **gliclazide** presents with **hypoglycaemia**.*Memantine, as combination therapy with donepezil shows limited additional benefit*- **Memantine** is indicated for **moderate to severe Alzheimer's disease**, which aligns with this patient's MMSE of 16/30.- Combination therapy with an **acetylcholinesterase inhibitor** and **memantine** is supported for moderate-to-severe AD and can help manage **cognitive symptoms** and **behavioral disturbances**, with a relatively low side-effect profile, making it a less urgent medication to stop.*Ramipril, as blood pressure targets can be relaxed in elderly patients with dementia*- While **blood pressure targets** can be relaxed in elderly patients with dementia, **ACE inhibitors** like ramipril are crucial for managing **hypertension**, preventing **stroke**, and mitigating **heart failure** risks, especially in a patient with atrial fibrillation.- Abruptly stopping antihypertensive medication can lead to **rebound hypertension** or other adverse cardiovascular events, which is a significant risk, but still less acute than the immediate danger of **hypoglycaemia** from gliclazide.

Question 17: During a practice-based quality improvement project, you are reviewing prescribing patterns in patients over 75 years taking 10 or more regular medications. You identify that 22% of patients in this group are taking a proton pump inhibitor (PPI) long-term without a documented indication. According to current evidence and guidance on deprescribing PPIs, which patient scenario would be the strongest indication for continuing long-term PPI therapy?

A. A 77-year-old woman taking aspirin 75mg daily for previous myocardial infarction with no history of gastrointestinal bleeding
B. An 80-year-old man with a history of duodenal ulcer 8 years ago, now asymptomatic, not taking NSAIDs or antiplatelet agents
C. A 78-year-old woman taking prednisolone 5mg daily for polymyalgia rheumatica and naproxen 500mg twice daily for osteoarthritis (Correct Answer)
D. A 76-year-old man with gastro-oesophageal reflux symptoms that resolved 2 years ago after lifestyle modifications
E. An 82-year-old woman taking alendronate for osteoporosis who had mild dyspepsia when starting treatment 5 years ago

Explanation: ***A 78-year-old woman taking prednisolone 5mg daily for polymyalgia rheumatica and naproxen 500mg twice daily for osteoarthritis*** - Co-administration of **NSAIDs (naproxen)** and **corticosteroids (prednisolone)** in elderly patients creates a multiplicative risk for **peptic ulceration** and gastrointestinal bleeding. - Clinical guidelines strongly recommend long-term **gastroprotection** with a PPI for high-risk patients concurrently using these ulcerogenic medications. *A 77-year-old woman taking aspirin 75mg daily for previous myocardial infarction with no history of gastrointestinal bleeding* - Low-dose **aspirin monotherapy** without a history of GI bleeding or additional major risk factors is generally not an absolute indication for long-term PPI therapy. - While age >65 years is a risk factor, it typically requires other co-factors or a history of GI bleeding for mandatory PPI co-prescription. *An 80-year-old man with a history of duodenal ulcer 8 years ago, now asymptomatic, not taking NSAIDs or antiplatelet agents* - A **remote history** of a duodenal ulcer in an asymptomatic patient not currently on high-risk medications is a prime candidate for **deprescribing**. - Continuing a PPI indefinitely without active risk factors or symptoms increases the risk of side effects like **C. difficile infection** or bone fractures. *A 76-year-old man with gastro-oesophageal reflux symptoms that resolved 2 years ago after lifestyle modifications* - If **GORD symptoms** have been resolved for 2 years with lifestyle changes, the PPI should be stepped down or discontinued to see if **remission** is maintained. - Long-term PPI use for resolved, mild GORD symptoms contributes to **polypharmacy** without clear clinical benefit and carries potential risks. *An 82-year-old woman taking alendronate for osteoporosis who had mild dyspepsia when starting treatment 5 years ago* - **Bisphosphonates** (alendronate) do not routinely require PPI co-prescription; PPIs can actually reduce calcium absorption and potentially worsen **osteoporosis** risks. - Mild **dyspepsia** five years ago is not a valid indication for lifelong PPI use, especially if symptoms are no longer present or severe.

Question 18: A 76-year-old man with atrial fibrillation, heart failure (NYHA class II), type 2 diabetes, and benign prostatic hyperplasia attends for review. His medications include apixaban 5mg twice daily, bisoprolol, ramipril, metformin, empagliflozin, and tamsulosin. He reports two falls in the past month, both occurring at night when getting up to use the toilet. He describes feeling dizzy and nearly fainting. His lying blood pressure is 136/78 mmHg and standing blood pressure (after 1 minute) is 104/62 mmHg. What is the most likely cause of his orthostatic hypotension and falls?

A. Additive effect of bisoprolol and ramipril causing excessive blood pressure reduction
B. Apixaban causing occult bleeding and anemia leading to postural symptoms
C. Empagliflozin causing volume depletion through glycosuria and natriuresis
D. Tamsulosin causing alpha-blockade and venous pooling on standing (Correct Answer)
E. Nocturnal polyuria from poorly controlled diabetes causing dehydration

Explanation: ***Tamsulosin causing alpha-blockade and venous pooling on standing***- **Tamsulosin** is an **alpha-1 adrenergic antagonist** used for **benign prostatic hyperplasia (BPH)**, which causes **vasodilation** in both arterial and venous beds.- This leads to **venous pooling** upon standing, reducing **venous return** and **cardiac output**, resulting in a significant **orthostatic drop** in blood pressure (32 mmHg systolic in this case), especially when changing position rapidly from lying down. *Additive effect of bisoprolol and ramipril causing excessive blood pressure reduction* - While **bisoprolol** (beta-blocker) and **ramipril** (ACE inhibitor) lower overall blood pressure, the patient's **lying blood pressure** (136/78 mmHg) is not excessively low, suggesting generalized hypotension is not the primary cause. - The pronounced **postural drop** is more indicative of a **failure of autonomic compensation** on standing rather than a simple additive reduction in baseline blood pressure. *Apixaban causing occult bleeding and anemia leading to postural symptoms* - **Apixaban** is an **anticoagulant** and does not directly affect vascular tone or cause orthostatic hypotension as a primary side effect. - While **occult bleeding** and subsequent **anemia** can cause dizziness and postural symptoms, the specific acute and pronounced drop upon standing, especially at night, points more strongly to an immediate vascular effect. *Empagliflozin causing volume depletion through glycosuria and natriuresis* - **Empagliflozin**, an SGLT2 inhibitor, can cause **osmotic diuresis** and lead to mild **volume depletion**, potentially contributing to hypotension. - However, the magnitude of the **postural drop** (32 mmHg systolic) is more characteristic of a significant failure of **vasoconstriction** upon standing (as seen with alpha-blockers) rather than simply mild hypovolemia. *Nocturnal polyuria from poorly controlled diabetes causing dehydration* - **Nocturnal polyuria** from poorly controlled diabetes can lead to **dehydration** and postural symptoms, especially at night. - The patient is on **metformin** and **empagliflozin**, indicating treatment for diabetes, and the clinical presentation is dominated by the acute failure of the baroreceptor reflex from **tamsulosin** rather than chronic dehydration, which would typically cause a lower baseline BP and possibly tachycardia.

Question 19: You are conducting a medication review for a 71-year-old woman with multimorbidity who takes 12 regular medications. She reports good adherence but admits she sometimes gets confused about which tablets to take and when. Her medication regimen includes twice-daily, three times daily, and once-daily medications, with some to be taken with food and others on an empty stomach. Which intervention has the strongest evidence base for improving medication adherence in patients with complex regimens?

A. Prescribing all medications as once-daily preparations where possible (Correct Answer)
B. Providing a multi-compartment compliance aid (dosette box)
C. Arranging weekly telephone calls from the practice pharmacist
D. Giving written information sheets about each medication
E. Setting up automated text message reminders for each dose

Explanation: ***Prescribing all medications as once-daily preparations where possible***- Reducing **dosing frequency** through regimen simplification has the strongest evidence base for improving adherence by decreasing the **cognitive burden** on the patient.- Studies consistently show that **once-daily dosing** results in significantly higher adherence compared to twice-daily or more frequent schedules across various chronic conditions.*Providing a multi-compartment compliance aid (dosette box)*- While widely used, the evidence for **dosette boxes** is surprisingly mixed and they do not fundamentally address the underlying problem of **regimen complexity**.- These aids carry risks, such as **drug stability issues** and potential confusion if the patient's medication is changed frequently.*Arranging weekly telephone calls from the practice pharmacist*- Although pharmacist-led interventions provide support, **telephone follow-ups** have less robust evidence for long-term adherence compared to simplifying the regimen itself.- This intervention is **resource-intensive** and may not be sustainable for patients managing long-term, multi-drug therapies.*Giving written information sheets about each medication*- **Written information** alone has a limited impact on adherence behaviors and may actually increase confusion in patients with already complex 12-drug regimens.- Standardized sheets often fail to address **functional barriers** to taking medication, such as timing and frequency of doses.*Setting up automated text message reminders for each dose*- **Text message reminders** show some promise, but their effectiveness is lower in **elderly populations** who may face technological or sensory barriers.- For a patient taking medications multiple times a day, frequent alerts can lead to **alarm fatigue** and may not solve the confusion regarding food requirements.

Question 20: A 70-year-old man attends for a medication review. He has COPD (post-bronchodilator FEV1 44% predicted), ischaemic heart disease, peripheral arterial disease, and has had two previous strokes. His current medications include aspirin, clopidogrel, atorvastatin, bisoprolol, ramipril, tiotropium, and salbutamol. He smoked 30 cigarettes daily until his last stroke 3 years ago and has not smoked since. What is the most appropriate modification to his antiplatelet therapy at this stage?

A. Continue dual antiplatelet therapy indefinitely given his high vascular risk
B. Stop clopidogrel and continue aspirin monotherapy (Correct Answer)
C. Stop aspirin and continue clopidogrel monotherapy
D. Stop both antiplatelet agents and start rivaroxaban 2.5mg twice daily
E. Add dipyridamole modified-release 200mg twice daily to the current regimen

Explanation: ***Stop clopidogrel and continue aspirin monotherapy*** - Long-term **dual antiplatelet therapy (DAPT)** beyond 6-12 months is generally not indicated for stable secondary prevention after a vascular event due to a significant increase in **bleeding risk**. - For this patient with stable ischemic heart disease and past strokes (over 3 years ago), **aspirin monotherapy** is the standard, effective choice for long-term reduction of major adverse cardiovascular and cerebrovascular events. *Continue dual antiplatelet therapy indefinitely given his high vascular risk* - While the patient has a high vascular risk, the **risk-benefit ratio** of indefinite DAPT does not favor continued dual therapy due to the increased risk of **major hemorrhage** in an elderly patient with multiple comorbidities. - Current guidelines recommend DAPT for a limited period (e.g., 6-12 months) post-event, after which **monotherapy** is preferred for long-term secondary prevention. *Stop aspirin and continue clopidogrel monotherapy* - While **clopidogrel monotherapy** is a valid alternative for secondary prevention, especially post-stroke, there is no specific indication to stop **aspirin** in this patient who also has **ischemic heart disease** and **peripheral arterial disease**, for which aspirin is well-established. - Continuing aspirin is a standard practice for multi-system vascular protection, and switching without a specific intolerance or indication is generally unnecessary. *Stop both antiplatelet agents and start rivaroxaban 2.5mg twice daily* - Low-dose **rivaroxaban** (COMPASS trial regimen) is indicated in combination with **aspirin**, not as a replacement for all antiplatelets, in very high-risk stable coronary or peripheral artery disease to further reduce MACE. - This regimen is not indicated for isolated stroke prevention, and there is no mention of **atrial fibrillation** which would warrant full-dose anticoagulation. *Add dipyridamole modified-release 200mg twice daily to the current regimen* - Adding **dipyridamole** to existing dual antiplatelet therapy (aspirin + clopidogrel) would result in triple antiplatelet therapy, which is associated with a significantly increased **bleeding risk** and is not recommended for stable secondary prevention. - While aspirin-dipyridamole combination is an option for secondary stroke prevention, it is not typically combined with clopidogrel, and adding a third agent would increase **polypharmacy** without clear additional benefit in this stable patient.

Question 21: You are reviewing a 68-year-old man with type 2 diabetes (HbA1c 64 mmol/mol), stage 3a CKD (eGFR 52 ml/min/1.73m²), and heart failure with reduced ejection fraction (LVEF 36%). His current diabetes medications are metformin 1g twice daily and gliclazide 160mg twice daily. He has had two episodes of hypoglycaemia in the past month (blood glucose 3.1 and 2.8 mmol/L). According to current evidence and guidelines, which medication adjustment would provide the most cardiovascular and renal benefit while reducing hypoglycaemia risk?

A. Stop gliclazide and add sitagliptin 50mg once daily
B. Reduce gliclazide to 80mg twice daily and add pioglitazone 15mg once daily
C. Stop gliclazide and add empagliflozin 10mg once daily (Correct Answer)
D. Continue current regimen but add acarbose 50mg three times daily with meals
E. Stop gliclazide and switch to insulin detemir starting at 10 units once daily

Explanation: ***Stop gliclazide and add empagliflozin 10mg once daily***- **SGLT2 inhibitors** like empagliflozin provide significant **cardiovascular and renal protection**, specifically reducing hospitalizations for **heart failure** and slowing **CKD progression**.- Stopping **gliclazide**, a sulfonylurea, directly addresses the patient's recent **hypoglycaemia** episodes while maintaininig glycemic control with a weight-neutral, low-hypoglycemia risk alternative.*Stop gliclazide and add sitagliptin 50mg once daily*- While **DPP-4 inhibitors** like sitagliptin have a low risk of **hypoglycaemia**, they are weight neutral and have not shown the same **cardioprotective or renoprotective** benefits as SGLT2 inhibitors.- In patients with established **heart failure**, SGLT2 inhibitors are the preferred add-on therapy according to current international guidelines (NICE, ADA, ESC).*Reduce gliclazide to 80mg twice daily and add pioglitazone 15mg once daily*- **Pioglitazone** is strictly contraindicated in patients with **heart failure** because it causes fluid retention and can exacerbate heart failure symptoms.- Maintaining any dose of **gliclazide** in a patient already experiencing symptomatic **hypoglycaemia** (BG < 3.0 mmol/L) remains a safety concern.*Continue current regimen but add acarbose 50mg three times daily with meals*- **Acarbose** has a very modest effect on **HbA1c** and lacks proven benefits for **heart failure with reduced ejection fraction (HFrEF)** or CKD.- Adding another agent while the patient is already experiencing frequent **hypoglycaemic episodes** on gliclazide does not address the primary safety issue.*Stop gliclazide and switch to insulin detemir starting at 10 units once daily*- Switching to **insulin** would likely increase the risk of further **hypoglycaemic events** and does not provide the specific disease-modifying benefits required for **HFrEF**.- Insulin therapy is usually reserved for when non-insulin therapies fail to achieve glycemic targets and won't address the patient's **heart failure** prognosis.

Question 22: A 73-year-old woman with Parkinson's disease, type 2 diabetes, recurrent falls, and urinary incontinence is taking co-careldopa, pramipexole, tolterodine, metformin, atorvastatin, and amlodipine. Over the past 3 months, she has had four falls with no clear precipitant. Her lying blood pressure is 142/84 mmHg and standing blood pressure is 138/80 mmHg. Her Parkinson's symptoms are reasonably well controlled. What aspect of her medication regimen is most likely contributing to her falls?

A. Orthostatic hypotension from co-careldopa and amlodipine
B. Anticholinergic burden from tolterodine affecting cognition and balance (Correct Answer)
C. Dopamine agonist-induced impulse control disorder affecting judgment
D. Statin-induced myopathy reducing muscle strength
E. Metformin-induced vitamin B12 deficiency affecting proprioception

Explanation: ***Anticholinergic burden from tolterodine affecting cognition and balance*** - **Tolterodine** is an antimuscarinic medication that adds to the **anticholinergic burden**, which is a significant risk factor for **falls, cognitive impairment, and delirium** in the elderly. - In patients with **Parkinson's disease**, anticholinergics are particularly problematic as they can exacerbate existing balance issues and potentially worsen cognitive function, increasing fall risk. *Orthostatic hypotension from co-careldopa and amlodipine* - The measured blood pressure drop (4 mmHg systolic) is not significant enough to be classified as **orthostatic hypotension**, which requires a drop of at least 20 mmHg systolic or 10 mmHg diastolic. - While both **co-careldopa** and **amlodipine** can cause hypotension, the absence of a significant drop in this case rules out orthostatic hypotension as the primary cause of falls. *Dopamine agonist-induced impulse control disorder affecting judgment* - **Pramipexole**, a dopamine agonist, is associated with **impulse control disorders** (e.g., pathological gambling, hypersexuality), which affect judgment but typically do not directly cause physical falls. - The patient's **Parkinson's symptoms** are reported as well controlled, suggesting that the current dose of pramipexole is unlikely to be causing new or exacerbated motor symptoms leading to falls. *Statin-induced myopathy reducing muscle strength* - **Statin-induced myopathy** typically presents with symptoms such as **muscle pain, tenderness**, or **proximal muscle weakness**, often accompanied by elevated **creatine kinase** levels. - The case description does not mention any signs or symptoms suggestive of myopathy, making it an unlikely cause for the recurrent falls in this patient. *Metformin-induced vitamin B12 deficiency affecting proprioception* - Long-term **metformin** use can lead to **vitamin B12 deficiency**, which may cause **peripheral neuropathy** and impair **proprioception**, contributing to falls. - However, this process is usually gradual, and there are no specific findings in the patient's presentation, such as numbness or tingling, to suggest significant proprioceptive loss from B12 deficiency as the primary cause of acute falls.

Question 23: During a practice audit, you identify a 67-year-old man with multimorbidity (ischaemic heart disease, heart failure with reduced ejection fraction, type 2 diabetes, COPD, and depression) who is taking 13 regular medications. His GP records show that his last comprehensive medication review was 26 months ago. He has had three unplanned hospital admissions in the past year. Which framework would be most appropriate for conducting a structured medication review for this patient?

A. The Beers Criteria for potentially inappropriate medications in older adults
B. The STOPP/START criteria version 2 (Correct Answer)
C. The Medication Appropriateness Index (MAI)
D. The NO TEARS tool for medication review
E. The Anticholinergic Burden Scale

Explanation: ***The STOPP/START criteria version 2***- This is the most suitable framework for European/UK settings as it systematically addresses both **potentially inappropriate medications (STOPP)** and **potential prescribing omissions (START)** across physiological systems.- It is highly effective for managing **multimorbidity** and reducing **adverse drug reactions** in patients with polypharmacy and frequent hospital admissions.*The Beers Criteria for potentially inappropriate medications in older adults*- Primarily developed for the **US healthcare system**, it lacks recommendations for **medication omissions** (starting beneficial drugs).- While useful for identifying high-risk drugs, it is less comprehensive for a **structured medication review** in the UK context compared to STOPP/START.*The Medication Appropriateness Index (MAI)*- Provides a scoring system based on 10 criteria for each drug, but it is **time-consuming** and focuses on individual drug assessment rather than clinical outcomes.- It lacks specific **clinical triggers** for starting new, evidence-based therapies for chronic conditions like heart failure or diabetes.*The NO TEARS tool for medication review*- Functions as a simple **aide-memoire** (Need, Objective, Toxicity, Efficacy, Adverse effects, Re-evaluation, Substitution) for general reviews.- It is less **evidence-based** and systematic than the STOPP/START criteria when dealing with complex, high-risk patients with multiple comorbidities.*The Anticholinergic Burden Scale*- Specifically evaluates the cumulative effect of **anticholinergic medications** on cognitive and physical function.- It is too narrow in scope and does not address the overall **appropriateness or omission** of drugs for heart failure, IHD, or diabetes.

Question 24: A 75-year-old woman with heart failure (LVEF 32%), atrial fibrillation, type 2 diabetes, and osteoarthritis takes 11 regular medications. She has been admitted to hospital twice in the past 6 months with acute decompensated heart failure. During a comprehensive medication review, you discover she has been taking ibuprofen 400mg three times daily (purchased over-the-counter) for knee pain for the past 8 months. What is the primary mechanism by which NSAIDs have contributed to her heart failure decompensation?

A. Direct myocardial toxicity leading to reduced contractility
B. Increased afterload due to peripheral vasoconstriction and sodium retention (Correct Answer)
C. Interference with the renin-angiotensin-aldosterone system blockade
D. Promotion of cardiac arrhythmias increasing ventricular filling pressure
E. Reduction in renal perfusion causing decreased diuretic effectiveness

Explanation: ***Increased afterload due to peripheral vasoconstriction and sodium retention***- **NSAIDs** inhibit **prostaglandins (PGE2 and PGI2)**, which are essential for maintaining **vasodilation** and promoting **sodium excretion (natriuresis)** in the kidneys.- The resulting **sodium and water retention** expands intravascular volume, while **peripheral vasoconstriction** increases **afterload**, both of which exacerbate heart failure symptoms and lead to decompensation.*Direct myocardial toxicity leading to reduced contractility*- **NSAIDs** do not possess a direct toxic effect on the cardiac **myocytes** or the contractile apparatus of the heart.- Heart failure exacerbation occurs through **hemodynamic changes** and fluid balance rather than structural or functional damage to cardiac tissue.*Interference with the renin-angiotensin-aldosterone system blockade*- While **NSAIDs** can attenuate the blood pressure-lowering effects of **ACE inhibitors**, this is a consequence of their renal actions rather than the primary cause of fluid overload.- This interference is a secondary interaction; the direct induction of **vasoconstriction** and **sodium retention** remains the dominant pathological mechanism.*Promotion of cardiac arrhythmias increasing ventricular filling pressure*- While chronic fluid overload and hypertension can eventually stretch the atria and trigger **atrial fibrillation**, **NSAIDs** are not primarily **arrhythmogenic** drugs.- The patient already has **atrial fibrillation**, but her decompensation is driven by **volume/pressure overload**, not a sudden change in heart rhythm induced by the ibuprofen.*Reduction in renal perfusion causing decreased diuretic effectiveness*- **NSAIDs** do decrease renal blood flow by inhibiting **prostaglandin-mediated afferent arteriolar vasodilation**, which can blunt the response to **loop diuretics**.- However, this is largely considered a component of the broader renal effects where **sodium retention** is the primary driver of the clinical presentation of edema and congestion.

Question 25: A 72-year-old man with chronic kidney disease stage 4 (eGFR 25 ml/min/1.73m²), type 2 diabetes, gout, and hypertension attends for review. His medications include insulin, allopurinol 100mg daily, amlodipine, doxazosin, and sodium bicarbonate. He reports three episodes of acute gout in the past 4 months despite treatment. His serum urate is 485 µmol/L (target <360 µmol/L). What is the most appropriate adjustment to his urate-lowering therapy?

A. Switch from allopurinol to febuxostat 80mg daily
B. Increase allopurinol to 200mg daily and monitor renal function closely (Correct Answer)
C. Add colchicine 500 micrograms twice daily as prophylaxis
D. Stop allopurinol and start probenecid 500mg twice daily
E. Continue current allopurinol dose and add benzbromarone

Explanation: ***Increase allopurinol to 200mg daily and monitor renal function closely*** - In patients with **chronic kidney disease (CKD)**, allopurinol should be started at a low dose and **gradually titrated upward** (by 50–100 mg increments) until the target serum urate level (<360 µmol/L) is reached. - While the risk of **Allopurinol Hypersensitivity Syndrome** is higher in CKD, evidence supports that allopurinol can be safely used at doses >100 mg provided there is **careful monitoring** of renal function and clinical side effects. *Switch from allopurinol to febuxostat 80mg daily* - **Febuxostat** is typically reserved for patients who are intolerant of allopurinol or where allopurinol is contraindicated, rather than as a first-line escalation step. - Current guidelines suggest caution with febuxostat in patients with severe **cardiovascular disease**, and it lacks the long-term safety profile of titrated allopurinol in this setting. *Add colchicine 500 micrograms twice daily as prophylaxis* - While **colchicine** is used for flare prophylaxis during the initiation of urate-lowering therapy, it does not address the underlying failure to reach the **target serum urate level**. - In **CKD stage 4**, the dose of colchicine must be significantly reduced (e.g., 500 mcg every 2-3 days) to avoid toxicity, and twice daily dosing would be contraindicated. *Stop allopurinol and start probenecid 500mg twice daily* - **Probenecid** is a uricosuric agent that is largely **ineffective** in patients with an eGFR less than 30–50 ml/min/1.73m² because its mechanism depends on adequate renal filtration. - Switching to an ineffective agent when a titration of the current effective medication is available would lead to poorly controlled **gout**. *Continue current allopurinol dose and add benzbromarone* - **Benzbromarone** is a potent uricosuric that can be used in renal impairment, but it is not commonly available and is typically reserved for specialist use only after allopurinol monotherapy fails. - The priority remains to **optimize the dose** of allopurinol through titration before considering complex combination therapies or specialist-only medications.

Question 26: According to NICE Clinical Knowledge Summaries guidance on medication reviews in primary care, which statement best describes when a structured medication review should be prioritized?

A. All patients aged over 65 years should have an annual structured medication review regardless of the number of medications
B. Patients taking 4 or more regular medicines who have multimorbidity should be targeted for structured medication reviews (Correct Answer)
C. Structured medication reviews are only indicated for patients experiencing adverse drug reactions
D. Patients with a single long-term condition requiring 10 or more medications should be reviewed every 3 months
E. Medication reviews should be conducted every 6 months for all patients on anticoagulation therapy

Explanation: ***Patients taking 4 or more regular medicines who have multimorbidity should be targeted for structured medication reviews***- According to **NICE NG56 guidance**, patients with **multimorbidity** who are taking a significant number of regular medicines (typically **4 or more**) are a primary target group for structured medication reviews.- This prioritization aims to address the complexities of **polypharmacy**, minimize associated harms, and ensure treatment aligns with individual patient goals and clinical priorities.*All patients aged over 65 years should have an annual structured medication review regardless of the number of medications*- While patients over 65 are at increased risk of drug-related problems, NICE guidance does not advocate for a universal annual structured review based solely on **age**.- The focus is on individuals with **multimorbidity**, **polypharmacy**, and **frailty**, rather than age alone, to ensure targeted and efficient reviews.*Structured medication reviews are only indicated for patients experiencing adverse drug reactions*- Structured medication reviews are primarily a **proactive intervention** designed to prevent potential drug-related issues, optimize therapy, and improve patient outcomes.- Waiting for an **adverse drug reaction** to occur before conducting a review would be a reactive approach, contrary to the preventative aims of CKS guidance.*Patients with a single long-term condition requiring 10 or more medications should be reviewed every 3 months*- There is no specific NICE guidance mandating a **3-month review frequency** solely for patients on 10 or more medications for a *single* long-term condition.- The frequency of review is determined by clinical judgment, **risk assessment**, and the stability and complexity of the patient's overall health, with **multimorbidity** often being a more significant driver for frequent structured reviews.*Medication reviews should be conducted every 6 months for all patients on anticoagulation therapy*- While patients on **anticoagulation therapy** require careful and regular monitoring (e.g., INR or renal function), a full **structured medication review** is not universally mandated every 6 months for *all* such individuals.- Priority for structured reviews is typically given based on **multimorbidity** and overall clinical complexity, rather than solely on the presence of a single drug class.

Question 27: A 69-year-old woman attends for a medication review. She has type 2 diabetes, hypertension, atrial fibrillation, and hypothyroidism. She reports feeling 'generally well' but mentions occasional episodes of light-headedness when standing. Her current medications include metformin, gliclazide, amlodipine, ramipril, bisoprolol, apixaban, and levothyroxine. Her blood pressure today is 118/68 mmHg (sitting) and 95/60 mmHg (standing). What is the most appropriate next step in managing her medications?

A. Reduce the dose of amlodipine and review in 2 weeks (Correct Answer)
B. Stop bisoprolol immediately and switch to digoxin for rate control
C. Discontinue ramipril and monitor blood pressure closely
D. Add midodrine to treat the orthostatic hypotension
E. Replace gliclazide with a DPP-4 inhibitor to reduce hypoglycaemia risk

Explanation: ***Reduce the dose of amlodipine and review in 2 weeks*** - The patient exhibits symptomatic **orthostatic hypotension** with a significant **systolic blood pressure drop of 23 mmHg** upon standing, accompanied by light-headedness. - **Amlodipine**, a dihydropyridine calcium channel blocker, is a potent vasodilator and contributor to orthostatic hypotension; its dose reduction is a safer initial step than altering medications vital for **organ protection** (ramipril) or **rate control** in atrial fibrillation (bisoprolol). *Stop bisoprolol immediately and switch to digoxin for rate control* - Abrupt discontinuation of **beta-blockers** like bisoprolol can lead to **rebound tachycardia**, myocardial ischemia, or worsening of angina. - **Bisoprolol** is crucial for **rate control** in her **atrial fibrillation**, and switching to **digoxin** without a clear indication and with the risk of precipitating arrhythmias is inappropriate. *Discontinue ramipril and monitor blood pressure closely* - **Ramipril**, an ACE inhibitor, provides significant **renoprotection** in patients with **type 2 diabetes** and **hypertension**, which is a high-priority benefit. - Discontinuing it without first attempting to reduce other BP-lowering agents would remove this crucial organ protection, which is generally maintained unless absolutely necessary. *Add midodrine to treat the orthostatic hypotension* - **Midodrine** is an alpha-1 adrenergic agonist used for orthostatic hypotension, but adding another drug to a patient already on **polypharmacy** is generally not the first step. - The priority should be to identify and **deprescribe** medications contributing to the hypotension before introducing new drugs that increase complexity and potential side effects. *Replace gliclazide with a DPP-4 inhibitor to reduce hypoglycaemia risk* - The patient's symptoms are clearly related to **standing** and a measurable **blood pressure drop**, indicating **orthostatic hypotension**, not hypoglycemia. - While **gliclazide** (a sulfonylurea) carries a risk of hypoglycemia, it is not the cause of the observed postural symptoms and replacing it would not address the primary issue.

Question 28: You are implementing a deprescribing initiative in your practice for patients with multimorbidity and polypharmacy. A 76-year-old man with heart failure (LVEF 42%), type 2 diabetes, hypertension, and previous stroke takes 14 regular medications including aspirin 75mg, clopidogrel 75mg, atorvastatin 80mg, ramipril 10mg, bisoprolol 10mg, furosemide 40mg, metformin 1g twice daily, sitagliptin 100mg, amlodipine 10mg, lansoprazole 30mg (started 4 years ago when dual antiplatelet therapy initiated), warfarin (INR target 2-3 for atrial fibrillation), levothyroxine 100mcg, and vitamin supplements. His stroke was 3.5 years ago. Which medication is most appropriate to consider for deprescribing?

A. Clopidogrel as 12 months of dual antiplatelet therapy post-stroke is sufficient
B. Lansoprazole as gastroprotection is no longer required with single antiplatelet therapy
C. Sitagliptin as dual therapy with metformin may be causing medication burden
D. Amlodipine as blood pressure may be adequately controlled without it
E. Aspirin as warfarin provides adequate anticoagulation (Correct Answer)

Explanation: ***Aspirin as warfarin provides adequate anticoagulation*** - In patients with **atrial fibrillation** requiring anticoagulation, adding **aspirin** to **warfarin** (or a DOAC) significantly increases the risk of **major bleeding** without providing additional benefit for stroke prevention. - Given the stroke was 3.5 years ago, the need for dual antiplatelet therapy has passed, and combining an antiplatelet (aspirin) with an anticoagulant (warfarin) is generally contraindicated in favor of **anticoagulant monotherapy** for AF. *Clopidogrel as 12 months of dual antiplatelet therapy post-stroke is sufficient* - For **long-term secondary prevention** of non-cardioembolic stroke, a single antiplatelet agent like **clopidogrel** is often recommended and typically continued indefinitely, not limited to 12 months. - Discontinuing clopidogrel while maintaining aspirin and warfarin would leave the patient on a less effective antiplatelet regimen for stroke prevention while still facing the high bleeding risk from the aspirin-warfarin combination. *Lansoprazole as gastroprotection is no longer required with single antiplatelet therapy* - This patient is on **warfarin** and **aspirin**, a combination that significantly elevates the risk of **gastrointestinal bleeding**, irrespective of previous dual antiplatelet use. - Continuing a **proton pump inhibitor (PPI)** like lansoprazole is strongly recommended for **gastroprotection** in patients on anticoagulation, especially with concomitant antiplatelet therapy or other GI bleeding risk factors. *Sitagliptin as dual therapy with metformin may be causing medication burden* - **Sitagliptin** is a well-tolerated oral agent with a low risk of hypoglycemia, making it a suitable add-on to metformin for **Type 2 Diabetes** management to achieve glycemic targets. - Deprescribing diabetes medication should be considered if the patient is experiencing hypoglycemia or if **HbA1c** is significantly below target, neither of which is indicated here, and it is a lower priority compared to high-risk bleeding combinations. *Amlodipine as blood pressure may be adequately controlled without it* - This patient has multiple strong indications for **strict blood pressure control**, including **heart failure**, **type 2 diabetes**, and a history of **stroke**. - Removing **amlodipine** without evidence of hypotension or adequate control on fewer agents could lead to uncontrolled hypertension, increasing the risk of adverse cardiovascular and cerebrovascular events.

Question 29: A 66-year-old woman with rheumatoid arthritis, hypertension, type 2 diabetes, and recurrent urinary tract infections attends for medication review. Her medications include methotrexate 15mg weekly, folic acid 5mg weekly, sulfasalazine 1g twice daily, prednisolone 7.5mg once daily, omeprazole 20mg once daily, ramipril 5mg once daily, amlodipine 5mg once daily, metformin 1g twice daily, and she has been taking trimethoprim 200mg at night continuously for 9 months as prophylaxis prescribed by urology. Her most recent blood results show: eGFR 58 ml/min/1.73m², Hb 98 g/L (MCV 102 fL), WCC 3.2 × 10⁹/L. What is the most likely explanation for her blood results?

A. Methotrexate toxicity causing bone marrow suppression
B. Interaction between methotrexate and sulfasalazine causing megaloblastic anaemia
C. Trimethoprim-methotrexate interaction causing folate antagonism and marrow suppression (Correct Answer)
D. Chronic disease anaemia secondary to rheumatoid arthritis
E. Vitamin B12 deficiency secondary to long-term metformin use

Explanation: ***Trimethoprim-methotrexate interaction causing folate antagonism and marrow suppression*** - Both **methotrexate** and **trimethoprim** are potent **folate antagonists**; trimethoprim inhibits dihydrofolate reductase, leading to an additive effect that severely depletes folate levels. - This pharmacological interaction causes **bone marrow suppression** and **pancytopenia**, explaining the patient's **macrocytic anaemia** (high MCV 102 fL) and **leucopenia** (low WCC 3.2 × 10⁹/L). The patient's eGFR of 58 ml/min/1.73m² would further increase methotrexate exposure, exacerbating this risk. *Methotrexate toxicity causing bone marrow suppression* - While **methotrexate** can cause **marrow suppression**, the patient is on a standard dose with **folic acid supplementation**, which significantly mitigates this risk in isolation. - The continuous use of **trimethoprim** for 9 months, a strong folate antagonist, is the primary driver of the observed **pancytopenia** in this clinical context rather than methotrexate alone. *Interaction between methotrexate and sulfasalazine causing megaloblastic anaemia* - While **sulfasalazine** can have some folate antagonistic properties and occasionally interfere with folate absorption, it does not typically cause the severe additive **bone marrow suppression** seen with more potent antifolate antibiotics. - The combination of **trimethoprim** and **methotrexate** is clinically much more potent and a higher risk for rapid and significant **hematologic decline** than with sulfasalazine. *Chronic disease anaemia secondary to rheumatoid arthritis* - **Anaemia of chronic disease** typically presents as **normocytic** or mildly microcytic, whereas this patient clearly has **macrocytosis** (MCV 102 fL). - Furthermore, it would not explain the accompanying **leucopenia**, as chronic inflammation generally results in normal or sometimes elevated white blood cell counts, not a decrease. *Vitamin B12 deficiency secondary to long-term metformin use* - Long-term **metformin** use can cause **vitamin B12 deficiency**, which can lead to **macrocytic anaemia**. - However, B12 deficiency is rarely the sole cause of significant **leucopenia** in this context, and the combined use of two strong folate antagonists provides a much more direct and comprehensive explanation for both the macrocytic anaemia and leucopenia.

Question 30: During a practice audit of medication reviews, you identify that 25% of patients over 75 years taking 10 or more medications have not had a structured medication review in the past 12 months. You are planning a quality improvement intervention. According to best practice guidance, which component is most essential to include in a structured medication review process for this population?

A. Checking concordance by counting remaining tablets in dispensed bottles
B. Assessing the indication, effectiveness, safety, and patient experience for each medication (Correct Answer)
C. Ensuring all medications are prescribed as branded products to avoid confusion
D. Conducting annual blood tests including full blood count, renal, and liver function
E. Referring all complex patients to clinical pharmacology for specialist review

Explanation: ***Assessing the indication, effectiveness, safety, and patient experience for each medication***- A **structured medication review (SMR)** must be a comprehensive, person-centered assessment that ensures every drug has a valid **indication** and yields the desired **clinical benefit**.- This approach aligns with the **7-step medication review process**, prioritizing **patient preferences** and safety to reduce the risks associated with **polypharmacy** and adverse drug reactions.*Checking concordance by counting remaining tablets in dispensed bottles*- While **pill counts** can identify potential non-compliance, they are an unreliable and outdated method for assessing **long-term adherence** and do not address the clinical logic of the prescription.- This focus is too narrow and fails to evaluate if the medications remain **effective** or necessary for the patient's current health status.*Ensuring all medications are prescribed as branded products to avoid confusion*- **Generic prescribing** is standard practice in primary care to ensure **cost-effectiveness**; switching to branded products without clinical justification is generally discouraged.- Confusion is better managed through the use of **patient information leaflets**, compliance aids, or simplifying the **medication regimen** rather than branding.*Conducting annual blood tests including full blood count, renal, and liver function*- While **monitoring** organ function is a vital safety component for specific drugs, these tests are not a universal requirement for every single medication in a review.- Blood tests are a **subset of the safety assessment** but do not constitute a full review of clinical need or patient experience.*Referring all complex patients to clinical pharmacology for specialist review*- Most medication reviews should be managed within **primary care** by general practitioners or **clinical pharmacists** who are familiar with the patient's holistic history.- Specialist referral is reserved for **complex diagnostic dilemmas** or highly specialized therapies, and routine referral is not an efficient or recommended use of resources.

Question 31: A 74-year-old man with Parkinson's disease, orthostatic hypotension, type 2 diabetes, and benign prostatic hyperplasia is taking levodopa/carbidopa 25/100 three times daily, pramipexole 1.05mg three times daily, metformin 500mg twice daily, tamsulosin 400mcg once daily, finasteride 5mg once daily, and bisoprolol 2.5mg once daily prescribed by cardiology for palpitations. He reports increasing frequency of falls, particularly when standing. Which medication is most appropriate to discontinue to reduce his fall risk?

A. Pramipexole due to dopamine agonist-associated impulse control disorders
B. Tamsulosin due to alpha-blocker effects on blood pressure
C. Bisoprolol due to effects on heart rate response to postural changes (Correct Answer)
D. Finasteride due to effects on muscle strength
E. Metformin due to risk of lactic acidosis

Explanation: ***Bisoprolol due to effects on heart rate response to postural changes*** - **Bisoprolol** is a beta-blocker that inhibits the normal **compensatory tachycardia** necessary to maintain blood pressure when standing, significantly worsening **orthostatic hypotension** in a patient already predisposed. - Given the patient's existing **Parkinson's disease** and history of falls, removing a drug that blunts the autonomic response to postural changes is a priority for reducing fall risk. *Pramipexole due to dopamine agonist-associated impulse control disorders* - While **dopamine agonists** like pramipexole can cause or worsen **orthostatic hypotension**, the reason for discontinuation specified here is **impulse control disorders**, which is not the direct cause of his falls when standing. - Abruptly stopping or significantly reducing Parkinson's medications can lead to severe **motor deterioration** and should be carefully considered, especially when other more direct contributors to falls exist. *Tamsulosin due to alpha-blocker effects on blood pressure* - **Tamsulosin** is a selective **alpha-1A blocker** primarily targeting the prostate, which typically has a much lower risk of causing significant systemic **hypotension** or exacerbating orthostatic hypotension compared to non-selective alpha-blockers. - Although all alpha-blockers can potentially contribute to orthostatic changes, bisoprolol has a more direct and substantial impact on the cardiovascular compensatory mechanisms essential for standing blood pressure maintenance. *Finasteride due to effects on muscle strength* - **Finasteride** is a 5-alpha-reductase inhibitor used for benign prostatic hyperplasia and does not have clinically significant effects on **skeletal muscle strength**, directly contribute to **orthostatic hypotension**, or increase fall risk. - Its mechanism of action is focused on hormonal modulation within the prostate, unrelated to neuromuscular function or cardiovascular stability. *Metformin due to risk of lactic acidosis* - **Metformin** is an oral hypoglycemic agent used for **type 2 diabetes** and is not associated with directly causing **orthostatic hypotension** or increasing the risk of falls due to its mechanism of action. - While **lactic acidosis** is a potential serious side effect, it is unrelated to the patient's primary complaint of falls specifically when standing, which points to orthostatic dysregulation.

Question 32: A 67-year-old woman with multimorbidity including type 2 diabetes, heart failure (NYHA class II), and severe osteoarthritis is reviewed. She takes 12 regular medications. She expresses feeling overwhelmed by her medication regimen and reports 'tablet fatigue'. According to the principles of realistic medicine and patient-centred care in multimorbidity management, what is the most appropriate initial approach?

A. Explore the patient's priorities, concerns, and what matters most to her regarding her conditions and treatments (Correct Answer)
B. Explain that all medications are necessary and provide detailed written instructions
C. Simplify the regimen by stopping the least important medications immediately
D. Refer to a specialist multimorbidity clinic for complex case management
E. Arrange for a compliance aid to improve medication adherence

Explanation: ***Explore the patient's priorities, concerns, and what matters most to her regarding her conditions and treatments*** - This approach is fundamental to **patient-centred care** and **realistic medicine**, directly addressing the patient's reported 'tablet fatigue' and feeling overwhelmed by eliciting her **perspectives and values**. - Understanding the patient's **priorities, treatment burden**, and what truly **matters to her** enables a **shared decision-making** process for optimizing her complex medication regimen. *Explain that all medications are necessary and provide detailed written instructions* - This is a **paternalistic approach** that ignores the patient's expressed **'tablet fatigue'** and high **treatment burden**, failing to acknowledge her distress. - Simply reinforcing the necessity of all medications without a review or patient input disregards the principles of **shared decision-making** and may worsen adherence and satisfaction. *Simplify the regimen by stopping the least important medications immediately* - While **deprescribing** is often appropriate in multimorbidity, doing so **immediately** and unilaterally without patient discussion or a thorough assessment of each medication's **benefit-harm ratio** is premature and potentially unsafe. - Determining which medications are 'least important' should be a collaborative process, considering the patient's **goals** and the potential for **adverse withdrawal effects**. *Refer to a specialist multimorbidity clinic for complex case management* - Although specialist input might eventually be beneficial, the **initial step** in managing multimorbidity in primary care is to engage directly with the patient to understand their **concerns and goals**. - Referral without this foundational patient-centred conversation bypasses the primary clinician's role in establishing a **therapeutic relationship** and addressing immediate patient distress. *Arrange for a compliance aid to improve medication adherence* - A **compliance aid** (e.g., pillbox) helps with the practical organization of medications but does not address the underlying **'tablet fatigue'** or the sheer **number of medications** the patient feels overwhelmed by. - This solution focuses solely on **adherence** without first exploring if the current medication burden is appropriate or aligned with the patient's overall **quality of life** and preferences.

Question 33: A 70-year-old man with type 2 diabetes, hypertension, stage 3b CKD (eGFR 38 ml/min/1.73m²), and gout takes multiple medications including metformin 500mg twice daily, sitagliptin 50mg once daily, ramipril 10mg once daily, amlodipine 10mg once daily, atorvastatin 80mg once daily, allopurinol 100mg once daily, and aspirin 75mg once daily. His recent blood tests show: HbA1c 52 mmol/mol, uric acid 420 µmol/L, potassium 5.2 mmol/L. He has had two acute gout attacks in the past 6 months. What is the most appropriate adjustment to optimise his gout management?

A. Add colchicine 500mcg twice daily for prophylaxis during dose adjustment
B. Stop allopurinol and switch to febuxostat 80mg once daily
C. Increase allopurinol to 200-300mg once daily with careful monitoring (Correct Answer)
D. Add benzbromarone 50mg once daily to enhance uric acid excretion
E. Continue current allopurinol dose and add prednisolone 5mg daily

Explanation: ***Increase allopurinol to 200-300mg once daily with careful monitoring*** - The patient's **serum uric acid (420 µmol/L)** is above the target of <360 µmol/L (or <300 µmol/L for recurrent gout), and the current 100mg dose is insufficient despite **CKD stage 3b**. - Modern guidelines emphasize a "treat-to-target" approach where **allopurinol** is uptitrated gradually, even in renal impairment, with close monitoring for toxicity and gradual dose increments to achieve the target uric acid. *Add colchicine 500mcg twice daily for prophylaxis during dose adjustment* - While **prophylactic colchicine** is recommended when initiating or increasing urate-lowering therapy to prevent flares, it does not address the underlying persistent **hyperuricaemia**. - In this patient with an **eGFR 38 ml/min/1.73m²**, the dose of colchicine would likely need to be reduced (e.g., 500mcg once daily) to avoid toxicity. *Stop allopurinol and switch to febuxostat 80mg once daily* - **Febuxostat** is typically reserved for patients who are intolerant to allopurinol, where allopurinol is contraindicated, or when it's ineffective at maximum doses, none of which apply here. - It carries specific **cardiovascular cautions** in certain patient populations and is not the first-line adjustment when allopurinol has not yet been optimized. *Add benzbromarone 50mg once daily to enhance uric acid excretion* - **Benzbromarone** is a uricosuric agent and is generally less effective in patients with an **eGFR below 30-50 ml/min**, making it unsuitable for this patient's CKD stage 3b. - It is not a standard first-line addition and is typically only available via **specialist secondary care** channels in many regions. *Continue current allopurinol dose and add prednisolone 5mg daily* - **Long-term corticosteroids** are not an appropriate management strategy for chronic gout due to significant side effects that would worsen the patient's **hypertension and diabetes**. - This approach fails to address the persistent **hyperuricaemia**, which is the root cause of the patient's frequent gout attacks and requires effective urate-lowering therapy.

Question 34: During a comprehensive medication review for a 72-year-old man with COPD (post-bronchodilator FEV1 45% predicted), ischaemic heart disease, and anxiety, you note he is taking salbutamol inhaler as required, tiotropium 18mcg once daily, fluticasone/salmeterol 500/50 twice daily, bisoprolol 5mg once daily, aspirin 75mg once daily, atorvastatin 80mg once daily, and diazepam 5mg twice daily for 2 years. Which medication poses the greatest concern for long-term use in this patient?

A. Bisoprolol due to risk of bronchospasm in COPD
B. Fluticasone/salmeterol due to increased pneumonia risk
C. Diazepam due to risk of dependence, falls, and cognitive impairment (Correct Answer)
D. Atorvastatin due to interaction with inhaled corticosteroids
E. Tiotropium due to cardiovascular effects in ischaemic heart disease

Explanation: ***Diazepam due to risk of dependence, falls, and cognitive impairment*** - Long-term use of **benzodiazepines** (over 4 weeks) is strongly discouraged in the elderly due to elevated risks of **cognitive impairment**, **falls**, and **respiratory depression**, especially in a patient with **COPD**. - The **STOPP criteria** specifically categorize long-term benzodiazepine use as potentially inappropriate medications (PIMs) in older adults to prevent adverse drug events. *Bisoprolol due to risk of bronchospasm in COPD* - **Cardioselective beta-blockers** like **bisoprolol** are generally safe in COPD patients and are strongly indicated here for the management of **ischaemic heart disease**. - Recent evidence suggests they do not significantly increase **bronchoconstriction** or reduce the efficacy of bronchodilators in the majority of COPD cases. *Fluticasone/salmeterol due to increased pneumonia risk* - While **Inhaled Corticosteroids (ICS)** are associated with an increased risk of **pneumonia** in COPD patients, they are still indicated when there is a risk of frequent exacerbations. - Although a concern, it is considered a manageable risk compared to the acute dangers associated with long-term **high-dose benzodiazepine** use in this age group. *Atorvastatin due to interaction with inhaled corticosteroids* - There is no clinically significant **pharmacokinetic interaction** between **atorvastatin** and **inhaled corticosteroids** such as fluticasone. - Atorvastatin is essential for **secondary prevention** in this patient given their history of **ischaemic heart disease**. *Tiotropium due to cardiovascular effects in ischaemic heart disease* - Long-acting muscarinic antagonists (**LAMAs**) like **tiotropium** have been proven safe in large trials for patients with co-existing **cardiovascular disease**. - It provides vital maintenance therapy for **COPD symptom control** and has not been linked to increased mortality in patients with heart disease.

Question 35: A 75-year-old woman with heart failure (LVEF 35%), atrial fibrillation, type 2 diabetes, and chronic pain from lumbar spinal stenosis attends for medication review. She takes bisoprolol, ramipril, furosemide, apixaban, metformin, atorvastatin, lansoprazole, and co-codamol 30/500 four times daily for the past 18 months. She reports chronic constipation requiring regular laxatives and occasional confusion noticed by her daughter. What is the most appropriate action regarding her analgesic management?

A. Continue co-codamol and add docusate regularly to manage constipation
B. Switch to tramadol 50mg four times daily for better pain control
C. Review pain management strategy and consider switching to paracetamol with topical NSAIDs (Correct Answer)
D. Add amitriptyline 10mg at night for neuropathic pain component
E. Increase co-codamol to 60/1000 for improved analgesia

Explanation: ***Review pain management strategy and consider switching to paracetamol with topical NSAIDs*** - Long-term **opioid use** (codeine in co-codamol) is likely contributing to the patient's **chronic constipation** and **confusion**, necessitating a reduction in opioid burden. - Switching to **paracetamol** and **topical NSAIDs** provides safer analgesia with a lower risk of systemic side effects like gastrointestinal bleeding or worsening **heart failure** compared to oral NSAIDs. *Continue co-codamol and add docusate regularly to manage constipation* - This approach fails to address the likely cause of the patient's **confusion** and potential **falls risk** associated with chronic opioid use. - It leads to **polypharmacy**, where a new medication is added solely to treat a side effect of an existing, potentially inappropriate medication. *Switch to tramadol 50mg four times daily for better pain control* - **Tramadol** is another opioid and would likely exacerbate the patient’s **constipation** and **confusion** due to its central nervous system effects. - It carries a risk of **serotonin syndrome** and lowered seizure threshold, especially in elderly patients with multiple comorbidities. *Add amitriptyline 10mg at night for neuropathic pain component* - Amitriptyline has strong **anticholinergic properties** that can worsen **confusion** and increase the risk of **urinary retention** and falls in the elderly. - It is listed in the **Beers Criteria** as potentially inappropriate for older adults, particularly those with existing cognitive impairment. *Increase co-codamol to 60/1000 for improved analgesia* - Increasing the dose would further worsen **opioid-induced constipation** and increase the severity of **confusion** and sedation. - High-dose opioids in a 75-year-old patient significantly increase the risk of **respiratory depression** and adverse cardiovascular events.

Question 36: According to the 2015 STOPP/START criteria, which of the following represents a STOPP criterion (potentially inappropriate medication) in older adults?

A. Absence of calcium and vitamin D supplementation in patients taking long-term corticosteroids
B. Use of proton pump inhibitors for uncomplicated peptic ulcer disease at full therapeutic dosage for more than 8 weeks (Correct Answer)
C. Absence of ACE inhibitor in systolic heart failure with reduced ejection fraction
D. Absence of antiplatelet therapy in patients with documented coronary artery disease
E. Use of aspirin and clopidogrel combination beyond 12 months after acute coronary syndrome

Explanation: ***Use of proton pump inhibitors for uncomplicated peptic ulcer disease at full therapeutic dosage for more than 8 weeks*** - This is a recognized **STOPP criterion** because prolonged **full-dose PPI** therapy for uncomplicated ulcers increases risks of **C. difficile infection**, **fractures**, and **hypomagnesemia**. - Uncomplicated peptic ulcers typically heal within 8 weeks, making continued full-dose PPI use beyond this period potentially **inappropriate** without clear indication. *Absence of calcium and vitamin D supplementation in patients taking long-term corticosteroids* - This is a **START criterion**, identifying a potential **prescribing omission** rather than an inappropriate medication to stop. - It highlights the importance of **osteoporosis prophylaxis** in older patients receiving systemic **corticosteroid therapy** to prevent fractures. *Absence of ACE inhibitor in systolic heart failure with reduced ejection fraction* - This represents a **START criterion** because **ACE inhibitors** are evidence-based treatments that improve survival and reduce hospitalizations in older adults with **systolic heart failure**. - Failure to prescribe these agents when indicated is considered a **potential prescribing omission** (PPO) in geriatric care for cardiovascular health. *Absence of antiplatelet therapy in patients with documented coronary artery disease* - This is another **START criterion** aimed at ensuring secondary prevention for patients with established **vascular disease**. - The criteria advocate for the **initiation** of antiplatelets to reduce the risk of future **myocardial infarction** and stroke. *Use of aspirin and clopidogrel combination beyond 12 months after acute coronary syndrome* - While long-term **dual antiplatelet therapy (DAPT)** increases bleeding risk, the 2015 STOPP/START criteria do not explicitly list this as a universal STOPP criterion in the same category as prolonged PPI use. - The duration of DAPT is often individualized based on factors like **stent type** and **ischemic risk** versus bleeding risk, rather than a strict mandate for discontinuation at 12 months for all patients.

Question 37: A 68-year-old man attends for his annual chronic disease review. He has type 2 diabetes, hypertension, stage 3a CKD (eGFR 52 ml/min/1.73m²), and gout. His current medications are metformin 1g twice daily, gliclazide 160mg twice daily, allopurinol 300mg once daily, ramipril 10mg once daily, and amlodipine 10mg once daily. His blood pressure is 142/88 mmHg and HbA1c is 64 mmol/mol (8%). He reports two episodes of nocturnal hypoglycaemia in the past month. What is the most appropriate adjustment to his medication regimen?

A. Add dapagliflozin 10mg once daily to improve glycaemic control
B. Reduce gliclazide to 80mg twice daily and monitor blood glucose (Correct Answer)
C. Switch from metformin to sitagliptin due to chronic kidney disease
D. Increase ramipril to 20mg once daily to improve blood pressure control
E. Add spironolactone 25mg once daily for resistant hypertension

Explanation: ***Reduce gliclazide to 80mg twice daily and monitor blood glucose*** - The patient is experiencing recurrent **nocturnal hypoglycaemia**, which is a high-priority safety concern; **sulfonylureas** like gliclazide are the most common cause of this in type 2 diabetes. - In an older patient with **multimorbidity** and an eGFR of 52, glycaemic targets should be individualized to avoid **over-treatment** and minimize the risk of dangerous hypoglycaemic events. *Add dapagliflozin 10mg once daily to improve glycaemic control* - While **SGLT2 inhibitors** have benefits in **CKD** and diabetes, adding a new glucose-lowering agent does not address the immediate danger of existing **hypoglycaemia**. - The primary clinical focus must be the discontinuation or reduction of the offending agent before intensifying the regimen further. *Switch from metformin to sitagliptin due to chronic kidney disease* - **Metformin** is safe to continue at full dose as long as the **eGFR** is above 45 ml/min/1.73m² and only requires dose reduction once it falls below 45. - **Sitagliptin** would not be a priority switch here as metformin remains first-line and is not the likely cause of the patient's **nocturnal hypoglycaemia**. *Increase ramipril to 20mg once daily to improve blood pressure control* - The current blood pressure of 142/88 mmHg is close to the standard target of **<140/90 mmHg**, and **10mg ramipril** is already the maximum licensed dose for hypertension. - Increasing the ACE inhibitor beyond maximum recommended doses increases the risk of **hyperkalaemia** and renal dysfunction in patients with **Stage 3 CKD**. *Add spironolactone 25mg once daily for resistant hypertension* - The patient does not meet the criteria for **resistant hypertension**, as his blood pressure is nearly controlled on two agents, and he is not yet on a diuretic. - **Spironolactone** carries a significant risk of **hyperkalaemia** in patients with CKD and should not be started without confirming potassium levels and maximizing first-line therapies.

Question 38: A 73-year-old woman with rheumatoid arthritis, osteoporosis, hypertension, and recurrent falls is taking methotrexate 15mg weekly, folic acid 5mg weekly, hydroxychloroquine 200mg twice daily, prednisolone 5mg once daily, alendronic acid 70mg weekly, calcium/vitamin D supplements, ramipril 5mg once daily, and bendroflumethiazide 2.5mg once daily. She has had three falls in the past 6 months with no clear mechanical cause. Which medication is most important to review and potentially discontinue to reduce fall risk?

A. Hydroxychloroquine due to potential visual disturbances
B. Prednisolone due to its effects on bone density and muscle weakness
C. Bendroflumethiazide due to risk of postural hypotension and electrolyte disturbance (Correct Answer)
D. Alendronic acid due to risk of oesophageal irritation
E. Ramipril due to risk of hypotension

Explanation: ***Bendroflumethiazide due to risk of postural hypotension and electrolyte disturbance***- Thiazide diuretics are a major risk factor for falls in the elderly as they cause **postural hypotension**, **hyponatremia**, and **hypokalemia**, which interfere with stability.- They also increase **urinary urgency**, leading to rushed movements (nocturia/urgency) that frequently result in accidents in patients with existing mobility issues.*Prednisolone due to its effects on bone density and muscle weakness*- While long-term steroids cause **proximal myopathy** and **osteoporosis**, this patient's 5mg dose is relatively low and essential for controlling her **rheumatoid arthritis**.- Abruptly stopping steroids is dangerous due to **adrenal insufficiency** risk, and it is less likely to be the trigger for immediate, unexplained falls compared to diuretics.*Hydroxychloroquine due to potential visual disturbances*- Hydroxychloroquine can cause **retinopathy**, but visual changes typically develop very slowly over many years and do not present as sudden, frequent falls.- It is not associated with **orthostatic hypotension** or acute neurological symptoms that would predispose a patient to stumbling.*Alendronic acid due to risk of oesophageal irritation*- Alendronic acid is used to treat **osteoporosis** and actually helps prevent fractures if a fall occurs; it does not impair **balance or gait**.- Its primary side effects are **gastrointestinal**, such as esophagitis, which are unrelated to the mechanisms causing recurrent mechanical falls.*Ramipril due to risk of hypotension*- Although ACE inhibitors like ramipril can cause **hypotension**, they are statistically less likely than **thiazide diuretics** to cause the syncopal episodes or electrolyte shifts associated with falls.- Ramipril is often continued for its **cardioprotective and renoprotective** benefits unless symptomatic hypotension is clearly documented.

Question 39: During a medication review for a 77-year-old man with atrial fibrillation, heart failure (NYHA class II), type 2 diabetes, and benign prostatic hyperplasia, you note he is taking apixaban 5mg twice daily, bisoprolol 2.5mg once daily, furosemide 40mg once daily, metformin 500mg twice daily, tamsulosin 400mcg once daily, and finasteride 5mg once daily. His most recent blood results show: eGFR 42 ml/min/1.73m², HbA1c 58 mmol/mol, potassium 5.8 mmol/L. What is the most appropriate immediate action?

A. Stop the apixaban and switch to warfarin for better control
B. Add spironolactone 25mg once daily to optimise heart failure management
C. Review the cause of hyperkalaemia and consider stopping metformin temporarily (Correct Answer)
D. Reduce the bisoprolol dose due to chronic kidney disease
E. Increase furosemide to 80mg once daily to improve diuresis

Explanation: ***Review the cause of hyperkalaemia and consider stopping metformin temporarily***- The patient's **potassium level of 5.8 mmol/L** is significantly elevated, indicating **hyperkalaemia**, which is a potentially life-threatening condition requiring immediate investigation and management.- Given his **eGFR of 42 ml/min/1.73m² (CKD Stage 3)**, his renal function is impaired. **Metformin** elimination is reduced in renal dysfunction, increasing the risk of **lactic acidosis** and should be reviewed, especially in the presence of acute kidney injury or other metabolic derangements that might contribute to hyperkalaemia.*Stop the apixaban and switch to warfarin for better control*- **Apixaban** is generally safe and effective in patients with an **eGFR down to 15 ml/min/1.73m²**, with a dose reduction typically considered for eGFR 15-29 and specific other criteria (age, weight, creatinine) or if eGFR is <15. An eGFR of 42 does not necessitate stopping apixaban.- Switching to **warfarin** would introduce more monitoring burden and potential drug interactions without offering a clear benefit over a **direct oral anticoagulant (DOAC)** like apixaban, especially as apixaban is a first-line agent for AF stroke prevention.*Add spironolactone 25mg once daily to optimise heart failure management*- **Spironolactone**, a **mineralocorticoid receptor antagonist (MRA)**, is an important drug for heart failure, but it can cause and worsen **hyperkalaemia**.- Initiating spironolactone when the **potassium level is already 5.8 mmol/L** is absolutely contraindicated due to the high risk of inducing severe, life-threatening hyperkalaemia.*Reduce the bisoprolol dose due to chronic kidney disease*- **Bisoprolol** is primarily metabolized by the liver, with only about 50% excreted unchanged by the kidneys. A dose of 2.5mg is already low.- Dose adjustment for bisoprolol is typically not required until **eGFR is significantly lower (e.g., <20 ml/min/1.73m²)**, or if the patient is experiencing symptoms such as severe bradycardia or hypotension.*Increase furosemide to 80mg once daily to improve diuresis*- While **furosemide** can help excrete potassium, increasing the dose without investigating the cause of hyperkalaemia and considering other medications (like metformin in CKD) is not the immediate priority.- Aggressively increasing diuresis could lead to **dehydration** and potentially worsen renal function (pre-renal acute kidney injury), which might exacerbate the hyperkalaemia or lead to other complications.

Question 40: A 69-year-old woman with heart failure (LVEF 40%), type 2 diabetes, hypertension, and depression takes 11 regular medications. During a structured medication review, she reports a dry cough that has persisted for 6 months. Her medications include ramipril 10mg once daily, bisoprolol 5mg once daily, furosemide 40mg once daily, atorvastatin 80mg once daily, aspirin 75mg once daily, metformin 1g twice daily, gliclazide 80mg twice daily, amlodipine 5mg once daily, sertraline 100mg once daily, lansoprazole 30mg once daily, and calcium/vitamin D supplements. What is the most appropriate initial management?

A. Request a chest X-ray to investigate the persistent cough
B. Switch ramipril to losartan and review symptoms in 2-4 weeks (Correct Answer)
C. Add codeine linctus for symptomatic relief of the cough
D. Refer to respiratory medicine for bronchoscopy
E. Stop the bisoprolol as beta-blockers can cause bronchospasm

Explanation: ***Switch ramipril to losartan and review symptoms in 2-4 weeks*** - A persistent dry cough is a well-known side effect of **ACE inhibitors** like **ramipril**, occurring in up to 15% of patients due to the accumulation of **bradykinin** and substance P. - Switching to an **Angiotensin II Receptor Blocker (ARB)** like **losartan** provides similar cardiovascular benefits for **heart failure** while eliminating the cough-inducing mechanism without needing to stop crucial medication. *Request a chest X-ray to investigate the persistent cough* - While a **chest X-ray** is a reasonable investigation for persistent cough, the most common and easily modifiable cause in this clinical scenario is the **ACE inhibitor**. - Initiating a medication trial (switching to an **ARB**) is the logical and least invasive initial step before proceeding with further diagnostic imaging. *Add codeine linctus for symptomatic relief of the cough* - Adding more medication to a patient already on **polypharmacy** increases the risk of **drug-drug interactions** and side effects (e.g., constipation, sedation). - **Codeine linctus** only provides symptomatic relief and does not address the underlying cause of the cough, which is the **bradykinin accumulation** from ramipril. *Refer to respiratory medicine for bronchoscopy* - **Bronchoscopy** is an invasive and costly procedure that is not indicated as an initial step when a common drug side effect is the most likely cause of the cough. - Referral to respiratory medicine and bronchoscopy should be considered only if the cough persists after discontinuation of the **ACE inhibitor** or if there are **red flag** symptoms. *Stop the bisoprolol as beta-blockers can cause bronchospasm* - While **beta-blockers** can cause **bronchospasm** in susceptible individuals (e.g., asthmatics), they typically do not cause a persistent, non-productive **dry cough**. - **Bisoprolol** is a vital medication for **Heart Failure with Reduced Ejection Fraction (HFrEF)**, and stopping it without a clear indication could worsen the patient's cardiac condition.

Question 41: A 71-year-old man with multimorbidity attends for review. He has type 2 diabetes, hypertension, chronic kidney disease stage 3a, ischaemic heart disease, and osteoarthritis. He reports difficulty managing his medication regimen and frequently forgets doses. His current pill burden is 9 tablets daily taken at different times. According to NICE guidance on multimorbidity, which approach is most appropriate to improve his medication adherence?

A. Arrange for a family member to supervise all medication administration
B. Simplify the medication regimen by rationalising dosing schedules and exploring once-daily formulations (Correct Answer)
C. Provide written instructions with detailed timings for each medication
D. Prescribe all medications as liquid formulations to ease administration
E. Refer to secondary care for specialist management of each condition

Explanation: ***Simplify the medication regimen by rationalising dosing schedules and exploring once-daily formulations***- **NICE guideline NG56** specifically recommends reducing **treatment burden** by simplifying regimens to improve **medication adherence** in patients with multimorbidity.- Rationalising schedules and using **once-daily formulations** directly addresses the primary cause of this patient's non-adherence: the high **pill burden** and complex timing.*Arrange for a family member to supervise all medication administration*- While social support can be beneficial, this approach fails to address the **root cause** of the complex and burdensome medication regimen itself.- Undue reliance on family members can undermine the patient's **autonomy** and is not the first-line recommendation for improving adherence in cognitively capable patients.*Provide written instructions with detailed timings for each medication*- Written instructions may improve understanding, but they do not reduce the **cognitive load** or physical burden of taking nine different tablets at varying intervals.- Documentation alone does not simplify a **complex regimen**, which is the most significant barrier to adherence in this clinical scenario.*Prescribe all medications as liquid formulations to ease administration*- **Liquid formulations** are primarily indicated for patients with **dysphagia** (swallowing difficulties), which this patient does not report.- Switching to liquids does not reduce the number of doses per day and may even increase the complexity of **storing and measuring** multiple medications.*Refer to secondary care for specialist management of each condition*- Managing multimorbidity in multiple secondary care clinics often leads to **fragmented care** and potentially more complex, conflicting regimens.- **Primary care** is the most appropriate setting to provide an **integrated approach**, focusing on holistic care and the coordination of the patient's overall treatment plan.

Question 42: A 68-year-old man with asthma, type 2 diabetes, hypertension, gastro-oesophageal reflux disease, and chronic lower back pain attends for a medication review. His medications include beclometasone/formoterol inhaler, salbutamol as needed, metformin, sitagliptin, amlodipine, bendroflumethiazide, lansoprazole, and he has been taking ibuprofen 400mg three times daily for 8 months purchased over the counter for back pain. He reports his asthma has been more troublesome recently with increased salbutamol use. Blood pressure is 156/94 mmHg (usually well-controlled), and eGFR has declined from 68 to 56 ml/min/1.73m² over 6 months. When applying medication review principles to identify the medication-related problem, what is the most appropriate action?

A. Uptitrate beclometasone/formoterol dose as his asthma control has deteriorated
B. Add a third antihypertensive agent as blood pressure is above target despite dual therapy
C. Stop ibuprofen and explore non-pharmacological management for back pain, as it is likely causing multiple medication-related problems (Correct Answer)
D. Switch bendroflumethiazide to indapamide as it may be more effective for blood pressure control
E. Investigate for secondary causes of hypertension given previously good control

Explanation: ***Stop ibuprofen and explore non-pharmacological management for back pain, as it is likely causing multiple medication-related problems*** - **Ibuprofen** is a non-steroidal anti-inflammatory drug (**NSAID**) that is likely responsible for the patient's deteriorating **asthma control**, elevated **blood pressure**, and declining **renal function** (**eGFR**). - **Multimorbidity** management requires identifying and removing medications that cause a **prescribing cascade**, where additional drugs are inappropriately added to treat side effects of an existing medication. *Uptitrate beclometasone/formoterol dose as his asthma control has deteriorated* - This action treats a symptom rather than the cause; up to 20% of adults with **asthma** have **NSAID-exacerbated respiratory disease**. - Increasing the dose without removing the **ibuprofen** trigger would lead to unnecessary medication burden and potentially poor therapeutic response. *Add a third antihypertensive agent as blood pressure is above target despite dual therapy* - **NSAIDs** interfere with the efficacy of **antihypertensive medications** (like bendroflumethiazide) by promoting **sodium retention** and reducing renal prostaglandin synthesis. - Adding more drugs instead of removing the **interfering agent** (**ibuprofen**) increases the risk of polypharmacy and side effects. *Switch bendroflumethiazide to indapamide as it may be more effective for blood pressure control* - While **indapamide** is a preferred thiazide-like diuretic, this change does not address the underlying **renal vasoconstriction** caused by chronic ibuprofen use. - The priority in a **medication review** is to address clearly identifiable **drug-disease interactions** before switching therapeutic agents within the same class. *Investigate for secondary causes of hypertension given previously good control* - Extensive investigation for **secondary hypertension** is unnecessary at this stage, as a clear secondary cause (**chronic NSAID use**) has already been identified in the history. - Clinical focus should remain on **deprescribing** the causative agent and monitoring for the reversal of clinical signs (**BP** and **eGFR**).

Question 43: A 70-year-old woman with type 2 diabetes, ischaemic heart disease, moderate-severe frailty (Clinical Frailty Scale 6), and dementia (MMSE 18/30) is reviewed following a fall resulting in a fractured wrist. She lives alone with twice-daily carer support. Her medications include aspirin, atorvastatin, ramipril, bisoprolol, metformin, gliclazide, alendronate, calcium/vitamin D, donepezil, and mirtazapine. Her daughter, who has lasting power of attorney for health and welfare, asks whether her mother should continue all these medications. Her HbA1c is 68 mmol/mol, and she has had no cardiovascular events for 6 years. When applying clinical reasoning to evaluate medication appropriateness in this scenario, which represents the most appropriate approach?

A. Continue all current medications as they are evidence-based and guideline-indicated for her conditions
B. Focus deprescribing on fall-risk medications: stop mirtazapine and reduce gliclazide dose initially
C. Engage in shared decision-making with daughter to establish goals of care, then align medication regimen with priorities, likely focusing on symptom control and quality of life over prognostic benefit (Correct Answer)
D. Stop statin and antiplatelet as life expectancy is limited and cardiovascular prevention is no longer relevant
E. Continue cardiovascular and diabetes medications but stop dementia medications as evidence of benefit is limited

Explanation: ***Engage in shared decision-making with daughter to establish goals of care, then align medication regimen with priorities, likely focusing on symptom control and quality of life over prognostic benefit***- For a patient with **moderate-severe frailty (CFS 6)**, **dementia**, and a recent fall, the focus of care shifts from aggressive disease management to **optimizing quality of life** and **minimizing harm** from polypharmacy.- **Shared decision-making** with the daughter, who holds **lasting power of attorney for health and welfare**, is crucial to align the medication regimen with the patient's values and established goals of care, such as **symptom control** and **fall prevention**.*Continue all current medications as they are evidence-based and guideline-indicated for her conditions*- This approach is inappropriate for a **frail, multimorbid elderly patient** as it risks **polypharmacy**, increased pill burden, and adverse drug reactions, including further falls.- Many guidelines are based on younger, healthier populations, and the **time-to-benefit** for some preventative medications may exceed this patient's **limited life expectancy**, offering little to no clinical advantage.*Focus deprescribing on fall-risk medications: stop mirtazapine and reduce gliclazide dose initially*- While deprescribing **fall-risk medications** like mirtazapine (sedation, anticholinergic effects) and gliclazide (hypoglycemia) is clinically relevant, this approach is **prescriptive** and bypasses the essential step of **shared decision-making**.- An initial focus solely on specific medications without establishing overall **goals of care** with the patient's legal representative is not the most appropriate comprehensive approach in this complex scenario.*Stop statin and antiplatelet as life expectancy is limited and cardiovascular prevention is no longer relevant*- While **deprescribing statins and antiplatelets** is often considered in patients with limited life expectancy or high frailty, unilaterally stopping them without a **discussion of goals of care** is not ideal.- Stopping these medications might align with a focus on **quality of life** over **prognostic benefit**, but this decision must be made in collaboration with the family through **shared decision-making**.*Continue cardiovascular and diabetes medications but stop dementia medications as evidence of benefit is limited*- This approach makes a **presumptive value judgment** about which conditions are most important, potentially overlooking the patient's and family's **priorities** regarding cognitive function and daily living.- While the evidence for **dementia medications** like donepezil can be modest, their discontinuation can sometimes lead to **worsening symptoms**; therefore, this should be part of a holistic review and shared decision-making, not a default action.

Question 44: During a practice-based quality improvement project on medication reviews, you identify a 79-year-old man taking 14 regular medications for heart failure, atrial fibrillation, COPD, type 2 diabetes, gout, and osteoarthritis. He reports feeling overwhelmed by his medication regimen and admits missing doses frequently. His quality of life is poor with MRC dyspnoea scale 4, and he has been hospitalized twice in the past year with heart failure decompensation. When applying shared decision-making principles and evaluating treatment burden versus benefit in this context, which approach best represents contemporary evidence-based management of multimorbidity?

A. Intensify monitoring and provide a dosette box to improve adherence to all guideline-indicated medications
B. Prioritize prognostic medications for life-limiting conditions while considering deprescribing symptom-only treatments, using patient priorities to guide decisions (Correct Answer)
C. Refer to specialist heart failure clinic for uptitration of therapy to prevent further hospitalization
D. Simplify regimen by stopping all non-essential medications and continue only cardiac medications
E. Continue current medications unchanged but provide detailed written instructions and education about each medication's importance

Explanation: ***Prioritize prognostic medications for life-limiting conditions while considering deprescribing symptom-only treatments, using patient priorities to guide decisions*** - This approach aligns with contemporary **evidence-based guidelines** for **multimorbidity**, such as those from **NICE**, advocating for **shared decision-making** to balance **treatment burden** against clinical benefit. - It focuses on medications providing **prognostic benefit** (e.g., for heart failure, COPD, diabetes) while systematically reviewing and potentially **deprescribing** those primarily for symptoms (e.g., osteoarthritis, gout if well-controlled) based on the patient's **quality of life** and priorities. *Intensify monitoring and provide a dosette box to improve adherence to all guideline-indicated medications* - While a dosette box can aid adherence, this approach fails to address the underlying problem of **polypharmacy** and the patient's stated feeling of being **overwhelmed** by the sheer number of medications. - Simply adhering to all **single-disease guidelines** in a patient with multimorbidity often leads to an excessive pill burden, increased risk of adverse drug reactions, and reduced overall quality of life. *Refer to specialist heart failure clinic for uptitration of therapy to prevent further hospitalization* - Referring for **uptitration** in this context would likely exacerbate the patient's already significant **pill burden** and sense of being overwhelmed, potentially worsening non-adherence. - A **specialist heart failure clinic** might focus primarily on optimizing cardiac outcomes, potentially overlooking the patient's holistic needs and the impact of other comorbidities or medications on their **quality of life**. *Simplify regimen by stopping all non-essential medications and continue only cardiac medications* - This approach is too aggressive and simplistic, potentially neglecting crucial treatments for conditions like **COPD** or **type 2 diabetes** that significantly impact the patient's health and functional status. - Arbitrarily stopping "non-essential" medications without a comprehensive, patient-centered review and **shared decision-making** process is not evidence-based and risks adverse outcomes. *Continue current medications unchanged but provide detailed written instructions and education about each medication's importance* - While education is important, it alone cannot mitigate the impact of an **excessive medication regimen** on a patient who explicitly states feeling **overwhelmed** and is missing doses. - This strategy fails to address the core issue of **treatment burden** and does not incorporate **patient priorities** or the potential for **deprescribing**, which are critical in multimorbidity management.

Question 45: A 66-year-old woman attends for an annual medication review. She has rheumatoid arthritis (well-controlled for 5 years on methotrexate), type 2 diabetes, hypertension, and recurrent urinary tract infections. She takes methotrexate 15mg weekly, folic acid, hydroxychloroquine, omeprazole 20mg daily (started 5 years ago when methotrexate initiated), metformin, gliclazide, ramipril, and has recently been prescribed long-term nitrofurantoin 50mg at night as UTI prophylaxis by urology. Blood tests show eGFR 52 ml/min/1.73m², calcium 2.58 mmol/L, and vitamin B12 268 ng/L (normal >200). Applying structured medication review principles and analyzing medication appropriateness, which represents the priority concern?

A. Omeprazole should be reviewed for discontinuation as long-term use without ongoing indication increases fracture and infection risk (Correct Answer)
B. Nitrofurantoin is contraindicated with eGFR <45 ml/min/1.73m² and should be changed to an alternative prophylactic agent
C. Gliclazide should be reviewed as it increases hypoglycaemia risk in the context of recurrent infections
D. Vitamin B12 level requires urgent replacement therapy as omeprazole-induced deficiency may be developing
E. Methotrexate dose should be reduced due to borderline renal impairment to prevent toxicity

Explanation: ***Omeprazole should be reviewed for discontinuation as long-term use without ongoing indication increases fracture and infection risk***- **Omeprazole** was likely initiated for gastroprotection when **methotrexate** was started; however, **PPIs** are not routinely indicated for methotrexate alone, especially if not combined with NSAIDs. After 5 years, the initial indication may no longer be relevant, and evidence for continued use should be assessed.- Long-term **Proton Pump Inhibitor (PPI)** use is associated with several adverse effects including increased risk of **osteoporotic fractures**, higher susceptibility to **Clostridioides difficile** infections, and malabsorption of **Vitamin B12** and magnesium, making its review a priority for patient safety.*Nitrofurantoin is contraindicated with eGFR <45 ml/min/1.73m² and should be changed to an alternative prophylactic agent*- Current **BNF guidelines** recommend avoiding **nitrofurantoin** if the **eGFR** is below 45 ml/min/1.73m² due to reduced renal excretion, leading to decreased efficacy in the urinary tract and increased risk of systemic toxicity, particularly **peripheral neuropathy**.- The patient's **eGFR is 52 ml/min/1.73m²**, which is above the contraindication threshold of 45 ml/min/1.73m², making its current use acceptable from a renal function perspective, though cautious monitoring is always advised in elderly patients.*Gliclazide should be reviewed as it increases hypoglycaemia risk in the context of recurrent infections*- **Sulfonylureas** like **gliclazide** do carry a risk of **hypoglycemia**, especially in elderly patients, those with renal impairment, or during acute illnesses like infection which can affect appetite or drug metabolism.- While it is a valid concern for long-term monitoring and patient education, the scenario does not present acute symptoms of hypoglycemia, nor does it represent an immediate, higher priority compared to addressing inappropriate **polypharmacy** with PPIs.*Vitamin B12 level requires urgent replacement therapy as omeprazole-induced deficiency may be developing*- The patient's **Vitamin B12** level is 268 ng/L, which falls within the stated **normal range** (>200 ng/L). Therefore, urgent replacement therapy is not indicated at this time.- Although long-term **omeprazole** and **metformin** use can both contribute to **Vitamin B12** malabsorption, the current level suggests a need for continued periodic monitoring rather than immediate intervention.*Methotrexate dose should be reduced due to borderline renal impairment to prevent toxicity*- For **methotrexate**, dose adjustments or cautious prescribing are typically required when the **eGFR** falls below 30 ml/min/1.73m² (indicating **Stage 4 Chronic Kidney Disease** or worse).- With an **eGFR of 52 ml/min/1.73m²** (Stage 3a CKD), the patient's renal function is generally considered sufficient to maintain the current weekly 15mg dose of **methotrexate** without an immediate need for reduction, especially given her rheumatoid arthritis is well-controlled.

Question 46: You are analyzing prescribing data for patients with multimorbidity in your practice. A 72-year-old man with heart failure (LVEF 28%), type 2 diabetes, chronic kidney disease stage 3b, and ischaemic heart disease takes bisoprolol 10mg, ramipril 10mg, furosemide 80mg, spironolactone 25mg, dapagliflozin, metformin, aspirin, and atorvastatin. Recent bloods show Na+ 134 mmol/L, K+ 5.6 mmol/L, eGFR 32 ml/min/1.73m², HbA1c 65 mmol/mol, BP 116/68 mmHg. He is asymptomatic with no fluid overload. When analyzing the risks and benefits of his current regimen in the context of worsening renal function, which represents the most evidence-based approach to medication optimization?

A. Stop spironolactone immediately due to hyperkalaemia and falling eGFR to prevent life-threatening complications
B. Continue current therapy unchanged as all medications are guideline-indicated and hyperkalaemia is mild
C. Reduce ramipril dose to 5mg to address hyperkalaemia while maintaining cardiovascular protection
D. Stop dapagliflozin as eGFR is approaching the threshold for discontinuation and it may contribute to hyperkalaemia
E. Continue spironolactone and add patiromer to manage hyperkalaemia while maintaining optimal prognostic therapy for heart failure (Correct Answer)

Explanation: ***Continue spironolactone and add patiromer to manage hyperkalaemia while maintaining optimal prognostic therapy for heart failure***- In patients with **heart failure with reduced ejection fraction (HFrEF)**, Mineralocorticoid Receptor Antagonists (MRAs) like **spironolactone** provide a significant mortality benefit that should be preserved if possible.- Evidence from the **DIAMOND trial** supports the use of potassium binders like **patiromer** to manage mild-to-moderate hyperkalaemia, allowing patients to remain on life-saving **RAAS inhibitors**.*Stop spironolactone immediately due to hyperkalaemia and falling eGFR to prevent life-threatening complications*- While hyperkalaemia is a risk, a potassium level of **5.6 mmol/L** is often manageable and does not warrant immediate cessation of a drug with clear **prognostic benefits**.- Abrupt discontinuation of MRAs in HFrEF patients is associated with **increased mortality** and a higher risk of heart failure hospitalisation.*Continue current therapy unchanged as all medications are guideline-indicated and hyperkalaemia is mild*- A potassium level of **5.6 mmol/L** exceeds the normal range and requires active intervention to prevent progression to **severe hyperkalaemia**.- Ignoring persistent hyperkalaemia in the context of **CKD Stage 3b** increases the risk of cardiac arrhythmias and clinical instability.*Reduce ramipril dose to 5mg to address hyperkalaemia while maintaining cardiovascular protection*- Reducing the dose of **ACE inhibitors** like **ramipril** may slightly lower potassium but at the cost of suboptimal **neurohormonal blockade** and reduced survival.- Managing the potassium directly with a binder is preferred over **down-titrating** therapy that is currently at its target evidence-based dose.*Stop dapagliflozin as eGFR is approaching the threshold for discontinuation and it may contribute to hyperkalaemia*- **SGLT2 inhibitors** like **dapagliflozin** can be continued until an **eGFR of 15-20 ml/min/1.73m²** in heart failure according to updated guidelines.- SGLT2 inhibitors actually tend to **reduce the risk** of hyperkalaemia or remain neutral, rather than contributing to it, making discontinuation inappropriate here.

Question 47: A 74-year-old man with Parkinson's disease, type 2 diabetes, benign prostatic hyperplasia, and orthostatic hypotension attends with his wife who reports he has been experiencing visual hallucinations and increased confusion over the past month. His medications include co-careldopa, ropinirole, selegiline, metformin, tamsulosin, and fludrocortisone. Examination reveals BP 142/86 mmHg sitting, 110/68 mmHg standing. MMSE is 22/30 (previously 26/30 six months ago). When analyzing the interaction between his conditions and medications causing cognitive decline, which medication modification represents the most appropriate initial strategy?

A. Stop fludrocortisone as improved orthostatic hypotension may reduce confusion
B. Reduce co-careldopa dose as excess levodopa commonly causes hallucinations
C. Stop selegiline as MAO-B inhibitors can precipitate confusion and hallucinations
D. Stop ropinirole as dopamine agonists are most likely to cause neuropsychiatric adverse effects including hallucinations and should be withdrawn first (Correct Answer)
E. Add quetiapine to manage hallucinations while continuing current Parkinson's medications

Explanation: ***Stop ropinirole as dopamine agonists are most likely to cause neuropsychiatric adverse effects including hallucinations and should be withdrawn first***- **Dopamine agonists** like ropinirole carry a much higher risk of inducing **visual hallucinations** and cognitive impairment compared to other antiparkinsonian agents.- In the hierarchy of drug withdrawal for Parkinson's psychosis, **dopamine agonists** should always be stopped or tapered first before considering reductions in MAO-B inhibitors or levodopa.*Stop fludrocortisone as improved orthostatic hypotension may reduce confusion*- **Fludrocortisone** is used to manage **orthostatic hypotension**, and stopping it would likely increase the patient's risk of syncope and falls given his significant postural drop (142/86 to 110/68).- While low cerebral perfusion can cause confusion, it does not typically cause the distinct **visual hallucinations** seen in medication-induced Parkinson's psychosis.*Reduce co-careldopa dose as excess levodopa commonly causes hallucinations*- **Levodopa** (co-careldopa) is the most effective drug for motor symptom control and is generally better tolerated cognitively than dopamine agonists.- It should be the **last** medication to be reduced because tapering it prematurely can lead to severe **motor deterioration** and immobility.*Stop selegiline as MAO-B inhibitors can precipitate confusion and hallucinations*- While **MAO-B inhibitors** like selegiline can contribute to neuropsychiatric symptoms, they are generally considered less potent triggers than **dopamine agonists**.- Clinical guidelines recommend withdrawing MAO-B inhibitors only **after** dopamine agonists have been successfully discontinued.*Add quetiapine to manage hallucinations while continuing current Parkinson's medications*- The primary strategy for managing **Parkinson's-related psychosis** is the reduction of offending dopaminergic medications rather than adding and increasing polypharmacy.- **Atypical antipsychotics** like quetiapine or clozapine are reserved for cases where symptoms persist despite the optimization and reduction of Parkinson's therapy.

Question 48: A 68-year-old woman with type 2 diabetes, hypertension, hypothyroidism, osteoporosis, and chronic pain syndrome attends for a medication review. She takes metformin, gliclazide, amlodipine, ramipril, levothyroxine, alendronate with calcium and vitamin D, and co-codamol 30/500 four times daily for 3 years. She reports ongoing lower back pain, constipation requiring regular laxatives, and daytime drowsiness affecting her daily activities. Her HbA1c is 62 mmol/mol. When applying structured medication review principles to optimize her management, which intervention should be prioritized?

A. Reduce gliclazide dose due to risk of hypoglycaemia with daytime drowsiness
B. Switch co-codamol to modified-release morphine for better pain control
C. Initiate a gradual opioid reduction plan with introduction of non-opioid analgesics and non-pharmacological pain management strategies (Correct Answer)
D. Add a stimulant laxative to better manage opioid-induced constipation
E. Switch amlodipine to an alternative antihypertensive as it may be contributing to drowsiness

Explanation: ***Initiate a gradual opioid reduction plan with introduction of non-opioid analgesics and non-pharmacological pain management strategies***- This patient is experiencing clear **opioid-related adverse effects**, including **constipation** and **daytime drowsiness**, secondary to long-term (3 years) high-dose **co-codamol** use.- Evidence-based guidelines for **chronic non-malignant pain** recommend tapering opioids to improve quality of life, as long-term use is associated with limited efficacy and significant harm like **dependence** or **falls risk**.*Reduce gliclazide dose due to risk of hypoglycaemia with daytime drowsiness*- While drowsiness can be a sign of hypoglycemia, the patient's **HbA1c of 62 mmol/mol** suggests her diabetes is currently suboptimal rather than over-controlled.- The sedative effect is more likely attributed to the **codeine** component of her analgesia rather than glucose-lowering therapy.*Switch co-codamol to modified-release morphine for better pain control*- Escalating to a stronger **opioid** like morphine is contraindicated in chronic primary pain and would likely worsen her **side effects** and long-term prognosis.- This approach ignores the principles of **deprescribing** in a patient already suffering from medication-related harm.*Add a stimulant laxative to better manage opioid-induced constipation*- Adding more medication to treat side effects of an existing drug is known as a **prescribing cascade**, which should be avoided in **polypharmacy** management.- Addressing the root cause by reducing the **opioid load** is medical priority over managing the symptom with additional drugs.*Switch amlodipine to an alternative antihypertensive as it may be contributing to drowsiness*- **Amlodipine** is a calcium channel blocker commonly associated with peripheral edema, but it is not a recognized cause of significant **daytime drowsiness**.- Prioritizing an antihypertensive switch would fail to address the high-risk **opioid burden** impacting the patient's daily activities.

Question 49: During a comprehensive medication review for a 70-year-old man with COPD (post-bronchodilator FEV1 45% predicted), type 2 diabetes, ischaemic heart disease, and depression, you identify he is taking 11 regular medications including fluticasone/vilanterol inhaler, tiotropium, carbocisteine, bisoprolol, aspirin, atorvastatin, ramipril, metformin, sertraline, omeprazole, and paracetamol. He has had three chest infections requiring antibiotics in the past 12 months and reports persistent low mood despite sertraline 100mg daily. Applying the principles of medication optimization in multimorbidity, what is the most appropriate action?

A. Add prednisolone 5mg daily as maintenance therapy to reduce COPD exacerbations
B. Switch bisoprolol to a cardioselective alternative as beta-blockers may worsen COPD
C. Add azithromycin prophylaxis three times weekly to reduce exacerbation frequency given recurrent infections
D. Increase sertraline to 150mg daily to optimize antidepressant therapy before considering alternatives
E. Consider referral to pulmonary rehabilitation and address potentially undiagnosed anxiety contributing to breathlessness and depression (Correct Answer)

Explanation: ***Consider referral to pulmonary rehabilitation and address potentially undiagnosed anxiety contributing to breathlessness and depression*** - In patients with **multimorbidity** and high **polypharmacy** (11 medications), non-pharmacological interventions like **pulmonary rehabilitation** are prioritized to improve quality of life and exercise tolerance. - **Pulmonary rehabilitation** has a strong evidence base for reducing symptoms of both **COPD** and associated **depression** and **anxiety**, addressing multiple comorbidities without increasing the drug burden. *Add prednisolone 5mg daily as maintenance therapy to reduce COPD exacerbations* - Maintenance **oral corticosteroids** are not recommended in routine COPD management due to significant side effects like **osteoporosis**, **diabetes worsening**, and increased **infection risk**. - The patient is already at high risk for infections and has **type 2 diabetes**, making chronic steroid therapy specifically contraindicated in this context. *Switch bisoprolol to a cardioselective alternative as beta-blockers may worsen COPD* - **Bisoprolol** is already a **cardioselective beta-blocker**, which is considered safe and indicated for patients with **ischaemic heart disease** even if they have COPD. - There is no clinical indication to switch, as cardioselective beta-blockers do not cause significant bronchoconstriction in the majority of COPD patients. *Add azithromycin prophylaxis three times weekly to reduce exacerbation frequency given recurrent infections* - While **prophylactic antibiotics** can reduce exacerbations, they should only be considered after **pulmonary rehabilitation**, smoking cessation, and inhaler technique have been optimized. - Adding more medication to a patient already on 11 drugs increases the risk of **adverse drug reactions** and **antimicrobial resistance** unnecessarily at this stage. *Increase sertraline to 150mg daily to optimize antidepressant therapy before considering alternatives* - Increasing the dose of **sertraline** contributes to **polypharmacy** and increases the risk of side effects like **hyponatremia** or GI upset in an elderly patient. - Holistic management requires investigating if **breathlessness-related anxiety** is the driver of low mood before escalating pharmacological treatment for depression.

Question 50: A 75-year-old woman with heart failure (LVEF 32%), atrial fibrillation, type 2 diabetes, and chronic kidney disease stage 3a attends for review. She takes bisoprolol, furosemide, spironolactone, apixaban, digoxin, metformin, and atorvastatin. She reports experiencing nausea, visual disturbances with yellow-tinged vision, and palpitations over the past week. Her pulse is irregularly irregular at 48 bpm, BP 118/72 mmHg. ECG shows atrial fibrillation with slow ventricular response and frequent ventricular ectopics. Blood tests show Na+ 136 mmol/L, K+ 5.8 mmol/L, creatinine 142 μmol/L (baseline 125), and eGFR 36 ml/min/1.73m². Applying clinical reasoning to this polypharmacy scenario, what is the most appropriate immediate action?

A. Reduce bisoprolol dose as bradycardia is likely beta-blocker related in the context of declining renal function
B. Stop digoxin immediately and check digoxin level as features suggest toxicity precipitated by hyperkalaemia and worsening renal function (Correct Answer)
C. Stop spironolactone due to hyperkalaemia and worsening renal function, and reassess in 48 hours
D. Reduce furosemide dose as overdiuresis may have precipitated acute kidney injury and electrolyte disturbance
E. Arrange urgent hospital admission for management of hyperkalaemia and bradycardia

Explanation: ***Stop digoxin immediately and check digoxin level as features suggest toxicity precipitated by hyperkalaemia and worsening renal function*** - The patient presents with classic features of **digoxin toxicity**, including gastrointestinal upset (**nausea**), **xanthopsia** (yellow-tinged vision), **bradycardia** (48 bpm), and **ventricular ectopics**. - Digoxin has a narrow therapeutic window, is primarily **renally excreted**, and its toxicity is exacerbated by **worsening renal function** (elevated creatinine and reduced eGFR) and can cause **hyperkalemia**. *Reduce bisoprolol dose as bradycardia is likely beta-blocker related in the context of declining renal function* - While **bisoprolol** contributes to bradycardia, it does not explain the multisystem symptoms like **visual disturbances** or **nausea**, which are hallmarks of digoxin toxicity. - Bisoprolol is metabolized by both the liver and kidneys, so while renal impairment is a factor, the overall clinical picture points to a more specific drug toxicity. *Stop spironolactone due to hyperkalaemia and worsening renal function, and reassess in 48 hours* - **Spironolactone** is an important contributor to **hyperkalemia** and should be reviewed, especially with worsening renal function. - However, stopping spironolactone alone does not address the acute, potentially life-threatening cardiac and neurological symptoms of **digoxin toxicity**, which is the more immediate concern. *Reduce furosemide dose as overdiuresis may have precipitated acute kidney injury and electrolyte disturbance* - The patient's blood pressure (118/72 mmHg) does not strongly suggest severe **volume depletion** from overdiuresis that would precipitate acute kidney injury in this context. - Reducing **furosemide** would not address the acute presentation of **digoxin toxicity**, which is the primary cause of her current symptoms. *Arrange urgent hospital admission for management of hyperkalaemia and bradycardia* - While hospital admission may be necessary for comprehensive management, the **most appropriate immediate action** in this scenario is to first discontinue the suspected offending agent, **digoxin**, to prevent further accumulation and worsening toxicity. - A potassium of **5.8 mmol/L** and heart rate of **48 bpm** in a patient with clear signs of drug toxicity mandate immediate drug cessation and evaluation, which can often precede or be initiated prior to formal admission.

Question 51: A 67-year-old man attends for a structured medication review using the NO TEARS framework. He has type 2 diabetes, ischaemic heart disease with previous myocardial infarction 3 years ago, hypertension, hyperlipidaemia, and benign prostatic hyperplasia. His medications include aspirin, clopidogrel, bisoprolol, ramipril, atorvastatin, metformin, gliclazide, and tamsulosin. He reports no symptoms or concerns. His HbA1c is 54 mmol/mol, BP 132/78 mmHg, and he has had no angina for 2 years. When applying the 'T' component (Time beyond which the drug may be ceased) of NO TEARS, which medication should be prioritized for review regarding potential cessation?

A. Gliclazide should be reviewed as his diabetes is well controlled with HbA1c of 54 mmol/mol
B. Clopidogrel should be reviewed as dual antiplatelet therapy is typically recommended for only 12 months post-myocardial infarction (Correct Answer)
C. Tamsulosin should be reviewed as he reports no urinary symptoms currently
D. Bisoprolol should be reviewed as he has had no angina for 2 years
E. Atorvastatin dose should be reviewed as he may be overtreated for secondary prevention

Explanation: ***Clopidogrel should be reviewed as dual antiplatelet therapy is typically recommended for only 12 months post-myocardial infarction*** - In the **NO TEARS** framework, **'T'** stands for **Time** beyond which a drug may be ceased; **dual antiplatelet therapy (DAPT)** is indicated for **12 months** post-MI before reverting to monotherapy. - This patient is **3 years post-MI**, making the continuation of **clopidogrel** unnecessary and increasing his risk of **major bleeding** without additional benefit. *Gliclazide should be reviewed as his diabetes is well controlled with HbA1c of 54 mmol/mol* - While **HbA1c** is well-controlled, this relates to the **'E' (Evidence/Effectiveness)** or **'N' (Need)** components of NO TEARS rather than a predefined **time limit** for cessation. - **Sulfonylureas** like **gliclazide** are not time-limited medications but are adjusted based on ongoing clinical control and **hypoglycemia** risk. *Tamsulosin should be reviewed as he reports no urinary symptoms currently* - **Tamsulosin** is used for **Benign Prostatic Hyperplasia (BPH)**; the absence of symptoms indicates the drug is **effective** rather than ready for cessation based on a time limit. - Stopping an **alpha-blocker** in a patient with BPH often leads to the **recurrence** of lower urinary tract symptoms (LUTS). *Bisoprolol should be reviewed as he has had no angina for 2 years* - **Beta-blockers** like **bisoprolol** are indicated for **long-term secondary prevention** following a **myocardial infarction** to reduce mortality and remodeling. - The absence of **angina** does not mean the medication should be stopped, as its primary role in this context is **prognostic** rather than purely symptomatic. *Atorvastatin dose should be reviewed as he may be overtreated for secondary prevention* - **Statins** are indicated **indefinitely** for **secondary prevention** in patients with established **ischaemic heart disease** regardless of symptom status. - There is no clinical evidence provided suggesting **side effects** or **overtreatment**, and statins are not considered time-limited medications in this setting.

Question 52: A 71-year-old woman with rheumatoid arthritis, chronic kidney disease stage 3b (eGFR 38 ml/min/1.73m²), hypertension, and recurrent gout attends for a medication review. She takes methotrexate 15mg weekly, folic acid, hydroxychloroquine, prednisolone 5mg daily, ramipril, indapamide, and allopurinol. Blood tests show Hb 98 g/L (MCV 102 fL), WCC 3.2 × 10⁹/L, platelets 145 × 10⁹/L. She reports increasing fatigue and mouth ulcers over the past month. Understanding the interaction between her multiple conditions and medications, what is the most likely explanation for her presentation?

A. Hydroxychloroquine toxicity manifesting as bone marrow suppression
B. Folate deficiency despite supplementation due to inadequate dosing in methotrexate therapy
C. Methotrexate toxicity precipitated by reduced renal clearance and drug interaction with indapamide (Correct Answer)
D. Anaemia of chronic disease secondary to active rheumatoid arthritis requiring biologics
E. Corticosteroid-induced immunosuppression leading to oral candidiasis

Explanation: ***Methotrexate toxicity precipitated by reduced renal clearance and drug interaction with indapamide*** - This patient presents with classic features of **methotrexate toxicity**, including **mucositis** (mouth ulcers) and **pancytopenia** (low Hb, WCC, and platelets) with **macrocytosis**. - Methotrexate is primarily **renally excreted**, making it high risk in **CKD stage 3b**; furthermore, **diuretics** like indapamide can compete for renal tubular secretion, further increasing toxic plasma levels.*Hydroxychloroquine toxicity manifesting as bone marrow suppression* - Hydroxychloroquine is generally considered **bone marrow-sparing** and is much more commonly associated with **retinal toxicity** than hematological suppression. - It does not cause the **macrocytic anemia** or mucosal ulcerations seen in this patient's clinical presentation.*Folate deficiency despite supplementation due to inadequate dosing in methotrexate therapy* - While folate deficiency causes macrocytosis, the patient is already receiving **folic acid supplementation**, making profound deficiency less likely than direct drug toxicity. - **Methotrexate toxicity** can occur even with standard folic acid dosing if renal clearance is impaired or if there are significant drug-drug interactions, leading to more severe effects than simple folate deficiency alone.*Anaemia of chronic disease secondary to active rheumatoid arthritis requiring biologics* - Anaemia of chronic disease is typically **normocytic** or **microcytic**, whereas this patient has a significantly elevated **MCV of 102 fL**. - This diagnosis does not explain the concurrent **leucopenia**, **thrombocytopenia**, or the presence of painful **mouth ulcers**.*Corticosteroid-induced immunosuppression leading to oral candidiasis* - Oral candidiasis (thrush) typically presents as **white plaques** rather than the painful ulcers (mucositis) characteristic of methotrexate toxicity. - Steroid use does not explain the **macrocytic pancytopenia**, as steroids typically cause **leukocytosis** (specifically neutrophilia) rather than leukopenia.

Question 53: During a practice quality improvement initiative, you identify that several elderly patients with multimorbidity are taking potentially inappropriate medications. A 78-year-old man with dementia, type 2 diabetes, hypertension, and recurrent falls is taking donepezil, gliclazide, amlodipine, and long-term diazepam (5mg twice daily) for anxiety. His HbA1c is 48 mmol/mol and blood pressure is 128/76 mmHg. Understanding the principles of deprescribing in multimorbidity, which medication represents the highest priority for review and potential discontinuation?

A. Donepezil due to limited efficacy in moderate-stage dementia
B. Gliclazide due to hypoglycaemia risk in elderly patients
C. Amlodipine as blood pressure is well controlled
D. Diazepam due to falls risk and long-term benzodiazepine dependence (Correct Answer)
E. All medications should be reviewed simultaneously with equal priority

Explanation: ***Diazepam due to falls risk and long-term benzodiazepine dependence*** - **Diazepam**, a long-acting benzodiazepine, significantly increases the risk of **recurrent falls** and cognitive impairment in elderly patients with dementia, making it a high priority for deprescribing. - Its long-term use in the elderly is generally considered inappropriate according to criteria like **STOPP/START**, due to the heightened risks of sedation, fractures, and dependency. *Donepezil due to limited efficacy in moderate-stage dementia* - While the efficacy of **donepezil** can be modest in moderate-stage dementia, it does not pose the immediate, severe safety risk of **falls** that benzodiazepines do. - Discontinuation of cholinesterase inhibitors should be a considered decision, but it's not the highest priority when acute safety issues like recurrent falls are present. *Gliclazide due to hypoglycaemia risk in elderly patients* - **Gliclazide** (a sulfonylurea) does carry a risk of **hypoglycemia** in the elderly, but the patient's HbA1c of **48 mmol/mol** indicates reasonable glycemic control that is not overly aggressive. - While monitoring is essential, its immediate risk for the patient's presenting problem of **recurrent falls** is lower compared to long-term benzodiazepine use. *Amlodipine as blood pressure is well controlled* - The patient's blood pressure of **128/76 mmHg** is well within target range, indicating **amlodipine** is effective and contributing to cardiovascular health. - Amlodipine is generally well-tolerated and not a primary contributor to **falls** in the same manner as sedative medications in elderly individuals. *All medications should be reviewed simultaneously with equal priority* - While a holistic **medication review** is always recommended in multimorbidity, clinical practice requires **prioritization** of medications that pose the greatest immediate harm or have the least benefit. - A **staged approach** to deprescribing allows for careful monitoring of withdrawal effects and determination of which changes yield the most significant clinical improvement.

Question 54: A 73-year-old woman with heart failure (LVEF 38%), type 2 diabetes, hypertension, and osteoarthritis attends for a medication review. She takes bisoprolol, ramipril, furosemide, spironolactone, metformin, amlodipine, atorvastatin, and co-codamol. She reports feeling increasingly tired and dizzy on standing over the past 6 weeks. Her sitting blood pressure is 108/64 mmHg, standing blood pressure is 88/52 mmHg after 3 minutes, and pulse is 58 bpm. Her most recent eGFR is 42 ml/min/1.73m² (previously stable at 48 for 2 years). What is the most appropriate understanding of her presentation?

A. Symptomatic orthostatic hypotension likely related to excessive diuretic therapy requiring dose reduction
B. Bradycardia-induced hypotension requiring reduction of beta-blocker dose
C. Progressive heart failure requiring uptitration of diuretic therapy
D. Multifactorial symptoms related to the cumulative effect of multiple cardiovascular medications and declining renal function (Correct Answer)
E. Adverse effects of spironolactone requiring discontinuation of aldosterone antagonist

Explanation: ***Multifactorial symptoms related to the cumulative effect of multiple cardiovascular medications and declining renal function*** - The patient exhibits symptomatic **orthostatic hypotension** (standing SBP drop >20 mmHg and DBP drop >10 mmHg) and **declining eGFR**, which are likely consequences of **polypharmacy** involving multiple blood pressure-lowering agents. - The interaction between **ACE inhibitors** (ramipril), **beta-blockers** (bisoprolol), **diuretics** (furosemide, spironolactone), and **calcium channel blockers** (amlodipine) in the context of aging and reduced renal clearance creates a high risk for **adverse drug events** and systemic hypoperfusion.*Symptomatic orthostatic hypotension likely related to excessive diuretic therapy requiring dose reduction* - While **furosemide** and **spironolactone** contribute to volume depletion and orthostasis, they are only part of a larger regimen that collectively lowers blood pressure. - Focusing solely on **diuretics** ignores the vasodilatory and bradycardic effects of her other five cardiovascular medications, leading to an incomplete understanding of the cause.*Bradycardia-induced hypotension requiring reduction of beta-blocker dose* - Her pulse of 58 bpm, while low, does not fully account for the significant **postural drop** in blood pressure, suggesting a more complex issue than isolated bradycardia. - Decreasing the **beta-blocker** may be necessary, but this single adjustment fails to address the combined hypotensive risk from her **ACE inhibitor**, **calcium channel blocker**, and **diuretics** in the setting of declining renal function.*Progressive heart failure requiring uptitration of diuretic therapy* - The primary presentation is **hypotension** and **dizziness**, which strongly suggests **over-treatment** or toxicity rather than fluid overload or worsening heart failure. - Increasing **diuretics** would further decrease **circulating volume** and **renal perfusion**, potentially precipitating acute kidney injury and worsening her orthostatic symptoms.*Adverse effects of spironolactone requiring discontinuation of aldosterone antagonist* - While **spironolactone** can cause hyperkalemia and contribute to decreased renal function, it is unlikely to be the sole cause of profound **orthostatic hypotension** within such a complex regimen. - Discontinuing spironolactone without addressing the other **antihypertensives** and **diuretics** would be an incomplete management strategy for her overall clinical instability and polypharmacy-related symptoms.

Question 55: A 69-year-old man with type 2 diabetes, hypertension, chronic obstructive pulmonary disease, and stable angina attends for his annual medication review. He currently takes 8 regular medications and reports good adherence. His most recent blood pressure is 136/82 mmHg, HbA1c is 58 mmol/mol, and his COPD has been stable without exacerbations for 18 months. According to NICE guidance on multimorbidity, which time frame is recommended for scheduling his next structured medication review?

A. 3 months
B. 6 months (Correct Answer)
C. 12 months
D. 18 months
E. 24 months

Explanation: ***6 months*** - For patients with **multimorbidity** (2+ long-term conditions) and **polypharmacy** (taking 8 medications), **NICE guidance** recommends a structured medication review every **6 months** to monitor for complex drug interactions. - This frequency is appropriate even when stable to ensure the ongoing rationale for each drug in a complex regimen and to adjust for potential **disease progression** or side effects. *3 months* - This shorter timeframe is typically reserved for patients experiencing **clinical instability**, such as recent **COPD exacerbations**, significant medication adjustments for **hypertension**, or uncontrolled diabetes. - Since the patient is currently **clinically stable** and reports good adherence, a quarterly review may be unnecessarily frequent and burdensome. *12 months* - While an **annual review** is a standard minimum for chronic diseases, it is often insufficient for patients with complex **multimorbidity** and a high medication burden. - Following **NICE guideline NG56**, more frequent reviews (6-monthly) are preferred when polypharmacy significantly increases the risk of **adverse drug events** or sub-optimal treatment. *18 months* - This interval is too long and fails to meet the **NICE guidelines** which mandate a minimum of an annual structured review for patients with chronic conditions. - Waiting this long could lead to missed opportunities for timely detection of issues related to **HbA1c** or blood pressure control in a patient with both **diabetes** and **hypertension**. *24 months* - A biennial (every 2 years) review is inappropriate for a patient with four chronic conditions and high-risk **polypharmacy**. - Standard primary care protocols for conditions like **Diabetes** and **Angina** require more frequent physiological monitoring and medication adjustment than a 2-year cycle allows.

Question 56: You are reviewing prescribing patterns in patients with multimorbidity in your practice. A 72-year-old man with COPD (post-bronchodilator FEV1 55% predicted), ischaemic heart disease, atrial fibrillation, and type 2 diabetes is taking multiple medications including regular prednisolone 5mg daily which was started 18 months ago following a COPD exacerbation and never discontinued. He has had no exacerbations in the past year. He recently sustained a fractured wrist following a minor fall. Which prescribing principle would best guide the management of his corticosteroid therapy?

A. Continue prednisolone long-term as it reduces COPD exacerbation frequency and improves lung function
B. Continue prednisolone but add calcium and vitamin D supplementation to prevent further fractures
C. Attempt to wean prednisolone gradually given limited benefit and significant potential harms (Correct Answer)
D. Switch from prednisolone to inhaled corticosteroid at high dose to maintain benefit with less systemic effect
E. Continue prednisolone but reduce to alternate-day dosing to minimize side effects

Explanation: ***Attempt to wean prednisolone gradually given limited benefit and significant potential harms*** - Long-term maintenance of **oral corticosteroids** in COPD is generally avoided because the risk of systemic adverse effects, such as **osteoporosis** and **fractures**, outweigh their clinical benefit. - Gradual weaning is essential in this patient to prevent an **adrenal crisis**, as he has been on treatment for 18 months and is already showing signs of **steroid-induced bone loss**. *Continue prednisolone long-term as it reduces COPD exacerbation frequency and improves lung function* - Clinical evidence indicates that **maintenance oral steroids** do not significantly improve long-term lung function (FEV1) compared to inhaled therapies. - Guidelines like **GOLD and NICE** explicitly discourage long-term oral use due to severe morbidity, including **weight gain**, **hypertension**, and **immunosuppression**. *Continue prednisolone but add calcium and vitamin D supplementation to prevent further fractures* - While **bone protection** is necessary for patients on steroids, this approach fails to address the underlying issue of **inappropriate prescribing** for a patient with stable COPD. - Supplementation alone cannot fully mitigate the increased fracture risk caused by high-dose **corticosteroid-induced osteoporosis**. *Switch from prednisolone to inhaled corticosteroid at high dose to maintain benefit with less systemic effect* - While **inhaled corticosteroids (ICS)** are used in COPD, they are typically reserved for patients with frequent exacerbations or high **blood eosinophil counts**, unlike this stable patient. - Switching does not negate the need for a **gradual taper** of the oral dose to avoid **secondary adrenal insufficiency**. *Continue prednisolone but reduce to alternate-day dosing to minimize side effects* - **Alternate-day dosing** is often insufficient for maintaining COPD control and does not significantly reduce the long-term risk of **osteoporotic fractures** in elderly patients. - This strategy still represents **prescribing inertia**, continuing a harmful medication that the patient no longer clinically requires.

Question 57: A 73-year-old woman with heart failure (LVEF 42%), atrial fibrillation, hypertension, type 2 diabetes, and chronic kidney disease stage 3a attends for medication review. She takes bisoprolol 10mg OD, ramipril 10mg OD, furosemide 80mg OD, spironolactone 25mg OD, edoxaban 60mg OD, metformin 1g BD, atorvastatin 80mg ON, and amlodipine 10mg OD. Blood tests show: sodium 128 mmol/L (135-145), potassium 5.8 mmol/L (3.5-5.0), eGFR 48 ml/min/1.73m² (stable), glucose 6.2 mmol/L. She reports feeling weak and lethargic. Which medication adjustment should be prioritized?

A. Stop spironolactone due to hyperkalaemia and reduce furosemide to prevent hyponatraemia
B. Reduce ramipril to 5mg daily to address both hyperkalaemia and hyponatraemia
C. Stop furosemide and switch to increased spironolactone dose for heart failure management
D. Temporarily withhold spironolactone and reduce ramipril until electrolytes normalize (Correct Answer)
E. Add sodium chloride supplements to correct hyponatraemia and continue current medications

Explanation: ***Temporarily withhold spironolactone and reduce ramipril until electrolytes normalize*** - The patient exhibits symptomatic **hyperkalaemia (5.8 mmol/L)** and **hyponatraemia (128 mmol/L)**, necessitating urgent intervention to mitigate the risk of cardiac arrhythmias. - Both **spironolactone** (a mineralocorticoid receptor antagonist) and **ramipril** (an ACE inhibitor) impair potassium excretion; therefore, reducing or temporarily withholding them is the priority to stabilize **serum potassium** and sodium. *Stop spironolactone due to hyperkalaemia and reduce furosemide to prevent hyponatraemia* - While stopping spironolactone appropriately addresses hyperkalaemia, reducing **furosemide** is counterproductive as loop diuretics contribute to potassium excretion and are crucial for managing **heart failure** fluid overload. - Decreasing furosemide could exacerbate the patient's **congestive heart failure** symptoms and would not effectively lower the elevated potassium level. *Reduce ramipril to 5mg daily to address both hyperkalaemia and hyponatraemia* - A simple dose reduction of ramipril may be insufficient to promptly control a potassium level of **5.8 mmol/L**, especially while the patient continues on **spironolactone**. - This approach neglects the substantial contribution of the **mineralocorticoid receptor antagonist** to the existing electrolyte imbalance. *Stop furosemide and switch to increased spironolactone dose for heart failure management* - Increasing the spironolactone dose in the context of current **hyperkalaemia** and **CKD stage 3a** is extremely dangerous and medically contraindicated. - Discontinuing **furosemide** would eliminate a potassium-wasting mechanism, further worsening the potentially life-threatening **hyperkalaemia**. *Add sodium chloride supplements to correct hyponatraemia and continue current medications* - Administering **sodium chloride supplements** is inappropriate for a patient with heart failure as it promotes fluid retention and risks exacerbating **pulmonary edema**. - This intervention critically overlooks the potentially fatal **hyperkalaemia** induced by the concurrent use of ACE inhibitors and potassium-sparing diuretics.

Question 58: During a practice audit of patients over 75 years taking 10 or more medications, you identify a 79-year-old man with heart failure (LVEF 35%), atrial fibrillation on apixaban, type 2 diabetes, and previous peptic ulcer disease. He takes 13 medications including aspirin 75mg daily which was started 8 years ago following a TIA. His CHADSVASC score is 5. According to current evidence on antithrombotic therapy in patients with atrial fibrillation and multimorbidity, what is the most appropriate action regarding his antiplatelet and anticoagulant therapy?

A. Continue both apixaban and aspirin as he has both atrial fibrillation and previous TIA
B. Stop aspirin and continue apixaban alone for stroke prevention (Correct Answer)
C. Stop apixaban and continue aspirin as dual therapy increases bleeding risk
D. Add a proton pump inhibitor and continue both antiplatelet and anticoagulant
E. Replace both with clopidogrel which has lower bleeding risk than combination therapy

Explanation: ***Stop aspirin and continue apixaban alone for stroke prevention***- In patients with **atrial fibrillation (AF)** and a high **CHA2DS2-VASc score**, oral anticoagulants (OACs) like **apixaban** are superior to antiplatelets for stroke prevention and are generally sufficient as monotherapy.- For patients with stable vascular disease (TIA >12 months ago), guidelines recommend stopping **aspirin** because dual therapy significantly increases the **major bleeding risk** without providing additional cardiovascular benefit.*Continue both apixaban and aspirin as he has both atrial fibrillation and previous TIA*- Long-term **combination therapy** with an anticoagulant and an antiplatelet is unnecessary for a stable TIA occurring 8 years ago and doubles the risk of **gastrointestinal bleeding**.- The **apixaban** alone provides contemporary protection against both AF-related cardioembolic strokes and secondary prevention of arterial events.*Stop apixaban and continue aspirin as dual therapy increases bleeding risk*- Stopping **apixaban** would be inappropriate as a **CHA2DS2-VASc score of 5** indicates a high risk of thromboembolic stroke that aspirin cannot adequately mitigate.- **Direct Oral Anticoagulants (DOACs)** are the gold standard for AF management; replacing them with aspirin would leave the patient under-treated.*Add a proton pump inhibitor and continue both antiplatelet and anticoagulant*- While a **PPI** reduces the risk of aspirin-induced gastric injury, it does not justify the inclusion of a redundant medication that offers no proven extra benefit for **stroke prevention**.- The clinical priority in **polypharmacy audits** for the elderly is to deprescribe medications that lack a current evidence-based indication to reduce the **bleeding burden**.*Replace both with clopidogrel which has lower bleeding risk than combination therapy*- **Clopidogrel monotherapy** is not an evidence-based substitute for anticoagulation in the context of **atrial fibrillation** and high stroke risk.- Anticoagulation (DOACs or Warfarin) is specifically required for AF to prevent **cardioembolic events**, for which clopidogrel is significantly less effective.

Question 59: A 68-year-old man with ischaemic heart disease, type 2 diabetes, COPD, and osteoarthritis attends for review. He takes aspirin, atorvastatin, metformin, sitagliptin, ramipril, bisoprolol, tiotropium, salbutamol, beclometasone inhaler, paracetamol, and codeine. He reports chronic constipation requiring frequent laxative use, and daytime drowsiness affecting his daily activities. His pain control is adequate. Which medication is the highest priority to review for potential deprescribing based on the principle of reducing treatment burden?

A. Bisoprolol as it may be causing fatigue and drowsiness
B. Codeine as it is causing constipation and sedation without essential benefit (Correct Answer)
C. Sitagliptin as it adds complexity without clear advantage over metformin alone
D. Beclometasone inhaler as COPD treatment should focus on bronchodilators
E. Ramipril as multiple cardiovascular medications increase treatment burden

Explanation: ***Codeine as it is causing constipation and sedation without essential benefit***- **Codeine** is the highest priority for deprescribing because it is causing direct, symptomatic harm including **chronic constipation** (requiring more medications) and **daytime drowsiness**.- In the context of **osteoarthritis**, the long-term benefits of opioids are limited, and since pain control is adequate, the **treatment burden** and side effects outweigh the clinical utility.*Bisoprolol as it may be causing fatigue and drowsiness*- Although **beta-blockers** can cause fatigue, this medication is vital for **secondary prevention** in a patient with **ischaemic heart disease**.- It provides essential **cardioprotective benefits** that generally supersede the subjective side effect of mild drowsiness compared to avoidable opioid use.*Sitagliptin as it adds complexity without clear advantage over metformin alone*- **Sitagliptin** is an appropriate second-line agent for **Type 2 Diabetes** when metformin alone is insufficient to reach glycaemic targets.- While it adds to the pill count, it does not carry the significant **sedative** or **gastrointestinal side effects** contributing to this patient's current distress.*Beclometasone inhaler as COPD treatment should focus on bronchodilators*- **Inhaled corticosteroids (ICS)** like beclometasone are indicated in **COPD** for patients with frequent exacerbations or asthmatic features.- Discontinuing it without clinical justification could risk a **COPD exacerbation**, and it does not contribute to the patient's sedation or constipation.*Ramipril as multiple cardiovascular medications increase treatment burden*- **Ramipril** provides critical **renoprotection** in diabetic patients and essential **cardiovascular risk reduction** in those with ischaemic heart disease.- Reducing **treatment burden** focuses on removing harmful or non-essential drugs; ACE inhibitors are considered **prognostic medications** with high clinical value in this patient profile.

Question 60: You are implementing a quality improvement project for medication reviews in your practice. According to the Royal Pharmaceutical Society guidance on structured medication reviews, which component is considered essential to include in Level 3 (clinical medication review) but NOT required in Level 1 (prescription review)?

A. Review of the medication list for accuracy and completeness
B. Patient interview to discuss medication concerns and adherence (Correct Answer)
C. Check for potential drug interactions and contraindications
D. Assessment of prescription safety and legal requirements
E. Review of indication for each prescribed medication

Explanation: ***Patient interview to discuss medication concerns and adherence***- A **clinical medication review (Level 3)** is defined by **direct patient engagement**, incorporating their health beliefs, preferences, and actual usage patterns into the review process.- Unlike technical reviews, this level requires access to the **full clinical record** and a consultation to address **adherence** and personal treatment goals.*Review of the medication list for accuracy and completeness*- This is a fundamental component of a **Level 1 (prescription review)**, which focuses on the technical accuracy of the medication record.- It can be performed as a **desk-based exercise** by a clinician without the need for the patient to be present.*Check for potential drug interactions and contraindications*- Identifying **safety issues** and drug-drug interactions is a standard part of any **technical review** of a patient's prescription list.- These checks are essential at **Level 1** to ensure the immediate safety and appropriateness of the ongoing repeats.*Assessment of prescription safety and legal requirements*- Ensuring **legal compliance** and technical safety (e.g., correct dosing, appropriate duration) is the primary goal of a **Level 1 prescription review**.- This process is focused on the **administrative and clinical safety** of the documents rather than the patient's lived experience with the drug.*Review of indication for each prescribed medication*- Matching a drug to its **documented diagnosis** is a prerequisite for a Level 1 review to ensure that every repeat medication serves a valid clinical purpose.- While important, this does not require a **patient interview**, as it can often be confirmed through a review of the **medical notes** and historical data.

Question 61: A 71-year-old woman with multimorbidity attends for a comprehensive medication review. She has atrial fibrillation, heart failure (NYHA II), type 2 diabetes, hypertension, and gastro-oesophageal reflux disease. Her current medications include apixaban 5mg BD, bisoprolol 5mg OD, ramipril 10mg OD, furosemide 40mg OD, metformin 1g BD, gliclazide 80mg BD, amlodipine 5mg OD, atorvastatin 80mg ON, and omeprazole 20mg OD. Her HbA1c is 48 mmol/mol and she has had three episodes of symptomatic hypoglycaemia in the past 2 months. What is the most appropriate medication modification?

A. Stop omeprazole as it interferes with apixaban metabolism
B. Reduce or stop gliclazide and accept slightly higher HbA1c target (Correct Answer)
C. Stop metformin and increase gliclazide to maintain glycaemic control
D. Reduce ramipril dose as it increases risk of hypoglycaemia
E. Add acarbose to reduce post-prandial glucose fluctuations

Explanation: ***Reduce or stop gliclazide and accept slightly higher HbA1c target*** - The patient's **HbA1c of 48 mmol/mol** indicates good glycaemic control, but she is experiencing **symptomatic hypoglycaemia**. - **Gliclazide**, a sulfonylurea, is a known cause of hypoglycaemia; in elderly patients with **multimorbidity**, relaxing the **HbA1c target** (e.g., to 53–58 mmol/mol) prioritizes safety and reduces hypoglycaemia risk. *Stop omeprazole as it interferes with apixaban metabolism* - There is no clinically significant interaction between **omeprazole** and **apixaban** metabolism that would necessitate stopping omeprazole. - This modification does not address the patient's immediate and dangerous problem of recurrent **hypoglycaemia** and could worsen her **GORD**, especially while on anticoagulants. *Stop metformin and increase gliclazide to maintain glycaemic control* - **Metformin** has a low risk of hypoglycaemia and is generally preferred for type 2 diabetes due to its beneficial effects and minimal hypoglycaemia risk. - Increasing the dose of **gliclazide** would directly worsen the frequency and severity of **hypoglycaemic episodes**, making this modification inappropriate and dangerous. *Reduce ramipril dose as it increases risk of hypoglycaemia* - While **ACE inhibitors** like **ramipril** may theoretically increase insulin sensitivity, they are not a primary or common cause of **symptomatic hypoglycaemia**. - Reducing **ramipril** would be detrimental as it provides essential **cardioprotection** and **renoprotection** for her heart failure, hypertension, and diabetes. *Add acarbose to reduce post-prandial glucose fluctuations* - Adding another glucose-lowering agent like **acarbose** increases the complexity of the medication regimen (**polypharmacy**) and does nothing to mitigate the **hypoglycaemia risk** from gliclazide. - **Acarbose** is often poorly tolerated due to gastrointestinal side effects and is not the recommended intervention for a patient with an already low **HbA1c of 48 mmol/mol** experiencing hypoglycaemia.

Question 62: You are conducting a medication review for a 76-year-old man taking 14 regular medications for multiple conditions including Parkinson's disease, type 2 diabetes, hypertension, benign prostatic hyperplasia, and depression. He reports worsening tremor, confusion, and visual hallucinations over the past month. His daughter mentions he started new medication recently. Which medication is most likely responsible for his deterioration through anticholinergic effects?

A. Tamsulosin for benign prostatic hyperplasia
B. Bisoprolol for hypertension
C. Oxybutynin for urinary urgency (Correct Answer)
D. Metformin for type 2 diabetes
E. Ropinirole for Parkinson's disease

Explanation: ***Oxybutynin for urinary urgency***- **Oxybutynin** is a potent **anticholinergic** agent that readily crosses the blood-brain barrier, leading to **central nervous system** toxicity including **confusion**, **visual hallucinations**, and worsening **tremor**.- In elderly patients, particularly those with **Parkinson's disease**, anticholinergics significantly increase the **anticholinergic burden**, exacerbating cognitive decline and motor symptoms by disrupting cholinergic balance.*Tamsulosin for benign prostatic hyperplasia*- **Tamsulosin** is an **alpha-1 adrenoceptor antagonist** that primarily relaxes smooth muscle in the prostate and bladder neck.- It lacks significant **anticholinergic properties** and is not associated with cognitive impairment, hallucinations, or worsening tremor through anticholinergic mechanisms.*Bisoprolol for hypertension*- **Bisoprolol** is a **beta-1 selective adrenergic blocker** that reduces sympathetic nervous system activity.- It has no significant **muscarinic receptor** antagonism and therefore does not produce the classic **anticholinergic syndrome** of confusion and hallucinations.*Metformin for type 2 diabetes*- **Metformin** is a **biguanide** that reduces hepatic glucose production and improves insulin sensitivity.- Its primary side effects are **gastrointestinal**, and it has no known **anticholinergic activity** or association with cognitive deterioration or hallucinations.*Ropinirole for Parkinson's disease*- **Ropinirole** is a **dopamine agonist** that can cause side effects like **hallucinations** and **confusion**, especially in elderly patients.- However, it would typically **improve** rather than worsen a **tremor** in Parkinson's disease, and its mechanism for cognitive side effects is not through **anticholinergic effects**.

Question 63: A 74-year-old woman with type 2 diabetes, chronic kidney disease stage 3b (eGFR 34 ml/min/1.73m²), heart failure, and osteoarthritis takes 11 regular medications. She has been prescribed ibuprofen 400mg TDS by a locum GP for worsening knee pain. At her medication review one month later, her eGFR has fallen to 24 ml/min/1.73m² (now CKD stage 4) and she reports ankle swelling. Which medication interaction and mechanism best explains this clinical deterioration?

A. NSAID interaction with ACE inhibitor causing acute tubular necrosis
B. NSAID-induced sodium retention worsening heart failure and reducing renal perfusion (Correct Answer)
C. NSAID interaction with metformin causing accumulation and lactic acidosis
D. NSAID inhibition of diuretic action leading to volume overload and pre-renal failure
E. NSAID-induced hyperkalaemia causing cardiac dysfunction and reduced renal blood flow

Explanation: ***NSAID-induced sodium retention worsening heart failure and reducing renal perfusion*** - **NSAIDs** inhibit **prostaglandin synthesis**, which causes **sodium and water retention**, explaining the patient's new-onset **ankle swelling** and heart failure exacerbation. - Reduced **renal perfusion** due to worsened heart failure and the loss of prostaglandin-mediated **afferent arteriolar vasodilation** leads to a significant fall in **eGFR**. *NSAID interaction with ACE inhibitor causing acute tubular necrosis* - While the combination with an **ACE inhibitor** (part of the "triple whammy") causes **haemodynamic acute kidney injury**, it typically results from **pre-renal** changes rather than **acute tubular necrosis**. - This explanation focuses on a structural injury, whereas the clinical presentation and **ankle swelling** point toward **fluid retention** and haemodynamic decline. *NSAID interaction with metformin causing accumulation and lactic acidosis* - **NSAIDs** do not have a direct pharmacological interaction with **metformin**, although they can indirectly cause metformin accumulation by reducing **renal clearance**. - The patient presents with **oedema** and a drop in **eGFR**, not the systemic symptoms of **metformin-associated lactic acidosis** (e.g., abdominal pain, tachypnea). *NSAID inhibition of diuretic action leading to volume overload and pre-renal failure* - **NSAIDs** do antagonize the effects of **diuretics** by reducing renal blood flow and interfering with **prostaglandin-dependent natriuresis**. - While this contributes to **volume overload**, the primary mechanisms for the **eGFR** drop in this complex patient are the direct **renal haemodynamic** changes and worsened cardiac output. *NSAID-induced hyperkalaemia causing cardiac dysfunction and reduced renal blood flow* - **NSAIDs** can cause **hyperkalaemia** by suppressing **renin and aldosterone** secretion, but this is rarely the primary driver of a 10 ml/min drop in **eGFR**. - **Cardiac dysfunction** in this scenario is driven by **fluid overload** and increased **afterload** due to systemic vasoconstriction, rather than potassium-induced arrhythmias.

Question 64: A 69-year-old man with type 2 diabetes, ischaemic heart disease, heart failure (LVEF 40%), and atrial fibrillation takes 12 regular medications. He reports difficulty remembering to take all his medications and admits missing doses several times weekly. His HbA1c has risen from 58 to 72 mmol/mol over 6 months, and his blood pressure is 152/94 mmHg. His renal function is stable (eGFR 52 ml/min/1.73m²). Which intervention has the strongest evidence base for improving medication adherence in patients with multimorbidity and polypharmacy?

A. Arranging for a pharmacist-led structured medication review addressing barriers to adherence (Correct Answer)
B. Setting up a monitored dosage system (dosette box) for medication administration
C. Increasing the frequency of GP appointments to monthly reviews for reinforcement
D. Providing written information leaflets about each medication and its importance
E. Switching to combination tablets wherever possible to reduce pill burden

Explanation: ***Arranging for a pharmacist-led structured medication review addressing barriers to adherence*** - **Pharmacist-led structured medication reviews** are evidence-based interventions specifically designed to identify and address individual **barriers to adherence**, whether intentional (e.g., side effects) or unintentional (e.g., forgetfulness or complexity) in patients with **multimorbidity** and **polypharmacy**. - This personalized approach allows for tailored solutions, such as simplifying regimens, adjusting timing, or addressing patient concerns, leading to significant improvements in adherence and clinical outcomes like **HbA1c** and **blood pressure**. *Setting up a monitored dosage system (dosette box) for medication administration* - While helpful for some patients, **monitored dosage systems** primarily aid in organizing medications and do not inherently address the underlying **cognitive or behavioral barriers** to adherence. - The evidence base for dosette boxes as a standalone intervention for improving long-term adherence or clinical outcomes in complex patients with **polypharmacy** is surprisingly weak. *Increasing the frequency of GP appointments to monthly reviews for reinforcement* - More frequent GP appointments mainly focus on **monitoring clinical parameters** and general health advice, which may not directly target the specific challenges of medication adherence. - This approach can increase the **treatment burden** on the patient and may not provide the detailed, patient-specific medication counseling required for managing **polypharmacy**. *Providing written information leaflets about each medication and its importance* - **Written information** alone is largely ineffective for improving long-term medication adherence, especially in older patients managing a large number of medications. - This passive method does not facilitate the crucial **dialogue** needed to uncover patient-specific barriers or misunderstandings about their complex medication regimen. *Switching to combination tablets wherever possible to reduce pill burden* - Reducing **pill burden** through combination tablets simplifies the regimen, which can be beneficial, but it does not address other critical factors like **forgetfulness**, side effects, or patient beliefs that contribute to non-adherence. - While a good adjunctive strategy, it lacks the comprehensive, **individualized assessment** and support offered by a structured medication review for multifactorial adherence issues.

Question 65: According to current NICE guidance on multimorbidity (NG56), which of the following patients would be most appropriate to offer a structured approach to multimorbidity care including comprehensive assessment and individualized management plan?

A. A 58-year-old man with well-controlled hypertension and type 2 diabetes
B. A 73-year-old woman with COPD, heart failure, and depression causing significant functional impairment (Correct Answer)
C. A 65-year-old man with three chronic conditions all well controlled on stable treatment
D. A 45-year-old woman with asthma and hypothyroidism managed in specialist clinics
E. A 70-year-old man with hypertension, hyperlipidaemia, and osteoarthritis who manages independently

Explanation: ***A 73-year-old woman with COPD, heart failure, and depression causing significant functional impairment***- According to **NICE NG56**, a structured management plan is indicated for patients with multiple conditions that result in **significant functional impairment** or high healthcare utilization.- The combination of **COPD, heart failure, and depression** represents high complexity where diseases and treatments frequently interact, requiring an **individualized management plan**.*A 58-year-old man with well-controlled hypertension and type 2 diabetes*- Patients with **well-controlled** chronic conditions do not automatically require the intensive structured approach if their current care is meeting their needs.- The focus for this patient remains on standard **routine monitoring** rather than a comprehensive, multidisciplinary multimorbidity assessment.*A 65-year-old man with three chronic conditions all well controlled on stable treatment*- The **number of conditions** alone does not trigger the NG56 structured approach; it is the impact on **quality of life** and care complexity that matters.- Since this patient is on **stable treatment** and well-controlled, the burden of multimorbidity is currently considered low.*A 45-year-old woman with asthma and hypothyroidism managed in specialist clinics*- Management in **specialist clinics** suggests that her current care arrangements are effectively addressing her specific medical needs.- There is no evidence of **functional impairment** or difficulty in managing the treatment burden that would necessitate a primary care-led multimorbidity review.*A 70-year-old man with hypertension, hyperlipidaemia, and osteoarthritis who manages independently*- **Managing independently** is a key indicator that the patient's current health status does not require a formal, resource-intensive structured assessment.- While he has multimorbidity, the lack of **frequent unplanned care** or significant functional loss means he does not meet the priority criteria for NG56 intervention.

Question 66: During a structured medication review using the STOPP/START criteria, you assess a 78-year-old man with heart failure (LVEF 38%), type 2 diabetes, benign prostatic hyperplasia, and recurrent lower urinary tract symptoms. His medications include bisoprolol, ramipril, furosemide, spironolactone, metformin, gliclazide, tamsulosin, and tolterodine 4mg BD which was started 3 months ago for urinary urgency. Since starting tolterodine, he reports worsening urinary hesitancy and has not noticed improvement in urgency. What is the most appropriate action according to STOPP/START criteria?

A. Increase tolterodine dose to 4mg three times daily for better symptom control
B. Continue tolterodine but add finasteride for benign prostatic hyperplasia
C. Stop tolterodine as antimuscarinic drugs worsen bladder outflow obstruction (Correct Answer)
D. Switch tolterodine to solifenacin which has fewer anticholinergic effects
E. Continue tolterodine but reduce tamsulosin dose to minimize interaction

Explanation: ***Stop tolterodine as antimuscarinic drugs worsen bladder outflow obstruction***- Tolterodine is an **antimuscarinic agent** that relaxes the detrusor muscle, which can worsen **bladder outflow obstruction** in patients with **benign prostatic hyperplasia (BPH)**.- The patient's **worsening urinary hesitancy** and lack of improvement in urgency since starting tolterodine clearly indicate an adverse effect, consistent with **STOPP criteria** to avoid anticholinergics in **BPH**.*Increase tolterodine dose to 4mg three times daily for better symptom control*- Increasing the dose of an antimuscarinic in a patient with **BPH** and worsening hesitancy would further inhibit detrusor contraction and increase the risk of **acute urinary retention**.- Since the current dose has not improved urgency and has worsened hesitancy over 3 months, further dose escalation is contraindicated and unsafe.*Continue tolterodine but add finasteride for benign prostatic hyperplasia*- Adding **finasteride**, a 5-alpha reductase inhibitor, primarily reduces prostate size over several months and does not address the immediate **bladder outflow obstruction** exacerbated by tolterodine.- The priority is to discontinue a medication that is actively causing harm or worsening symptoms before introducing new agents.*Switch tolterodine to solifenacin which has fewer anticholinergic effects*- **Solifenacin** is also an **antimuscarinic agent**, sharing the same mechanism of action as tolterodine, and therefore carries similar risks of worsening **bladder outflow obstruction** in BPH.- While solifenacin might have a different side effect profile, it does not resolve the fundamental contraindication of using this drug class in patients with significant **prostatism** according to **STOPP criteria**.*Continue tolterodine but reduce tamsulosin dose to minimize interaction*- **Tamsulosin** is an alpha-blocker used to improve urine flow in **BPH** by relaxing prostatic smooth muscle, directly opposing the effect of bladder outflow obstruction.- Reducing tamsulosin would likely worsen the patient's **bladder outflow obstruction** and increase the risk of urinary retention, contradicting the goal of improving voiding. There's no significant harmful interaction necessitating tamsulosin dose reduction in this context.

Question 67: A 72-year-old woman attends for her annual medication review. She has rheumatoid arthritis, type 2 diabetes, hypertension, and recurrent urinary tract infections. Her current medications include methotrexate 15mg weekly, folic acid 5mg weekly, prednisolone 5mg daily, metformin 1g BD, ramipril 5mg daily, amlodipine 5mg daily, and atorvastatin 40mg at night. She mentions she takes cranberry supplements daily to prevent UTIs. What is the most important medication safety concern to address?

A. Methotrexate should be taken daily rather than weekly with folic acid
B. Prednisolone dose should be taken on alternate days to reduce side effects
C. Metformin and ramipril combination increases risk of lactic acidosis
D. Cranberry supplements may interact with atorvastatin increasing myopathy risk (Correct Answer)
E. Folic acid should be taken on the same day as methotrexate for optimal effect

Explanation: ***Cranberry supplements may interact with atorvastatin increasing myopathy risk*** - **Cranberry products** can inhibit **Cytochrome P450 enzymes** (specifically CYP3A4), which are responsible for the metabolism of **atorvastatin**. - This inhibition leads to increased plasma concentrations of the statin, significantly raising the risk of **statin-induced myopathy** and **rhabdomyolysis**. *Methotrexate should be taken daily rather than weekly with folic acid* - **Methotrexate** must be taken **once weekly** for rheumatoid arthritis; daily dosing is a dangerous error that can lead to fatal **bone marrow suppression**. - The patient's current regimen of 15mg weekly is correct and safe, so this is not a concern to address. *Prednisolone dose should be taken on alternate days to reduce side effects* - **Prednisolone 5mg daily** is a standard, low-dose maintenance therapy for **rheumatoid arthritis** and is generally well-tolerated. - While alternate-day dosing can reduce **HP-axis suppression**, daily dosing is the conventional clinical practice for managing symptomatic RA flare prevention. *Metformin and ramipril combination increases risk of lactic acidosis* - There is no specific direct interaction between **Metformin** and **Ramipril** that increases the risk of **lactic acidosis**. - The primary risk for metformin-induced lactic acidosis is **renal impairment**, which requires monitoring but is not exacerbated specifically by the presence of an ACE inhibitor alone. *Folic acid should be taken on the same day as methotrexate for optimal effect* - **Folic acid** should be taken **at least 24 hours after** the methotrexate dose to avoid reducing its therapeutic efficacy. - Taking it on the same day can function as an antidote, potentially preventing the **methotrexate** from effectively treating the arthritis symptoms.

Question 68: A 67-year-old man with multimorbidity attends for a medication review. He has type 2 diabetes, ischaemic heart disease, hypertension, and chronic kidney disease stage 3b (eGFR 38 ml/min/1.73m²). He takes 10 regular medications. He reports feeling dizzy on standing and has had two falls in the past month. His sitting blood pressure is 118/68 mmHg, standing blood pressure 95/55 mmHg. His most recent HbA1c is 48 mmol/mol. Which medication class is the highest priority to review and potentially reduce in this clinical scenario?

A. Antihypertensive agents (Correct Answer)
B. Antiplatelet therapy
C. Proton pump inhibitors
D. Statins
E. Metformin

Explanation: ***Antihypertensive agents*** - The patient exhibits symptomatic **orthostatic hypotension**, with a 23 mmHg systolic drop upon standing, which is the direct cause of his reported **dizziness** and **falls**. - Given his multimorbidity, current polypharmacy, and well-controlled sitting blood pressure, reviewing and reducing antihypertensive medication is the highest priority to improve safety and prevent further injury from falls. *Antiplatelet therapy* - **Antiplatelet agents** are crucial for the **secondary prevention** of cardiovascular events in patients with ischaemic heart disease and do not typically induce **orthostatic hypotension**. - Discontinuing this therapy would significantly increase the risk of serious **thrombotic events** without addressing the patient's immediate fall risk. *Proton pump inhibitors* - **Proton pump inhibitors (PPIs)** are used for gastric protection and do not have any direct hemodynamic effects that would contribute to **orthostatic hypotension** or falls. - While often a target for **deprescribing** in polypharmacy, they are not implicated in the acute symptoms of dizziness and recurrent falls observed. *Statins* - **Statins** are essential medications for managing **ischaemic heart disease** to lower cholesterol and reduce cardiovascular risk, and they are not known to cause **orthostatic hypotension**. - Removing statin therapy would increase the risk of future **cardiovascular events** and would not alleviate the current issue of postural dizziness and falls. *Metformin* - **Metformin** is a first-line agent for **type 2 diabetes** and does not typically cause **hypotension** or **orthostatic dizziness**. - The patient's HbA1c is well-controlled, and Metformin is not responsible for the significant postural blood pressure drop observed.

Question 69: A 70-year-old woman presents for a routine chronic disease review. She has five long-term conditions: type 2 diabetes mellitus, hypertension, osteoarthritis, hypothyroidism, and depression. She takes 9 regular medications and reports good adherence. Her HbA1c is 52 mmol/mol, blood pressure 138/82 mmHg, and she feels generally well. According to current best practice guidance for managing patients with multimorbidity, what is the most appropriate approach to her ongoing care?

A. Refer to secondary care for specialist multimorbidity clinic assessment
B. Focus consultations on single disease targets to optimize each condition
C. Adopt a holistic approach prioritizing patient preferences and treatment burden (Correct Answer)
D. Increase monitoring frequency to monthly reviews given multiple conditions
E. Add additional preventative medications to reduce future complication risk

Explanation: ***Adopt a holistic approach prioritizing patient preferences and treatment burden*** - For patients with **multimorbidity** (the presence of two or more long-term conditions), best practice guidance, such as **NICE NG56**, emphasizes shifting from single-disease frameworks to **patient-centered care**. - This approach focuses on improving **quality of life** by identifying what matters most to the patient, reducing **polypharmacy**, and managing the collective **treatment burden** of multiple medications. *Refer to secondary care for specialist multimorbidity clinic assessment* - Managing multimorbidity is a core function of **Primary Care**; most stable patients do not require specialist clinics for multi-system management. - Referral is only indicated for highly complex cases where **clinical interactions** between conditions cannot be safely managed in general practice. *Focus consultations on single disease targets to optimize each condition* - Following multiple single-disease guidelines can lead to **inappropriate polypharmacy** and contradictory treatment goals in elderly patients. - Prioritizing **individualized targets** over rigid clinical markers helps avoid over-treatment and reduces the risk of **adverse drug reactions**. *Increase monitoring frequency to monthly reviews given multiple conditions* - Frequent monitoring increases the **treatment burden** and can negatively impact the patient's lifestyle and well-being without clear clinical benefit. - When conditions are **clinically stable** (as indicated by her HbA1c and BP), reviews should be scheduled based on necessity rather than a fixed, high-frequency interval. *Add additional preventative medications to reduce future complication risk* - Adding more drugs increases the risk of **non-adherence** and **drug-drug interactions**, which is a significant concern for a patient already taking **9 regular medications**. - Best practice focuses on **deprescribing** and rationalizing medication rather than reflexively adding preventative agents in the context of high polypharmacy.

Question 70: A 75-year-old man with ischaemic heart disease, heart failure (NYHA class II), type 2 diabetes, COPD, and chronic kidney disease stage 3b takes 11 regular medications. During a comprehensive medication review, you use the Medicines Optimisation principles from the Royal Pharmaceutical Society. You have already ensured he understands why he takes each medicine (Principle 1) and that he chooses medicines based on conversations about what matters to him (Principle 2). You are now addressing whether each medicine is working optimally (Principle 3). His recent blood tests show: HbA1c 64 mmol/mol, eGFR 38 ml/min/1.73m², NT-proBNP 680 ng/L (previously 420 ng/L 6 months ago), and BP 146/88 mmHg. Which single parameter most urgently requires medication optimization?

A. Blood pressure control
B. Glycaemic control
C. Heart failure status (Correct Answer)
D. Proteinuria monitoring
E. Renal function

Explanation: ***Heart failure status*** - The significant rise in **NT-proBNP** from 420 to 680 ng/L indicates **deteriorating heart failure** and an increased risk of hospitalization or mortality. - **Medicines optimization** (Principle 3) is urgent here to ensure the patient is on the maximal tolerated doses of **prognostic medications** such as ACE inhibitors, beta-blockers, and SGLT2 inhibitors. *Blood pressure control* - A blood pressure of **146/88 mmHg** is above the ideal target but does not represent an **acute clinical risk** compared to heart failure progression. - Blood pressure will often improve as a secondary benefit when **heart failure medications** (like SGLT2 inhibitors or RAAS blockers) are optimized. *Glycaemic control* - An **HbA1c of 64 mmol/mol** is slightly above the typical target of 58 mmol/mol but does not constitute a **glycaemic emergency**. - For a 75-year-old with **multimorbidity**, overly tight glycaemic control is often avoided to prevent the high risk of **hypoglycaemia**. *Proteinuria monitoring* - While monitoring for **proteinuria** is a standard part of **CKD management**, it is a screening/staging tool rather than a parameter needing urgent medication change in this context. - The current clinical focus must remain on the **hemodynamic stability** indicated by the rising cardiac biomarkers. *Renal function* - An **eGFR of 38 ml/min/1.73m²** matches the patient's known diagnosis of **CKD stage 3b** and appears stable. - While renal function must be monitored when adjusting heart failure drugs, it is the **rising NT-proBNP**, not the baseline eGFR, that triggers the need for immediate intervention.

Question 71: A practice pharmacist conducts an audit of patients aged over 75 taking 10 or more regular medications. She identifies that 22% are taking a benzodiazepine or Z-drug for more than 4 weeks, and 15% are taking a non-steroidal anti-inflammatory drug regularly. The practice decides to implement a targeted deprescribing program. According to evidence on deprescribing interventions in primary care, which single approach is most likely to achieve successful and sustained medication discontinuation?

A. Practice nurse telephoning patients to discuss stopping problematic medications
B. GP sending personalized letter to each patient recommending medication review
C. Pharmacist conducting face-to-face structured medication reviews with patients (Correct Answer)
D. Pharmacist sending educational leaflets about medication risks to identified patients
E. System-generated alerts in electronic medical records when prescribing these medications

Explanation: ***Pharmacist conducting face-to-face structured medication reviews with patients*** - **Pharmacist-led structured reviews** are the most effective intervention for sustained **deprescribing**, as they allow for comprehensive assessment, **shared decision-making**, and development of **individualized tapering plans**. - This approach facilitates addressing patient fears, managing **withdrawal symptoms**, and ensuring follow-up, which yields higher success rates than passive methods. *Practice nurse telephoning patients to discuss stopping problematic medications* - While useful for initial outreach, **telephone consultations** may lack the depth of engagement and comprehensive assessment required for complex deprescribing of long-term medications. - Success in stopping chronic medications like **benzodiazepines** often requires the specialized pharmacological knowledge and systematic approach typically associated with **clinical pharmacists** in face-to-face settings. *GP sending personalized letter to each patient recommending medication review* - **Personalized letters** are a form of **passive intervention** that, while identifying a potential issue, often result in **low patient engagement** and minimal behavior change without direct interaction. - A letter alone does not provide the crucial **clinical support**, patient education, or monitoring necessary to safely navigate the **withdrawal symptoms** or address psychological dependence associated with deprescribing. *Pharmacist sending educational leaflets about medication risks to identified patients* - **Educational leaflets** used in isolation are considered a **passive strategy** and have been shown to have limited impact on actual medication cessation and **long-term discontinuation**. - Evidence suggests that providing information without a **structured clinical intervention**, personalized plan, or direct patient interaction rarely leads to successful changes in chronic medication use. *System-generated alerts in electronic medical records when prescribing these medications* - **Electronic alerts** are primarily effective for preventing **new inappropriate prescriptions** or flagging *current* problematic prescribing, rather than actively *deprescribing* established, long-term medications. - These alerts are often subject to **alert fatigue** and do not address the crucial **patient-side barriers** such as motivation, fears, or the need for a personalized tapering plan.

Question 72: A 67-year-old woman with heart failure (LVEF 38%), atrial fibrillation, type 2 diabetes, and depression attends for medication review. She takes bisoprolol 5mg once daily, ramipril 10mg once daily, furosemide 40mg once daily, spironolactone 25mg once daily, apixaban 5mg twice daily, metformin 500mg twice daily, empagliflozin 10mg once daily, and sertraline 50mg once daily. She reports significant fatigue limiting her daily activities and wonders if her tablets might be responsible. Her BP is 118/72 mmHg, pulse 58/min, and recent bloods show: Na+ 140 mmol/L, K+ 4.4 mmol/L, creatinine 94 µmol/L (eGFR 58 ml/min/1.73m²), HbA1c 52 mmol/mol, TSH 3.2 mU/L, Hb 118 g/L. Which single medication is most likely contributing to her fatigue?

A. Apixaban
B. Bisoprolol (Correct Answer)
C. Ramipril
D. Empagliflozin
E. Sertraline

Explanation: ***Bisoprolol*** - **Beta-blockers** like bisoprolol are notorious for causing **fatigue**, lethargy, and reduced exercise tolerance by limiting peak cardiac output. - Her heart rate of **58/min** is near the lower clinical limit, suggesting the current dose may be excessive for her metabolic needs and causing symptomatic **bradycardia**. *Apixaban* - As a **Direct Oral Anticoagulant (DOAC)**, apixaban is generally well-tolerated and is not classically associated with systemic fatigue. - While it can increase bleeding risk leading to **anemia**, this patient's **hemoglobin (118 g/L)** is near-normal and does not explain her significant exhaustion. *Ramipril* - **ACE inhibitors** are more frequently associated with a dry cough or **hypotension** rather than isolated fatigue. - The patient's blood pressure of **118/72 mmHg** is within a healthy range for heart failure and does not suggest the fatigue is due to **low perfusion pressure**. *Empagliflozin* - **SGLT2 inhibitors** typically improve heart failure symptoms; their primary side effects are **urinary tract infections** and volume depletion. - There is no clinical evidence of **dehydration** or electrolyte imbalance (sodium and creatinine are normal) to suggest this is causing her fatigue. *Sertraline* - While **SSRIs** can cause initial somnolence, they are often used to treat the lethargy associated with **depression**. - Her fatigue is specifically limiting her daily activities and occurred in the context of heart failure medications, making a pharmacological **beta-blockade** effect more likely than the antidepressant.

Question 73: A 76-year-old man with Parkinson's disease, type 2 diabetes, and benign prostatic hyperplasia takes co-careldopa 25/100mg four times daily, pramipexole 0.88mg three times daily, metformin 500mg twice daily, gliclazide 40mg twice daily, tamsulosin 400mcg once daily, and finasteride 5mg once daily. He presents with visual hallucinations and paranoid ideation that developed over 2 weeks. His wife reports he is also more confused. Examination shows BP 106/68 mmHg, pulse 78/min regular, temperature 36.8°C. Capillary blood glucose is 7.2 mmol/L. Neurological examination shows stable Parkinsonian features. What is the single most appropriate initial medication management?

A. Reduce co-careldopa to three times daily dosing
B. Reduce gliclazide dose to 40mg once daily
C. Stop tamsulosin
D. Reduce pramipexole to 0.88mg twice daily (Correct Answer)
E. Stop finasteride

Explanation: ***Reduce pramipexole to 0.88mg twice daily*** - In patients with Parkinson's presenting with **hallucinations**, the standard management is to reduce or stop medications in a specific order, prioritising the withdrawal of **dopamine agonists** like **pramipexole** before levodopa. - **Pramipexole** is more frequently associated with **neuropsychiatric side effects** (confusion, paranoia, and visual hallucinations) in the elderly compared to levodopa-based treatments. *Reduce co-careldopa to three times daily dosing* - **Levodopa** (co-careldopa) is the most effective drug for motor symptom control and should be the **last medication** to be reduced or stopped. - Reducing it prematurely could lead to significant **motor deterioration** while leaving the more likely culprit (the dopamine agonist) unchanged. *Reduce gliclazide dose to 40mg once daily* - **Gliclazide** can cause confusion secondary to **hypoglycemia**; however, this patient's capillary blood glucose is **7.2 mmol/L**, which is within the normal range. - There is no clinical indication that **sulfonylurea** toxicity is the driver of his acute paranoid ideation and hallucinations. *Stop tamsulosin* - While **tamsulosin** can cause orthostatic hypotension, it is rarely the primary cause of complex **visual hallucinations** and paranoid ideation. - **Anticholinergic** medications used for bladder issues are more likely to cause confusion, but the **dopamine agonist** remains a much stronger suspect for psychosis. *Stop finasteride* - **Finasteride** is a 5-alpha reductase inhibitor with few **psychiatric side effects**; it is not a recognized cause of acute visual hallucinations in this clinical context. - The management of Parkinson-related psychosis focuses on **dopaminergic modulation**, making the discontinuation of this BPH medication inappropriate as an initial step.

Question 74: During a practice-based quality improvement project, you are reviewing patients with multimorbidity taking 10 or more medications. You identify a 72-year-old man taking 14 medications including multiple cardiovascular drugs, metformin, and medications for BPH, GORD, and insomnia. He reports poor quality of life and feeling 'overwhelmed' by his tablets. When applying the principles of realistic medicine and shared decision-making for multimorbidity, what approach should be prioritized?

A. Apply STOPP/START criteria systematically to identify inappropriate medications
B. Calculate anticholinergic burden score and deprescribe high-risk medications first
C. Explore what matters most to the patient and align treatment with his priorities (Correct Answer)
D. Reduce medication burden by switching to combination products where possible
E. Review each condition separately against relevant clinical guidelines

Explanation: ***Explore what matters most to the patient and align treatment with his priorities*** - In the context of **multimorbidity** and **realistic medicine**, the primary goal is to shift from a disease-centered to a **patient-centered approach** that prioritizes the individual's values. - Since the patient feels **overwhelmed** and reports **poor quality of life**, identifying his specific goals is the essential first step to guide **shared decision-making** and subsequent **deprescribing**. *Apply STOPP/START criteria systematically to identify inappropriate medications* - The **STOPP/START criteria** are useful evidence-based tools for identifying potentially inappropriate medications in older adults but are secondary to the patient's own priorities. - Relying solely on a systematic tool fails to address the patient's reported feeling of being **overwhelmed** by the **treatment burden** and individual preferences. *Calculate anticholinergic burden score and deprescribe high-risk medications first* - Calculating the **anticholinergic burden** is a specific technical maneuver to reduce risk (e.g., falls, cognitive decline) but does not encompass the holistic requirements of **realistic medicine**. - This approach addresses safety but may not address the medications the patient finds most burdensome or least beneficial to his **quality of life**. *Reduce medication burden by switching to combination products where possible* - While **combination products** may reduce the number of physical pills, they do not necessarily reduce the **polypharmacy burden** or the biological complexity of the treatment regimen. - This is a technical solution for **adherence** that bypasses the necessary discussion regarding whether the drugs are desired or medically necessary for this specific patient, failing to address his feeling of being **overwhelmed**. *Review each condition separately against relevant clinical guidelines* - Traditional **single-disease guidelines** often conflict in multimorbid patients, leading to **polypharmacy** and potential harm from drug-drug or drug-disease interactions. - This approach is the antithesis of **realistic medicine**, as it prioritizes clinical metric targets over the patient's overall **functional status** and preference.

Question 75: A 70-year-old woman with rheumatoid arthritis, hypertension, chronic kidney disease stage 3a, and osteoporosis attends for review. She takes methotrexate 15mg weekly, folic acid 5mg weekly, hydroxychloroquine 200mg twice daily, prednisolone 5mg once daily, alendronic acid 70mg weekly, calcium and vitamin D, ramipril 5mg once daily, and amlodipine 5mg once daily. She reports feeling generally well but has developed peripheral oedema. Blood tests show: Na+ 142 mmol/L, K+ 4.6 mmol/L, creatinine 118 µmol/L (eGFR 46 ml/min/1.73m², previously 52), albumin 38 g/L. Urinalysis shows protein ++. What is the most appropriate next investigation to guide medication review?

A. 24-hour urinary protein quantification
B. Echocardiogram to assess cardiac function
C. Renal ultrasound scan
D. Serum methotrexate level
E. Urine albumin:creatinine ratio (Correct Answer)

Explanation: ***Urine albumin:creatinine ratio***- The **Urine albumin:creatinine ratio (uACR)** is the preferred first-line test according to **NICE guidelines** for the quantification of **proteinuria** in chronic kidney disease (CKD).- Assessing the severity of proteinuria is critical here to guide the adjustment of potentially nephrotoxic medications like **methotrexate** and to manage her **declining eGFR**.*24-hour urinary protein quantification*- This method is cumbersome for patients and has largely been replaced by **spot uACR** or **uPCR** in routine clinical practice for quantifying proteinuria.- It does not offer significant clinical advantages over the more convenient **uACR** for initial medication review and risk stratification.*Echocardiogram to assess cardiac function*- While **peripheral oedema** can indicate heart failure, the presence of **proteinuria (++ on dipstick)** and a decrease in **eGFR** more directly points toward a renal cause.- An echocardiogram would be indicated if there were symptoms like orthopnoea or paroxysmal nocturnal dyspnoea, rather than as a primary tool for drug-induced nephrotoxicity review.*Renal ultrasound scan*- **Renal ultrasound** is useful for assessing kidney size and excluding **obstruction**, but it does not quantify the degree of protein leak or functional damage.- It is generally reserved for patients with rapid declines in eGFR, visible **haematuria**, or suspected structural abnormalities rather than initial protein quantification.*Serum methotrexate level*- **Serum methotrexate levels** are used to monitor toxicity in high-dose oncology regimens but are not routinely measured for patients on low-dose **weekly methotrexate** for rheumatoid arthritis.- Monitoring for methotrexate toxicity in primary care involves regular **Full Blood Count (FBC)** and **Liver/Renal function tests**, rather than serum concentrations.

Question 76: A 68-year-old man with ischaemic heart disease, type 2 diabetes, COPD, and gastro-oesophageal reflux disease is taking aspirin 75mg, atorvastatin 80mg, bisoprolol 2.5mg, ramipril 5mg, metformin 1g twice daily, tiotropium inhaler, salbutamol inhaler, and lansoprazole 30mg once daily. He has been on this regimen for 3 years. At a medication review, you consider deprescribing the lansoprazole as there is no clear ongoing indication. According to evidence-based deprescribing principles, what is the most appropriate approach to stopping the proton pump inhibitor?

A. Advise patient to stop immediately and contact the surgery if symptoms develop
B. Gradually reduce lansoprazole by 50% every 2 weeks before stopping completely
C. Gradually reduce lansoprazole dose over 4-6 weeks and switch to alginate therapy (Correct Answer)
D. Stop lansoprazole and replace with ranitidine 150mg twice daily for 2 weeks
E. Switch to on-demand lansoprazole 30mg when symptoms occur

Explanation: ***Gradually reduce lansoprazole dose over 4-6 weeks and switch to alginate therapy*** - Long-term **proton pump inhibitor (PPI)** use leads to **rebound acid hypersecretion** due to gastrin elevation, making a gradual taper essential to prevent symptom flare-ups. - A structured reduction (e.g., halving the dose for several weeks) combined with **alginate therapy** or **on-demand** use manages breakthrough symptoms and improves the success rate of deprescribing. *Advise patient to stop immediately and contact the surgery if symptoms develop* - **Abrupt cessation** of long-term PPIs frequently causes sudden rebound dyspepsia, which the patient may misinterpret as a return of their original condition. - This approach has a higher failure rate and often leads to the **unnecessary restarting** of the medication. *Gradually reduce lansoprazole by 50% every 2 weeks before stopping completely* - While tapering is correct, a 2-week total reduction period is often **too rapid** for someone who has been on the medication for several years. - Current evidence-based guidelines generally recommend a more prolonged **4-to-8 week tapering window** to minimize the physiological effects of hypergastrinemia. *Stop lansoprazole and replace with ranitidine 150mg twice daily for 2 weeks* - **Ranitidine** and other H2-receptor antagonists are largely unavailable or withdrawn in many markets due to **NDMA contamination** concerns. - Switching to another daily acid suppressant does not effectively facilitate the goal of **deprescribing** and physiological adjustment. *Switch to on-demand lansoprazole 30mg when symptoms occur* - Moving directly to on-demand use from a high-dose daily regimen without a **step-down phase** often fails due to the severity of rebound symptoms. - On-demand therapy is better utilized as the **final stage** of a tapering protocol rather than the initial step for a patient on long-term therapy.

Question 77: A 73-year-old woman attends with her daughter who reports her mother has become increasingly confused over the past month. She has type 2 diabetes, hypertension, depression, and overactive bladder. Her medications include: metformin 500mg twice daily, gliclazide 80mg twice daily, ramipril 5mg once daily, amlodipine 5mg once daily, citalopram 20mg once daily, oxybutynin 5mg three times daily, and recently started amitriptyline 25mg at night for neuropathic pain. Cognitive screening shows AMTS 6/10. Blood glucose monitoring shows readings 4.2-6.8 mmol/L. What is the single most likely medication-related cause of her cognitive decline?

A. Anticholinergic burden from combination of oxybutynin and amitriptyline (Correct Answer)
B. Cerebral hypoperfusion from ramipril and amlodipine combination
C. Hypoglycaemia from combination of metformin and gliclazide
D. Hyponatraemia secondary to citalopram
E. Worsening depression inadequately treated with current citalopram dose

Explanation: ***Anticholinergic burden from combination of oxybutynin and amitriptyline***- Elderly patients are highly sensitive to medications with **anticholinergic activity**, and the cumulative effect of **oxybutynin** and the recently added **amitriptyline** significantly increases the risk of delirium and cognitive impairment.- **Amitriptyline** and **oxybutynin** both cross the blood-brain barrier, leading to central adverse effects such as **confusion**, memory loss, and a reduced **AMTS** score.*Cerebral hypoperfusion from ramipril and amlodipine combination*- While antihypertensives can cause **postural hypotension** and falls in the elderly, they are less likely to cause a subacute 1-month progressive cognitive decline without associated syncopal or presyncopal symptoms.- The patient's primary issue is **confusion** rather than physical instability or documented **orthostatic hypotension**.*Hypoglycaemia from combination of metformin and gliclazide*- The provided blood glucose monitoring results (4.2-6.8 mmol/L) are within a **safe range**, making symptomatic **hypoglycaemia** an unlikely cause for the confusion.- **Metformin** itself does not typically cause hypoglycemia, and while **gliclazide** (a sulfonylurea) can, the readings do not support it in this scenario.*Hyponatraemia secondary to citalopram*- **SSRIs** like **citalopram** are known causes of **SIADH** and subsequent **hyponatraemia** in the elderly, which can present as confusion.- However, the pharmacological addition of **amitriptyline** recently makes the **anticholinergic burden** a more immediate and likely culprit for the acute-on-chronic change.*Worsening depression inadequately treated with current citalopram dose*- While **pseudodementia** (depression presenting as cognitive loss) is possible, the temporal relationship between starting a new **highly anticholinergic medication** (amitriptyline) and the onset of confusion points toward a drug side effect.- In any elderly patient with new-onset confusion, **medication review** for adverse drug-drug interactions is the priority over assuming a primary psychiatric decline.

Question 78: According to the Royal Pharmaceutical Society's guidance on structured medication reviews in primary care, which single patient group should be prioritized for medication review in a general practice setting?

A. All patients aged 65 years and over taking 5 or more regular medications
B. All patients with a single long-term condition requiring hospital admission in the past year
C. Patients experiencing harm or at high risk of harm from medications (Correct Answer)
D. Patients requesting medication reviews due to side effects
E. Patients with newly diagnosed chronic conditions requiring medication initiation

Explanation: ***Patients experiencing harm or at high risk of harm from medications*** - The **Royal Pharmaceutical Society (RPS)** guidance on **structured medication reviews (SMRs)** prioritizes patients based on their **clinical risk of harm** from medications. - This includes individuals with **polypharmacy** (often 10+ medications), **severe frailty**, or those taking drugs with a **narrow therapeutic index**, where the potential for adverse drug reactions or medication errors is highest. *All patients aged 65 years and over taking 5 or more regular medications* - While **age over 65** and **polypharmacy** are known risk factors for medication-related problems, the RPS emphasizes a **risk-stratified approach** rather than solely relying on arbitrary age or medication count thresholds. - Many patients in this demographic may be stable, whereas others, irrespective of age, with **complex multimorbidity** or **deteriorating renal function**, might be at higher clinical risk. *All patients with a single long-term condition requiring hospital admission in the past year* - A recent **unplanned hospital admission** is a significant trigger for review, but the **RPS guidance** specifically focuses on **multimorbidity** and the complexity of medication regimens as key drivers of risk. - The priority group targets situations where **medication complexity** or specific drug-related issues are likely contributing to the patient's instability or readmission risk, rather than any single long-term condition. *Patients requesting medication reviews due to side effects* - Patient-initiated concerns, especially regarding **side effects**, are crucial for **patient-centered care** and must be addressed clinically; however, they do not automatically place a patient in the highest **population-level priority** for structured reviews. - The SMR framework aims for a **proactive identification** of high-risk individuals through risk stratification, not solely a reactive response to patient requests, unless the reported harm is severe. *Patients with newly diagnosed chronic conditions requiring medication initiation* - Patients starting new medications for **chronic conditions** require careful prescribing and initial follow-up, which is typically covered by standard clinical consultations and services such as the **New Medicine Service (NMS)**. - **Structured medication reviews** are primarily designed for the **optimization and deprescribing** of established, often complex regimens in patients with long-standing medication use and potential accumulated risks.

Question 79: A 66-year-old man attends for an annual review. He has hypertension, type 2 diabetes, dyslipidaemia, and obstructive sleep apnoea. His BMI is 38 kg/m². He takes ramipril 10mg once daily, amlodipine 10mg once daily, metformin 1g twice daily, gliclazide 160mg twice daily, atorvastatin 80mg at night, and uses CPAP nightly. Recent results show: BP 162/96 mmHg (average of 3 readings), HbA1c 76 mmol/mol, total cholesterol 5.8 mmol/L, eGFR 64 ml/min/1.73m². He reports good medication adherence. According to NICE guidance on managing multimorbidity, what is the most appropriate next step in his management?

A. Add dapagliflozin for additional cardiovascular and glycaemic benefit
B. Add indapamide for blood pressure control
C. Initiate insulin therapy to improve glycaemic control
D. Refer to weight management service and review treatment plan in 3 months (Correct Answer)
E. Switch gliclazide to sitagliptin to reduce hypoglycaemia risk

Explanation: ***Refer to weight management service and review treatment plan in 3 months*** - According to **NICE NG56** on multimorbidity, the priority is to address common **modifiable risk factors** like obesity (BMI 38 kg/m²) that adversely impact all his conditions simultaneously. - This approach aims to reduce **treatment burden** and polypharmacy by potentially improving blood pressure, glucose, and OSA through **lifestyle intervention** rather than simply adding more medications. *Add dapagliflozin for additional cardiovascular and glycaemic benefit* - While beneficial for type 2 diabetes and cardiovascular risk, adding an **SGLT2 inhibitor** increases the patient's existing medication burden. - The multimorbidity framework suggests prioritizing **non-pharmacological interventions** that address the root cause before intensifying drug therapy. *Add indapamide for blood pressure control* - Adding a **thiazide-like diuretic** is conventional for Step 3 hypertension treatment, but it ignores the patient's high BMI and the cumulative impact of multiple medications. - A **holistic review** of clinical priorities and weight management is preferred over siloed management of individual clinical targets. *Initiate insulin therapy to improve glycaemic control* - Insulin would likely lead to further **weight gain**, exacerbating both his obesity and **obstructive sleep apnoea**. - Transitioning to injectable therapy significantly increases **complexity of care**, which should be avoided in multimorbidity management if simpler lifestyle alternatives are available. *Switch gliclazide to sitagliptin to reduce hypoglycaemia risk* - While **DPP-4 inhibitors** have a lower hypo risk, there is no evidence the patient is currently experiencing hypoglycemia or that this switch would improve his **HbA1c of 76 mmol/mol**. - This represents a lateral shift in medication that does not address the fundamental issue of **metabolic syndrome** and obesity.

Question 80: A 77-year-old woman with atrial fibrillation, heart failure (LVEF 42%), type 2 diabetes, and hypertension is taking warfarin, bisoprolol, ramipril, furosemide, metformin, and atorvastatin. She presents with recurrent falls over the past 3 months, having fallen four times without clear precipitant. Her INR has been stable (range 2.2-2.8 over past 6 months), and her CHA₂DS₂-VASc score is 6. During assessment, her lying BP is 126/78 mmHg and standing BP is 98/64 mmHg. Her mobility is reduced due to fear of falling. What is the single most appropriate next management step regarding her medications?

A. Reduce bisoprolol dose and monitor blood pressure response
B. Reduce furosemide dose and monitor fluid balance
C. Reduce ramipril dose and monitor renal function
D. Switch from warfarin to apixaban
E. Undertake comprehensive medication review addressing all contributors to falls (Correct Answer)

Explanation: ***Undertake comprehensive medication review addressing all contributors to falls*** - The patient exhibits significant **orthostatic hypotension** (systolic drop of 28 mmHg) and is on multiple medications (**bisoprolol, ramipril, furosemide**) that contribute to this risk. - A **comprehensive medication review** is the standard of care for older adults with **recurrent falls** to evaluate polypharmacy, drug-drug interactions, and the overall benefit-risk ratio rather than adjusting drugs in isolation. *Reduce bisoprolol dose and monitor blood pressure response* - While **beta-blockers** can contribute to hypotension and falls, reducing this alone may be insufficient when several other agents are also involved. - Bisoprolol is essential for **rate control in atrial fibrillation** and managing **heart failure**, so it should only be altered as part of a holistic review. *Reduce furosemide dose and monitor fluid balance* - **Furosemide** can cause **volume depletion**, leading to orthostatic hypotension, but it is a critical component of her **heart failure** management. - Adjusting the diuretic without assessing other antihypertensives fails to address the combined **hypotensive effect** of her entire regimen. *Reduce ramipril dose and monitor renal function* - **ACE inhibitors** like **ramipril** are known causes of postural BP drops; however, simply reducing one drug does not tackle the underlying issue of **polypharmacy**. - This ignores the potential contribution of other drugs, such as **metformin** (hypoglycemia risk) or the diuretic, to the patient's instability. *Switch from warfarin to apixaban* - While **DOACs (apixaban)** have a lower risk of **intracranial hemorrhage** compared to warfarin, this switch does not address the actual cause of her **orthostatic falls**. - Clinical guidelines emphasize that a high **CHA₂DS₂-VASc score (6)** justifies anticoagulation, but focus must first be on preventing the mechanical cause of falling.

Question 81: During a structured medication review for a 69-year-old man taking 12 regular medications for multiple chronic conditions, you are applying the 7-Steps approach recommended by the General Medical Council. After identifying his current medications (Step 1) and determining which ones are essential, beneficial, or potentially harmful (Step 2), you identify that he is taking two proton pump inhibitors prescribed by different specialists. What is the next most appropriate step in the medication review process?

A. Calculate the patient's adherence rate using prescription collection data
B. Check for potential drug-drug interactions using the BNF (Correct Answer)
C. Contact both specialists to inform them of the duplication
D. Document the findings and arrange follow-up in 3 months
E. Stop one of the proton pump inhibitors immediately

Explanation: ***Check for potential drug-drug interactions using the BNF***- Step 3 of the **7-Steps approach** to medication review involves identifying **potential drug-drug interactions** and adverse drug reactions to ensure patient safety across the entire regimen.- Systematically checking for interactions, often using the **BNF**, must occur before tailoring or changing therapy, even if a clear duplication is found earlier.*Calculate the patient's adherence rate using prescription collection data*- Assessing **adherence** is a critical component of Step 4 (unnecessary medicines) or Step 5 (effectiveness), but is not the immediate priority after categorizing medications.- While collection data is useful, the **7-Steps framework** prioritizes safety and interaction screening (Step 3) before specific adherence audits.*Contact both specialists to inform them of the duplication*- Coordinating with specialists is part of **Step 7 (Communicate)**, which occurs at the end of the review process once all intended changes are finalized.- Communication is necessary for **integrated care**, but the clinical assessment must be completed before informing other clinicians of the proposed plan.*Document the findings and arrange follow-up in 3 months*- **Documentation** and monitoring represent the final stage (**Step 7**) of the structured review process and cannot replace the assessment steps.- Delaying the resolution of **polypharmacy** and duplication for three months would be inappropriate given the identified risk of dual PPI scripts.*Stop one of the proton pump inhibitors immediately*- Changes to therapy, such as **deprescribing**, should only occur in Step 5 (Optimisation) after discussing the clinical need and rationale with the patient in **Step 6**.- Stopping a medication immediately without completing the full **systematic safety assessment** or consulting the patient bypasses essential shared decision-making protocols.

Question 82: A 71-year-old woman with heart failure (NYHA class III), type 2 diabetes, and chronic kidney disease stage 3b attends for her six-monthly review. Her medications include bisoprolol 10mg once daily, ramipril 10mg once daily, spironolactone 25mg once daily, furosemide 80mg twice daily, metformin 500mg twice daily, empagliflozin 10mg once daily, and atorvastatin 40mg at night. Blood tests show: Na+ 136 mmol/L, K+ 5.8 mmol/L, urea 14.2 mmol/L, creatinine 168 µmol/L (eGFR 28 ml/min/1.73m²), HbA1c 58 mmol/mol. What is the single most appropriate immediate medication change?

A. Increase furosemide to 120mg twice daily
B. Reduce ramipril to 5mg once daily
C. Stop empagliflozin
D. Stop metformin
E. Stop spironolactone (Correct Answer)

Explanation: ***Stop spironolactone***- The patient has significant **hyperkalaemia** (K+ 5.8 mmol/L), which is a serious adverse effect exacerbated by spironolactone, a **potassium-sparing aldosterone antagonist**.- Given the patient's **reduced renal function** (eGFR 28 ml/min/1.73m²), spironolactone's potassium-sparing effect is amplified, necessitating immediate discontinuation to prevent life-threatening cardiac arrhythmias.*Increase furosemide to 120mg twice daily*- Increasing **furosemide**, a loop diuretic, would primarily address fluid overload, which is not highlighted as the most urgent issue, and would not directly correct **hyperkalaemia**.- A higher dose of furosemide could potentially lead to **volume depletion** and further worsen renal function, which is already compromised.*Reduce ramipril to 5mg once daily*- While **ACE inhibitors** like ramipril can contribute to hyperkalaemia, spironolactone is a more potent cause of potassium elevation, and discontinuing it should be the priority.- Ramipril is crucial for **cardioprotection** in heart failure and **renoprotection** in CKD; a dose reduction might be considered later if hyperkalaemia persists, but it is not the immediate, most appropriate change.*Stop empagliflozin*- **SGLT2 inhibitors** like empagliflozin have a low risk of causing hyperkalaemia and provide significant **cardio-renal protective benefits** in patients with heart failure and CKD, even at this eGFR.- Although its glucose-lowering efficacy reduces with lower eGFR, its benefits for **heart failure outcomes** typically warrant continuation until eGFR is much lower (e.g., <15 ml/min/1.73m²).*Stop metformin*- Metformin should be reviewed as the eGFR is below **30 ml/min/1.73m²** due to the risk of **lactic acidosis**, but it does not directly contribute to the patient's **hyperkalaemia**.- While metformin might need adjustment, addressing the immediate and potentially life-threatening hyperkalaemia caused by spironolactone takes precedence.

Question 83: A 74-year-old man with type 2 diabetes, hypertension, asthma, and osteoarthritis attends for a medication review. He takes 8 regular medications including metformin, gliclazide, ramipril, amlodipine, beclometasone/formoterol inhaler, salbutamol inhaler, ibuprofen 400mg three times daily, and omeprazole. He reports good control of his conditions but mentions occasional indigestion despite the omeprazole. His recent blood results show HbA1c 52 mmol/mol, eGFR 58 ml/min/1.73m², and blood pressure 138/82 mmHg. Which single medication would be most appropriate to stop first?

A. Ibuprofen (Correct Answer)
B. Metformin
C. Omeprazole
D. Amlodipine
E. Gliclazide

Explanation: ***Ibuprofen***- **Ibuprofen** should be stopped first because it is an **NSAID** which significantly increases the risk of **peptic ulceration** (suggested by persistent indigestion despite omeprazole) and **nephrotoxicity** in an elderly patient with an **eGFR of 58 ml/min/1.73m²**.- Chronic NSAID use can also exacerbate **asthma** and increase **cardiovascular risk**, making its discontinuation the most critical step in medication rationalization for this patient. *Metformin*- **Metformin** is a foundational medication for **Type 2 Diabetes**, and the patient's **HbA1c of 52 mmol/mol** indicates good glycemic control that should be maintained.- While **renal function** requires monitoring, metformin dose adjustment is typically considered when **eGFR falls below 45 ml/min/1.73m²**, which is not the case here. *Omeprazole*- **Omeprazole** is currently providing **gastroprotection** against the gastrointestinal side effects of **ibuprofen**.- Stopping omeprazole while the patient is still on a high-dose NSAID would significantly increase the risk of a **gastrointestinal bleed** or ulcer, making it an inappropriate first medication to discontinue. *Amlodipine*- **Amlodipine** is an effective **antihypertensive** medication, and the patient's blood pressure is currently well-controlled at **138/82 mmHg**.- There is no clinical indication that amlodipine is causing the patient's indigestion or contributing to renal decline, thus stopping it is not warranted. *Gliclazide*- **Gliclazide**, a sulfonylurea, is essential for maintaining the patient's **glycemic control** as indicated by his target **HbA1c of 52 mmol/mol**.- Discontinuing gliclazide without a clinical need could lead to a **loss of metabolic control** and **hyperglycemia**, which is detrimental for a diabetic patient.

Question 84: A 75-year-old woman with heart failure (LVEF 38%), atrial fibrillation, hypertension, type 2 diabetes, and depression takes 12 regular medications. She attends with her daughter who manages her medications using a dosette box filled weekly by the pharmacy. The daughter reports her mother has been admitted to hospital three times in the past year with heart failure exacerbations, and they struggle to manage all the medications. Her current quality of life is poor. During a comprehensive medication review, which framework would be MOST appropriate to facilitate shared decision-making about treatment priorities?

A. The QRISK3 cardiovascular risk calculator to quantify benefits of each medication
B. The Edmonton Frail Scale to assess frailty and determine which medications to stop
C. A patient-centred approach exploring the patient's goals, priorities, and what matters most to them (Correct Answer)
D. The Charlson Comorbidity Index to calculate life expectancy and stop preventative medications
E. The Rockwood Clinical Frailty Scale to categorize frailty level and adjust all medications accordingly

Explanation: ***A patient-centred approach exploring the patient's goals, priorities, and what matters most to them*** - This approach is crucial in **complex multimorbidity** and **polypharmacy**, especially when a patient's **quality of life** is poor and **treatment burden** is high, as it directly addresses their values and preferences. - It facilitates **shared decision-making** by focusing on what the patient and their family prioritize, whether it's symptom management, functional independence, or reducing medication load, rather than solely disease-specific guidelines. *The QRISK3 cardiovascular risk calculator to quantify benefits of each medication* - **QRISK3** is designed for **primary prevention** in a general population and has limited utility for a 75-year-old with established **heart failure** and multiple comorbidities. - It quantifies future risk but doesn't provide a framework for discussing current **treatment burden**, patient values, or making decisions about **deprescribing** in complex cases. *The Edmonton Frail Scale to assess frailty and determine which medications to stop* - While the **Edmonton Frail Scale** helps identify **frailty**, it is an assessment tool, not a framework for **shared decision-making** about treatment priorities. - Determining medication changes solely based on a frailty score overlooks the patient's personal **goals**, potential benefits of some medications, and the importance of a holistic discussion. *The Charlson Comorbidity Index to calculate life expectancy and stop preventative medications* - The **Charlson Comorbidity Index** predicts **mortality risk** based on comorbidities but does not provide a comprehensive framework for patient-centered **shared decision-making** regarding their current **quality of life** or treatment priorities. - Stopping preventative medications solely based on a predicted life expectancy without considering patient preferences can be inappropriate and misses the opportunity for a broader discussion about care goals. *The Rockwood Clinical Frailty Scale to categorize frailty level and adjust all medications accordingly* - The **Rockwood Clinical Frailty Scale** is an excellent tool for **categorizing frailty** and informing clinical judgment, but it's primarily an assessment tool. - It does not, on its own, provide a structured framework for a **shared decision-making conversation** about a patient's individual **goals** and priorities in the context of polypharmacy and multimorbidity.

Question 85: You are developing a practice protocol for identifying patients who would benefit from structured medication review. According to NHS England guidance and the Network Contract DES requirements, which patient group should be prioritized for structured medication reviews in primary care?

A. All patients taking any regular medication regardless of age or number of conditions
B. Patients aged 75 years and over taking 5 or more medications, or patients with problematic polypharmacy (Correct Answer)
C. Only patients with dementia taking any regular medications
D. Patients aged 65 years and over taking 3 or more medications
E. Only patients who request a medication review themselves

Explanation: ***Patients aged 75 years and over taking 5 or more medications, or patients with problematic polypharmacy*** - According to **NHS England guidance** and the **Network Contract DES**, patients aged **75 years and over** taking **5 or more medications** are a top priority for **Structured Medication Reviews (SMR)** to reduce medication-related harm. - This cohort is specifically targeted to address **problematic polypharmacy**, where the risks of multiple medications may outweigh clinical benefits, necessitating a shared decision-making approach. *All patients taking any regular medication regardless of age or number of conditions* - This approach is not feasible or recommended as it does not **prioritize resources** towards those at the highest risk of **adverse drug reactions** or **suboptimal medication use**. - **Structured Medication Reviews (SMRs)** are comprehensive clinical assessments meant for specific **high-risk groups**, not a universal screening tool for all prescribing. *Only patients with dementia taking any regular medications* - While patients with **dementia** or those in **care homes** are indeed a priority group within the broader SMR guidance, prioritizing them *exclusively* incorrectly omits other significant high-risk elderly populations. - The guidance encompasses a broader range of clinical vulnerabilities, including those with **frailty**, **complex multi-morbidity**, or recent hospital discharge, beyond just dementia. *Patients aged 65 years and over taking 3 or more medications* - This threshold is lower than the specific **NHS England criteria** for the primary SMR priority group, which defines it as those aged **75 and over** on **5 or more medications**. - Using a lower age or medication count would capture a much larger population than the **Network Contract DES requirements** currently mandate for structured clinical prioritization, potentially overstretching resources. *Only patients who request a medication review themselves* - **Structured Medication Reviews (SMRs)** must be **proactive and systematic**, identifying high-risk patients based on clinical data and agreed criteria rather than being purely **reactive** to patient requests. - Relying solely on patient requests would fail to identify many **vulnerable or frail** individuals who may not recognize or be able to articulate their need for a medication review.

Question 86: A 73-year-old man with Parkinson's disease, type 2 diabetes, benign prostatic hyperplasia, and gastro-oesophageal reflux takes co-careldopa 25/100mg four times daily, pramipexole 0.88mg three times daily, metformin 1g twice daily, tamsulosin 400 micrograms daily, and lansoprazole 30mg daily. His wife reports he has been experiencing vivid dreams, visual hallucinations of people in the house, and increased confusion over the past 3 months. His Parkinson's symptoms are well controlled. What is the MOST appropriate medication management strategy?

A. Stop co-careldopa immediately as it is the most common cause of psychosis in Parkinson's disease
B. Add quetiapine to manage the psychotic symptoms while continuing all Parkinson's medications
C. Gradually reduce and stop pramipexole as dopamine agonists commonly cause neuropsychiatric side effects (Correct Answer)
D. Increase co-careldopa dose to improve dopaminergic control and reduce psychotic symptoms
E. Stop tamsulosin as alpha-blockers can cause hallucinations in older adults

Explanation: ***Gradually reduce and stop pramipexole as dopamine agonists commonly cause neuropsychiatric side effects***- **Dopamine agonists** like **pramipexole** are more likely than levodopa to cause **neuropsychiatric adverse effects**, including **visual hallucinations**, confusion, and vivid dreams.- The management hierarchy for Parkinson's psychosis dictates withdrawing non-essential medications first; dopamine agonists should be **tapered gradually** to avoid **Dopamine Agonist Withdrawal Syndrome (DAWS)**.*Stop co-careldopa immediately as it is the most common cause of psychosis in Parkinson's disease*- **Levodopa (co-careldopa)** is actually the last medication to be reduced because it provides the best **motor symptom** control and is less frequently associated with psychosis than agonists.- Abrupt cessation of dopaminergic therapy can trigger **neuroleptic malignant-like syndrome**, a life-threatening complication.*Add quetiapine to manage the psychotic symptoms while continuing all Parkinson's medications*- While **quetiapine** or **clozapine** are used for Parkinson's psychosis, the first-line intervention must be the **reduction or withdrawal** of precipitating dopaminergic medications.- Adding more drugs increases the risk of **polypharmacy** and side effects before addressing the underlying pharmacological cause.*Increase co-careldopa dose to improve dopaminergic control and reduce psychotic symptoms*- Increasing the dopaminergic load will **exacerbate hallucinations** and confusion rather than treating them.- **Psychosis** in Parkinson's is typically a result of overstimulation of the **mesolimbic dopaminergic pathways**.*Stop tamsulosin as alpha-blockers can cause hallucinations in older adults*- **Tamsulosin** primarily acts on **alpha-1 receptors** in the bladder neck and is not a recognized cause of visual hallucinations.- The patient's symptoms are classic markers of **dopaminergic toxicity** rather than an adverse reaction to BPH treatment.

Question 87: During a practice audit of patients aged over 75 taking 10 or more regular medications, you identify that 22% are taking a proton pump inhibitor (PPI) long-term without documented indication. According to current evidence and guidance on deprescribing, which statement about long-term PPI use in older adults with polypharmacy is MOST accurate?

A. PPIs should never be stopped once started due to severe rebound acid hypersecretion causing gastric ulceration
B. Long-term PPI use is associated with increased risks of Clostridium difficile infection, osteoporotic fractures, and possible hypomagnesaemia (Correct Answer)
C. PPIs provide cardiovascular protection in patients taking aspirin and should be continued indefinitely in all patients over 75
D. Stopping PPIs requires hospital admission for gastroprotection monitoring
E. PPIs have no significant drug interactions and are safe indefinitely in all patients with polypharmacy

Explanation: ***Long-term PPI use is associated with increased risks of Clostridium difficile infection, osteoporotic fractures, and possible hypomagnesaemia*** - Prolonged use of **proton pump inhibitors (PPIs)** reduces gastric acidity, diminishing a key defense against pathogens, thus increasing the risk of **Clostridium difficile infection** and other enteric infections. - Chronic PPI use can impair the absorption of essential nutrients like **calcium** and **magnesium**, leading to an increased risk of **osteoporotic fractures** and **hypomagnesaemia**, especially in older adults. *PPIs should never be stopped once started due to severe rebound acid hypersecretion causing gastric ulceration* - While **rebound acid hypersecretion** can occur upon stopping PPIs, it is usually managed by a **gradual dose taper** or short-term symptomatic treatment, not typically resulting in severe gastric ulceration. - The principle of **deprescribing** inappropriate or unnecessary medications in older adults outweighs the temporary discomfort of rebound acidity, which can be mitigated. *PPIs provide cardiovascular protection in patients taking aspirin and should be continued indefinitely in all patients over 75* - PPIs primarily provide **gastroprotection** against upper gastrointestinal bleeding in patients taking aspirin or NSAIDs, but they do not offer independent **cardiovascular protection**. - Decisions for long-term PPI use with aspirin should be individualized based on **gastrointestinal bleeding risk factors**, rather than continued indefinitely in all older patients. *Stopping PPIs requires hospital admission for gastroprotection monitoring* - **Deprescribing PPIs** is a common practice that can typically be managed safely in an **outpatient primary care setting**, with careful patient education and monitoring for symptom recurrence. - Hospital admission is generally not required for PPI cessation unless there are severe underlying conditions or acute complications demanding inpatient care. *PPIs have no significant drug interactions and are safe indefinitely in all patients with polypharmacy* - PPIs have several **significant drug interactions**, including with **clopidogrel** (reducing its efficacy) and certain antiretrovirals, antifungals, and iron salts due to altered gastric pH. - Long-term safety in patients with **polypharmacy** is a concern, as PPIs can contribute to adverse effects like **Vitamin B12 deficiency**, **acute interstitial nephritis**, and potential **chronic kidney disease**, adding to the overall medication burden.

Question 88: A 69-year-old woman with painful diabetic neuropathy, depression, hypertension, and osteoarthritis has been taking duloxetine 60mg twice daily for the past 2 years for neuropathic pain. She also takes metformin, amlodipine, ramipril, and paracetamol. She reports her pain is well controlled but has noticed increasing frequency of bruising and had two nosebleeds in the past month. She is not taking any antiplatelet or anticoagulant medication. Recent blood tests including full blood count, renal and liver function are normal. What is the MOST likely explanation for her bleeding symptoms?

A. Undiagnosed platelet function disorder revealed by detailed haematological testing
B. Drug interaction between duloxetine and ramipril causing vasculitis
C. Duloxetine affecting serotonin reuptake in platelets leading to platelet dysfunction (Correct Answer)
D. Occult metformin-induced thrombocytopenia despite normal platelet count
E. Amlodipine causing capillary fragility and increased bleeding tendency

Explanation: ***Duloxetine affecting serotonin reuptake in platelets leading to platelet dysfunction*** - **Duloxetine**, an SNRI, inhibits the **serotonin transporter (SERT)** on platelets, preventing them from taking up serotonin which is essential for **platelet aggregation**. - This leads to a functional **platelet defect** rather than a quantitative one, resulting in symptoms like **bruising** and **epistaxis** even when the **full blood count** is normal. *Undiagnosed platelet function disorder revealed by detailed haematological testing* - While it presents similarly to drug-induced dysfunction, the **new onset** of symptoms synchronized with chronic high-dose medication makes a late-presentation genetic disorder highly unlikely. - The patient has no prior history of abnormal bleeding during **surgery** or **trauma**, which would typically be present in a primary disorder. *Drug interaction between duloxetine and ramipril causing vasculitis* - There is no clinical or pharmacological evidence to support a **drug interaction** between SNRIs and ACE inhibitors that manifests as **vasculitis**. - Vasculitis usually presents with **palpable purpura**, systemic malaise, or organ involvement, rather than isolated **bruising and nosebleeds**. *Occult metformin-induced thrombocytopenia despite normal platelet count* - **Thrombocytopenia** is defined by a low platelet count; the term "occult" is not applicable when a **normal full blood count** has been confirmed. - **Metformin** is not typically associated with bone marrow suppression or drug-induced immune destruction of platelets. *Amlodipine causing capillary fragility and increased bleeding tendency* - **Amlodipine** is a calcium channel blocker commonly associated with **peripheral oedema**, but it does not cause **capillary fragility** or affect the coagulation cascade. - Bleeding tendencies in elderly patients on amlodipine are usually due to **comorbidities** or concurrent use of antiplatelets, not the drug itself.

Question 89: You are reviewing the medication regimen of an 83-year-old man with heart failure (LVEF 32%), atrial fibrillation, type 2 diabetes, and stage 4 CKD (eGFR 24 ml/min/1.73m²). He takes bisoprolol 10mg daily, ramipril 2.5mg daily, furosemide 80mg twice daily, spironolactone 25mg daily, digoxin 125 micrograms daily, edoxaban 30mg daily, empagliflozin 10mg daily, and insulin glargine 28 units daily. Recent bloods show K⁺ 5.8 mmol/L, eGFR 24 ml/min/1.73m². He feels well with no symptoms. What is the MOST appropriate immediate management of his medication regimen?

A. Stop empagliflozin as it is contraindicated with eGFR <30 ml/min/1.73m² and may be contributing to hyperkalaemia
B. Stop spironolactone immediately due to hyperkalaemia and severe CKD (Correct Answer)
C. Reduce ramipril dose to 1.25mg daily to lower potassium levels while maintaining cardiovascular protection
D. Stop digoxin as it accumulates in renal impairment and check digoxin level urgently
E. Admit to hospital immediately for management of life-threatening hyperkalaemia

Explanation: ***Stop spironolactone immediately due to hyperkalaemia and severe CKD*** - Spironolactone is a **mineralocorticoid receptor antagonist (MRA)** that significantly increases the risk of **hyperkalaemia**, especially in patients with **severe renal impairment** (eGFR <30 mL/min/1.73m²). - With the patient's **eGFR of 24 ml/min/1.73m²** and a potassium level of **5.8 mmol/L**, discontinuing spironolactone is the most appropriate and immediate action to prevent worsening hyperkalaemia. *Stop empagliflozin as it is contraindicated with eGFR <30 ml/min/1.73m² and may be contributing to hyperkalaemia* - While **SGLT2 inhibitors** like empagliflozin have historical eGFR cutoffs for initiation, current guidelines recommend continuing them for **cardiorenal protection** in heart failure and CKD even at lower eGFRs if already established. - SGLT2 inhibitors typically have a **potassium-lowering** or neutral effect and are therefore unlikely to be the primary cause of this patient's hyperkalaemia. *Reduce ramipril dose to 1.25mg daily to lower potassium levels while maintaining cardiovascular protection* - While **ACE inhibitors** like ramipril can contribute to **hyperkalaemia**, their effect is generally less pronounced than that of MRAs, and they provide significant **cardiovascular benefits** in heart failure. - Prioritizing the cessation of the more potent hyperkalaemic agent (spironolactone) while preserving the beneficial effects of **RAAS inhibition** is crucial in this scenario. *Stop digoxin as it accumulates in renal impairment and check digoxin level urgently* - **Digoxin** is primarily cleared renally, and a dose adjustment or monitoring of levels is necessary in **CKD** to prevent toxicity; however, digoxin does not directly cause **hyperkalaemia**. - Although a dose of 125 micrograms daily might be high for an eGFR of 24, managing potential digoxin toxicity is not the immediate priority for an asymptomatic patient with elevated potassium. *Admit to hospital immediately for management of life-threatening hyperkalaemia* - A potassium level of **5.8 mmol/L** is considered **moderate hyperkalaemia**. Since the patient is **asymptomatic** and no ECG changes are mentioned, it can often be managed in the outpatient setting by medication adjustment. - **Life-threatening hyperkalaemia**, typically defined as potassium **≥6.5 mmol/L** or any level with **ECG changes** (e.g., peaked T waves, QRS widening), would warrant immediate hospital admission for urgent intervention.

Question 90: A 71-year-old woman with rheumatoid arthritis, osteoporosis, type 2 diabetes, and ischaemic heart disease attends for medication review. She takes methotrexate 15mg weekly, folic acid 5mg weekly (taken day after methotrexate), prednisolone 5mg daily, alendronic acid 70mg weekly, metformin 1g twice daily, aspirin 75mg daily, atorvastatin 80mg daily, and ramipril 10mg daily. She reports good disease control but has developed mouth ulcers and feels increasingly tired. Recent blood tests show Hb 98 g/L (MCV 102 fL), WCC 3.2 × 10⁹/L, platelets 145 × 10⁹/L, eGFR 58 ml/min/1.73m². What is the MOST likely medication-related cause of her symptoms and blood results?

A. Ramipril is causing bone marrow suppression and should be switched to an alternative antihypertensive
B. Metformin is causing vitamin B12 deficiency leading to macrocytic anaemia
C. Alendronic acid is causing gastrointestinal blood loss leading to anaemia
D. Inadequate folic acid supplementation with methotrexate is causing folate deficiency (Correct Answer)
E. Atorvastatin is interacting with methotrexate causing increased toxicity

Explanation: ***Inadequate folic acid supplementation with methotrexate is causing folate deficiency*** - **Methotrexate** is a **folate antagonist** that inhibits **dihydrofolate reductase**; inadequate supplementation leads to **macrocytic anaemia**, **leukopenia**, and painful **mucosal ulcers**. - While the patient takes a weekly dose, the presence of **pancytopenia** (low Hb, WCC, and borderline platelets) and symptoms suggests she requires a higher frequency of **folic acid** (e.g., 5mg daily except on methotrexate day) to counteract toxicity. *Ramipril is causing bone marrow suppression and should be switched to an alternative antihypertensive* - **ACE inhibitors** like ramipril are not typically associated with **bone marrow suppression** or macrocytic changes. - Their most common serious side effects relate to **renal function impairment**, hyperkalaemia, or chronic dry cough, rather than cytopenias. *Metformin is causing vitamin B12 deficiency leading to macrocytic anaemia* - **Metformin** can indeed cause **Vitamin B12 deficiency** and macrocytosis, but it does not explain the acute development of **mouth ulcers**. - B12 deficiency usually presents over a much longer period and would not typically cause the **leukopenia** seen in this acute clinical picture as prominently as folate depletion. *Alendronic acid is causing gastrointestinal blood loss leading to anaemia* - GI blood loss from bisphosphonate-induced **esophagitis** or ulceration would result in an **iron-deficiency anaemia**, which is characteristically **microcytic** (low MCV). - This patient has a **macrocytic** (high MCV) picture, which is inconsistent with simple chronic blood loss. *Atorvastatin is interacting with methotrexate causing increased toxicity* - There is no clinically significant pharmacological interaction between **atorvastatin** and methotrexate that leads to **hematologic toxicity**. - Methotrexate toxicity is more commonly precipitated by drugs that compete for renal excretion, such as **NSAIDs** or **Penicillins**, or conditions like worsening **renal impairment** (eGFR 58).

Question 91: A 67-year-old man with multiple sclerosis, recurrent urinary tract infections, depression, and insomnia takes solifenacin 10mg daily, trimethoprim prophylaxis 100mg nightly, mirtazapine 30mg at night, and zopiclone 7.5mg at night. He attends with his wife who reports he has become increasingly forgetful, had difficulty passing urine requiring catheterisation last month, and has been unsteady on his feet. What aspect of his medication regimen represents the MOST significant contributor to his cognitive and functional decline?

A. Trimethoprim is causing folate deficiency leading to cognitive impairment
B. Mirtazapine and zopiclone combination is causing excessive sedation and cognitive impairment
C. Solifenacin anticholinergic effects are contributing to cognitive impairment and urinary retention (Correct Answer)
D. Zopiclone is causing paradoxical insomnia and rebound anxiety affecting cognition
E. The combination of all four medications is causing a rare serotonin syndrome

Explanation: ***Solifenacin anticholinergic effects are contributing to cognitive impairment and urinary retention*** - **Solifenacin** is a potent antimuscarinic agent, known to significantly contribute to **anticholinergic burden**, which manifests as cognitive impairment (forgetfulness), confusion, and increased fall risk (unsteadiness) in elderly patients. - Its mechanism directly inhibits detrusor muscle contraction, leading to **urinary retention**, which aligns perfectly with the patient's recent need for catheterization and represents the most direct explanation for the combination of symptoms. *Trimethoprim is causing folate deficiency leading to cognitive impairment* - While **trimethoprim** is a folate antagonist, the prophylactic dose of 100mg nightly is generally well-tolerated, and significant **folate deficiency** leading to acute cognitive decline is a rare occurrence. - This explanation does not account for the acute onset of **urinary retention** or the patient's reported unsteadiness on his feet. *Mirtazapine and zopiclone combination is causing excessive sedation and cognitive impairment* - Both **mirtazapine** and **zopiclone** are sedating agents that can contribute to cognitive impairment, drowsiness, and increased risk of falls, particularly in older adults. - However, this combination does not typically cause acute **urinary retention** requiring catheterization, making it a less comprehensive explanation for the constellation of symptoms than solifenacin. *Zopiclone is causing paradoxical insomnia and rebound anxiety affecting cognition* - **Paradoxical reactions** to Z-drugs like zopiclone are uncommon and usually involve agitation, confusion, or hallucinations, rather than the memory loss, unsteadiness, and urinary retention described. - This explanation also fails to address the significant symptom of **urinary retention** requiring catheterization, which is a key part of the patient's decline. *The combination of all four medications is causing a rare serotonin syndrome* - **Serotonin syndrome** is characterized by a triad of mental status changes, autonomic hyperactivity, and neuromuscular abnormalities (e.g., clonus, hyperreflexia, rigidity). - This patient's symptoms (forgetfulness, urinary retention, unsteadiness) do not align with the typical presentation of **serotonin syndrome**, and only mirtazapine has significant serotonergic activity in his regimen.

Question 92: You are conducting a medication review for a 79-year-old woman with dementia (MMSE 18/30), type 2 diabetes, hypertension, and chronic constipation. Her daughter reports that her mother has become increasingly confused and had a fall last week. Current medications include: donepezil 10mg daily, gliclazide 80mg twice daily, amlodipine 5mg daily, codeine phosphate 30mg four times daily (for osteoarthritis pain), and docusate 100mg twice daily. Random blood glucose today is 16.2 mmol/L. What is the SINGLE most important medication-related concern to address?

A. Donepezil may be causing confusion and should be stopped immediately
B. Gliclazide dose is inadequate as blood glucose is elevated and should be increased
C. Codeine is likely contributing to confusion, fall risk, and constipation despite laxative use (Correct Answer)
D. Amlodipine is causing postural hypotension leading to falls and should be stopped
E. Docusate is ineffective and should be changed to senna for better constipation management

Explanation: ***Codeine is likely contributing to confusion, fall risk, and constipation despite laxative use***- **Codeine** is an opioid that significantly increases the risk of **delirium**, sedation, and **falls** in elderly patients, particularly those with pre-existing **dementia**.- It is a major cause of **chronic constipation** which often remains refractory to stool softeners like docusate, necessitating a review of the analgesic regimen.*Donepezil may be causing confusion and should be stopped immediately*- **Donepezil** is an **acetylcholinesterase inhibitor** intended to improve cognitive function and should not be stopped abruptly as it may lead to a decline in **MMSE scores**.- Confusion is a symptom of progressive dementia or medication toxicity from other sources, rather than a typical side effect of **cholinergic therapy**.*Gliclazide dose is inadequate as blood glucose is elevated and should be increased*- Increasing **Gliclazide** (a sulfonylurea) in an elderly patient with cognitive impairment poses a critical risk of **hypoglycemia**, which can lead to further falls or coma.- Elevated **random blood glucose** may be transient or related to current illness and should be managed with caution rather than an immediate dose escalation in a high-risk patient.*Amlodipine is causing postural hypotension leading to falls and should be stopped*- While some antihypertensives cause **orthostatic hypotension**, **Amlodipine** is a calcium channel blocker more commonly associated with **peripheral edema** than significant postural drops.- There is no clinical objective evidence provided, such as **postural blood pressure** readings, to justify stopping an essential medication for hypertension management.*Docusate is ineffective and should be changed to senna for better constipation management*- While **Docusate** is a weak softener, the underlying issue is the **opioid-induced constipation** caused by the codeine, which requires addressing the primary cause.- Switching laxatives is a secondary management step that does not address the more dangerous risks of **confusion and falls** posed by the current medication profile.

Question 93: A 74-year-old man with COPD, ischaemic heart disease, permanent atrial fibrillation, and stage 3a CKD attends for his annual review. His current medications are: tiotropium inhaler, salmeterol/fluticasone inhaler, bisoprolol 2.5mg daily, ramipril 5mg daily, atorvastatin 80mg daily, apixaban 5mg twice daily, and calcium carbonate/vitamin D3 daily. He reports increasing breathlessness on exertion. Spirometry shows FEV1 52% predicted with no significant reversibility. His heart rate is 76 bpm, blood pressure 132/78 mmHg, oxygen saturation 94% on air. Recent blood tests show eGFR 54 ml/min/1.73m², HbA1c 41 mmol/mol. What medication change would be MOST appropriate?

A. Stop calcium carbonate/vitamin D3 as there is no documented osteoporosis (Correct Answer)
B. Reduce apixaban dose to 2.5mg twice daily due to CKD stage 3a
C. Increase bisoprolol to 5mg daily to improve heart rate control in atrial fibrillation
D. Stop salmeterol/fluticasone and prescribe salmeterol alone, as inhaled corticosteroids may increase cardiovascular risk
E. Continue all medications and add oral prednisolone for his worsening breathlessness

Explanation: ***Stop calcium carbonate/vitamin D3 as there is no documented osteoporosis*** - In a **multimorbidity** medication review, medications without a clear indication, documented **vitamin D deficiency**, or secondary hyperparathyroidism should be discontinued to reduce **polypharmacy**. - There is no clinical evidence provided in the history of **osteoporosis** or bone fragility to justify the continued use of these supplements. *Reduce apixaban dose to 2.5mg twice daily due to CKD stage 3a* - **Apixaban dose reduction** is only indicated if at least two of the following are met: age ≥80 years, weight ≤60kg, or **serum creatinine** ≥133 micromol/L. - A patient with an **eGFR of 54 ml/min** likely has a creatinine level below the threshold, meaning the full 5mg twice-daily dose remains appropriate. *Increase bisoprolol to 5mg daily to improve heart rate control in atrial fibrillation* - His current **heart rate of 76 bpm** indicates adequate rate control for **permanent atrial fibrillation**, typically targeted at <110 bpm at rest. - Increasing the **beta-blocker** dose unnecessarily could risk bradycardia or potentially exacerbate his **COPD** symptoms if not tolerated well. *Stop salmeterol/fluticasone and prescribe salmeterol alone, as inhaled corticosteroids may increase cardiovascular risk* - **Inhaled corticosteroids (ICS)** are indicated in COPD for patients with persistent breathlessness or exacerbations despite LABA/LAMA therapy; they do not carry a primary **cardiovascular contraindication**. - While ICS increase the risk of **pneumonia**, they are a standard component of triple therapy (LAMA + LABA + ICS) which this patient is correctly receiving for symptomatic disease. *Continue all medications and add oral prednisolone for his worsening breathlessness* - **Oral prednisolone** is indicated for acute **COPD exacerbations** but is not recommended for long-term maintenance therapy due to significant side effects like **osteoporosis** and diabetes. - There is no evidence of an acute infection or increased sputum purulence to suggest an exacerbation requiring a steroid course at this time.

Question 94: During a medication review for a 68-year-old woman with fibromyalgia, depression, type 2 diabetes, and hypertension, you note she has been taking amitriptyline 50mg at night for 4 years for pain management. She also takes sertraline, metformin, and amlodipine. She reports ongoing daytime drowsiness, dry mouth, and two falls in the past 6 months. Her blood pressure is 138/82 mmHg. What is the MOST appropriate management approach?

A. Continue amitriptyline as it is effectively managing her fibromyalgia pain and drowsiness will improve with time
B. Increase amlodipine dose as postural hypotension from inadequate blood pressure control may be causing falls
C. Gradually reduce and stop amitriptyline, considering alternative pain management strategies (Correct Answer)
D. Add ondansetron to manage the anticholinergic side effects of amitriptyline
E. Switch sertraline to citalopram to reduce drug interactions with amitriptyline

Explanation: ***Gradually reduce and stop amitriptyline, considering alternative pain management strategies***- Amitriptyline is a **tricyclic antidepressant (TCA)** with significant **anticholinergic and sedative** effects, contributing to this patient's dry mouth, daytime drowsiness, and increased **fall risk**.- According to the **Beers Criteria** and **STOPP criteria**, TCAs should generally be avoided in older adults due to the risk of **orthostatic hypotension** and CNS depression; tapering is necessary to prevent **withdrawal symptoms**.*Continue amitriptyline as it is effectively managing her fibromyalgia pain and drowsiness will improve with time*- After four years of use, the patient is still experiencing **persistent sedation**, making it unlikely that she will develop further tolerance to this side effect.- The clinical priority is addressing the **two recent falls**, which represent a significant safety risk that outweighs the benefits of chronic TCA use in this age group.*Increase amlodipine dose as postural hypotension from inadequate blood pressure control may be causing falls*- The patient's blood pressure is 138/82 mmHg, which is within the acceptable range for a 68-year-old with **type 2 diabetes** and hypertension.- Increasing antihypertensives would more likely **increase the risk of falls** by worsening potential **orthostatic hypotension**, a common side effect of both TCAs and amlodipine.*Add ondansetron to manage the anticholinergic side effects of amitriptyline*- Ondansetron is an antiemetic that does not treat **anticholinergic symptoms** like dry mouth; it can actually worsen **constipation**, another common side effect.- Managing side effects by adding more medication (the "**prescribing cascade**") is inappropriate when the primary drug itself should be discontinued or replaced.*Switch sertraline to citalopram to reduce drug interactions with amitriptyline*- While both drugs can interact with TCAs, switching one **SSRI** for another does not address the patient's primary complaints of drowsiness and falls.- The combination of any SSRI with amitriptyline carries a risk of **Serotonin Syndrome** and increased TCA levels, but the most direct solution to her symptoms is the cessation of **amitriptyline**.

Question 95: A 76-year-old man with heart failure, atrial fibrillation, type 2 diabetes, and benign prostatic hyperplasia takes 10 medications including warfarin, bisoprolol, furosemide, ramipril, metformin, tamsulosin, finasteride, atorvastatin, aspirin, and omeprazole. His INR is stable at 2.5. What is the MOST important medication-related issue to address?

A. The combination of ramipril and bisoprolol increases the risk of hypotension and should be reviewed
B. Aspirin should be discontinued as it provides no additional benefit with warfarin and increases bleeding risk (Correct Answer)
C. Omeprazole should be stopped immediately due to interaction with warfarin
D. Metformin dose should be reduced due to increased risk of lactic acidosis with furosemide
E. Finasteride should be discontinued as it has no cardiovascular benefit

Explanation: ***Aspirin should be discontinued as it provides no additional benefit with warfarin and increases bleeding risk*** - Concurrent use of **aspirin** and **warfarin** significantly increases the risk of **major bleeding** without providing additional thromboembolic protection in patients with **atrial fibrillation** managed with warfarin. - Unless there is a specific, recent indication such as an **acute coronary syndrome** or **coronary stenting** within the last 12 months, antiplatelet therapy in combination with oral anticoagulation should generally be avoided to minimize **bleeding risk**. *The combination of ramipril and bisoprolol increases the risk of hypotension and should be reviewed* - This combination of an **ACE inhibitor** (ramipril) and a **beta-blocker** (bisoprolol) is a cornerstone therapy for **heart failure with reduced ejection fraction** and provides significant **mortality benefits**. - While these medications can lower blood pressure, they are essential for **cardiac remodeling** and **symptom control** in heart failure, and their combination is medically appropriate and not a primary issue to address in a stable patient. *Omeprazole should be stopped immediately due to interaction with warfarin* - While **omeprazole** (and other PPIs) can weakly inhibit **CYP2C19**, which metabolizes warfarin, the clinical significance is generally small, especially when the **INR is stable** at 2.5. - In fact, **proton pump inhibitors (PPIs)** are often recommended for patients on anticoagulants to reduce the risk of **gastrointestinal bleeding**, making its discontinuation potentially harmful. *Metformin dose should be reduced due to increased risk of lactic acidosis with furosemide* - The primary concern for **lactic acidosis** with **metformin** is in patients with significant **renal impairment** or acute kidney injury, not a direct interaction with **furosemide**. - While furosemide can cause dehydration and potentially affect kidney function, in a stable patient with adequate **renal function**, this combination does not warrant an immediate metformin dose reduction solely due to furosemide. *Finasteride should be discontinued as it has no cardiovascular benefit* - **Finasteride** is prescribed for **benign prostatic hyperplasia (BPH)**, a condition the patient has, and its benefit is to reduce prostate size and improve urinary symptoms. - A medication does not need to have **cardiovascular benefit** to be appropriate; its indication is for the specific condition it is treating, which in this case is symptomatic BPH.

Question 96: A 70-year-old woman with type 2 diabetes, hypertension, osteoarthritis, and chronic kidney disease stage 3b (eGFR 38 ml/min/1.73m²) takes 9 regular medications. She reports good medication adherence but admits confusion about which tablets to take at different times of day. Which validated tool would be MOST appropriate to systematically assess medication-related problems during her review?

A. The FRAX tool
B. The MUST screening tool
C. The NO TEARS mnemonic (Correct Answer)
D. The PHQ-9 questionnaire
E. The ABCD2 score

Explanation: ***The NO TEARS mnemonic***- This tool is specifically designed for **medication reviews** in primary care, encompassing Need, Open questions, Tests, Evidence, Adverse events, Risk reduction, and **Simplification** components.- It is highly appropriate for patients with **polypharmacy** and medication confusion, as it systematically guides the clinician to assess the necessity, effectiveness, and safety of each drug, while also seeking opportunities for **simplification** of the regimen.*The FRAX tool*- This tool is used to estimate the **10-year probability of a major osteoporotic fracture** based on various clinical risk factors.- It does not assess the appropriateness of **multimorbidity medications** or help in resolving patient confusion regarding medication schedules.*The MUST screening tool*- The **Malnutrition Universal Screening Tool (MUST)** is used to identify adults who are malnourished, at risk of **malnutrition**, or obese.- While important for geriatric health, it has no utility in identifying or managing **medication-related problems** or confusion about medication timing.*The PHQ-9 questionnaire*- This is a validated **depression screening** and severity monitoring tool, assessing the presence and intensity of depressive symptoms over the past two weeks.- While depression could contribute to medication confusion, the PHQ-9 is not a **functional tool for systematic medication review** or addressing adherence issues directly.*The ABCD2 score*- This clinical prediction rule is used to estimate the risk of **stroke** within 2, 7, and 90 days following a **Transient Ischemic Attack (TIA)**.- It considers age, blood pressure, clinical features of TIA, duration of symptoms, and diabetes, but is entirely unrelated to **polypharmacy management** or medication adherence.

Question 97: A 72-year-old man with multimorbidity is taking 11 regular medications. During his annual review, you decide to conduct a structured medication review using an evidence-based framework. According to NICE guidance on multimorbidity, what is the PRIMARY purpose of a structured medication review in patients with multimorbidity?

A. To reduce the number of medications by at least 50% to improve adherence
B. To optimise treatment regimens, reduce potential harm, and improve patient outcomes (Correct Answer)
C. To ensure all medications are prescribed generically to reduce healthcare costs
D. To identify all drug interactions and switch to alternative medications without interactions
E. To consolidate prescribing to once-daily preparations to simplify medication regimens

Explanation: ***To optimise treatment regimens, reduce potential harm, and improve patient outcomes***\n- According to **NICE NG56**, the primary goal of a structured medication review is a holistic assessment to ensure each medication is beneficial while minimizing the risks of **polypharmacy** and drug-related harm.\n- It emphasizes **shared decision-making** with the patient, aligning treatment with their **personal priorities**, values, and overall quality of life.\n*To reduce the number of medications by at least 50% to improve adherence*\n- While **deprescribing** is often an outcome of a medication review, setting an arbitrary percentage reduction target is not a recommended primary purpose by clinical guidelines.\n- The focus should be on the **appropriateness**, clinical **utility**, and **safety** of each medication for the individual, rather than a fixed reduction in quantity.\n*To ensure all medications are prescribed generically to reduce healthcare costs*\n- **Cost-effectiveness** is a valid consideration in prescribing decisions and overall healthcare management, but it is not the **primary clinical purpose** of a structured medication review in multimorbidity.\n- The main objective remains **patient safety**, clinical effectiveness, and improving patient outcomes, rather than purely administrative or financial goals.\n*To identify all drug interactions and switch to alternative medications without interactions*\n- Identifying and managing **drug-drug interactions** is a crucial component of a medication review, but it is often impossible to eliminate all interactions in patients with complex multimorbidity.\n- The primary goal is to weigh the **risk-benefit ratio** of essential medications and manage interactions appropriately, rather than attempting to switch to entirely interaction-free alternatives which may not be clinically optimal.\n*To consolidate prescribing to once-daily preparations to simplify medication regimens*\n- **Regimen simplification**, such as consolidating to once-daily preparations, is a valuable strategy to improve **adherence** and reduce patient burden, but it is a secondary management approach rather than the overarching primary objective.\n- The fundamental purpose of the review is to assess the **overall appropriateness** and effectiveness of all therapies for the patient's specific health needs and goals.

Question 98: Your practice is implementing a quality improvement project for patients with multimorbidity and polypharmacy. The project aims to reduce potentially inappropriate prescribing and improve patient outcomes. The practice team has identified 240 patients aged 75+ taking ≥10 medications. You are asked to recommend an evidence-based approach to structuring medication reviews. Evaluating the available tools and frameworks, which combination would provide the MOST comprehensive approach to identifying and addressing prescribing issues in this population?

A. STOPP/START criteria combined with medication reconciliation at each review
B. Beers Criteria combined with comprehensive geriatric assessment tools
C. STOPP/START criteria combined with patient-centred discussion of goals and priorities (Correct Answer)
D. Anticholinergic Burden Calculator combined with falls risk assessment
E. Medication Appropriateness Index combined with QRISK3 cardiovascular risk assessment

Explanation: ***STOPP/START criteria combined with patient-centred discussion of goals and priorities*** - The **STOPP/START criteria** provide a validated, systematic framework for identifying **potentially inappropriate medications (PIMs)** and **potential prescribing omissions (PPOs)** specifically in the elderly. - Combining these criteria with a **patient-centred discussion** ensures that clinical decisions align with the patient’s **quality of life**, preferences, and personal goals, which is a core recommendation of **NICE guidance (NG56)** on multimorbidity. *STOPP/START criteria combined with medication reconciliation at each review* - **Medication reconciliation** is vital for ensuring the list is accurate across care transitions, but it does not evaluate the **clinical appropriateness** of the medications themselves. - While it prevents technical errors, it lacks the **holistic evaluation** of patient priorities required for complex multimorbidity management. *Beers Criteria combined with comprehensive geriatric assessment tools* - The **Beers Criteria** are primarily developed in the **USA** and include some medications and practices that do not directly translate to **UK primary care** settings. - While **Comprehensive Geriatric Assessment (CGA)** is valuable, it is a resource-intensive diagnostic process rather than a specific structured tool for **polypharmacy rationalization** in a practice-wide project. *Anticholinergic Burden Calculator combined with falls risk assessment* - These tools are highly specific but only address a **subset of risks** (anticholinergic side effects and falls) rather than the total medication profile. - This approach would miss many other **potentially inappropriate prescriptions**, such as long-term PPI use or inappropriate NSAID use, that STOPP/START would identify. *Medication Appropriateness Index combined with QRISK3 cardiovascular risk assessment* - The **Medication Appropriateness Index (MAI)** is thorough but very **time-consuming** to apply in routine clinical practice compared to the more efficient STOPP/START criteria. - **QRISK3** is focused specifically on **cardiovascular risk** and does not provide a comprehensive framework for addressing the diverse issues found in geriatric polypharmacy.

Question 99: A 72-year-old man with COPD (post-bronchodilator FEV1 48% predicted), ischaemic heart disease, heart failure (LVEF 42%), and depression takes 13 medications. Following a comprehensive medication review using the NO TEARS tool, you identify that he is taking regular co-codamol 30/500 four times daily for chronic back pain, which he has taken for 3 years. He also takes senna regularly for constipation. His pain is reasonably well-controlled (average 4/10). Considering principles of deprescribing opioid therapy in chronic non-cancer pain, what is the MOST appropriate next step?

A. Switch from co-codamol to a sustained-release opioid preparation for better pain control
B. Discuss gradual opioid reduction plan with patient and optimize non-pharmacological approaches (Correct Answer)
C. Continue co-codamol at current dose as pain is well-controlled and changing risks pain exacerbation
D. Stop co-codamol immediately and replace with regular ibuprofen 400mg TDS
E. Refer to specialist pain service for consideration of opioid rotation

Explanation: ***Discuss gradual opioid reduction plan with patient and optimize non-pharmacological approaches*** - Long-term **opioid therapy** in older adults with **multimorbidity** (COPD, Heart Failure) poses significant risks, including respiratory depression and falls, necessitating a **deprescribing** review. - A **gradual tapering plan** (e.g., 10% reduction every 2–4 weeks) combined with **non-pharmacological strategies** is the gold standard for managing chronic non-cancer pain safely. *Switch from co-codamol to a sustained-release opioid preparation for better pain control* - Sustained-release opioids do not address the underlying risks of **long-term opioid use** and may actually increase the total daily dose and side-effect profile. - The patient’s pain is already **reasonably well-controlled**, so escalating to stronger forms of opioid therapy is not clinically indicated. *Continue co-codamol at current dose as pain is well-controlled and changing risks pain exacerbation* - Continuing high-dose codeine indefinitely ignores the **cumulative risks** of adverse effects, such as the **opioid-induced constipation** he is currently experiencing. - **Polypharmacy management** (13 medications) requires active attempts to reduce potentially inappropriate medications to improve the patient's overall health outcomes. *Stop co-codamol immediately and replace with regular ibuprofen 400mg TDS* - **Abrupt cessation** of opioids after three years of use can trigger severe **withdrawal symptoms** and a significant flare-up of chronic pain. - **NSAIDs** like ibuprofen are strictly **contraindicated** in patients with **heart failure** as they cause fluid retention and increase the risk of cardiovascular events. *Refer to specialist pain service for consideration of opioid rotation* - **Opioid rotation** is typically reserved for patients with poor pain control or intolerable side effects where clinical benefit is still expected, which is not the priority here. - The primary care physician should first attempt a **patient-centered deprescribing** plan before considering escalation or specialist referral for rotation.

Question 100: A 67-year-old woman with heart failure (LVEF 35%), atrial fibrillation, CKD stage 3a, and type 2 diabetes takes bisoprolol 10mg, ramipril 10mg, furosemide 40mg, apixaban 5mg BD, metformin 1g BD, and atorvastatin 80mg. She was recently admitted with acute heart failure exacerbation. At discharge, sacubitril-valsartan 49/51mg BD was initiated and ramipril stopped. She attends for post-discharge review 10 days later. Her BP is 108/66 mmHg, eGFR has decreased from 54 to 42 ml/min/1.73m², and potassium is 5.4 mmol/L. What is the MOST appropriate management approach?

A. Stop sacubitril-valsartan immediately and restart ramipril due to decline in renal function
B. Reduce bisoprolol dose to 5mg to improve blood pressure and allow continuation of ARNI
C. Continue current medications and recheck renal function in 1-2 weeks (Correct Answer)
D. Stop metformin due to declining renal function and monitor renal function closely
E. Reduce furosemide dose to 20mg daily to improve renal perfusion

Explanation: ***Continue current medications and recheck renal function in 1-2 weeks*** - A decline in **eGFR of up to 25%** and a potassium level up to **5.5 mmol/L** are acceptable following the initiation of an **ARNI (sacubitril-valsartan)** or ACE inhibitor. - This patient's eGFR reduction (approx. 22%) and potassium (5.4 mmol/L) remain within safe limits, and her **systolic BP (>95 mmHg)** is stable, necessitating monitoring rather than intervention. *Stop sacubitril-valsartan immediately and restart ramipril due to decline in renal function* - Discontinuation is only indicated if the **creatinine increases by >30%** or eGFR drops by >25%; her current decline is expected and often stabilizes within 4 weeks. - Sacubitril-valsartan provides superior **mortality and hospitalization benefits** compared to ACE inhibitors in HFrEF, so it should be maintained if clinically safe. *Reduce bisoprolol dose to 5mg to improve blood pressure and allow continuation of ARNI* - The patient's blood pressure is **108/66 mmHg**, which is adequate and does not indicate **symptomatic hypotension** requiring a beta-blocker reduction. - Reducing **bisoprolol**, a key pillar of HFrEF therapy, should be avoided unless the patient is bradycardic or severely hypotensive. *Stop metformin due to declining renal function and monitor renal function closely* - **Metformin** is generally safe to continue until the **eGFR falls below 30 ml/min/1.73m²**, although the dose may be reviewed when eGFR is between 30-45. - The current eGFR of **42 ml/min** does not mandate immediate cessation, especially as the decline is likely a hemodynamic response to ARNI initiation. *Reduce furosemide dose to 20mg daily to improve renal perfusion* - There is no clinical evidence of **hypovolemia** or dehydration in this post-exacerbation review that would justify reducing the diuretic dose. - Prematurely reducing **furosemide** in a recently hospitalized heart failure patient carries a high risk of triggering **fluid overload** and re-admission.

Question 101: You are analyzing prescribing quality indicators for patients with multimorbidity in your practice. You identify that 22% of patients aged 75+ taking ≥10 medications have not had a structured medication review in the past 12 months. The practice decides to implement a systematic approach to medication reviews. According to NHS England guidance on structured medication reviews, which patients should be prioritized for review FIRST?

A. All patients over 80 years regardless of medication number or clinical stability
B. Patients prescribed medications from the highest risk medication categories
C. Patients with the highest number of medications regardless of other factors
D. Patients who have had recent hospital admissions or changes in clinical condition (Correct Answer)
E. Patients with poorest adherence as identified by prescription collection data

Explanation: ***Patients who have had recent hospital admissions or changes in clinical condition***- According to **NHS England guidance** and the **Network Contract DES**, patients with recent **hospital admissions** or acute clinical changes are the highest priority for **Structured Medication Reviews (SMRs)**.- These patients are at the greatest risk of **medication-related harm**, drug interactions, and inappropriate prescribing following transitions of care or clinical deterioration.*All patients over 80 years regardless of medication number or clinical stability*- **Age alone** is not the primary determinant for prioritization in the SMR framework; focus is on **clinical vulnerability** and complexity.- Prioritizing solely by age may overlook younger, high-risk patients with **multimorbidity** or frequent hospital attendances.*Patients prescribed medications from the highest risk medication categories*- While patients on **high-risk drugs** like anticoagulants or NSAIDs require monitoring, they are often reviewed periodically through specific **safety audits**.- High-risk medication use is a key trigger for an SMR, but a **recent hospital discharge** represents a more immediate clinical priority for review.*Patients with the highest number of medications regardless of other factors*- While **polypharmacy** (e.g., taking ≥10 medications) is a criterion for SMR eligibility, it does not automatically define the **immediate priority**.- A stable patient on many medications may be at lower immediate risk than a patient on fewer medications who has just experienced a **major health change**.*Patients with poorest adherence as identified by prescription collection data*- Addressing **non-adherence** is a vital component of a medication review, but it does not carry the same degree of **acute clinical risk** as recent hospitalization.- Poor adherence data should prompt an investigation into **patient barriers**, but systematic prioritization favors those with recent **clinical instability**.

Question 102: A 75-year-old man with Parkinson's disease, type 2 diabetes, hypertension, and depression takes 11 medications including co-careldopa 25/100 TDS, ropinirole PR 8mg daily, metformin 1g BD, gliclazide 80mg BD, amlodipine 10mg daily, ramipril 5mg daily, atorvastatin 20mg daily, citalopram 20mg daily, and senna two tablets at night. He reports postural dizziness and a fall last week. Lying BP 142/86 mmHg, standing BP 106/68 mmHg (after 3 minutes). Which medication adjustment should be prioritized based on his orthostatic hypotension?

A. Reduce ramipril dose as ACE inhibitors commonly cause postural hypotension
B. Stop amlodipine as calcium channel blockers cause vasodilation and hypotension
C. Review ropinirole dose as dopamine agonists frequently cause orthostatic hypotension (Correct Answer)
D. Discontinue senna as chronic laxative use can lead to fluid and electrolyte depletion
E. Reduce gliclazide dose as hypoglycaemia may be contributing to dizziness

Explanation: ***Review ropinirole dose as dopamine agonists frequently cause orthostatic hypotension*** - **Dopamine agonists** like **ropinirole** are strongly associated with **orthostatic hypotension** due to peripheral vasodilation and interference with autonomic cardiovascular reflexes. - In patients with **Parkinson’s disease**, it is standard practice to prioritize adjusting **dopaminergic agents** over life-saving antihypertensives when the patient remains hypertensive while supine (142/86 mmHg). *Reduce ramipril dose as ACE inhibitors commonly cause postural hypotension* - While **ACE inhibitors** can contribute to hypotension, the patient's **lying BP** is 142/86 mmHg, suggesting that his hypertension is not currently over-controlled. - Withdrawing **ramipril** may lead to inadequate **cardiovascular protection** and worsening supine hypertension, a common complication in autonomic failure. *Stop amlodipine as calcium channel blockers cause vasodilation and hypotension* - **Amlodipine** causes peripheral vasodilation, but it is less likely than **ropinirole** to be the primary driver of a sharp 36 mmHg **systolic drop** upon standing. - Discontinuing it would leave his **lying blood pressure** above the target range, increasing his long-term risk of stroke and target organ damage. *Discontinue senna as chronic laxative use can lead to fluid and electrolyte depletion* - While extreme **fluid depletion** can cause hypotension, there is no clinical evidence provided (such as tachycardia or dry mucous membranes) to suggest **senna** is causing hypovolemia. - Constipation is a significant issue in **Parkinson’s disease**, and stopping laxatives might worsen patient comfort without fixing the autonomic drop. *Reduce gliclazide dose as hypoglycaemia may be contributing to dizziness* - **Hypoglycemia** typically presents with sweating, tremor, and confusion rather than a specific **postural drop** in blood pressure. - Dizziness from low blood sugar is not specifically tied to the **act of standing** (orthostasis), which is the primary finding in this clinical examination.

Question 103: During a practice audit of patients over 75 years taking 10 or more medications, you identify a 76-year-old man taking aspirin 75mg, clopidogrel 75mg, lansoprazole 30mg, atorvastatin 80mg, bisoprolol 10mg, ramipril 10mg, furosemide 40mg, spironolactone 25mg, allopurinol 300mg, and paracetamol 1g QDS for chronic knee pain. He had a drug-eluting stent inserted 16 months ago. His recent eGFR is 48 ml/min/1.73m², potassium 4.9 mmol/L. What is the MOST appropriate medication change to consider at this review?

A. Stop spironolactone due to risk of hyperkalaemia with declining renal function
B. Discontinue clopidogrel as dual antiplatelet therapy is no longer required (Correct Answer)
C. Reduce allopurinol dose to 200mg daily due to renal impairment
D. Stop lansoprazole as indication for gastroprotection will cease with clopidogrel
E. Replace paracetamol with codeine for better pain control

Explanation: ***Discontinue clopidogrel as dual antiplatelet therapy is no longer required*** - **Dual antiplatelet therapy (DAPT)** with aspirin and clopidogrel after drug-eluting stent (DES) insertion is typically recommended for **6-12 months**; at 16 months, the risk of stent thrombosis is low, and the **bleeding risk** outweighs the benefit. - Continuing **aspirin monotherapy** is sufficient for long-term secondary prevention, which reduces **polypharmacy** and the patient's overall bleeding risk. *Stop spironolactone due to risk of hyperkalaemia with declining renal function* - The patient's potassium level of **4.9 mmol/L** is within the normal range, and spironolactone offers significant **mortality benefits** in conditions like heart failure. - While an **eGFR of 48 ml/min/1.73m²** necessitates careful monitoring, stopping spironolactone is only warranted if potassium levels consistently exceed **5.5 mmol/L** or renal function significantly deteriorates. *Reduce allopurinol dose to 200mg daily due to renal impairment* - Allopurinol 300mg daily is generally considered appropriate for patients with an **eGFR above 30 ml/min/1.73m²**. - Dose reduction is primarily recommended when the eGFR falls below **30 ml/min/1.73m²** to minimize the risk of **allopurinol hypersensitivity syndrome**. *Stop lansoprazole as indication for gastroprotection will cease with clopidogrel* - Even after discontinuing clopidogrel, the patient remains on **aspirin**, which itself carries a risk of **gastrointestinal bleeding**, especially in elderly individuals. - The patient's age (76 years) is an independent risk factor for upper GI bleeding, suggesting a continued need for **gastroprotection**, or at least a thorough review of the ongoing indication rather than immediate cessation. *Replace paracetamol with codeine for better pain control* - Introducing **opioids** like codeine in an elderly patient on multiple medications increases the risk of adverse effects such as **falls, constipation, confusion, and respiratory depression**. - Given the patient's **renal impairment**, active metabolites of codeine can accumulate, leading to **toxicity**, making paracetamol a safer choice for chronic pain management.

Question 104: A 70-year-old woman with rheumatoid arthritis, osteoporosis, hypertension, and type 2 diabetes attends for her annual medication review. Her medications include: methotrexate 15mg weekly, folic acid 5mg weekly, hydroxychloroquine 200mg BD, prednisolone 5mg daily, alendronic acid 70mg weekly, amlodipine 5mg daily, ramipril 10mg daily, and metformin 1g BD. She mentions she takes all her tablets together on Sunday morning for convenience. What is the MOST important prescribing issue to address?

A. Methotrexate and folic acid should be taken on different days
B. Alendronic acid must be taken separately on an empty stomach before other medications (Correct Answer)
C. Prednisolone should be taken in the morning with food, not as a single weekly dose
D. Hydroxychloroquine should be taken with food to reduce gastrointestinal side effects
E. Ramipril dose should be split to twice daily for better blood pressure control

Explanation: ***Alendronic acid must be taken separately on an empty stomach before other medications***- **Alendronic acid** has extremely poor bioavailability and must be taken with plain water on an **empty stomach**, at least 30 minutes before any food or other medications, to ensure absorption.- Taking it with other tablets and food (as the patient does on Sunday) essentially renders the medication ineffective, increasing the risk of **osteoporotic fractures** and potentially causing **oesophageal irritation**.*Methotrexate and folic acid should be taken on different days*- While **folic acid** is typically taken at least 24 hours after **methotrexate** to reduce gastrointestinal and mucosal side effects, this is a management preference rather than a strict contraindication that negates drug efficacy.- The critical failure of **bisphosphonate** absorption in this patient’s routine takes clinical priority over the precise timing of folate supplementation, making it the most important issue.*Prednisolone should be taken in the morning with food, not as a single weekly dose*- The patient is taking **prednisolone** daily, not weekly; the prompt indicates she takes *all her tablets together on Sunday morning* for convenience, which includes her daily prednisolone. However, the critical issue is the complete loss of efficacy for alendronic acid due to improper administration.- While **prednisolone** should ideally be taken daily in the morning with food to mimic **circadian cortisol** rhythms and reduce GI upset, improper bisphosphonate administration represents a more immediate and severe treatment failure.*Hydroxychloroquine should be taken with food to reduce gastrointestinal side effects*- **Hydroxychloroquine** is indeed better tolerated when taken with food to minimize **GI upset**, but it does not have the strict fasting requirements or severe bioavailability issues of bisphosphonates.- Failure to take it with food may cause discomfort but does not negate the drug's therapeutic efficacy in **rheumatoid arthritis** or pose the same immediate risk of fracture due to complete drug failure.*Ramipril dose should be split to twice daily for better blood pressure control*- **Ramipril** is an ACE inhibitor that is effectively dosed **once daily** due to its long half-life and duration of action, ensuring adequate blood pressure control throughout the 24-hour period.- Splitting the dose is not standard practice for **hypertension** management and does not address the immediate safety and efficacy concerns of the alendronic acid.

Question 105: You are conducting a structured medication review for a 73-year-old man with COPD, ischaemic heart disease, hypertension, benign prostatic hyperplasia, and chronic back pain. His medications include: aspirin 75mg, atorvastatin 80mg, bisoprolol 2.5mg, ramipril 5mg, tiotropium inhaler, salbutamol inhaler, tamsulosin 400mcg, co-codamol 30/500 QDS, and diazepam 5mg at night (prescribed 18 months ago for sleep). He reports daytime drowsiness and two recent falls. Applying STOPP/START criteria, which medication represents the HIGHEST priority for discontinuation?

A. Co-codamol due to risk of constipation and cognitive impairment
B. Diazepam due to long-term benzodiazepine use increasing fall risk (Correct Answer)
C. Bisoprolol due to potential exacerbation of COPD symptoms
D. Tamsulosin due to hypotensive effects contributing to falls
E. Aspirin due to lack of clear indication in stable ischaemic heart disease

Explanation: ***Diazepam due to long-term benzodiazepine use increasing fall risk*** - According to **STOPP criteria**, long-term use (>4 weeks) of **benzodiazepines** in older adults is inappropriate due to the high risk of **sedation**, **cognitive impairment**, and **falls**. - This patient’s **daytime drowsiness** and **recent falls** are classic complications of long-acting drugs like diazepam, making its gradual withdrawal the highest priority. *Co-codamol due to risk of constipation and cognitive impairment* - While opioids like **codeine** contribute to sedation and falls, they may be necessary for managing his **chronic back pain**, making discontinuation a secondary consideration. - The priority is lower compared to the benzodiazepine, which has no valid long-term indication for sleep in this clinical context. *Bisoprolol due to potential exacerbation of COPD symptoms* - **Bisoprolol** is a **cardioselective beta-blocker** and is generally safe to use in **COPD** patients, especially when required for **ischaemic heart disease**. - The benefits for his cardiac health currently outweigh the low risk of bronchospasm at this low dose (2.5mg). *Tamsulosin due to hypotensive effects contributing to falls* - **Tamsulosin** is an alpha-blocker that can lead to **orthostatic hypotension**, but it is essential for managing symptoms of **benign prostatic hyperplasia (BPH)**. - It should be reviewed if falls persist after withdrawing sedatives, but it is not the primary culprit for his current **daytime drowsiness**. *Aspirin due to lack of clear indication in stable ischaemic heart disease* - **Aspirin** is indicated for the **secondary prevention** of cardiovascular events in patients with documented **ischaemic heart disease**. - Discontinuing it would increase the risk of myocardial infarction and does not address the patient's immediate problem of falls and drowsiness.

Question 106: A 79-year-old woman with heart failure (LVEF 40%), atrial fibrillation, type 2 diabetes, and osteoporosis takes 12 medications including bisoprolol 5mg daily, furosemide 40mg daily, apixaban 5mg BD, metformin 500mg BD, alendronic acid 70mg weekly, and omeprazole 20mg daily. She has been taking omeprazole for 6 years, initially prescribed for dyspepsia. She has had no dyspeptic symptoms for over 3 years. Recent bone density scan shows ongoing osteoporosis. What is the MOST appropriate action regarding her proton pump inhibitor?

A. Continue omeprazole as it provides gastroprotection for her multiple medications
B. Switch to ranitidine as this has fewer interactions with her other medications
C. Attempt to stop omeprazole with a trial period off treatment (Correct Answer)
D. Reduce omeprazole to alternate days before considering complete discontinuation
E. Continue omeprazole but add calcium supplementation to mitigate bone effects

Explanation: ***Attempt to stop omeprazole with a trial period off treatment*** - Long-term **Proton Pump Inhibitor (PPI)** use without a clear indication significantly increases the risk of **fractures** and exacerbates **osteoporosis**, which is highly relevant given this patient's ongoing bone density issues despite alendronate. - As the patient has been completely asymptomatic for 3 years and lacks high-risk indications for ongoing gastroprotection (e.g., concurrent **NSAID** use, dual antiplatelet therapy, or a history of upper GI bleed), **deprescribing** via a trial cessation is the most appropriate clinical step. *Continue omeprazole as it provides gastroprotection for her multiple medications* - While the patient is on numerous medications, none of them (such as **Apixaban**, **Bisoprolol**, or **Metformin**) strictly necessitate long-term PPI gastroprotection in the absence of a history of peptic ulcers or current use of gastrotoxic drugs like NSAIDs. - Routine, indefinite use of PPIs solely for "polypharmacy" is not recommended and contributes to **medication-related harm** and increased pill burden in the elderly population. *Switch to ranitidine as this has fewer interactions with her other medications* - **H2 antagonists** like ranitidine are not indicated for an asymptomatic patient with no active dyspeptic symptoms, and ranitidine specifically has faced global **regulatory withdrawals** due to potential N-nitrosodimethylamine (NDMA) impurities. - Switching to another acid-suppressant does not address the primary goal of reducing **unnecessary medications** (deprescribing) in an elderly patient who has no ongoing indication for acid suppression. *Reduce omeprazole to alternate days before considering complete discontinuation* - While dose tapering can sometimes be used to mitigate **rebound acid hypersecretion** after long-term PPI use, for a patient who has been entirely asymptomatic for 3 years, a direct trial off treatment is the most appropriate and efficient initial step for deprescribing. - Alternate-day dosing is often less effective for gradual withdrawal than a consistent **"step-down"** approach (e.g., reducing to a lower daily dose) if symptoms were actually present, which they are not in this case. *Continue omeprazole but add calcium supplementation to mitigate bone effects* - Adding more pills (e.g., calcium supplementation) to an already extensive medication list (12 drugs) increases **polypharmacy**, **pill burden**, and the risk of further drug interactions or non-adherence. - PPIs can specifically impair the **absorption of calcium carbonate** by reducing gastric acid, making this approach potentially ineffective in fully mitigating the **osteoporosis risk** compared to simply stopping the unnecessary PPI.

Question 107: A 66-year-old man attends for a medication review. He has been taking 14 regular medications for various conditions including hypertension, type 2 diabetes, hyperlipidaemia, GORD, benign prostatic hyperplasia, and insomnia. He reports that managing his medications has become burdensome and he sometimes forgets doses. His recent HbA1c is 51 mmol/mol, blood pressure 138/82 mmHg, and lipid profile shows total cholesterol 4.2 mmol/L. When applying deprescribing principles in this scenario, what is the MOST important first step?

A. Discontinue the medication with the highest risk of adverse effects immediately
B. Explore the patient's understanding of his medications and his goals of care (Correct Answer)
C. Calculate his QRISK3 score to determine if lipid-lowering therapy can be reduced
D. Review each medication against STOPP/START criteria systematically
E. Stop medications for conditions where targets are already achieved

Explanation: ***Explore the patient's understanding of his medications and his goals of care*** - The first and most critical step in **deprescribing** is engaging in **shared decision-making** to align medical interventions with the patient's values and priorities. - Understanding the patient's **treatment burden** and goals ensures that any changes to the regimen are sustainable and respect the patient's **quality of life**. *Discontinue the medication with the highest risk of adverse effects immediately* - Stopping medications abruptly without a **structured plan** or patient consultation can lead to **rebound symptoms** or withdrawal syndromes. - Identifying high-risk drugs is part of the clinical review, but it should not precede the establishment of **goals of care**. *Calculate his QRISK3 score to determine if lipid-lowering therapy can be reduced* - While **risk assessment tools** are useful for evaluating the necessity of primary prevention, they represent a technical step rather than the **initial holistic approach**. - A score alone does not address the patient's primary complaint of **medication burden** and forgetfulness. *Review each medication against STOPP/START criteria systematically* - **STOPP/START criteria** are evidence-based tools used to identify **potentially inappropriate medications**, but they are supplementary to the clinical conversation. - These criteria provide a framework for the review process but should be applied only after the patient’s **preferences and context** have been established. *Stop medications for conditions where targets are already achieved* - Meeting clinical targets (like **HbA1c** or **Blood Pressure**) often means the medication is working effectively, and stopping them could lead to loss of **disease control**. - **Deprescribing** is about assessing the ongoing **risk-benefit ratio** for the individual, not simply removing drugs once a numerical target is reached.

Question 108: A 68-year-old woman with multiple sclerosis, depression, type 2 diabetes, and hypertension attends with her husband. She has recently developed urinary incontinence and recurrent urinary tract infections. Her current medications include glatiramer acetate, sertraline 100mg daily, metformin 500mg BD, lisinopril 10mg daily, and oxybutynin 5mg TDS which was started by urology 2 months ago. She reports worsening memory problems and constipation since starting the new medication. What is the BEST interpretation of this clinical scenario?

A. Her multiple sclerosis is progressing and causing cognitive decline and autonomic dysfunction
B. She is experiencing anticholinergic adverse effects from oxybutynin (Correct Answer)
C. Her depression is inadequately controlled leading to cognitive symptoms
D. She has developed a dementia syndrome requiring specialist assessment
E. The urinary symptoms and cognitive decline suggest a new neurological event

Explanation: ***She is experiencing anticholinergic adverse effects from oxybutynin***- The temporal relationship between starting **oxybutynin** and the onset of **worsening memory problems** and **constipation** strongly indicates an adverse drug effect in this elderly patient.- **Oxybutynin** is an **anticholinergic medication** known to cause cognitive impairment, constipation, and urinary retention (which can lead to recurrent UTIs), particularly in older adults due to its **CNS penetration** and high anticholinergic burden.*Her multiple sclerosis is progressing and causing cognitive decline and autonomic dysfunction*- While **MS progression** can lead to cognitive and autonomic symptoms, the *acute onset* directly following the initiation of a new medication makes this less likely to be the *best* primary interpretation.- The specific cluster of **memory issues**, **constipation**, and altered bladder function aligning with known anticholinergic side effects points away from solely MS progression.*Her depression is inadequately controlled leading to cognitive symptoms*- Although **depression** can cause cognitive symptoms (sometimes termed **pseudodementia**), it would not typically explain new physical symptoms like **constipation** appearing directly after starting a non-antidepressant medication.- The patient is already on **sertraline**, and the clear temporal link to oxybutynin strongly suggests a drug-related adverse effect rather than uncontrolled depression.*She has developed a dementia syndrome requiring specialist assessment*- A diagnosis of **dementia** requires chronic progression and, importantly, the exclusion of **reversible causes**, with medication-induced cognitive impairment being a key reversible factor.- The sudden onset of cognitive decline alongside other specific symptoms (constipation, urinary issues) after starting **oxybutynin** makes a primary dementia diagnosis less likely as the *initial* interpretation.*The urinary symptoms and cognitive decline suggest a new neurological event*- While a new **neurological event** such as a stroke or an MS relapse could cause sudden changes, the constellation of **memory impairment**, **constipation**, and urinary issues, all appearing after starting a known **anticholinergic drug**, makes an adverse drug reaction a more direct and probable explanation.- It is critical to first rule out **iatrogenic causes** (e.g., drug side effects) before considering a complex new neurological event, especially in an older patient on multiple medications.

Question 109: You are reviewing a 74-year-old man with type 2 diabetes, ischaemic heart disease, heart failure (LVEF 38%), and hypertension who takes 9 medications including aspirin, atorvastatin, bisoprolol, ramipril, furosemide, metformin, gliclazide, and omeprazole. Recent blood tests show eGFR 38 ml/min/1.73m², HbA1c 64 mmol/mol, and potassium 5.2 mmol/L. Understanding the principles of managing multimorbidity, which aspect of his care requires MOST urgent review?

A. His diabetes control as HbA1c is above target and may require intensification
B. His medication regimen in light of declining renal function and hyperkalaemia (Correct Answer)
C. His heart failure management as LVEF suggests suboptimal beta-blocker dosing
D. His cardiovascular risk as he may benefit from adding ezetimibe to his statin
E. His proton pump inhibitor use as long-term omeprazole may not be indicated

Explanation: ***His medication regimen in light of declining renal function and hyperkalaemia*** - The patient has **Stage 3b Chronic Kidney Disease (CKD)** with an eGFR of 38 ml/min/1.73m² and **hyperkalaemia** (potassium 5.2 mmol/L), which creates immediate safety risks regarding his current prescriptions. - **Ramipril** can worsen hyperkalaemia and needs dose adjustment in CKD, while **Metformin** (risk of lactic acidosis) and **Gliclazide** (risk of hypoglycaemia) require urgent review in the context of impaired renal function. *His diabetes control as HbA1c is above target and may require intensification* - While an **HbA1c of 64 mmol/mol** is above the standard target, guidelines for older patients with multimorbidity prioritize safety and **individualized, less stringent glycemic targets** to prevent **hypoglycaemia**. - Intensifying diabetes treatment now, especially with **gliclazide**, without addressing the **renal impairment** would significantly increase the risk of severe adverse events. *His heart failure management as LVEF suggests suboptimal beta-blocker dosing* - Optimizing **bisoprolol** for heart failure with reduced ejection fraction (HFrEF) is important for long-term outcomes but is not an acute safety concern requiring the *most urgent* review. - Any dose adjustments to heart failure medications should be considered after stabilizing **renal function** and **electrolyte balance**. *His cardiovascular risk as he may benefit from adding ezetimibe to his statin* - Adding **ezetimibe** for secondary prevention of ischaemic heart disease is a chronic management step that does not take precedence over **acute metabolic derangements** and medication safety concerns. - Managing **polypharmacy** and preventing immediate medication-related harm is more urgent in this patient than further adjusting lipid-lowering therapy. *His proton pump inhibitor use as long-term omeprazole may not be indicated* - **Deprescribing** non-essential medications like **omeprazole** is a good principle in reducing polypharmacy, but it is not as medically urgent as managing hyperkalaemia and reviewing medications posing direct risks in renal impairment. - While PPIs have long-term considerations, the immediate risk posed by drugs like **Ramipril**, **Metformin**, and **Gliclazide** in the presence of **CKD** and **hyperkalaemia** is far greater.

Question 110: A 71-year-old man with type 2 diabetes, COPD, chronic kidney disease stage 3a (eGFR 52 ml/min/1.73m²), and hypertension attends for review. His HbA1c is 58 mmol/mol on metformin 1g BD. His blood pressure is consistently 148/88 mmHg on amlodipine 10mg daily. He also takes tiotropium and salbutamol inhalers. His main concern is breathlessness limiting his ability to garden. What is the MOST appropriate approach to managing his competing health priorities?

A. Intensify diabetes treatment to achieve HbA1c below 53 mmol/mol as per guidelines
B. Add an ACE inhibitor to improve blood pressure control and provide renal protection
C. Focus on optimising his COPD management as this is causing his main symptom (Correct Answer)
D. Arrange comprehensive geriatric assessment to address all conditions simultaneously
E. Refer to secondary care for specialist management of his complex multimorbidity

Explanation: ***Focus on optimising his COPD management as this is causing his main symptom***- In patients with **multimorbidity**, clinical guidelines suggest prioritizing the **patient's main concern**, which in this case is breathlessness limiting his quality of life.- Optimizing **COPD** (e.g., checking inhaler technique or upgrading to LAMA/LABA) directly addresses his functional impairment and aligns with **patient-centered care** as per **NICE NG56**.*Intensify diabetes treatment to achieve HbA1c below 53 mmol/mol as per guidelines*- Rigidly following **disease-specific guidelines** for HbA1c in elderly patients with multimorbidity can increase the risk of **hypoglycemia** and polypharmacy.- His current HbA1c of 58 mmol/mol is reasonable given his age and comorbidities; it is not the cause of his acute **functional limitation**.*Add an ACE inhibitor to improve blood pressure control and provide renal protection*- While an **ACE inhibitor** is indicated for **CKD** and hypertension, it does not address the patient's primary complaint of **breathlessness**.- Adding more medication should be balanced against the patient's **treatment burden** and prioritized after symptomatic relief is achieved.*Arrange comprehensive geriatric assessment to address all conditions simultaneously*- While a **Comprehensive Geriatric Assessment (CGA)** is useful for frailty, clinical management should first address the **symptomatic priority** identified during the consultation.- A CGA may be overly complex for a focused review of a patient whose primary barrier to activity is a specific **respiratory symptom**.*Refer to secondary care for specialist management of his complex multimorbidity*- Most patients with stable **multimorbidity** can be managed effectively in **primary care** by prioritizing concerns and coordinating treatment.- Referral should be reserved for specific diagnostic uncertainty or **treatment-resistant symptoms** rather than general complexity.

Question 111: A 69-year-old woman with five chronic conditions attends for her annual review. She takes 11 regular medications. According to NICE guidance on multimorbidity, which ONE of the following is the PRIMARY purpose of individualised care planning for patients with multimorbidity?

A. To reduce overall medication burden by at least 30%
B. To prioritise treatment of the condition with highest mortality risk
C. To take into account the patient's individual needs, preferences and priorities (Correct Answer)
D. To ensure all prescribing adheres strictly to individual disease-specific guidelines
E. To identify and discontinue all medications without strong evidence base

Explanation: ***To take into account the patient's individual needs, preferences and priorities*** - According to **NICE NG56**, the core objective of individualized care planning is to customize management based on the **patient's personal goals** and values rather than just disease metrics. - This approach facilitates **shared decision-making** to improve the patient's quality of life and reduce the **treatment burden** associated with multiple conditions. *To reduce overall medication burden by at least 30%* - While **polypharmacy** management is a key component, there is no specific **percentage-based target** for medication reduction in clinical guidelines. - Focus is placed on the **appropriateness** of medications rather than achieving an arbitrary numerical reduction. *To prioritise treatment of the condition with highest mortality risk* - Clinical management in multimorbidity should prioritize what is **most important to the patient**, which may be **symptom control** or functional independence rather than mortality risk. - Treating only the highest mortality risk condition ignores the **synergistic impact** of multiple chronic conditions on daily living. *To ensure all prescribing adheres strictly to individual disease-specific guidelines* - Strict adherence to multiple **single-disease guidelines** often leads to problematic polypharmacy and conflicting treatment recommendations. - NICE emphasizes moving away from **specialty-based silos** toward a holistic view that considers the interaction between different treatments. *To identify and discontinue all medications without strong evidence base* - While **stopping ineffective treatments** is part of a medication review, the primary goal of care planning is broader than just clinical evidence evaluation. - Some medications may lack a robust evidence base for the specific elderly multimorbid population but still provide **symptomatic relief** valued by the patient.

Question 112: A 72-year-old man attends with his wife who reports he has become increasingly confused over the past two weeks. He has heart failure (LVEF 40%), atrial fibrillation, COPD, type 2 diabetes, and benign prostatic hyperplasia. Current medications: digoxin 125mcg OD, bisoprolol 5mg OD, furosemide 80mg OD, ramipril 10mg OD, apixaban 5mg BD, tiotropium inhaler OD, salbutamol inhaler PRN, metformin 1g BD, sitagliptin 100mg OD, and oxybutynin 5mg TDS (started 3 weeks ago for urinary frequency). Examination: pulse 56 bpm irregular, BP 118/76 mmHg, mild peripheral oedema. Chest clear. Recent bloods: Na+ 128 mmol/L (was 138 three months ago), K+ 3.2 mmol/L, eGFR 44 ml/min/1.73m², digoxin level 2.8 mcg/L (therapeutic range 0.5-2.0). What is the most likely primary cause of his confusion?

A. Digoxin toxicity secondary to hypokalaemia and renal impairment
B. Hyponatraemia secondary to increased furosemide effect and SIADH from sitagliptin
C. Anticholinergic effects from oxybutynin causing delirium in an elderly patient (Correct Answer)
D. Cerebral hypoperfusion from excessive bradycardia due to digoxin and bisoprolol combination
E. Hypoglycaemia from metformin and sitagliptin combination in the context of reduced renal function

Explanation: ***Anticholinergic effects from oxybutynin causing delirium in an elderly patient*** - The initiation of **oxybutynin** three weeks ago matches the temporal onset of the patient's confusion, and it is a known high-risk medication for **anticholinergic-induced delirium** in the elderly. - Elderly patients with **polypharmacy** and clinical comorbidities like heart failure are particularly susceptible to the **cognitive burden** of anticholinergic drugs. *Digoxin toxicity secondary to hypokalaemia and renal impairment* - While the **digoxin level is elevated (2.8 mcg/L)** and exacerbated by low potassium and renal dysfunction, toxicity typically presents with gastrointestinal upset and **xanthopsia** (yellow-tinted vision) before delirium. - A heart rate of **56 bpm** in a patient taking both **bisoprolol** and digoxin is relatively stable and unlikely to be the sole driver of acute confusion. *Hyponatraemia secondary to increased furosemide effect and SIADH from sitagliptin* - A sodium level of **128 mmol/L** can cause confusion, but the acuity and temporal onset of the patient's symptoms more closely align with the introduction of the new **antimuscarinic medication**. - Hyponatremia in this patient is more likely a multifactorial issue, involving **furosemide** use and the underlying **heart failure**, rather than primarily a drug side effect like SIADH from sitagliptin being the sole cause of acute delirium. *Cerebral hypoperfusion from excessive bradycardia due to digoxin and bisoprolol combination* - The heart rate of **56 bpm** is considered mild bradycardia and is generally sufficient to maintain **cerebral perfusion** without causing acute confusion in an otherwise stable patient. - Blood pressure is **118/76 mmHg**, indicating that the patient is not in a state of clinical shock or significant systemic hypoperfusion that would typically cause acute delirium. *Hypoglycaemia from metformin and sitagliptin combination in the context of reduced renal function* - Neither **metformin** nor **sitagliptin** (a DPP-4 inhibitor) are typically associated with a high risk of **hypoglycemia** when used without insulin or sulfonylureas. - While metformin accumulation can occur in **renal impairment**, it primarily leads to **lactic acidosis** rather than acute hypoglycemia, and symptoms would differ.

Question 113: You are developing a practice protocol for structured medication reviews in patients with multimorbidity and polypharmacy. Evidence from systematic reviews and trials examining different medication review approaches has shown variable effects on clinical outcomes. Which statement best represents the current evidence regarding the effectiveness of structured medication reviews in reducing hospital admissions and mortality in patients with multimorbidity?

A. Structured medication reviews consistently reduce hospital admissions and mortality across all patient groups with multimorbidity
B. Medication reviews reduce medication-related problems and potentially inappropriate prescribing, but evidence for reducing hospital admissions and mortality is inconsistent (Correct Answer)
C. Medication reviews are effective only when conducted by clinical pharmacists, not by GPs or practice pharmacists
D. Medication reviews have no demonstrated benefit and represent an inefficient use of primary care resources
E. Medication reviews are effective only in patients taking more than 15 medications

Explanation: ***Medication reviews reduce medication-related problems and potentially inappropriate prescribing, but evidence for reducing hospital admissions and mortality is inconsistent*** - Systematic reviews consistently show that structured medication reviews are highly effective in identifying **potentially inappropriate prescribing (PIP)** and improving overall **medication appropriateness scores**. - However, despite these benefits, large-scale trials and meta-analyses have provided **inconsistent or limited evidence** for a significant reduction in 'hard' clinical outcomes such as **hospital admissions** or **mortality** rates. *Structured medication reviews consistently reduce hospital admissions and mortality across all patient groups with multimorbidity* - This statement overstates the current evidence, as many robust studies have not found a consistent or statistically significant reduction in **all-cause mortality** or **hospitalization** directly attributable to medication reviews. - The complex nature of **multimorbidity** often involves numerous non-medication-related factors that significantly influence clinical outcomes, making isolated impacts harder to demonstrate. *Medication reviews are effective only when conducted by clinical pharmacists, not by GPs or practice pharmacists* - Evidence supports that the effectiveness of medication reviews is largely dependent on the **structured approach** and **validated tools** used, rather than exclusively on the professional background of the reviewer. - **GPs**, **practice pharmacists**, and **clinical pharmacists** can all effectively conduct reviews, particularly when utilizing interdisciplinary collaboration and established criteria like **STOPP/START**. *Medication reviews have no demonstrated benefit and represent an inefficient use of primary care resources* - This statement is incorrect as medication reviews offer clear benefits in **reducing adverse drug reactions (ADRs)**, improving **patient adherence**, and lowering **treatment burden**. - They are considered a crucial component of **patient safety** and **quality improvement** initiatives in managing complex polypharmacy. *Medication reviews are effective only in patients taking more than 15 medications* - There is no specific number of medications, such as **15**, that defines the threshold for effectiveness; benefits are observed across various degrees of **polypharmacy** (often defined as ≥5 medications). - Patients with fewer medications but who are **frail** or on **high-risk drugs** (e.g., anticoagulants, opioids) can also greatly benefit from structured medication reviews to optimize therapy and prevent harm.

Question 114: A 75-year-old woman with heart failure (LVEF 35%), atrial fibrillation, CKD stage 3b (eGFR 36 ml/min/1.73m²), and type 2 diabetes attends for review. Medications: bisoprolol 10mg OD, ramipril 10mg OD, spironolactone 25mg OD, furosemide 40mg OD, apixaban 5mg BD, empagliflozin 10mg OD, and atorvastatin 20mg ON. Blood tests show: Na+ 138 mmol/L, K+ 5.8 mmol/L, eGFR 36 ml/min/1.73m², HbA1c 56 mmol/mol. She feels well with no symptoms. ECG shows atrial fibrillation, rate 68 bpm, no acute changes. What is the most appropriate immediate management?

A. Stop spironolactone immediately and recheck potassium in 5-7 days (Correct Answer)
B. Stop empagliflozin due to declining renal function and recheck potassium in one week
C. Reduce ramipril to 5mg OD and add calcium resonium 15g TDS until potassium normalises
D. Arrange urgent same-day review for ECG monitoring and consideration of intravenous calcium gluconate
E. Continue all medications but add patiromer 8.4g OD to manage hyperkalaemia while maintaining heart failure treatment

Explanation: ***Stop spironolactone immediately and recheck potassium in 5-7 days*** - This patient has significant **hyperkalaemia (K+ 5.8 mmol/L)**. Guidelines recommend discontinuing potassium-sparing diuretics like **spironolactone** when potassium exceeds **5.5 mmol/L**, especially in the context of **CKD stage 3b**, to prevent life-threatening levels. - **Spironolactone** is a potent contributor to hyperkalaemia. Its discontinuation is the most direct and effective immediate step to reduce potassium and is prioritized over other medications in this setting. *Stop empagliflozin due to declining renal function and recheck potassium in one week* - **SGLT-2 inhibitors** like empagliflozin provide crucial cardiorenal protection and are generally safe to continue as long as the **eGFR is >25 ml/min/1.73m²**, which is the case here (36 ml/min/1.73m²). - Empagliflozin typically has a neutral or even a slightly **potassium-lowering effect**, so it is unlikely to be the primary cause of this patient's hyperkalaemia. *Reduce ramipril to 5mg OD and add calcium resonium 15g TDS until potassium normalises* - While **ACE inhibitors (ramipril)** contribute to hyperkalaemia, stopping the more potent potassium-sparing diuretic (spironolactone) is a more appropriate initial step in this scenario, especially for maintaining optimal heart failure therapy. - **Calcium resonium** (sodium polystyrene sulfonate) is often poorly tolerated due to gastrointestinal side effects and is generally not the first-line outpatient management for mild-to-moderate hyperkalaemia, particularly without first adjusting causative medications. *Arrange urgent same-day review for ECG monitoring and consideration of intravenous calcium gluconate* - Urgent treatment with **IV calcium gluconate** is indicated for severe hyperkalaemia (typically **K+ ≥6.5 mmol/L**) or when there are **ECG changes** (e.g., peaked T-waves, QRS widening) indicating cardiac toxicity. - The patient is **asymptomatic**, and her ECG shows **no acute changes** with a potassium level of 5.8 mmol/L, which does not warrant emergency IV treatment. *Continue all medications but add patiromer 8.4g OD to manage hyperkalaemia while maintaining heart failure treatment* - **Potassium binders** like patiromer are typically used for chronic hyperkalaemia management, often in a specialist setting, to enable continuation of essential RAAS inhibitors in patients with persistent hyperkalaemia. - The immediate priority for a K+ of 5.8 mmol/L in an asymptomatic patient is to **discontinue the most prominent offending agent** (spironolactone) to ensure safety, rather than adding another medication straight away.

Question 115: During a practice audit of patients aged over 75 taking 10+ medications, you identify that 28% are taking a proton pump inhibitor (PPI) long-term without documented indication. You review one such patient: an 80-year-old man taking lansoprazole 30mg OD for 6 years, alongside aspirin 75mg OD, atorvastatin 80mg ON, bisoprolol 5mg OD, and ramipril 10mg OD for secondary prevention following myocardial infarction 7 years ago. He has no dyspepsia, reflux symptoms, or history of peptic ulcer disease. What is the most appropriate management of his PPI?

A. Continue lansoprazole indefinitely as gastroprotection for aspirin in elderly patient
B. Switch to famotidine 20mg OD to avoid long-term PPI-related risks while maintaining gastroprotection
C. Attempt to stop lansoprazole completely, warning about potential rebound dyspepsia, with trial of stopping aspirin if symptoms develop
D. Reduce lansoprazole to 15mg OD and continue long-term at this lower dose
E. Attempt to stop lansoprazole with step-down approach, restarting only if dyspepsia develops, while continuing aspirin (Correct Answer)

Explanation: ***Attempt to stop lansoprazole with step-down approach, restarting only if dyspepsia develops, while continuing aspirin***- Proper **deprescribing** is essential for patients over 75 on multiple medications when no clear indication for a **Proton Pump Inhibitor (PPI)** exists, as long-term use increases risks of **Clostridium difficile**, **osteoporosis**, and **hypomagnesaemia**.- A **step-down approach** helps manage **rebound acid hypersecretion**, which often causes transient symptoms that might otherwise be mistaken for a return of underlying disease.*Continue lansoprazole indefinitely as gastroprotection for aspirin in elderly patient*- Routine **gastroprotection** with aspirin is only indicated for high-risk patients, such as those with a history of **peptic ulcer disease**, concurrent **NSAID** use, or **anticoagulation**.- Continuing medication without a valid clinical indication contributes to **polypharmacy** and unnecessary side effect risks in the elderly.*Switch to famotidine 20mg OD to avoid long-term PPI-related risks while maintaining gastroprotection*- Switching to an **H2-receptor antagonist** does not address the core issue that acid suppression is not clinically indicated for this patient.- While it might reduce certain PPI-specific risks, it still adds to the patient's **pill burden** and carries its own side effect profile.*Attempt to stop lansoprazole completely, warning about potential rebound dyspepsia, with trial of stopping aspirin if symptoms develop*- **Aspirin** is mandatory for **secondary prevention** following a myocardial infarction; stopping it to manage acid symptoms is clinically inappropriate and increases cardiovascular risk.- Abrupt cessation without a **tapering** or step-down strategy increases the likelihood of patient failure due to severe **rebound dyspepsia**.*Reduce lansoprazole to 15mg OD and continue long-term at this lower dose*- Reducing the dose is a good first step in tapering, but maintaining it indefinitely still exposes the patient to **long-term risks** without a documented benefit.- Current guidelines emphasize **stopping** therapy entirely when there is no history of GORD or peptic ulcers requiring maintenance.

Question 116: You are reviewing a 77-year-old man with Parkinson's disease, type 2 diabetes, hypertension, benign prostatic hyperplasia, and recurrent postural hypotension. Current medications: co-careldopa 25/100 TDS, ropinirole 8mg TDS, metformin 1g BD, linagliptin 5mg OD, amlodipine 10mg OD, doxazosin 4mg ON, tamsulosin 400mcg OD, and fludrocortisone 100mcg OD for postural hypotension. His lying BP is 156/88 mmHg, standing BP is 98/62 mmHg with dizziness. What represents the most rational approach to reducing his treatment burden while improving his symptoms?

A. Stop amlodipine and increase fludrocortisone to 200mcg OD to better manage postural hypotension
B. Stop doxazosin, continue tamsulosin alone, review need for amlodipine, and consider reducing dopaminergic medication if possible (Correct Answer)
C. Stop both doxazosin and tamsulosin, as combination therapy is causing excessive hypotension
D. Add midodrine 2.5mg TDS to improve postural hypotension while continuing current antihypertensives
E. Stop fludrocortisone as it is ineffective, and add compression stockings as non-pharmacological management

Explanation: ***Stop doxazosin, continue tamsulosin alone, review need for amlodipine, and consider reducing dopaminergic medication if possible*** - **Doxazosin** is a non-selective **alpha-blocker** that significantly contributes to **postural hypotension**; using it alongside **tamsulosin** (a selective alpha-1A blocker) for BPH represents unnecessary **polypharmacy** and a major contributor to symptoms. - Managing symptomatic **orthostatic hypotension** takes priority over treating asymptomatic **supine hypertension** in Parkinson's disease, necessitating a review of **amlodipine** and potential reduction of **dopaminergic agents** like co-careldopa and ropinirole which can exacerbate hypotension. *Stop amlodipine and increase fludrocortisone to 200mcg OD to better manage postural hypotension* - Increasing **fludrocortisone** without addressing other major causes of hypotension like doxazosin and dopaminergics increases the risk of **supine hypertension** and fluid overload. - This approach adds to the **treatment burden** rather than reducing it through rational **deprescribing** of offending agents. *Stop both doxazosin and tamsulosin, as combination therapy is causing excessive hypotension* - Completely stopping all BPH medications (doxazosin and tamsulosin) would likely lead to a recurrence of bothersome **lower urinary tract symptoms (LUTS)** due to prostatic obstruction. - **Tamsulosin** is uroselective and less likely than **doxazosin** to cause systemic hypotension, making it the preferred agent to retain for symptom control if BPH treatment is needed. *Add midodrine 2.5mg TDS to improve postural hypotension while continuing current antihypertensives* - Adding **midodrine** introduces a "prescribing cascade" where a new drug is used to treat the side effects of existing medications (**amlodipine/doxazosin/dopaminergics**). - It fails to address the **iatrogenic** nature of the patient's symptoms and increases the complexity and pill burden of his medication regimen. *Stop fludrocortisone as it is ineffective, and add compression stockings as non-pharmacological management* - Stopping **fludrocortisone** abruptly in a patient with significant postural drops may lead to a worsening of **syncopal risk** if the vasodilatory medications are not addressed first. - While **non-pharmacological** measures are helpful, they are insufficient to counteract the potent hypotensive effects of his current **polypharmacy** and do not reduce the treatment burden.

Question 117: A 68-year-old woman with atrial fibrillation, heart failure (LVEF 42%), hypertension, type 2 diabetes, and osteoarthritis is taking warfarin (target INR 2-3), bisoprolol, furosemide, ramipril, metformin, gliclazide, and co-codamol. Her INR has been unstable over the past 4 months, ranging from 1.6 to 4.2, requiring frequent monitoring. Adherence appears good. She has no symptoms of heart failure decompensation or bleeding. What medication-related factor is most likely contributing to her INR instability?

A. Interaction between warfarin and bisoprolol affecting hepatic metabolism
B. Co-codamol containing paracetamol which potentiates warfarin effect with regular use (Correct Answer)
C. Gliclazide causing variable caloric intake due to hypoglycaemia episodes affecting vitamin K intake
D. Furosemide causing dehydration and concentration changes affecting warfarin levels
E. Ramipril interaction with warfarin through effects on hepatic clearance

Explanation: ***Co-codamol containing paracetamol which potentiates warfarin effect with regular use***- Regular use of **paracetamol** (typically >2g per day for several days) can inhibit the metabolism of **vitamin K-dependent clotting factors**, leading to an elevated **INR**.- In patients with **osteoarthritis**, the chronic use of combination analgesics like **co-codamol** is a common but frequently overlooked cause of **INR instability**.*Interaction between warfarin and bisoprolol affecting hepatic metabolism*- **Bisoprolol** is a cardioselective **beta-blocker** that does not significantly induce or inhibit **CYP450 enzymes** involved in **warfarin** metabolism.- There is no clinically documented interaction between these two drugs that would result in frequent **INR fluctuations**.*Gliclazide causing variable caloric intake due to hypoglycaemia episodes affecting vitamin K intake*- While **gliclazide** can cause **hypoglycemia**, there is no evidence in the history that the patient is experiencing frequent episodes or significant **dietary changes**.- Variations in **vitamin K** intake from green leafy vegetables affect INR, but this is less likely to cause such persistent and wide ranges (1.6 to 4.2) than a direct **drug interaction**.*Furosemide causing dehydration and concentration changes affecting warfarin levels*- **Furosemide** is a **loop diuretic** that does not have a direct pharmacological interaction with **warfarin** or its metabolic pathways.- While severe **dehydration** can theoretically affect drug concentrations, it would typically present with symptoms of **renal impairment** or hypotension, which are not described here.*Ramipril interaction with warfarin through effects on hepatic clearance*- **Ramipril** is an **ACE inhibitor** primarily excreted by the kidneys and does not interfere with the **liver's** ability to process warfarin.- **ACE inhibitors** are generally considered safe for use alongside **oral anticoagulants** without the need for additional **INR monitoring**.

Question 118: During a structured medication review using the NO TEARS tool for a 73-year-old woman with rheumatoid arthritis, hypertension, type 2 diabetes, and chronic pain, you identify that she takes: methotrexate 15mg weekly, folic acid 5mg weekly, hydroxychloroquine 200mg BD, prednisolone 5mg OD, amlodipine 5mg OD, ramipril 5mg OD, metformin 1g BD, tramadol 50mg QDS, and paracetamol 1g QDS. She reports constipation and daytime drowsiness. Which component of the NO TEARS mnemonic is most relevant to addressing her symptoms?

A. Need and indication - questioning whether prednisolone 5mg daily is still indicated
B. Open questions - exploring her understanding of why she takes each medication
C. Tests and monitoring - checking that methotrexate monitoring is up to date
D. Evidence and guidelines - reviewing whether tramadol is appropriate first-line for chronic pain
E. Adverse effects - identifying tramadol as the likely cause of constipation and drowsiness (Correct Answer)

Explanation: ***Adverse effects - identifying tramadol as the likely cause of constipation and drowsiness***- The **Adverse effects** component of the **NO TEARS** tool directly addresses identifying and managing medication side effects, which aligns perfectly with her reported symptoms. - **Tramadol**, being a weak **opioid**, commonly causes **constipation** due to reduced gut motility and **daytime drowsiness** through its central nervous system depressant effects.*Need and indication - questioning whether prednisolone 5mg daily is still indicated*- While **prednisolone** dosage requires regular review, it is unlikely to be the cause of her current **constipation** or **drowsiness** at this dose. - This component focuses on ensuring each medication still has a valid **clinical indication** and meets a specific therapeutic need.*Open questions - exploring her understanding of why she takes each medication*- **Open questions** are crucial for assessing a patient's **understanding** of their regimen and **adherence**, but they do not directly identify the underlying cause of adverse drug reactions. - This part of the review aims to gain insight into the patient's perspective and build a **patient-centered** care plan.*Tests and monitoring - checking that methotrexate monitoring is up to date*- **Methotrexate** requires routine **hematological** and **liver function** monitoring to prevent serious adverse effects, but these tests are not related to her reported symptoms. - This component ensures that medications requiring close surveillance are being safely managed through appropriate **diagnostic testing**.*Evidence and guidelines - reviewing whether tramadol is appropriate first-line for chronic pain*- While reviewing the **appropriateness** of **tramadol** for chronic pain based on guidelines is important, this step focuses on overall drug selection and efficacy rather than directly identifying present **adverse effects**. - This component assesses if the prescribed medications align with current **clinical guidelines** and best practice for her conditions.

Question 119: A 71-year-old man with COPD (post-bronchodilator FEV1 52% predicted), type 2 diabetes, hypertension, benign prostatic hyperplasia, and depression attends for annual review. Medications: metformin 1g BD, gliclazide 80mg BD, amlodipine 10mg OD, ramipril 10mg OD, tamsulosin 400mcg OD, finasteride 5mg OD, sertraline 100mg OD, tiotropium inhaler OD, salbutamol inhaler PRN, and beclometasone/formoterol 200/6 two puffs BD. He reports two COPD exacerbations in the past year requiring oral prednisolone and antibiotics. His recent HbA1c is 72 mmol/mol. What change to his treatment regimen best addresses both his COPD exacerbations and diabetes control?

A. Add azithromycin 250mg OD three times per week as prophylaxis for COPD exacerbations
B. Switch from gliclazide to empagliflozin 10mg OD for diabetes management (Correct Answer)
C. Add roflumilast 500mcg OD to reduce COPD exacerbations and improve glucose control
D. Increase beclometasone/formoterol to 400/12 two puffs BD to prevent further exacerbations
E. Add a GLP-1 receptor agonist for diabetes control and anti-inflammatory effects

Explanation: ***Switch from gliclazide to empagliflozin 10mg OD for diabetes management***- **SGLT-2 inhibitors** like empagliflozin have been shown to reduce the frequency of **acute exacerbations of COPD**, likely through anti-inflammatory and metabolic effects.- This switch addresses the patient's **poorly controlled diabetes** (HbA1c 72 mmol/mol), provides **cardiovascular and renal protection**, and avoids the **hypoglycemia risk** associated with gliclazide, especially when oral steroids are used for exacerbations.*Add azithromycin 250mg OD three times per week as prophylaxis for COPD exacerbations*- While **macrolide prophylaxis** can reduce COPD exacerbations in frequent exacerbators, it offers **no benefit** for the patient's poorly controlled **Type 2 diabetes**.- Long-term azithromycin use requires careful monitoring for risks such as **QT prolongation**, **ototoxicity**, and increased **antibiotic resistance**.*Add roflumilast 500mcg OD to reduce COPD exacerbations and improve glucose control*- **Roflumilast**, a PDE4 inhibitor, is indicated for severe COPD with chronic bronchitis and frequent exacerbations but does **not possess glucose-lowering properties**.- It is often associated with significant **gastrointestinal side effects** and **weight loss**, which might limit its tolerability and doesn't address the primary diabetes issue.*Increase beclometasone/formoterol to 400/12 two puffs BD to prevent further exacerbations*- Increasing the dose of **inhaled corticosteroids (ICS)** above recommended levels can increase the risk of local (e.g., oral candidiasis) and systemic side effects without guaranteeing a proportional additional reduction in exacerbations.- Higher ICS doses can potentially **worsen glycemic control** and increase the risk of **pneumonia** in COPD patients, which is counterproductive for this patient.*Add a GLP-1 receptor agonist for diabetes control and anti-inflammatory effects*- **GLP-1 receptor agonists** are highly effective for lowering HbA1c and promoting weight loss, but they **lack the specific evidence base** that SGLT-2 inhibitors have for reducing **COPD exacerbations**.- While they may have general anti-inflammatory effects, they are **not a recognized strategy** for managing recurrent COPD exacerbations compared to SGLT-2 inhibitors.

Question 120: You are conducting a medication review for a 76-year-old woman with osteoarthritis, osteoporosis, gastro-oesophageal reflux disease, and recurrent urinary tract infections. She takes alendronic acid 70mg weekly, calcium/vitamin D daily, omeprazole 20mg OD, paracetamol 1g QDS, and recently completed a 7-day course of trimethoprim. She mentions she has been taking ibuprofen 400mg TDS purchased over-the-counter for the past 3 months for worsening hip pain. Recent blood tests show: Hb 102 g/L (previous 128 g/L six months ago), MCV 78 fL, ferritin 18 mcg/L, eGFR 42 ml/min/1.73m² (previous 58 ml/min/1.73m² six months ago). What is the most important immediate action?

A. Arrange urgent upper gastrointestinal endoscopy for investigation of iron deficiency anaemia
B. Stop ibuprofen immediately and arrange to review in one week after checking renal function (Correct Answer)
C. Add lansoprazole 30mg OD and continue ibuprofen with gastroprotection for pain management
D. Stop omeprazole as prolonged PPI use may be causing iron malabsorption and anaemia
E. Refer to orthopaedics for consideration of hip replacement given inadequate pain control

Explanation: ***Stop ibuprofen immediately and arrange to review in one week after checking renal function*** - The patient has developed significant **acute kidney injury** (eGFR drop from 58 to 42) and **iron deficiency anaemia** (low Hb, low MCV, low ferritin) directly linked to chronic **NSAID use**. - Stopping the causative agent (ibuprofen) is the **immediate priority** to prevent further renal deterioration and potentially life-threatening gastrointestinal blood loss. *Arrange urgent upper gastrointestinal endoscopy for investigation of iron deficiency anaemia* - While investigation of **iron deficiency anaemia** is essential, it is not the very first immediate action before addressing the ongoing cause of harm. - **Urgent endoscopy** may eventually be required, but stabilization and cessation of the NSAID must occur first to prevent further acute complications. *Add lansoprazole 30mg OD and continue ibuprofen with gastroprotection for pain management* - Continuing **ibuprofen** is contraindicated given the established **acute kidney injury** and suspected **gastrointestinal bleeding**. - Adding a **PPI** offers insufficient protection when clear evidence of NSAID-induced harm (anaemia, AKI) is already present, and it does not mitigate nephrotoxicity. *Stop omeprazole as prolonged PPI use may be causing iron malabsorption and anaemia* - A significant drop in **Hb** (128 to 102) over six months is far more consistent with **NSAID-induced gastrointestinal bleeding** than with subtle iron malabsorption from PPI use. - Stopping **omeprazole** in a patient with GORD who is likely experiencing NSAID-related gastrointestinal irritation could worsen her reflux symptoms. *Refer to orthopaedics for consideration of hip replacement given inadequate pain control* - This addresses a long-term management strategy for **osteoarthritis** but completely overlooks the **acute medical emergency** of kidney injury and severe anaemia. - The immediate focus must be on stabilizing the patient from the adverse drug reaction before considering elective surgical referrals.

Question 121: A 69-year-old man with type 2 diabetes, ischaemic heart disease, heart failure (LVEF 38%), stage 3b CKD (eGFR 38 ml/min/1.73m²), and gout attends for review. His medications include: metformin 500mg BD, gliclazide 160mg BD, aspirin 75mg OD, atorvastatin 80mg ON, bisoprolol 10mg OD, ramipril 10mg OD, furosemide 40mg OD, and allopurinol 100mg OD. Recent HbA1c is 64 mmol/mol. He reports two episodes of feeling shaky and sweaty in the past month, relieved by eating. What is the most appropriate next step in his medication management?

A. Add empagliflozin 10mg OD for additional cardiovascular and renal protection
B. Stop metformin due to CKD stage 3b and replace with a DPP-4 inhibitor
C. Reduce or stop gliclazide and consider replacing with a GLP-1 receptor agonist or SGLT-2 inhibitor (Correct Answer)
D. Increase allopurinol to 300mg OD to improve uric acid control and reduce cardiovascular risk
E. Add spironolactone 25mg OD to optimise heart failure management

Explanation: ***Reduce or stop gliclazide and consider replacing with a GLP-1 receptor agonist or SGLT-2 inhibitor*** - The patient is experiencing symptomatic **hypoglycaemia** (shaky, sweaty, relieved by food), and **Gliclazide** is the most likely cause, as it is a **sulfonylurea** that carries a high risk of low blood sugar, especially in patients with **CKD** due to impaired drug clearance. - Replacing it with an **SGLT-2 inhibitor** or **GLP-1 receptor agonist** addresses the hypoglycaemia risk and provides superior **cardiovascular and renal protection** for his heart failure (LVEF 38%) and Stage 3b CKD without inducing hypoglycaemia. *Add empagliflozin 10mg OD for additional cardiovascular and renal protection* - While an **SGLT-2 inhibitor** like empagliflozin is strongly indicated for his heart failure and CKD, simply adding it to his current regimen does not address the immediate danger of **Gliclazide-induced hypoglycaemia**. - The clinical priority in a patient already experiencing symptomatic hypos is to **deprescribe** or reduce the offending agent (Gliclazide) before adding new glucose-lowering drugs, especially if the HbA1c is not excessively high. *Stop metformin due to CKD stage 3b and replace with a DPP-4 inhibitor* - **Metformin** only requires a dose reduction (max 1g/day) at an **eGFR of 30-45 ml/min/1.73m²** and does not need to be stopped entirely until the eGFR falls below **30 ml/min/1.73m²**. The patient's current eGFR is 38. - While a **DPP-4 inhibitor** is weight-neutral and safe in CKD, it does not offer the same robust **cardioprotective benefits** (specifically for HF) as SGLT-2 inhibitors or GLP-1 receptor agonists, nor does stopping metformin address the hypoglycaemia. *Increase allopurinol to 300mg OD to improve uric acid control and reduce cardiovascular risk* - Increasing **Allopurinol** does not address the patient's acute presentation of **hypoglycaemia**, which is the most pressing clinical safety issue requiring immediate attention. - In patients with **Stage 3b CKD** (eGFR 38), allopurinol doses should be titrated cautiously, and 100mg OD might already be appropriate, or require careful titration, due to the risk of **Allopurinol Hypersensitivity Syndrome** and renal clearance considerations. *Add spironolactone 25mg OD to optimise heart failure management* - Although **Mineralocorticoid Receptor Antagonists (MRAs)** like spironolactone are indicated for **HFrEF** (LVEF 38%), adding one in a patient with stage 3b CKD already on a high-dose ACE inhibitor (**Ramipril 10mg OD**) poses a significant risk of **hyperkalaemia**. - This intervention also ignores the symptomatic **hypoglycaemia**, which is an immediate safety concern that requires prompt medication adjustment to prevent falls or more severe neuroglycopenic events.

Question 122: A 74-year-old woman with heart failure (NYHA class II), atrial fibrillation, type 2 diabetes, and chronic kidney disease stage 3a presents for medication review. She takes bisoprolol, ramipril, spironolactone, furosemide, apixaban, metformin, and atorvastatin. Her recent blood tests show: eGFR 48 ml/min/1.73m², potassium 5.2 mmol/L, HbA1c 58 mmol/mol. She reports good adherence and no symptoms of heart failure decompensation. What concept best explains why further intensification of her heart failure treatment should be approached cautiously?

A. Therapeutic ceiling - the maximum benefit from ACE inhibitor and beta-blocker has been achieved
B. Diminishing returns - additional benefit from further treatment is outweighed by potential harm (Correct Answer)
C. Therapeutic competition - treatments for different conditions are working against each other
D. Cascading prescribing - adding medications to treat side effects of existing medications
E. Treatment saturation - the patient is at maximum capacity for medication adherence

Explanation: ***Diminishing returns - additional benefit from further treatment is outweighed by potential harm*** - This patient exhibits **diminishing returns** because she is already on guideline-directed therapy for heart failure, and further intensification poses significant risks like **hyperkalaemia** (potassium already 5.2 mmol/L) or **acute kidney injury** due to her stage 3a **CKD**. - In **multimorbidity**, the incremental benefit of adding a new drug often decreases while the **cumulative risk** of adverse effects and drug interactions increases, making further intensification less favorable. *Therapeutic ceiling - the maximum benefit from ACE inhibitor and beta-blocker has been achieved* - This refers to a pharmacological limit where increasing the dose no longer produces a **therapeutic effect**, rather than a clinical balance of risks and benefits. - The patient is currently asymptomatic at **NYHA class II**, but the reason to stop is not necessarily pharmacological saturation, but clinical safety regarding **potassium** and **renal function**. *Therapeutic competition - treatments for different conditions are working against each other* - This occurs when a drug for one condition, such as an **NSAID**, worsens another condition, such as **Heart Failure**; this is not the primary issue here as her drugs are generally compatible. - While some drugs like **spironolactone** and **ramipril** both affect the kidneys, they are indicated for the same condition rather than treating competing pathologies. *Cascading prescribing - adding medications to treat side effects of existing medications* - This describes a cycle where a **side effect** of one drug is misinterpreted as a new medical condition, leading to another prescription (e.g., prescribing a diuretic for **amlodipine-induced edema**). - It is not applicable here as the patient's current medications address her specific diagnosed comorbidities like **diabetes** and **atrial fibrillation**. *Treatment saturation - the patient is at maximum capacity for medication adherence* - This refers to the **burden of treatment** where a patient can no longer manage the complexity or volume of their regimen, leading to **non-adherence**. - While relevant to elderly patients with polypharmacy, the clinical focus of the question is on the **biochemical risks** (potassium/eGFR) rather than the patient's psychological or logistical ability to take more pills.

Question 123: During a medication review of a 72-year-old man with type 2 diabetes, COPD, and hypertension, you identify that he is taking metformin 1g BD, gliclazide 80mg BD, bisoprolol 5mg OD, ramipril 10mg OD, salbutamol inhaler PRN, and tiotropium inhaler OD. His recent HbA1c is 52 mmol/mol, BP 128/78 mmHg, and he reports no hypoglycaemic episodes. What aspect of his medication regimen best demonstrates the principle of treatment burden in multimorbidity?

A. The potential for bisoprolol to worsen COPD symptoms and mask hypoglycaemia from gliclazide (Correct Answer)
B. The use of multiple inhalers requiring different techniques in a patient with diabetes
C. The need to take gliclazide twice daily with meals while managing multiple other medications
D. The risk of postural hypotension from the combination of ramipril and bisoprolol
E. The requirement for regular monitoring of renal function due to metformin and ramipril

Explanation: ***The potential for bisoprolol to worsen COPD symptoms and mask hypoglycaemia from gliclazide*** - This demonstrates **treatment burden** by highlighting how a medication for one condition (hypertension) negatively interferes with the **management and safety** of two other unrelated conditions (COPD and diabetes). - Bisoprolol can cause **bronchoconstriction** in COPD and mask **adrenergic symptoms** of hypoglycaemia (e.g., tremor, palpitations) induced by gliclazide, significantly increasing patient vigilance and risk. *The use of multiple inhalers requiring different techniques in a patient with diabetes* - While this illustrates **practical workload** and potential adherence issues, it primarily focuses on the **mechanical complexity** of polypharmacy, not the intricate therapeutic conflicts between treatments for distinct comorbidities. - It represents a component of treatment burden but not the **cross-condition clinical interactions** that are central to managing multimorbidity. *The need to take gliclazide twice daily with meals while managing multiple other medications* - This points to **regimen complexity** and challenges with medication timing, which is a facet of treatment burden. - However, it represents a relatively straightforward adherence challenge for one drug rather than a **complex therapeutic interaction** or conflict spanning multiple disease systems. *The risk of postural hypotension from the combination of ramipril and bisoprolol* - This is a common **drug-drug interaction** leading to a side effect when combining two antihypertensive medications, affecting the **same disease (hypertension)**. - It adds to monitoring requirements but does not exemplify the **competing priorities** or symptom masking across unrelated conditions typical of high multimorbidity treatment burden. *The requirement for regular monitoring of renal function due to metformin and ramipril* - This represents **healthcare-related workload** (e.g., blood tests, clinic visits) which is part of treatment burden. - However, it is a **routine safety measure** for these medications and does not involve the direct therapeutic conflicts or masking of symptoms between different conditions that demonstrate a higher level of multimorbidity burden.

Question 124: A 67-year-old woman with asthma, hypertension, osteoarthritis, hypothyroidism, and depression presents for review. She takes salbutamol, beclometasone inhaler, amlodipine, ramipril, levothyroxine, paracetamol, ibuprofen, and sertraline. She reports good control of all conditions but mentions occasional indigestion. What is the most appropriate understanding of her polypharmacy status?

A. This represents problematic polypharmacy requiring immediate deprescribing
B. This is appropriate polypharmacy but requires gastroprotection with a proton pump inhibitor
C. This represents appropriate polypharmacy with evidence-based treatments, but the ibuprofen requires review (Correct Answer)
D. This is minor polypharmacy that does not require structured medication review
E. This requires urgent referral to a clinical pharmacist for comprehensive review

Explanation: ***This represents appropriate polypharmacy with evidence-based treatments, but the ibuprofen requires review*** - The patient's medications for asthma, hypertension, hypothyroidism, and depression are largely **evidence-based** and she reports good control, indicating appropriate polypharmacy for her chronic conditions. - However, the use of **ibuprofen** (an NSAID) in a 67-year-old taking **ramipril** (an ACE inhibitor) and **sertraline** (an SSRI) poses significant risks of **renal impairment** (the "triple whammy") and **gastrointestinal bleeding/indigestion**, necessitating its review. *This represents problematic polypharmacy requiring immediate deprescribing* - Many of her medications, such as **amlodipine, ramipril, levothyroxine, salbutamol, beclometasone**, and **sertraline**, are essential for managing her well-controlled chronic conditions. - While one medication (ibuprofen) is problematic, labeling the entire regimen as such, and suggesting *immediate deprescribing* of multiple agents, is inappropriate given her stable conditions. *This is appropriate polypharmacy but requires gastroprotection with a proton pump inhibitor* - While gastroprotection might address the indigestion, simply adding a **proton pump inhibitor (PPI)** doesn't resolve the more critical risk of **acute kidney injury** from the combination of **NSAID** and **ACE inhibitor** in an elderly patient. - Prioritizing the addition of another drug over reviewing the potentially harmful drug (ibuprofen) is not the most appropriate initial management strategy. *This is minor polypharmacy that does not require structured medication review* - Taking multiple medications (8 in this case) for several chronic conditions is defined as **polypharmacy**, not minor, especially when a new symptom (indigestion) arises. - The presence of a high-risk medication interaction (**NSAID + ACEi**) and a new symptom definitely warrants a **structured medication review** to optimize therapy and prevent harm. *This requires urgent referral to a clinical pharmacist for comprehensive review* - While a clinical pharmacist's review is valuable, this scenario, though concerning due to the ibuprofen-ramipril interaction, is not an **urgent medical emergency** requiring immediate specialist referral. - A primary care physician or general practitioner should be capable of identifying and addressing this common **drug interaction** and modifying the pain management strategy in a routine consultation.

Question 125: A 78-year-old man with multiple comorbidities attends for review. He takes 13 different medications daily. According to current UK guidance on medicines optimisation in patients with polypharmacy, what is the recommended minimum frequency for structured medication reviews in this patient?

A. Every 3 months
B. Every 6 months
C. Every 12 months (Correct Answer)
D. Every 18 months
E. Only when clinically indicated

Explanation: ***Every 12 months*** - According to **NICE guidelines** and standard UK primary care practice, patients on significant **polypharmacy** (often 10+ medications) should undergo a **structured medication review (SMR)** at least **annually**. - This review aims to optimize therapy, reduce **medication-related harm**, and facilitate **deprescribing** where the risks of a drug outweigh the clinical benefits. *Every 3 months* - A 3-month cycle is not the recommended minimum for a routine structured review, as it would likely be unsustainable for **primary care capacity** without specific acute indications. - Such frequent monitoring is usually reserved for specific high-risk drugs like **lithium** or **DMARDs**, rather than a whole-patient medication review. *Every 6 months* - While 6-monthly reviews may be clinically appropriate for individuals with high **clinical complexity** or those moving between care settings, it is not the standard minimum requirement. - Clinicians may choose this frequency for patients with rapidly fluctuating **multimorbidity**, but the baseline recommendation remains yearly. *Every 18 months* - An 18-month interval is considered too long for a patient on 13 medications, as it increases the risk of **adverse drug reactions** going undetected. - Waiting this long exceeds the **national Quality and Outcomes Framework (QOF)** and NICE expectations for proactive medicines optimization. *Only when clinically indicated* - **Structured medication reviews** are intended to be **proactive** and preventative rather than purely reactive to clinical events. - Relying solely on clinical indication ignores the asymptomatic accumulation of **drug-drug interactions** and the slow decline in **renal function** common in elderly patients.

Question 126: A practice pharmacist reviews prescribing data and identifies that 18% of patients with heart failure and reduced ejection fraction are not prescribed an ACE inhibitor or angiotensin receptor blocker (ARB), and 35% are not on a beta-blocker. Many have documented 'patient declined' or 'not tolerated' in their records from several years ago. From a multimorbidity management perspective, which single interpretation of this data is most appropriate?

A. This represents clear evidence of suboptimal prescribing requiring immediate prescription of these medications
B. The documentation suggests appropriate shared decision-making and patient choice should be respected
C. These patients should be identified for clinical review to reassess tolerance and discuss current evidence with patients (Correct Answer)
D. The practice should implement automatic prescribing protocols for all newly diagnosed heart failure patients
E. This data suggests patients are appropriately managed as ACE inhibitors and beta-blockers are overemphasized in guidelines

Explanation: ***These patients should be identified for clinical review to reassess tolerance and discuss current evidence with patients***- Documentation of **'patient declined'** or **'not tolerated'** from several years ago does not account for changes in clinical status, newer formulations, or evolving **patient preferences** over time.- Reassessing these patients helps overcome **therapeutic inertia**, ensuring they are offered **evidence-based therapies** like ACE inhibitors and beta-blockers that significantly reduce mortality in **HFrEF**.*This represents clear evidence of suboptimal prescribing requiring immediate prescription of these medications*- Prescribing without a **clinical review** is unsafe as patients may have valid **contraindications** (e.g., severe renal impairment or hyperkalemia) not immediately visible in summary data.- Immediate prescription bypasses the essential process of **informed consent** and individualized assessment required in **multimorbidity management**.*The documentation suggests appropriate shared decision-making and patient choice should be respected*- While prior choices are noted, **shared decision-making** is a continuous process; a decision made years ago may no longer reflect the patient’s **current goals of care**.- Relying solely on historical notes may lead to **under-treatment** of a progressive condition where the benefits of therapy may now outweigh previous concerns.*The practice should implement automatic prescribing protocols for all newly diagnosed heart failure patients*- **Automatic protocols** ignore the complexity of patients with **multimorbidity** who require tailored dosing and monitoring to ensure safety and adherence.- Guidelines emphasize **individualized care**, and a "one size fits all" approach fails to address specific patient **comorbidities** and potential drug interactions.*This data suggests patients are appropriately managed as ACE inhibitors and beta-blockers are overemphasized in guidelines*- These medications are **cornerstone therapies** for heart failure with reduced ejection fraction, with robust evidence supporting their **mortality and morbidity benefits**.- Labelling them as "overemphasized" contradicts current **clinical guidelines** (e.g., NICE, ESC) which prioritize these agents to improve long-term patient outcomes.

Question 127: During a comprehensive medication review for a 75-year-old woman with COPD, hypertension, atrial fibrillation, and depression, you identify she is taking 12 regular medications. She reports feeling overwhelmed by her medication regimen and sometimes missing doses. According to principles of medicines optimization, which single approach would best support her adherence?

A. Arrange for all medications to be dispensed in a monitored dosage system (blister pack)
B. Simplify the regimen where possible, explore her concerns, and develop a shared plan with written information (Correct Answer)
C. Reduce her medication review interval to monthly to ensure better monitoring
D. Prescribe all medications as once-daily preparations regardless of standard dosing
E. Arrange for district nurses to supervise all medication administration

Explanation: ***Simplify the regimen where possible, explore her concerns, and develop a shared plan with written information***- This approach aligns with **NICE medicines optimization** guidelines by addressing both **intentional and unintentional non-adherence** through patient-centered communication.- **Simplifying polypharmacy** and providing **written information** reduces the cognitive burden on the patient while fostering **shared decision-making** and engagement.*Arrange for all medications to be dispensed in a monitored dosage system (blister pack)*- **Monitored dosage systems (MDS)** are not a universal solution and there is limited evidence that they improve clinical outcomes or adherence for all patients.- They may reduce a patient's **autonomy** and understanding of their medication, and are intended only for specific needs rather than a first-line intervention for complexity.*Reduce her medication review interval to monthly to ensure better monitoring*- **Monthly reviews** are resource-intensive for the healthcare system and may become an additional burden to the patient without addressing the root cause of feeling overwhelmed.- **Medicines optimization** focuses on the quality of the review and patient empowerment rather than the frequency of appointments.*Prescribe all medications as once-daily preparations regardless of standard dosing*- Changing medications to **once-daily dosing** without regard for pharmacokinetics or clinical evidence can lead to **sub-therapeutic levels** or increased toxicity.- While reducing frequency is helpful, it must be clinically appropriate and evidence-based for each specific drug in the **polypharmacy** regimen.*Arrange for district nurses to supervise all medication administration*- This intervention is overly restrictive for a patient living independently and may lead to a loss of **self-management skills**.- **District nurse** intervention should be reserved for those with physical or cognitive impairments that make self-administration impossible, rather than those who are simply overwhelmed.

Question 128: A 77-year-old man with type 2 diabetes, heart failure (LVEF 30%), and recurrent falls takes metformin, gliclazide, insulin glargine, bisoprolol, ramipril, furosemide, and atorvastatin. His HbA1c is 42 mmol/mol, and he has had three episodes of documented hypoglycaemia (glucose 2.8-3.2 mmol/L) in the past month, two occurring at night. Which single medication adjustment would most appropriately address his hypoglycaemia risk while maintaining adequate glycaemic control?

A. Stop gliclazide and continue metformin and insulin glargine (Correct Answer)
B. Stop insulin glargine and increase gliclazide dose to maintain control
C. Reduce insulin glargine dose by 20% and continue all other diabetes medications
D. Stop both gliclazide and insulin glargine and start a GLP-1 receptor agonist
E. Stop metformin as it increases hypoglycaemia risk in combination with sulfonylureas

Explanation: ***Stop gliclazide and continue metformin and insulin glargine*** - The patient's **HbA1c of 42 mmol/mol (6.0%)** is below the target for an elderly, frail individual with comorbidities, indicating **overtreatment** and explaining the recurrent hypoglycaemia. - **Gliclazide**, a sulfonylurea, is a major contributor to **hypoglycaemia**, especially nocturnal events, and should be discontinued first in favour of the safer **metformin** and basal **insulin glargine** combination. *Stop insulin glargine and increase gliclazide dose to maintain control* - Increasing the **gliclazide dose** would significantly exacerbate the risk of **hypoglycaemia**, which is the primary and most dangerous problem for this elderly patient. - Sulfonylureas are associated with less predictable glucose lowering and a higher risk of severe hypoglycaemia compared to basal insulin, making them less suitable for frail patients. *Reduce insulin glargine dose by 20% and continue all other diabetes medications* - While reducing **insulin glargine** might help, continuing **gliclazide** in a patient with recurrent hypoglycaemia and a very low HbA1c still leaves a significant risk of further episodes. - This approach does not fully address the significant risk posed by the **sulfonylurea** in an elderly patient who is already over-treated. *Stop both gliclazide and insulin glargine and start a GLP-1 receptor agonist* - Abruptly stopping both **insulin glargine** and **gliclazide** could lead to uncontrolled hyperglycaemia, and starting a new injectable like a **GLP-1 receptor agonist** may cause gastrointestinal side effects. - While GLP-1 agonists have benefits, the immediate priority in this patient is to safely **deprescribe** the medication most responsible for hypoglycaemia rather than initiating complex new therapies. *Stop metformin as it increases hypoglycaemia risk in combination with sulfonylureas* - **Metformin** has a very low intrinsic risk of **hypoglycaemia** and is generally continued in type 2 diabetes due to its cardiovascular benefits and weight-neutral profile. - Removing metformin while keeping the **sulfonylurea (gliclazide)** would fail to address the primary cause of this patient's recurrent, documented hypoglycaemia.

Question 129: You are evaluating the implementation of a structured medication review service for patients with polypharmacy in your practice. Initial data shows that 45% of patients aged over 75 on 10+ medications have had a structured review in the past 12 months. The QOF target is at least annual review. Which single factor would most significantly improve the effectiveness of medication reviews in reducing adverse outcomes?

A. Increasing the frequency of medication reviews to every 6 months for all patients
B. Ensuring medication reviews result in documented agreed actions with follow-up arrangements (Correct Answer)
C. Training all reception staff to identify patients requiring medication reviews
D. Implementing computer alerts for all potential drug interactions
E. Requiring all medication reviews to be conducted by clinical pharmacists

Explanation: ***Ensuring medication reviews result in documented agreed actions with follow-up arrangements*** - A structured review is only effective if it leads to **meaningful clinical changes** that are implemented, monitored, and followed up to ensure safety. - Documentation of **specific actions** (e.g., deprescribing, dose adjustments) and clear **follow-up arrangements** ensures accountability and aligns with **NICE medicines optimization** guidelines. *Increasing the frequency of medication reviews to every 6 months for all patients* - Simply increasing frequency without improving the **quality of the process** does not guarantee better clinical outcomes and may be a poor use of resources. - It risks **process fatigue** and may not prioritize high-risk patients who require more intensive monitoring over stable patients. *Training all reception staff to identify patients requiring medication reviews* - While this improves **identification and scheduling** efficiency, it does not directly impact the **clinical quality** of the review or the management of adverse effects. - Outcomes are determined by the **clinical interventions** made during the review, not the administrative process of flagging patients. *Implementing computer alerts for all potential drug interactions* - Over-reliance on automated alerts often leads to **alert fatigue**, where clinicians ignore significant warnings due to the high volume of clinically irrelevant notifications. - Alerts are a **decision-support tool** but do not replace the comprehensive, patient-centered approach of a structured medication review. *Requiring all medication reviews to be conducted by clinical pharmacists* - While clinical pharmacists have specialized expertise, the **systematic process** and follow-through are more critical for effectiveness than the specific healthcare professional involved. - Effectiveness depends on the **integration of the review** into the patient's care plan and the ability to execute agreed clinical changes across the multidisciplinary team.

Question 130: A 68-year-old woman with rheumatoid arthritis, osteoporosis, hypertension, and stage 3a CKD takes methotrexate, folic acid, hydroxychloroquine, alendronic acid, calcium/vitamin D, amlodipine, and lansoprazole. She has been on lansoprazole for 4 years, originally started for dyspepsia. She is concerned about long-term PPI use after reading about risks. Her rheumatoid arthritis is well controlled. What is the single most appropriate management of her PPI therapy?

A. Continue lansoprazole indefinitely as she needs gastroprotection with methotrexate
B. Switch to ranitidine as it has fewer long-term risks than PPIs
C. Attempt gradual PPI withdrawal with on-demand use if dyspepsia recurs (Correct Answer)
D. Stop lansoprazole immediately and start antacids for symptom relief
E. Continue lansoprazole as it reduces risk of alendronic acid-related oesophagitis

Explanation: ***Attempt gradual PPI withdrawal with on-demand use if dyspepsia recurs*** - Long-term **proton pump inhibitor (PPI)** use is associated with several risks relevant to this patient, including **osteoporosis** progression (fracture risk), **CKD** progression, and **hypomagnesaemia**. - Since the original indication was **dyspepsia** four years ago and she is not taking high-risk medications like **NSAIDs** or oral steroids, a step-down approach (gradual withdrawal) prevents **rebound acid hypersecretion** and allows for **on-demand therapy** if symptoms return. *Continue lansoprazole indefinitely as she needs gastroprotection with methotrexate* - Low-dose **methotrexate** for rheumatoid arthritis is not a primary indication for routine **gastroprotection** in the absence of **NSAIDs** or significant risk factors. - The patient's **rheumatoid arthritis** is well-controlled, and there is no mention of concurrent gastrotoxic medications that mandate indefinite PPI use. *Switch to ranitidine as it has fewer long-term risks than PPIs* - **Ranitidine**, an H2 receptor antagonist, has been largely withdrawn from many markets due to **nitrosamine contamination** concerns. - While H2 blockers are an alternative for **dyspepsia**, switching does not address the fundamental need for **deprescribing** in a patient with no current clear indication for acid suppression. *Stop lansoprazole immediately and start antacids for symptom relief* - **Immediate cessation** of long-term PPI therapy frequently leads to **rebound acid hypersecretion**, causing a return of symptoms and failed withdrawal. - A **gradual dose reduction** (e.g., lower dose or alternate-day dosing) is clinically preferred over abrupt stopping to improve success rates. *Continue lansoprazole as it reduces risk of alendronic acid-related oesophagitis* - While **alendronic acid** can cause **oesophagitis**, current guidelines do not recommend routine PPI co-prescription just for **bisphosphonate** use. - Paradoxically, chronic PPI use may worsen **osteoporosis** by reducing **calcium absorption**, potentially counteracting the benefits of her **osteoporosis** treatment.

Question 131: According to the STOPP/START criteria for potentially inappropriate prescribing in older adults, which single statement most accurately describes the principle behind these criteria?

A. STOPP identifies medications to stop in all circumstances, START identifies essential medications that must be prescribed
B. STOPP identifies potentially inappropriate medications, START identifies potentially beneficial medications that may be omitted (Correct Answer)
C. STOPP focuses on drug-drug interactions, START focuses on drug-disease interactions
D. STOPP applies only to patients over 80 years, START applies to patients over 65 years
E. STOPP addresses polypharmacy by limiting prescriptions to maximum 8 medications in older adults

Explanation: ***STOPP identifies potentially inappropriate medications, START identifies potentially beneficial medications that may be omitted*** - **STOPP** (Screening Tool of Older Persons' Prescriptions) aims to reduce **adverse drug reactions** by identifying medications where the risks may outweigh clinical benefits in older adults. - **START** (Screening Tool to Alert to Right Treatment) addresses **under-prescribing** by highlighting evidence-based medications that should be considered for specific clinical conditions that are currently untreated. *STOPP identifies medications to stop in all circumstances, START identifies essential medications that must be prescribed* - These criteria are **advisory tools** and do not mandate absolute clinical actions; they require **clinical judgment** based on individual patient goals and clinical context. - The phrase "in all circumstances" is inaccurate as medication appropriateness is highly **patient-specific** and context-dependent, not an absolute rule. *STOPP focuses on drug-drug interactions, START focuses on drug-disease interactions* - Both STOPP and START address a broad range of issues, including **drug-disease interactions**, **duplicate therapy**, and medications without a clear **indication**, not just drug-drug interactions. - While they include some **drug-drug interactions**, this is not the exclusive or primary focus of either component of the criteria. *STOPP applies only to patients over 80 years, START applies to patients over 65 years* - Both STOPP and START criteria are designed for use in **older adults**, generally defined as those aged **65 years and older**, without a specific differential age cut-off for each tool. - The application is based on the **vulnerability** and **polypharmacy risk** often associated with advanced age, not arbitrary age limits of 80 or 65 years for distinct tools. *STOPP addresses polypharmacy by limiting prescriptions to maximum 8 medications in older adults* - The criteria focus on the **appropriateness** and **clinical necessity** of individual medications rather than enforcing an an arbitrary numerical limit on the total number of prescriptions. - While they indirectly help manage **polypharmacy** by identifying unnecessary or missing medications, they do not define a specific cut-off like "maximum 8 medications."

Question 132: A 73-year-old man with COPD, ischaemic heart disease, heart failure with preserved ejection fraction (HFpEF), and type 2 diabetes attends for medication review. He takes aspirin, atorvastatin, bisoprolol, furosemide, metformin, and uses tiotropium and salbutamol inhalers. He reports increasing breathlessness. Examination reveals bibasal fine crackles, mild peripheral oedema, and peak expiratory flow rate 65% of predicted (unchanged from previous). Which single medication change is most likely to improve his symptoms?

A. Add spironolactone for additional diuretic effect in heart failure
B. Increase furosemide dose to manage fluid overload more effectively (Correct Answer)
C. Stop bisoprolol as it may worsen COPD and contribute to breathlessness
D. Add a long-acting beta-agonist (LABA) inhaler for better COPD control
E. Add ramipril as ACE inhibitors benefit both heart failure and diabetes

Explanation: ***Increase furosemide dose to manage fluid overload more effectively*** - The presence of **bibasal fine crackles**, **peripheral oedema**, and increasing breathlessness, alongside an *unchanged* **peak flow rate**, strongly indicates **fluid overload** due to **heart failure decompensation** (HFpEF). - **Loop diuretics** like **furosemide** are the most effective intervention for acute symptom relief in **HFpEF** by promoting **diuresis** and reducing congestion, directly addressing the patient's immediate problem. *Add spironolactone for additional diuretic effect in heart failure* - While **mineralocorticoid receptor antagonists (MRAs)** like **spironolactone** are beneficial in HFpEF for reducing hospitalizations, their role is not for rapid **symptomatic relief** of acute volume overload. - Optimizing the dose of the existing **loop diuretic** (furosemide) is the primary and most direct approach to achieve timely **decongestion** when fluid overload is evident. *Stop bisoprolol as it may worsen COPD and contribute to breathlessness* - **Cardioselective beta-blockers** such as **bisoprolol** are generally safe in patients with stable **COPD** and are crucial for improving outcomes in patients with **ischaemic heart disease** and heart failure. - Abruptly stopping **bisoprolol** could worsen the patient's underlying **ischaemic heart disease** or heart failure, potentially leading to **tachycardia** or increased myocardial oxygen demand. *Add a long-acting beta-agonist (LABA) inhaler for better COPD control* - The patient's **peak expiratory flow rate (PEFR)** is *unchanged* from previous, suggesting that his **COPD** is stable and not the primary cause of his acute increase in breathlessness. - A **LABA** is indicated for persistent respiratory symptoms in COPD, but it would not address the **bibasal crackles** and **peripheral oedema**, which point to a cardiac cause. *Add ramipril as ACE inhibitors benefit both heart failure and diabetes* - **ACE inhibitors** are beneficial in many cardiovascular conditions and diabetes, but their mortality benefit in **HFpEF** is less established compared to **HFrEF**. - While potentially useful long-term, initiating an **ACE inhibitor** will not provide the rapid **diuresis** and symptomatic relief from **fluid overload** that the patient currently needs.

Question 133: You are reviewing prescribing patterns in patients with multimorbidity in your practice. A 79-year-old woman with heart failure, atrial fibrillation, chronic kidney disease stage 3b, and previous gastrointestinal bleeding is taking bisoprolol, furosemide, apixaban 2.5mg twice daily, lansoprazole, and ferrous sulfate. Her weight is 54kg, creatinine 145 μmol/L, and age is 79 years. According to the apixaban dose reduction criteria, how many factors does she have that would justify the reduced dose she is receiving?

A. None - she should be on the standard 5mg twice daily dose
B. One factor only
C. Two factors meeting the criteria for dose reduction (Correct Answer)
D. Three factors all meeting dose reduction criteria
E. Dose reduction is appropriate due to previous GI bleeding regardless of other factors

Explanation: ***Two factors meeting the criteria for dose reduction*** - Apixaban requires a dose reduction to 2.5mg twice daily if at least **two of three** criteria are met: **age ≥80 years**, **weight ≤60kg**, or **serum creatinine ≥133 μmol/L**. - This patient meets **two factors**: her weight of **54kg** is below 60kg, and her serum creatinine of **145 μmol/L** is above 133 μmol/L. Her age of 79 years does not meet the 80 years threshold.*None - she should be on the standard 5mg twice daily dose* - This is incorrect because the patient already satisfies the **mandatory threshold** (two criteria) for a lower dose to prevent toxicity. - Standard dosing (5mg) in patients meeting these criteria significantly increases the risk of **major bleeding** events.*One factor only* - Although the patient's age (79) is close to the threshold, only **weight** and **creatinine** qualify as positive criteria in this scenario. - Identifying only one factor would mistakenly suggest she should be on the higher 5mg dose, which is clinically inappropriate here.*Three factors all meeting dose reduction criteria* - The patient is **79 years old**, which does not meet the age criterion of **≥80 years** required for the third factor. - While she has multimorbidity, the specific pharmacokinetic rules for **Apixaban** are strictly defined by those three specific clinical parameters.*Dose reduction is appropriate due to previous GI bleeding regardless of other factors* - A history of **gastrointestinal bleeding** is a clinical concern but is not a formal criterion for the automatic dose reduction of Apixaban in **atrial fibrillation**. - Clinical guidelines for AFib require dose adjustment based on the **ABC criteria** (Age, Body weight, Creatinine) rather than just bleeding history alone.

Question 134: A 76-year-old man with Parkinson's disease, type 2 diabetes, benign prostatic hyperplasia, and anxiety presents with worsening tremor and rigidity. His medications include co-careldopa, atorvastatin, metformin, tamsulosin, and he recently started prochlorperazine for dizziness prescribed by the out-of-hours service. What is the single most likely explanation for his deteriorating Parkinson's symptoms?

A. Natural progression of Parkinson's disease requiring increased co-careldopa dose
B. Drug interaction between tamsulosin and co-careldopa reducing levodopa efficacy
C. Prochlorperazine-induced dopamine antagonism worsening Parkinsonian symptoms (Correct Answer)
D. Atorvastatin-related myopathy mimicking worsening Parkinson's disease
E. Metformin-induced vitamin B12 deficiency affecting neurological function

Explanation: ***Prochlorperazine-induced dopamine antagonism worsening Parkinsonian symptoms***- **Prochlorperazine** is a first-generation **dopamine D2 receptor antagonist** that can cross the blood-brain barrier and directly counteract the effects of **levodopa**.- Its use is contraindicated in patients with **Parkinson’s disease** as it significantly exacerbates motor symptoms like **tremor** and **rigidity**; safer alternatives include **cyclizine** or **domperidone**.*Natural progression of Parkinson's disease requiring increased co-careldopa dose*- While Parkinson's is a **progressive neurodegenerative** condition, the acute deterioration following a new medication suggests an **iatrogenic** cause rather than natural decline.- **Temporal association** with the initiation of the out-of-hours prescription makes pharmaceutical interference the primary suspect.*Drug interaction between tamsulosin and co-careldopa reducing levodopa efficacy*- **Tamsulosin** is an alpha-1 blocker used for BPH; it does not interfere with the **mechanism of action** or absorption of **levodopa**.- Potential side effects of combining these include **orthostatic hypotension**, but not a direct increase in **extrapyramidal symptoms**.*Atorvastatin-related myopathy mimicking worsening Parkinson's disease*- **Statin-induced myopathy** typically presents with symmetrical **proximal muscle pain** and weakness, rather than an increase in **resting tremor** or **lead-pipe rigidity**.- It is often associated with elevated **creatine kinase (CK)** levels and does not explain the worsening of specific neurological motor signs.*Metformin-induced vitamin B12 deficiency affecting neurological function*- Long-term **metformin** use can cause **vitamin B12 deficiency**, which usually presents as **subacute combined degeneration** of the cord or **peripheral neuropathy**.- This deficiency leads to sensory loss and **atxia** rather than the acute worsening of core **Parkinsonian motor features**.

Question 135: During a practice audit of patients aged over 75 on 10 or more medications, you identify that 23% are taking a proton pump inhibitor (PPI) without documented indication. Which single action represents the most appropriate quality improvement intervention?

A. Send letters to all affected patients asking them to stop their PPI immediately
B. Generate a list for clinical review to assess for appropriate deprescribing with individual patient consultations (Correct Answer)
C. Change practice policy to automatically stop PPIs after 8 weeks unless consultant-initiated
D. Add a PPI monitoring template to be completed annually for all patients
E. Send an email to all prescribers reminding them of PPI prescribing guidelines

Explanation: ***Generate a list for clinical review to assess for appropriate deprescribing with individual patient consultations***- **Individualized patient consultation** is essential to ensure safe **deprescribing**, as it allows the clinician to identify undocumented indications and discuss potential **rebound acid hypersecretion**.- This approach promotes **shared decision-making** and addresses risks associated with long-term PPI use such as **osteoporosis**, **hypomagnesaemia**, and **C. difficile infection**.*Send letters to all affected patients asking them to stop their PPI immediately*- Stopping medications abruptly via letter is unsafe as it lacks the necessary **clinical oversight** to prevent complications or symptom relapse.- It fails to differentiate between patients who may actually have a **valid clinical need** for the medication that was simply not documented correctly.*Change practice policy to automatically stop PPIs after 8 weeks unless consultant-initiated*- Rigid automatic stop policies do not account for **patient-specific clinical requirements** and can lead to inadequate treatment for chronic conditions like **Barrett's esophagus**.- Primary care clinicians have the authority to initiate and continue PPIs without consultant input if there is a **valid clinical indication**.*Add a PPI monitoring template to be completed annually for all patients*- While a template might improve documentation, it does not directly address the **quality improvement** goal of reducing **inappropriate polypharmacy** in this specific cohort.- Monitoring alone does not actively facilitate the **deprescribing process** for those who no longer require the medication.*Send an email to all prescribers reminding them of PPI prescribing guidelines*- Education-based interventions (passive dissemination) are generally less effective than **active clinical review** in changing practice outcomes or addressing existing errors.- An email reminder does not systematically identify or manage the **23% of patients** already identified as being on potentially inappropriate therapy.

Question 136: A 70-year-old woman attends for a medication review. She has hypertension, type 2 diabetes, hypothyroidism, and recurrent urinary tract infections. She takes amlodipine, metformin, gliclazide, levothyroxine, and has been on prophylactic trimethoprim 100mg daily for 6 months following three UTIs in 4 months. Her recent HbA1c is 48 mmol/mol, BP 132/78 mmHg, eGFR 52 ml/min/1.73m². She has had no further UTIs. What is the single most appropriate next step in her medication management?

A. Continue trimethoprim prophylaxis for a total of 12 months then review
B. Stop trimethoprim and provide advice on non-antibiotic measures for UTI prevention (Correct Answer)
C. Switch trimethoprim to nitrofurantoin for long-term prophylaxis given better safety profile
D. Stop gliclazide as HbA1c is well controlled and reduce hypoglycaemia risk
E. Reduce amlodipine dose as blood pressure target is achieved

Explanation: ***Stop trimethoprim and provide advice on non-antibiotic measures for UTI prevention***- Guidelines recommend that **antibiotic prophylaxis** for recurrent UTIs should be reviewed and usually **discontinued after 6 months** if the patient remains infection-free.- Stopping the medication reduces the risk of **antimicrobial resistance**, side effects, and promotes **non-antibiotic measures** like hydration and hygiene for long-term prevention.*Continue trimethoprim prophylaxis for a total of 12 months then review*- Prophylaxis is typically intended for a **3 to 6-month period**; extending it to 12 months without further infections unnecessarily increases the risk of **adverse effects**.- Continuing treatment in a patient who has been stable for 6 months goes against the principles of **antibiotic stewardship**.*Switch trimethoprim to nitrofurantoin for long-term prophylaxis given better safety profile*- Switching to another antibiotic is not indicated when the current goal should be **discontinuation** due to successful prevention and the absence of further UTIs.- **Nitrofurantoin** carries risks of pulmonary and hepatic toxicity with long-term use, and its efficacy is reduced in patients with an **eGFR below 60 ml/min**, like this patient's eGFR of 52.*Stop gliclazide as HbA1c is well controlled and reduce hypoglycaemia risk*- An **HbA1c of 48 mmol/mol** reflects good control, but completely stopping a **sulfonylurea** like gliclazide without evidence of hypoglycemic episodes could lead to a loss of glycemic control.- The primary concern in this medication review is the **long-term antibiotic use**, which has reached its recommended duration limit, rather than adjusting well-controlled diabetes medication.*Reduce amlodipine dose as blood pressure target is achieved*- The blood pressure of **132/78 mmHg** is within the target range for a patient with diabetes and hypertension, suggesting the current dose of **amlodipine** is appropriate and effective.- Reducing the dose purely because the target is met may lead to **rebound hypertension** and an increased cardiovascular risk, while the current regimen is clearly working.

Question 137: An 81-year-old man with heart failure (LVEF 35%), atrial fibrillation, type 2 diabetes, and osteoarthritis attends for review. His medications include bisoprolol, ramipril, spironolactone, furosemide, apixaban, metformin, and co-codamol. He reports increasing constipation and reduced mobility. His most recent blood results show: Na+ 133 mmol/L, K+ 5.4 mmol/L, eGFR 34 ml/min/1.73m². Which single combination of factors most strongly suggests the need for urgent medication review?

A. Hyponatraemia and reduced eGFR indicating over-diuresis requiring furosemide dose reduction
B. High-normal potassium and reduced eGFR suggesting risk of hyperkalaemia from combined ACE inhibitor and spironolactone (Correct Answer)
C. Constipation and reduced mobility suggesting opioid-related adverse effects requiring laxatives
D. Multiple cardiac medications and diabetes suggesting polypharmacy requiring simplification
E. Atrial fibrillation and reduced eGFR suggesting apixaban dose adjustment needed

Explanation: ***High-normal potassium and reduced eGFR suggesting risk of hyperkalaemia from combined ACE inhibitor and spironolactone*** - The concurrent use of **ramipril** (ACE inhibitor) and **spironolactone** (mineralocorticoid receptor antagonist) in a patient with significantly decreased **eGFR (34 ml/min/1.73m²)** creates a high risk for life-threatening **hyperkalaemia**. - A potassium level of **5.4 mmol/L** is at the upper limit of normal; given the renal impairment, these medications require urgent review to prevent serious **cardiac arrhythmias**. *Hyponatraemia and reduced eGFR indicating over-diuresis requiring furosemide dose reduction* - While **furosemide** and **ramipril** can contribute to **hyponatraemia** (133 mmol/L), this mild electrolyte imbalance is less acutely dangerous than the potential for rapidly rising potassium in a renally impaired patient. - Reduced **eGFR** in heart failure often necessitates careful balancing of diuresis with perfusion, making this a management consideration rather than the most urgent safety risk. *Constipation and reduced mobility suggesting opioid-related adverse effects requiring laxatives* - **Co-codamol** frequently causes **constipation**, which can reduce the mobility of an elderly patient and significantly impact their quality of life. - While important for patient comfort and overall well-being, these symptoms do not pose an immediate **biochemical or life-threatening risk** compared to the profound dangers of hyperkalaemia. *Multiple cardiac medications and diabetes suggesting polypharmacy requiring simplification* - The patient is receiving **Guideline-Directed Medical Therapy (GDMT)** for heart failure with reduced ejection fraction (LVEF 35%), which inherently involves **polypharmacy**. - While polypharmacy merits regular review, simplifying for the sake of reducing pill count is secondary to managing the **acute safety risks** associated with specific drug-drug and drug-disease interactions. *Atrial fibrillation and reduced eGFR suggesting apixaban dose adjustment needed* - **Apixaban** dosing for atrial fibrillation generally requires adjustment if at least two of the following criteria are met: age ≥80 years, weight ≤60 kg, or **creatinine ≥133 µmol/L**. - With an **eGFR of 34 ml/min/1.73m²**, a dose adjustment might be necessary, but this logistical dose check is less urgent than addressing the patient's immediate **potassium levels and renal status** to prevent life-threatening complications.

Question 138: You are conducting annual medication reviews in your practice. According to the NICE guideline on multimorbidity, which single criterion best defines a structured medication review approach?

A. Reviewing all medications prescribed in the past 12 months and discontinuing those without clear indication
B. Prioritizing medications based on drug costs and stopping the most expensive unnecessary treatments
C. Assessing individual medications against patient's current conditions, considering risks, benefits, and patient preferences (Correct Answer)
D. Using only the Beers Criteria to identify potentially inappropriate medications in all adult patients
E. Conducting annual blood tests to monitor for drug interactions and adverse effects

Explanation: ***Assessing individual medications against patient's current conditions, considering risks, benefits, and patient preferences*** - NICE guidelines for **multimorbidity (NG56)** define a structured medication review as a comprehensive, **patient-centered** assessment aimed at optimizing the balance of **clinical benefit and harm**. - It emphasizes **shared decision-making**, ensuring treatment aligns with the patient's personal **values, preferences, and treatment goals** in the context of multiple chronic conditions. *Reviewing all medications prescribed in the past 12 months and discontinuing those without clear indication* - While identifying **polypharmacy** and omitting drugs without indication is part of the process, it lacks the broader assessment of **patient-focused goals** required by NICE. - This approach is purely clinical and does not necessarily incorporate the **patient's voice** or the complex interaction of multimorbidities. *Prioritizing medications based on drug costs and stopping the most expensive unnecessary treatments* - The primary goal of a structured clinical review is **patient safety** and **clinical effectiveness**, not cost-saving or budgetary prioritisation. - Decisions should be based on the **risk-benefit ratio** for the individual patient rather than the unit price of the medication. *Using only the Beers Criteria to identify potentially inappropriate medications in all adult patients* - The **Beers Criteria** is specifically developed for **older adults** (typically >65) and lacks evidence-based applicability for the general adult population with multimorbidity. - A structured review should use various tools (like **STOPP/START criteria**) but must ultimately rely on personalized clinical judgment rather than a single checklist. *Conducting annual blood tests to monitor for drug interactions and adverse effects* - Biological monitoring is a component of **medication safety** and surveillance but does not constitute the holistic **structured review** process described by NICE. - Monitoring is a reactive or maintenance step, whereas a structured review is an active **re-evaluation** of the entire therapeutic strategy.

Question 139: A 74-year-old woman with type 2 diabetes, hypertension, osteoarthritis, and depression is taking metformin, ramipril, amlodipine, paracetamol, ibuprofen, sertraline, and omeprazole. She reports a recent fall at home. On examination, her BP is 108/62 mmHg sitting and 88/54 mmHg standing. Her eGFR is 38 ml/min/1.73m². Which single medication is the most appropriate to discontinue first?

A. Amlodipine
B. Ibuprofen (Correct Answer)
C. Omeprazole
D. Ramipril
E. Sertraline

Explanation: ***Ibuprofen*** - **NSAIDs** are contraindicated in patients with an **eGFR < 30** and should be used with extreme caution or stopped in those with an eGFR of **38 ml/min/1.73m² (CKD stage 3b)** due to the risk of acute kidney injury. - Stopping ibuprofen reduces the risk of **renal deterioration** and gastrointestinal complications, while paracetamol remains a safer alternative for her **osteoarthritis**. *Amlodipine* - While this **calcium channel blocker** may contribute to hypotension, it is less likely than other agents to cause significant **postural hypotension** leading to falls. - Management of blood pressure is secondary to preventing **nephrotoxicity** from NSAIDs in the setting of established renal impairment. *Omeprazole* - **Proton pump inhibitors** are not typically associated with **postural hypotension** or an increased risk of falls in the acute setting. - While long-term use has risks like **fractures** or C. difficile, it is not the most urgent priority compared to managing her **renal health**. *Ramipril* - Although this **ACE inhibitor** can cause hypotension and may need dose adjustment, it provides essential **renoprotection** and cardiovascular benefits for a diabetic patient. - Discontinuing this before the **nephrotoxic NSAID** would be counterproductive for managing her **diabetic kidney disease**. *Sertraline* - **SSRIs** are associated with an increased fall risk in the elderly due to **hyponatremia** or sedation, but they do not cause the patient's primary renal issue. - Sudden discontinuation of sertraline can lead to **discontinuation syndrome**, making it a less suitable choice for immediate withdrawal over an NSAID.

Question 140: You are analyzing prescribing quality indicators for your practice and identify a 73-year-old man with heart failure (ejection fraction 35%), post-myocardial infarction (18 months ago), hypertension, and type 2 diabetes who is currently taking aspirin, atorvastatin, ramipril 10mg daily, bisoprolol 10mg daily, furosemide 40mg daily, metformin, and empagliflozin. His recent blood pressure is 128/76 mmHg, heart rate 68 bpm, eGFR 48 ml/min/1.73m², potassium 4.3 mmol/L. According to current NICE guidance on optimizing heart failure with reduced ejection fraction treatment, which medication addition would provide the GREATEST mortality benefit?

A. Add spironolactone 25mg daily for additional mineralocorticoid receptor antagonism (Correct Answer)
B. Add ivabradine to reduce heart rate further below 60 bpm
C. Add hydralazine and isosorbide dinitrate for additional vasodilation
D. Add digoxin to improve symptoms and reduce hospitalizations
E. No additional medication needed as patient is on optimal medical therapy

Explanation: ***Add spironolactone 25mg daily for additional mineralocorticoid receptor antagonism*** - This patient is missing a **Mineralocorticoid Receptor Antagonist (MRA)**, one of the four foundational drug classes for **Heart Failure with reduced Ejection Fraction (HFrEF)**, which offers a significant **mortality benefit**. - His current **eGFR** (48 ml/min/1.73m²) and **potassium** (4.3 mmol/L) are within the safe parameters for initiating spironolactone according to **NICE guidelines**. *Add ivabradine to reduce heart rate further below 60 bpm* - **Ivabradine** is indicated for patients in **sinus rhythm** with a heart rate of **≥ 75 bpm** (NICE) or **> 70 bpm** (ESC) despite optimal beta-blocker therapy. - The patient's heart rate of **68 bpm** does not meet the established criteria for initiating ivabradine, making it an unsuitable next step. *Add hydralazine and isosorbide dinitrate for additional vasodilation* - This combination is typically reserved for patients of **Black African or Caribbean origin** or those who are **intolerant to ACE inhibitors/ARBs/ARNIs**. - While it can improve outcomes, it does not provide the *greatest mortality benefit* as the next addition for a general HFrEF patient who is already tolerating ACEi, beta-blocker, and SGLT2i, compared to an MRA. *Add digoxin to improve symptoms and reduce hospitalizations* - **Digoxin** can improve symptoms and reduce hospitalizations in patients with severe HFrEF, particularly those with atrial fibrillation, but it has **no proven mortality benefit**. - The question specifically asks for the medication providing the **greatest mortality benefit**, which digoxin does not offer. *No additional medication needed as patient is on optimal medical therapy* - This statement is incorrect because the patient is currently on three of the **four pillar** medications for HFrEF (ACE inhibitor, beta-blocker, and SGLT2 inhibitor). - **Optimal Medical Therapy (OMT)** for HFrEF includes the addition of an **MRA** (like spironolactone) to maximize survival benefit.

Question 141: During a comprehensive medication review, you see a 71-year-old woman with COPD, osteoporosis, hypothyroidism, and gastro-oesophageal reflux disease. She takes tiotropium, salmeterol/fluticasone combination inhaler, alendronic acid 70mg weekly, calcium and vitamin D, levothyroxine 100mcg daily, and omeprazole 20mg daily (started 4 years ago for reflux symptoms which resolved after 6 months). Recent bone density scan shows stable T-scores. What is the primary concern regarding her long-term proton pump inhibitor use in the context of her other conditions?

A. Reduced levothyroxine absorption leading to suboptimal thyroid hormone replacement
B. Increased risk of COPD exacerbations through altered gastric pH and bacterial overgrowth
C. Reduced calcium absorption potentially compromising osteoporosis management and fracture prevention (Correct Answer)
D. Drug interaction with inhaled corticosteroids increasing pneumonia risk
E. Impaired vitamin B12 absorption leading to peripheral neuropathy

Explanation: ***Reduced calcium absorption potentially compromising osteoporosis management and fracture prevention***- Long-term **Proton Pump Inhibitor (PPI)** use significantly reduces **gastric acid** production, which is crucial for the absorption of certain forms of calcium, particularly **calcium carbonate**.- In a patient with **osteoporosis** receiving **alendronic acid** and **calcium/vitamin D** supplementation, impaired calcium absorption can hinder bone mineralization and increase the risk of **fragility fractures**, despite stable T-scores currently.*Reduced levothyroxine absorption leading to suboptimal thyroid hormone replacement*- **Levothyroxine** absorption can be reduced by PPIs due to increased gastric pH, as an acidic environment optimizes its dissolution and absorption.- While a valid concern, this interaction is typically managed by monitoring **TSH levels** and adjusting the levothyroxine dose; it's often considered less acute than the direct impact on bone health in an osteoporosis patient already on bone-protective therapy.*Increased risk of COPD exacerbations through altered gastric pH and bacterial overgrowth*- Long-term PPI use has been associated with an increased risk of **community-acquired pneumonia** due to altered gastric pH leading to bacterial overgrowth and aspiration.- However, a direct, strong, and consistently proven link to increased **COPD exacerbations** specifically is less established compared to the clear impact on calcium absorption in osteoporosis.*Drug interaction with inhaled corticosteroids increasing pneumonia risk*- There is no direct pharmacokinetic or pharmacodynamic **drug-drug interaction** between PPIs and **inhaled corticosteroids (ICS)** that would synergistically increase pneumonia risk.- While ICS themselves are a known risk factor for pneumonia in COPD patients, the PPI does not compound this risk through a direct interaction with the ICS medication.*Impaired vitamin B12 absorption leading to peripheral neuropathy*- Chronic PPI use can lead to **vitamin B12 deficiency** due to inhibition of gastric acid and pepsin, which are necessary to release B12 from food proteins for absorption.- While a significant long-term concern that can lead to neurological symptoms like **peripheral neuropathy**, the immediate and primary concern in an elderly patient with **osteoporosis** on bone-protective therapy is the direct impact on calcium absorption and fracture risk.

Question 142: A 69-year-old man with hypertension, type 2 diabetes, stage 3a CKD, and a history of peptic ulcer disease (treated 3 years ago) attends for review. He takes ramipril, amlodipine, metformin, atorvastatin, and aspirin 75mg daily (started for primary prevention 8 years ago when he was found to have impaired glucose tolerance). His blood pressure is 132/78 mmHg, BMI 28 kg/m², HbA1c 51 mmol/L, total cholesterol 4.2 mmol/L, eGFR 52 ml/min/1.73m². He has never had cardiovascular disease. According to current evidence-based guidance, what is the MOST appropriate management of his aspirin?

A. Continue aspirin as he has multiple cardiovascular risk factors including diabetes and CKD
B. Stop aspirin as he has no cardiovascular disease and bleeding risk outweighs benefit in primary prevention (Correct Answer)
C. Continue aspirin but add a proton pump inhibitor given history of peptic ulcer disease
D. Switch aspirin to clopidogrel which has a better safety profile for primary prevention
E. Reduce aspirin to 75mg on alternate days to minimize bleeding risk while maintaining cardiovascular protection

Explanation: ***Stop aspirin as he has no cardiovascular disease and bleeding risk outweighs benefit in primary prevention*** - In **primary prevention**, major clinical trials (e.g., **ASCEND**, **ASPREE**, **ARRIVE**) consistently demonstrate that the modest **cardiovascular benefits** of aspirin are generally outweighed by a significant increase in **major bleeding** events. - This patient, without established **cardiovascular disease**, has an increased **bleeding risk** due to his age and history of **peptic ulcer disease**, making aspirin discontinuation the most appropriate management. *Continue aspirin as he has multiple cardiovascular risk factors including diabetes and CKD* - Despite multiple **cardiovascular risk factors** like **diabetes** and **CKD**, current evidence-based guidelines do not recommend aspirin for **primary prevention** due to the unfavorable risk-benefit profile, particularly the increased **bleeding risk**. - His cardiovascular risk is adequately managed with existing medications like **statins**, **ACE inhibitors**, and **metformin**, which have proven benefits in primary prevention without the added bleeding burden of aspirin. *Continue aspirin but add a proton pump inhibitor given history of peptic ulcer disease* - While a **proton pump inhibitor (PPI)** can mitigate the **gastrointestinal bleeding risk** associated with aspirin, it does not justify the use of aspirin for **primary prevention** when there is no established **cardiovascular disease**. - Adding a PPI introduces further **polypharmacy** without addressing the fundamental lack of indication for aspirin in this primary prevention setting. *Switch aspirin to clopidogrel which has a better safety profile for primary prevention* - **Clopidogrel** is primarily indicated for **secondary prevention** of cardiovascular events or in specific high-risk conditions, not for routine **primary prevention** in patients without established disease. - Like aspirin, clopidogrel also carries a **bleeding risk**, and there is no evidence to support its use as a safer or more effective alternative for primary prevention. *Reduce aspirin to 75mg on alternate days to minimize bleeding risk while maintaining cardiovascular protection* - There is no clinical evidence or guideline support for **alternate-day dosing** of aspirin as an effective strategy to minimize bleeding risk while maintaining cardiovascular protection for **primary prevention**. - Even reduced or intermittent dosing of aspirin still inhibits **platelet function** and carries a risk of **mucosal injury**, failing to eliminate the bleeding danger in high-risk patients.

Question 143: You are conducting a structured medication review using the Beers Criteria for a 74-year-old man with benign prostatic hyperplasia, chronic constipation, glaucoma (well-controlled with eye drops), and anxiety. He takes tamsulosin, movicol, latanoprost eye drops, and has been taking amitriptyline 25mg nightly for 5 years for anxiety (started by previous GP). He reports the amitriptyline helps him sleep but mentions increasing difficulty passing urine. Which statement BEST describes the application of the Beers Criteria to this patient's medication regimen?

A. Amitriptyline is potentially inappropriate due to its anticholinergic effects worsening urinary retention and constipation (Correct Answer)
B. Tamsulosin should be stopped as alpha-blockers are potentially inappropriate in elderly males with glaucoma
C. Movicol is potentially inappropriate as osmotic laxatives increase electrolyte disturbance risk in elderly patients
D. Latanoprost is potentially inappropriate as prostaglandin analogues worsen urinary symptoms
E. All current medications are appropriate according to Beers Criteria given documented clinical benefit

Explanation: ***Amitriptyline is potentially inappropriate due to its anticholinergic effects worsening urinary retention and constipation***- **Amitriptyline** is a Tricyclic Antidepressant (TCA) with strong **anticholinergic properties**, which are explicitly flagged in the **Beers Criteria** as potentially inappropriate for older adults.- These effects directly exacerbate this patient's pre-existing **benign prostatic hyperplasia (BPH)** and **chronic constipation**, likely contributing to his worsening urinary symptoms.*Tamsulosin should be stopped as alpha-blockers are potentially inappropriate in elderly males with glaucoma*- **Tamsulosin** is a selective alpha-1 blocker and remains a standard, appropriate treatment for **BPH** symptoms in older men.- It is not contraindicated in **glaucoma**; however, clinicians should be aware of **Intraoperative Floppy Iris Syndrome (IFIS)** if the patient undergoes cataract surgery.*Movicol is potentially inappropriate as osmotic laxatives increase electrolyte disturbance risk in elderly patients*- **Movicol (Macrogol)** is an osmotic laxative generally considered safe and effective for **chronic constipation** in the elderly.- Unlike stimulant laxatives or certain saline enemas, it does not carry a high risk of **electrolyte disturbances** when used at standard maintenance doses.*Latanoprost is potentially inappropriate as prostaglandin analogues worsen urinary symptoms*- **Latanoprost** is a first-line topical treatment for **glaucoma** and is considered highly appropriate due to its localized action.- There is no clinical evidence or pharmacological mechanism suggesting that **prostaglandin analogues** administered as eye drops worsen **lower urinary tract symptoms**.*All current medications are appropriate according to Beers Criteria given documented clinical benefit*- This statement is incorrect because **amitriptyline** is a well-documented **Potentially Inappropriate Medication (PIM)** in the elderly due to high risk of adverse effects.- Clinical benefit for sleep or anxiety does not override the **Beers Criteria** recommendation to avoid TCAs when safer alternatives like SSRIs or non-pharmacological therapies exist.

Question 144: A 77-year-old woman with dementia, type 2 diabetes, ischaemic heart disease, and recurrent falls is brought by her care home manager for medication review. She takes donepezil, memantine, aspirin, atorvastatin, bisoprolol, amlodipine, metformin, and gliclazide. Her recent HbA1c is 42 mmol/mol, blood pressure 118/70 mmHg lying and 95/60 mmHg standing. She has had three documented falls in the past two months with no clear precipitant. Applying the principles of comprehensive geriatric assessment and deprescribing, which medication change would provide the GREATEST reduction in falls risk while maintaining essential treatment?

A. Stop gliclazide and accept slightly higher HbA1c target given fall risk and tight glycaemic control
B. Stop amlodipine given orthostatic hypotension and already achieving blood pressure target (Correct Answer)
C. Stop both donepezil and memantine as cognitive medications increase falls through dizziness
D. Stop aspirin as the bleeding risk from falls outweighs cardiovascular benefit
E. Reduce bisoprolol dose by half to minimize bradycardia-related falls

Explanation: ***Stop amlodipine given orthostatic hypotension and already achieving blood pressure target***- The patient has documented **orthostatic hypotension** (a systolic drop of 23 mmHg from 118/70 to 95/60 mmHg), which is a significant modifiable **risk factor for falls** in the elderly.- Amlodipine is a **vasodilatory agent** that directly contributes to hypotension and orthostasis; her blood pressure is already well-controlled, making its removal a primary intervention to reduce falls.*Stop gliclazide and accept slightly higher HbA1c target given fall risk and tight glycaemic control*- While her **HbA1c of 42 mmol/mol** is low for a frail elderly patient, there is no clinical evidence of **hypoglycemia** being the primary trigger for her falls.- Though reducing medication burden is appropriate, stopping an antihypertensive agent provides a more direct intervention for her proven **postural drop**.*Stop both donepezil and memantine as cognitive medications increase falls through dizziness*- Donepezil and memantine provide important **cognitive benefits** in dementia and are not typically the primary drivers of gait instability compared to cardiovascular drugs.- Abruptly stopping these medications can lead to a significant **decline in cognitive function** and increased behavioral symptoms, without a guaranteed or immediate reduction in falls risk.*Stop aspirin as the bleeding risk from falls outweighs cardiovascular benefit*- There is no mention of **anticoagulation complications** or severe bleeding events that would currently necessitate stopping secondary prevention for her **ischaemic heart disease**.- Aspirin does not cause hemodynamic instability or dizziness, so its cessation would not directly prevent the mechanics of her **recurrent falls**.*Reduce bisoprolol dose by half to minimize bradycardia-related falls*- Bisoprolol is essential for managing her **ischaemic heart disease**, and there is no documentation of symptomatic **bradycardia** in the patient's presentation.- While beta-blockers can contribute to hypotension, the significant **orthostatic drop** is more characteristically exacerbated by pure vasodilators like calcium channel blockers (amlodipine) than by bisoprolol.

Question 145: You are reviewing a 70-year-old man with type 2 diabetes, chronic kidney disease stage 3b, heart failure with preserved ejection fraction (HFpEF), and gout. His medications include metformin 500mg twice daily, empagliflozin 10mg daily, ramipril 10mg daily, furosemide 40mg daily, and allopurinol 100mg daily. Recent blood tests show: eGFR 38 ml/min/1.73m², HbA1c 58 mmol/mol, uric acid 420 μmol/L (had gout attack 2 months ago). What represents the MOST evidence-based medication optimization for this patient?

A. Stop metformin as eGFR is below 45 ml/min/1.73m² and continue empagliflozin alone
B. Increase allopurinol to 300mg daily to achieve target uric acid <360 μmol/L (Correct Answer)
C. Stop empagliflozin due to increased genital infection risk in CKD and optimize metformin
D. Add spironolactone as evidence shows mortality benefit in HFpEF
E. Switch ramipril to sacubitril-valsartan for improved heart failure outcomes

Explanation: ***Increase allopurinol to 300mg daily to achieve target uric acid <360 μmol/L***- The patient's uric acid is **420 μmol/L** and he recently had a gout attack, making the **treat-to-target** goal for **uric acid <360 μmol/L** (or lower for severe gout) crucial to prevent future attacks.- Allopurinol should be **titrated upwards** gradually, even in **CKD stage 3b**, to reach the target, as the current 100mg dose is subtherapeutic and dose adjustments are safe with monitoring. *Stop metformin as eGFR is below 45 ml/min/1.73m² and continue empagliflozin alone*- Metformin typically requires a **dose reduction** (to a maximum of 1000mg/day) when **eGFR is between 30-45 ml/min/1.73m²**, which the current 500mg BID dose adheres to.- Complete cessation of metformin is generally recommended only when **eGFR falls below 30 ml/min/1.73m²** due to increased risk of lactic acidosis. *Stop empagliflozin due to increased genital infection risk in CKD and optimize metformin*- **SGLT2 inhibitors** like empagliflozin provide significant and evidence-based **cardiorenal protection** in patients with **CKD** and **HFpEF** (e.g., EMPA-KIDNEY and EMPEROR-Preserved trials).- The benefits of empagliflozin in reducing cardiovascular events, heart failure hospitalizations, and kidney disease progression typically **outweigh the manageable risk** of genital infections. *Add spironolactone as evidence shows mortality benefit in HFpEF*- The **TOPCAT trial** did not demonstrate a significant **mortality benefit** for spironolactone in HFpEF, unlike in HFrEF, making its routine use for mortality reduction less established in this population.- Adding spironolactone to ramipril in a patient with **CKD stage 3b** significantly increases the risk of **hyperkalemia**, requiring very careful monitoring or contraindication. *Switch ramipril to sacubitril-valsartan for improved heart failure outcomes*- **Sacubitril-valsartan (ARNI)** is primarily indicated and has strong evidence for improving outcomes in heart failure with **reduced ejection fraction (HFrEF)**.- The **PARAGON-HF trial** in HFpEF did not meet its primary endpoint for a significant reduction in heart failure hospitalizations or cardiovascular death across the overall study population, limiting its widespread recommendation for HFpEF.

Question 146: A 75-year-old woman attends with her daughter who is concerned about her mother's memory. The patient has type 2 diabetes, hypertension, atrial fibrillation, and osteoarthritis. Her current medications include metformin, gliclazide, ramipril, bisoprolol, apixaban, and oxybutynin 5mg twice daily (started 6 months ago for urinary frequency). On cognitive screening, her MoCA score is 22/30 with particular deficits in attention and short-term memory. Physical examination is unremarkable. What medication change is MOST likely to improve her cognitive function?

A. Stop gliclazide and optimize metformin to prevent hypoglycaemia-related cognitive impairment
B. Reduce bisoprolol dose as beta-blockers can cause cognitive slowing in elderly patients
C. Stop oxybutynin due to its anticholinergic effects on cognition (Correct Answer)
D. Switch apixaban to warfarin to improve cerebral perfusion through better anticoagulation control
E. Add donepezil to counteract early cognitive decline

Explanation: ***Stop oxybutynin due to its anticholinergic effects on cognition***- **Oxybutynin** is a potent **anticholinergic** agent that readily crosses the blood-brain barrier and is strongly associated with **cognitive impairment**, delirium, and memory deficits in elderly patients.- The recent initiation of oxybutynin (6 months ago) coincides with the onset of the patient's cognitive concerns, making it the most likely reversible cause.*Stop gliclazide and optimize metformin to prevent hypoglycaemia-related cognitive impairment*- While **hypoglycemia** can acutely impair cognitive function, there is no clinical evidence in the patient's presentation (e.g., blood glucose levels, symptoms) to suggest this is the primary cause of her chronic cognitive decline.- Gliclazide is a standard medication for Type 2 Diabetes, and discontinuing it without specific indications of hypoglycemia would not address the more prominent reversible cause of cognitive impairment.*Reduce bisoprolol dose as beta-blockers can cause cognitive slowing in elderly patients*- **Bisoprolol** is a hydrophilic beta-blocker, meaning it has limited penetration into the central nervous system and is less likely to cause **cognitive side effects** compared to lipophilic beta-blockers.- Given her history of **hypertension** and **atrial fibrillation**, bisoprolol serves important cardiovascular functions and is unlikely to be the primary driver of her specific cognitive deficits.*Switch apixaban to warfarin to improve cerebral perfusion through better anticoagulation control*- **Apixaban**, a direct oral anticoagulant (DOAC), is often preferred over **warfarin** in elderly patients due to its more predictable anticoagulant effect and lower risk of bleeding, particularly intracranial hemorrhage.- Switching to warfarin would increase monitoring burden and does not offer any proven benefit for **cerebral perfusion** or cognitive function compared to apixaban for stroke prevention in atrial fibrillation.*Add donepezil to counteract early cognitive decline*- Adding an **acetylcholinesterase inhibitor** like donepezil is generally not recommended before evaluating and eliminating all **reversible causes** of cognitive impairment.- Donepezil works by increasing **acetylcholine** levels, so administering it while the patient is still taking **oxybutynin** (an anticholinergic) would result in pharmacological antagonism, potentially negating donepezil's intended effect.

Question 147: During a practice-based audit of patients with multimorbidity, you identify a 68-year-old man with COPD, ischaemic heart disease, type 2 diabetes, and depression taking 11 regular medications. His recent spirometry shows FEV1 45% predicted. He is on maximum inhaled therapy including LABA/LAMA/ICS triple therapy, and has had two moderate COPD exacerbations in the past year requiring oral corticosteroids. His medications also include aspirin, atorvastatin, bisoprolol, ramipril, metformin, sitagliptin, and sertraline. According to current NICE guidance on multimorbidity, what is the MOST appropriate next step in his management?

A. Refer to respiratory specialist for consideration of azithromycin prophylaxis
B. Initiate immediate deprescribing plan to reduce pill burden below 10 medications
C. Arrange holistic medication and care review focused on patient priorities and quality of life (Correct Answer)
D. Add roflumilast to reduce exacerbation frequency in severe COPD
E. Refer to community pharmacy for compliance aids to manage polypharmacy

Explanation: ***Arrange holistic medication and care review focused on patient priorities and quality of life***- **NICE guideline NG56** recommends a patient-centered approach for individuals with **multimorbidity** and high **treatment burden**, specifically focusing on what matters most to the patient.- This review aims to identify **treatment goals**, assess the impact of symptoms on daily life, and utilize **shared decision-making** rather than following separate disease-specific protocols.*Refer to respiratory specialist for consideration of azithromycin prophylaxis*- While clinically indicated for frequent COPD exacerbations, this is a **disease-specific** step that ignores the broader context of **multimorbidity** management.- Adding a chronic antibiotic increases the **pill burden** and potential for side effects/interactions in a patient already on 11 medications.*Initiate immediate deprescribing plan to reduce pill burden below 10 medications*- Deprescribing should be a result of a **holistic review** rather than an arbitrary target based on the total number of medications.- A rush to stop medications without a **clinical assessment** of their benefits could worsen the patient's underlying conditions like **IHD** or **depression**.*Add roflumilast to reduce exacerbation frequency in severe COPD*- Roflumilast can be considered for chronic bronchitis in severe COPD, but adding more drugs addresses only one condition and potentially increases **polypharmacy** issues.- **NICE multimorbidity guidance** prioritizes reducing treatment burden over simply adding further pharmacological interventions.*Refer to community pharmacy for compliance aids to manage polypharmacy*- **Compliance aids** (e.g., dosette boxes) may help with administration but do not address the appropriateness of the medications or the **patient's priorities**.- The primary issue is the complexity of managing multiple conditions, which requires a **clinical review** by the primary care team rather than just a technical aid.

Question 148: A 72-year-old woman with chronic kidney disease stage 4 (eGFR 22 ml/min/1.73m²), type 2 diabetes, and heart failure with reduced ejection fraction presents for review. Her current medications include insulin, furosemide, spironolactone, bisoprolol, and atorvastatin. Recent bloods show potassium 5.8 mmol/L (repeat confirmed), HbA1c 64 mmol/mol, and bicarbonate 18 mmol/L. She is asymptomatic. Which medication adjustment represents the MOST appropriate immediate management?

A. Stop spironolactone and recheck potassium in one week (Correct Answer)
B. Reduce insulin dose to prevent further hyperkalaemia
C. Stop atorvastatin due to increased rhabdomyolysis risk in CKD
D. Increase furosemide to enhance potassium excretion
E. Add calcium resonium to bind excess potassium while continuing current medications

Explanation: ***Stop spironolactone and recheck potassium in one week*** - The patient has **hyperkalaemia (5.8 mmol/L)** and **CKD Stage 4** (eGFR 22 ml/min/1.73m²); **spironolactone**, a potassium-sparing diuretic, is a major contributor and should be discontinued immediately. - Guidelines for **HFrEF** management advise extreme caution or avoidance of **Mineralocorticoid Receptor Antagonists** when the eGFR is below 30 mL/min/1.73m² due to the high risk of life-threatening arrhythmias. *Reduce insulin dose to prevent further hyperkalaemia* - **Insulin** actually drives potassium into cells, effectively **lowering serum potassium**; reducing the dose would likely worsen hyperkalaemia and lead to hyperglycaemia. - While insulin deficiency can contribute to hyperkalaemia, reducing exogenous insulin would be counterproductive to managing elevated potassium. *Stop atorvastatin due to increased rhabdomyolysis risk in CKD* - While **statin** metabolism can be altered in renal impairment, **atorvastatin** does not require dose adjustment in CKD and is not the cause of the acute electrolyte abnormality. - **Cardiovascular protection** is vital in diabetic CKD patients, and there is no clinical evidence of myopathy or rhabdomyolysis in this asymptomatic patient to warrant discontinuation. *Increase furosemide to enhance potassium excretion* - Although **loop diuretics** like furosemide increase potassium excretion, this is an indirect treatment that does not address the **offending medication** (spironolactone) currently causing the elevation. - Increasing furosemide without stopping spironolactone carries a risk of **acute kidney injury** and dehydration in a patient with already advanced CKD. *Add calcium resonium to bind excess potassium while continuing current medications* - **Cation-exchange resins** like calcium resonium are generally used as a bridge to other therapies for severe or symptomatic hyperkalaemia and are poorly tolerated due to **gastrointestinal side effects**. - The primary management of drug-induced hyperkalaemia must always be the **withdrawal of the causative medication** rather than adding further pharmacological binding agents.

Question 149: You are conducting a structured medication review for a 79-year-old man with Parkinson's disease, type 2 diabetes, benign prostatic hyperplasia, and insomnia. His medications include co-careldopa, pramipexole, metformin, sitagliptin, tamsulosin, and zopiclone 7.5mg nightly (prescribed 18 months ago). He reports his sleep has not improved and he feels unsteady in the mornings. What is the MOST appropriate management of his zopiclone?

A. Continue zopiclone as insomnia is common in Parkinson's disease and requires ongoing treatment
B. Increase zopiclone dose to 10mg as current dose is sub-therapeutic
C. Initiate gradual withdrawal as he has been on zopiclone beyond recommended duration (Correct Answer)
D. Switch to a benzodiazepine which has a better safety profile in Parkinson's disease
E. Add melatonin while continuing zopiclone for enhanced sleep benefit

Explanation: ***Initiate gradual withdrawal as he has been on zopiclone beyond recommended duration***- **Z-drugs** should only be used for short periods, typically **2-4 weeks**, to prevent **tolerance**, dependence, and sedation-related adverse effects such as **falls**.- This patient's **morning unsteadiness** and long-term use (18 months) without benefit clearly indicate the need for **gradual withdrawal** to improve safety and mobility.*Continue zopiclone as insomnia is common in Parkinson's disease and requires ongoing treatment*- While insomnia is prevalent in **Parkinson's disease**, chronic use of **hypnotics** like zopiclone is not a recommended long-term management strategy.- Prolonged use in elderly patients significantly elevates the risk of **cognitive impairment**, **daytime somnolence**, and **hip fractures** due to nocturnal or morning instability.*Increase zopiclone dose to 10mg as current dose is sub-therapeutic*- Increasing the dose would exacerbate the patient's existing **unsteadiness** and heighten the risk of severe confusion or **respiratory depression**.- A dose of **7.5mg** is already the maximum recommended; in elderly individuals, a lower starting dose of **3.75mg** is typically advised.*Switch to a benzodiazepine which has a better safety profile in Parkinson's disease*- **Benzodiazepines** do not possess a better safety profile than Z-drugs and carry similar risks of **daytime somnolence**, **ataxia**, and increased **fall risk**.- Substituting one sedating agent for another (a "prescribing cascade" or "flip-flop") fails to address the underlying problem of **medication-induced instability** and polypharmacy.*Add melatonin while continuing zopiclone for enhanced sleep benefit*- Adding **melatonin** while continuing zopiclone increases **polypharmacy** and the potential for drug-drug interactions in this complex elderly patient.- The management priority should be to deprescribe **potentially inappropriate medications** (PIMs) like zopiclone rather than introducing additional sedatives.

Question 150: A 67-year-old woman with rheumatoid arthritis, osteoporosis, hypertension, and depression attends for a comprehensive medication review. She takes methotrexate 15mg weekly, folic acid, alendronic acid 70mg weekly, calcium and vitamin D, amlodipine, and sertraline. She mentions that she occasionally takes ibuprofen purchased over-the-counter for joint pain. What is the MOST concerning aspect of her medication use requiring immediate action?

A. Regular NSAID use with methotrexate increases haematological toxicity risk
B. Alendronic acid may not be absorbed effectively with calcium supplementation
C. Sertraline combined with NSAIDs significantly increases upper gastrointestinal bleeding risk (Correct Answer)
D. Methotrexate dose is too high for a patient also taking an NSAID
E. Folic acid should be taken on the same day as methotrexate for optimal effect

Explanation: ***Sertraline combined with NSAIDs significantly increases upper gastrointestinal bleeding risk*** - **SSRIs** (like sertraline) interfere with serotonin uptake in platelets, which impairs **platelet aggregation** and weakens the gastric mucosal defense. - When combined with **NSAIDs**, the risk of **upper gastrointestinal bleeding** increases synergistically (estimated 6-fold increase), requiring immediate cessation or **PPI co-prescription**. *Regular NSAID use with methotrexate increases haematological toxicity risk* - NSAIDs can reduce the **renal clearance** of methotrexate, potentially increasing its systemic levels and toxic effects. - While clinically relevant, this interaction is generally manageable with **blood monitoring** and is considered less of an immediate safety threat than a major GI bleed at this dose. *Alendronic acid may not be absorbed effectively with calcium supplementation* - **Calcium carbonate** can bind to bisphosphonates in the gut, significantly reducing the **bioavailability** and efficacy of alendronic acid. - This is a significant **counseling point** regarding the timing of doses (separating them by at least 2 hours), but it does not represent an acute safety emergency. *Methotrexate dose is too high for a patient also taking an NSAID* - A weekly dose of **15mg methotrexate** is a standard maintenance dose for **rheumatoid arthritis** and is not considered inherently excessive. - The presence of an NSAID necessitates careful **monitoring of FBC and LFTs** but does not automatically mandate a dose reduction of the DMARD. *Folic acid should be taken on the same day as methotrexate for optimal effect* - Taking **folic acid** on the same day as methotrexate can potentially reduce the **therapeutic efficacy** of the drug by competing for enzymes. - Guidelines usually recommend taking folic acid at least **24 hours after** the methotrexate dose to mitigate side effects like nausea and oral ulcers.

Question 151: During a medication review for an 80-year-old man with heart failure, atrial fibrillation, type 2 diabetes, and benign prostatic hyperplasia, you note he is taking warfarin (INR target 2-3), furosemide, bisoprolol, ramipril, metformin, tamsulosin, and has recently been prescribed trimethoprim by an out-of-hours service for a urinary tract infection. He is due to collect his prescription today. What is the MOST important immediate action?

A. Contact the patient urgently to advise INR monitoring within 3-5 days due to warfarin interaction (Correct Answer)
B. Switch trimethoprim to nitrofurantoin to avoid warfarin interaction
C. Reduce warfarin dose prophylactically while on trimethoprim
D. Advise the patient to stop warfarin temporarily during antibiotic course
E. Arrange hospital admission for IV antibiotics to avoid oral drug interactions

Explanation: ***Contact the patient urgently to advise INR monitoring within 3-5 days due to warfarin interaction*** - **Trimethoprim** inhibits the metabolism of **warfarin**, significantly increasing the **INR** and elevating the risk of life-threatening bleeding. - The current gold standard for managing this interaction is close **biochemical monitoring** (typically within 3-5 days) rather than preemptive dose adjustment. *Switch trimethoprim to nitrofurantoin to avoid warfarin interaction* - While **nitrofurantoin** has a lower interaction profile with warfarin, it is often contraindicated in elderly patients with **heart failure** and potential renal impairment (eGFR <45). - Clinical guidelines prioritize managing the existing prescription through monitoring unless the patient is already at a high baseline bleeding risk. *Reduce warfarin dose prophylactically while on trimethoprim* - Prophylactic dose reduction is risky because the **magnitude of interaction** varies significantly between individuals, potentially leading to sub-therapeutic levels. - **Under-anticoagulation** in a patient with **atrial fibrillation** creates an unnecessary risk of thromboembolic events like stroke. *Advise the patient to stop warfarin temporarily during antibiotic course* - Temporarily stopping warfarin for a simple UTI is inappropriate and dangerously increases the risk of **ischaemic stroke**. - Managing the interaction through **INR monitoring** ensures the patient remains within the therapeutic window safely. *Arrange hospital admission for IV antibiotics to avoid oral drug interactions* - Hospital admission for an **uncomplicated UTI** is unnecessary and increases the risk of hospital-acquired infections and delirium in an 80-year-old. - **Drug interactions** should be managed in the primary care setting through appropriate monitoring and patient education.

Question 152: A 73-year-old woman with type 2 diabetes, ischaemic heart disease, and chronic kidney disease stage 3a attends for review. She takes aspirin, clopidogrel, atorvastatin, bisoprolol, ramipril, metformin, and omeprazole. Recent blood tests show: eGFR 52 ml/min/1.73m², HbA1c 51 mmol/mol, potassium 5.2 mmol/L. She reports no symptoms of angina or heart failure. According to current evidence-based guidelines, what is the primary rationale for her dual antiplatelet therapy?

A. Standard long-term treatment for all patients with ischaemic heart disease
B. Time-limited therapy following acute coronary syndrome or coronary intervention (Correct Answer)
C. Prevention of stroke in patients with chronic kidney disease
D. Enhanced cardiovascular protection when combined with ACE inhibitors
E. Mandatory therapy for diabetic patients with cardiovascular disease

Explanation: ***Time-limited therapy following acute coronary syndrome or coronary intervention*** - **Dual antiplatelet therapy (DAPT)**, such as aspirin and clopidogrel, is specifically indicated for a **limited duration** (usually 6-12 months) after an **ACS** or **stent insertion** to prevent thrombosis. - In stable **ischaemic heart disease**, continuing DAPT long-term is generally avoided because the **bleeding risk** eventually outweighs the cardiovascular benefits. *Standard long-term treatment for all patients with ischaemic heart disease* - Long-term management of stable IHD typically involves **mono-antiplatelet therapy** (usually aspirin or clopidogrel alone), not both. - Chronic use of DAPT without a specific recent vascular event significantly increases the risk of **gastrointestinal haemorrhage**. *Prevention of stroke in patients with chronic kidney disease* - While CKD increases cardiovascular risk, **DAPT** is not the standard regimen for stroke prevention in these patients unless they have specific cardiovascular indications. - Anticoagulants, rather than DAPT, are the primary choice for **ischaemic stroke prevention** in specific conditions like **atrial fibrillation**. *Enhanced cardiovascular protection when combined with ACE inhibitors* - There is no evidence that DAPT provides a synergistic effect specifically when used with **ACE inhibitors** like ramipril. - ACE inhibitors are used for **blood pressure control** and **renal protection**, while DAPT is used specifically for its **anti-thrombotic properties** in the arterial system. *Mandatory therapy for diabetic patients with cardiovascular disease* - Diabetes is a high-risk factor, but it does not make **long-term DAPT** mandatory; management focuses on tight **HbA1c control** and **statin therapy**. - Evidence-based guidelines emphasize **mono-antiplatelet therapy** for diabetic patients with stable macrovascular disease to balance efficacy and safety.

Question 153: A 76-year-old man presents for his annual chronic disease review. He has type 2 diabetes, hypertension, chronic obstructive pulmonary disease (COPD), and osteoarthritis. His current medications include metformin, gliclazide, ramipril, amlodipine, salbutamol inhaler, tiotropium inhaler, and regular co-codamol. His HbA1c is 48 mmol/mol, blood pressure 138/82 mmHg, and eGFR 58 ml/min/1.73m². What is the MOST appropriate definition of his condition according to current UK guidance?

A. Multimorbidity defined as having two or more long-term health conditions (Correct Answer)
B. Polypharmacy defined as taking five or more regular medications
C. Complex multimorbidity due to involvement of three or more body systems
D. Medication overload requiring immediate deprescribing
E. Multiple pathology requiring specialist referral

Explanation: ***Multimorbidity defined as having two or more long-term health conditions*** - This is the standard definition used by **NICE (NG56)**, referring to the presence of two or more long-term health conditions in a single individual. - The patient meets this criteria as he has four distinct long-term conditions: **type 2 diabetes**, **hypertension**, **COPD**, and **osteoarthritis**. *Polypharmacy defined as taking five or more regular medications* - While this patient is experiencing **polypharmacy** (taking 7 unique medications), this describes his treatment regimen rather than his overall clinical condition. - Polypharmacy is often a consequence of **multimorbidity**, but it is not the primary definition for the coexistence of multiple chronic diseases. *Complex multimorbidity due to involvement of three or more body systems* - **Complex multimorbidity** is sometimes used to describe the involvement of multiple systems, but it is not the standard term used in overarching **UK guidance** for general diagnosis. - The baseline definition for identifying these patients for review remains the presence of **two or more** conditions. *Medication overload requiring immediate deprescribing* - **Medication overload** is a clinical judgment, and in this case, his markers (HbA1c 48, BP 138/82) suggest his conditions are **well-controlled** on his current regimen. - There is no clinical evidence of toxicity or adverse interactions presented that would necessitate **immediate deprescribing** at this review. *Multiple pathology requiring specialist referral* - **Multiple pathology** is an older term and does not denote an automatic need for **specialist referral**. - These conditions are characteristically managed within **primary care** using a holistic, patient-centered approach rather than fragmented specialist care.

Question 154: You are reviewing prescribing data for your practice and note that 15% of patients over 75 are taking 10 or more regular medications. According to current evidence and UK guidance on managing polypharmacy in primary care, which statement best describes the relationship between the number of medications and clinical outcomes in older adults?

A. Medication reviews should only be conducted annually for patients on multiple medications
B. Polypharmacy (≥5 medications) is always inappropriate and should be actively reduced
C. The number of medications is less important than the appropriateness of each individual medication (Correct Answer)
D. Patients taking ≥10 medications should be referred to clinical pharmacy for specialist review
E. Polypharmacy increases mortality regardless of the appropriateness of prescribing

Explanation: ***The number of medications is less important than the appropriateness of each individual medication*** - Current UK guidance emphasizes **appropriate polypharmacy**, where multiple medications are correctly prescribed to manage complex **multimorbidity** according to evidence-based guidelines. - Clinical focus should shift from the raw number of drugs to identifying **problematic polypharmacy**, where risks like **adverse drug reactions** outweigh the therapeutic benefits. *Medication reviews should only be conducted annually for patients on multiple medications* - Patients with complex needs or **high-risk medications** often require more frequent monitoring than a standard **annual review** to ensure safety. - NICE guidelines advocate for **individualised intervals** based on clinical stability and the risk of drug-drug interactions. *Polypharmacy (≥5 medications) is always inappropriate and should be actively reduced* - Polypharmacy is defined as taking 5 or more drugs, but it can be **appropriate** if each drug is clinically indicated and preferred by the patient. - **Deprescribing** should be based on clinical need and **shared decision-making** rather than arbitrary thresholds for the number of tablets. *Patients taking ≥10 medications should be referred to clinical pharmacy for specialist review* - While clinical pharmacists are vital in **medicines optimisation**, primary care physicians are also responsible for conducting regular **structured medication reviews**. - Referral is based on **complexity** and the risk of harm rather than a mandatory numerical trigger of ten medications. *Polypharmacy increases mortality regardless of the appropriateness of prescribing* - The association between polypharmacy and mortality is often **confounded by indication**, as patients with more severe underlying illnesses naturally require more medication. - **Appropriate polypharmacy** is intended to improve quality of life and outcomes, whereas only **inappropriate prescribing** is consistently linked to increased preventable mortality.

Question 155: A 77-year-old man attends for a comprehensive medication review. He has heart failure (NYHA II), atrial fibrillation, COPD (GOLD stage 2), osteoarthritis, and benign prostatic hyperplasia. His medication list includes: bisoprolol 5mg OD, ramipril 10mg OD, furosemide 40mg OD, apixaban 5mg BD, tiotropium 18mcg OD, salbutamol PRN, paracetamol 1g QDS, codeine 30mg QDS, tamsulosin 400mcg OD, finasteride 5mg OD, and omeprazole 20mg OD. He reports chronic constipation and poor mobility. Applying prescribing principles for multimorbidity, which represents the most appropriate deprescribing priority?

A. Codeine due to contributing to constipation and fall risk with limited benefit (Correct Answer)
B. Tamsulosin as it may worsen postural hypotension when combined with other antihypertensives
C. Finasteride as it takes months to work and may cause sexual dysfunction
D. Paracetamol as regular use increases cardiovascular risk in heart failure
E. Omeprazole as there is no documented indication for gastroprotection

Explanation: ***Codeine due to contributing to constipation and fall risk with limited benefit*** - **Codeine** is an opioid that significantly exacerbates **chronic constipation** through its action on mu-receptors in the GI tract, and its sedative properties increase **fall risk** in older adults with poor mobility. - In elderly patients with **osteoarthritis**, the long-term benefit of weak opioids like codeine is often minimal compared to the substantial risks of **cognitive impairment**, **respiratory depression** (especially with **COPD**), and **dependency**. *Tamsulosin as it may worsen postural hypotension when combined with other antihypertensives* - While **tamsulosin** can cause **postural hypotension**, it provides crucial symptomatic relief for **benign prostatic hyperplasia (BPH)** and significantly improves the patient's quality of life by reducing urinary symptoms. - Abrupt cessation could lead to **acute urinary retention** or worsening of lower urinary tract symptoms, making it a lower priority for deprescribing compared to a medication with direct, ongoing harm like codeine. *Finasteride as it takes months to work and may cause sexual dysfunction* - **Finasteride** is prescribed to reduce prostate size, prevent BPH progression, and reduce the risk of acute urinary retention; its benefits are long-term and may take months to become evident. - Although **sexual dysfunction** is a known side effect, it is often present in this demographic, and the drug's role in preventing long-term BPH complications is valuable, outweighing the immediate need for deprescribing. *Paracetamol as regular use increases cardiovascular risk in heart failure* - There is no strong clinical evidence to support a direct increase in **cardiovascular risk** in **heart failure** patients with regular use of **paracetamol** at recommended doses. - **Paracetamol** remains the preferred first-line analgesic for **osteoarthritis** as it lacks the significant gastrointestinal and renal toxicities associated with NSAIDs, making it safer for this multimorbid patient. *Omeprazole as there is no documented indication for gastroprotection* - While the specific indication for **omeprazole** is not documented, in a multimorbid elderly patient, it often serves as gastroprotection, especially considering the potential for **NSAID use** (even over-the-counter) or other risk factors for **peptic ulcer disease**. - Deprescribing a **proton pump inhibitor (PPI)** can lead to **rebound acid hypersecretion** and worsening reflux symptoms, making it a secondary priority compared to addressing the immediate harms caused by codeine.

Question 156: A 71-year-old woman with Parkinson's disease, osteoporosis, hypertension, and recurrent UTIs is brought by her family due to acute confusion and visual hallucinations over the past 48 hours. Her medications include co-careldopa 25/100mg QDS, pramipexole 1.05mg TDS, bisoprolol 2.5mg OD, amlodipine 5mg OD, alendronic acid 70mg weekly, calcium/vitamin D supplementation, and oxybutynin 5mg TDS (started 1 week ago for urinary frequency). Temperature is 37.2°C, BP 135/78 mmHg, and urinalysis shows 2+ leucocytes, 1+ protein, no nitrites. What is the most likely cause of her acute deterioration requiring immediate medication adjustment?

A. Urinary tract infection requiring antibiotic treatment
B. Dopamine agonist psychosis from pramipexole
C. Acute worsening of Parkinson's disease requiring dose increase
D. Anticholinergic effects from oxybutynin causing delirium (Correct Answer)
E. Hypercalcaemia from calcium supplementation

Explanation: ***Anticholinergic effects from oxybutynin causing delirium*** - The temporal link between starting **oxybutynin** one week ago and the onset of **acute confusion** and hallucinations strongly indicates drug-induced **delirium**. - Patients with **Parkinson’s disease** are highly susceptible to central **anticholinergic side effects** because they have an underlying cholinergic deficit in the brain. *Urinary tract infection requiring antibiotic treatment* - While the urinalysis shows **leucocytes**, the absence of **nitrites** and lack of high fever makes a UTI a less likely primary trigger for acute delirium compared to the new medication. - Recurrent UTIs are common, but the introduction of a high-risk medication like **oxybutynin** is a more immediate pharmacological concern for acute mental status changes. *Dopamine agonist psychosis from pramipexole* - **Pramipexole** can cause visual hallucinations, but the patient has likely been stable on this dose, making it less likely than the recently introduced **anticholinergic** agent. - Psychosis from stable Parkinson's medications typically develops gradually or with dose increases, not as an acute 48-hour deterioration in a stable regimen. *Acute worsening of Parkinson's disease requiring dose increase* - Parkinson's disease progression typically involves a **gradual worsening** of motor and non-motor symptoms; an acute onset of severe confusion and hallucinations points to an acute precipitant like **delirium**, not typical disease progression. - Increasing the **dopaminergic dose** in a patient experiencing acute psychosis would likely worsen the hallucinations and confusion rather than improve them. *Hypercalcaemia from calcium supplementation* - Standard **calcium and vitamin D** supplementation for osteoporosis is unlikely to cause hypercalcaemia severe enough to induce acute delirium. - Hypercalcaemia typically presents with symptoms like **polyuria**, **polydipsia**, **constipation**, and muscle weakness, and is usually associated with underlying conditions such as malignancy or hyperparathyroidism.

Question 157: During a structured medication review using the STOPP/START criteria, you identify that an 80-year-old man with heart failure (LVEF 35%), atrial fibrillation, hypertension, and type 2 diabetes is not taking a beta-blocker. His current medications include digoxin 125mcg OD, furosemide 40mg BD, ramipril 5mg OD, apixaban 5mg BD, metformin 500mg BD, and simvastatin 40mg nocte. His heart rate is 76 bpm and blood pressure is 142/86 mmHg. Which principle of the START criteria is most relevant to this clinical scenario?

A. Beta-blockers should be prescribed for all patients with atrial fibrillation for rate control
B. Beta-blockers are indicated in systolic heart failure unless contraindicated (Correct Answer)
C. Beta-blockers should be added when ACE inhibitors alone fail to control blood pressure
D. Beta-blockers are recommended in diabetes to reduce cardiovascular risk
E. Beta-blockers should replace digoxin in elderly patients with heart failure

Explanation: ***Beta-blockers are indicated in systolic heart failure unless contraindicated*** - The patient has **heart failure with reduced ejection fraction (LVEF 35%)**, for which beta-blockers are a cornerstone therapy recommended by **START criteria** to reduce mortality and morbidity. - Despite current medications, the absence of a beta-blocker represents a significant omission in managing his **systolic heart failure**. *Beta-blockers should be prescribed for all patients with atrial fibrillation for rate control* - While beta-blockers are important for **atrial fibrillation rate control**, the patient's heart rate is already 76 bpm on **digoxin**, suggesting his rate is adequately controlled. - The **START criteria**'s priority in this scenario is the **prognostic benefit** of beta-blockers in **systolic heart failure**, rather than solely for rate control. *Beta-blockers should be added when ACE inhibitors alone fail to control blood pressure* - Although the patient has **hypertension** (142/86 mmHg), the primary driver for a beta-blocker from a START perspective here is his **systolic heart failure**, not specifically uncontrolled blood pressure. - Beta-blockers are not typically the first-line addition for **hypertension** when an ACE inhibitor is already in use, unless there's a compelling comorbidity like heart failure. *Beta-blockers are recommended in diabetes to reduce cardiovascular risk* - While beta-blockers can be used in **diabetes**, the START criteria do not broadly recommend them solely for **cardiovascular risk reduction** in all diabetic patients. - The patient is already receiving **ramipril** and **simvastatin**, which are key for cardiovascular and renal protection in **Type 2 Diabetes**. *Beta-blockers should replace digoxin in elderly patients with heart failure* - Beta-blockers and **digoxin** often serve complementary roles in managing patients with both **heart failure and atrial fibrillation** and are not mutually exclusive. - The **START criteria** aim to identify important medications that are *missing* rather than promoting the *replacement* of an existing, potentially beneficial drug like digoxin.

Question 158: A 69-year-old man with COPD, ischaemic heart disease, type 2 diabetes, and depression presents with recurrent falls. He is taking tiotropium 18mcg OD, salmeterol/fluticasone 25/250mcg BD, bisoprolol 5mg OD, aspirin 75mg OD, atorvastatin 40mg OD, metformin 1g BD, lisinopril 10mg OD, mirtazapine 30mg nocte, and diazepam 5mg BD for anxiety. Examination shows postural hypotension (lying BP 138/82 mmHg, standing BP 110/68 mmHg). Which medication change would most effectively reduce his fall risk while maintaining optimal chronic disease management?

A. Stop bisoprolol as beta-blockers cause postural hypotension
B. Stop tiotropium as anticholinergics increase fall risk in elderly
C. Reduce lisinopril dose to 5mg OD to address postural hypotension
D. Switch mirtazapine to sertraline to reduce sedation
E. Stop diazepam and address anxiety with psychological interventions (Correct Answer)

Explanation: ***Stop diazepam and address anxiety with psychological interventions*** - **Benzodiazepines** like **diazepam** are strongly associated with increased fall risk in the elderly due to **central nervous system (CNS) depression**, leading to **sedation**, impaired coordination, and prolonged reaction times. - The **STOPP/START criteria** explicitly recommend avoiding benzodiazepines in patients with a history of falls, especially considering diazepam's **long half-life** and its lack of mortality benefit for chronic physiological conditions. *Stop bisoprolol as beta-blockers cause postural hypotension* - **Bisoprolol** is a crucial medication for the management of **ischaemic heart disease**, reducing morbidity and mortality. Abrupt discontinuation can lead to **rebound tachycardia** or worsening angina. - While beta-blockers can influence blood pressure, the primary driver of **postural hypotension** in this patient is likely multifactorial. Stopping a **cardioprotective agent** without a strong indication would compromise essential chronic disease management. *Stop tiotropium as anticholinergics increase fall risk in elderly* - **Tiotropium** is a long-acting muscarinic antagonist (LAMA) vital for **COPD symptom control** and reducing exacerbation frequency. - Inhaled anticholinergics like tiotropium have **minimal systemic absorption** compared to oral anticholinergics, making them far less likely to contribute significantly to falls or cognitive impairment. *Reduce lisinopril dose to 5mg OD to address postural hypotension* - **Lisinopril** is an angiotensin-converting enzyme (ACE) inhibitor crucial for managing **hypertension**, **ischaemic heart disease**, and **renal protection** in type 2 diabetes, benefits which could be compromised by dose reduction. - While lisinopril contributes to blood pressure regulation, addressing the more significant and modifiable sedative medication (diazepam) is a higher priority for **fall prevention**. *Switch mirtazapine to sertraline to reduce sedation* - Although **mirtazapine** can cause sedation, it is treating a primary condition (depression); switching antidepressants can be complex and may destabilize his mood. - **Sertraline** (an SSRI) also carries its own set of risks in the elderly, including potential for **hyponatremia** and gastrointestinal side effects, and some SSRIs have also been associated with an increased fall risk. **Diazepam** presents a more direct and readily reversible fall risk.

Question 159: You are conducting a medication review for a 75-year-old woman with type 2 diabetes, ischaemic heart disease, heart failure (NYHA class II), and chronic kidney disease stage 3a. Her medications include metformin 1g BD, gliclazide 160mg BD, ramipril 10mg OD, bisoprolol 10mg OD, furosemide 40mg OD, spironolactone 25mg OD, aspirin 75mg OD, and atorvastatin 80mg OD. Her HbA1c is 52 mmol/mol, eGFR is 48 mL/min/1.73m², and potassium is 5.2 mmol/L. Which medication requires the most urgent review?

A. Metformin should be stopped due to renal impairment
B. Ramipril should be stopped temporarily to manage potassium
C. Spironolactone should be stopped due to hyperkalaemia risk (Correct Answer)
D. Gliclazide dose is excessive and should be reduced
E. Bisoprolol should be reduced as it may be causing fatigue

Explanation: ***Spironolactone should be stopped due to hyperkalaemia risk***- The patient has **hyperkalaemia** (potassium 5.2 mmol/L, with a normal range typically up to 5.0) which is significantly exacerbated by the combination of an **ACE inhibitor** (ramipril) and a **mineralocorticoid receptor antagonist (MRA)** in the presence of **CKD stage 3a**.- While beneficial for **heart failure**, MRAs carry a high risk of life-threatening hyperkalaemia, especially when the **eGFR** is reduced, making it the most urgent medication to review and likely discontinue.*Metformin should be stopped due to renal impairment*- Metformin only requires a dose reduction when the **eGFR** falls below 45 mL/min/1.73m² and should be stopped completely if it falls below **30 mL/min/1.73m²**.- With an **eGFR of 48 mL/min/1.73m²**, the current dose is acceptable, though it warrants close monitoring as the patient approaches the threshold for reduction.*Ramipril should be stopped temporarily to manage potassium*- **ACE inhibitors** (like ramipril) provide critical cardio-renal protection in patients with **heart failure** and **diabetes**.- Potassium should be managed by first stopping non-essential potassium-elevating agents (like MRAs) or addressing diet before considering stopping the **ACE inhibitor**.*Gliclazide dose is excessive and should be reduced*- A dose of **160mg BD** is within the standard therapeutic range for gliclazide, and an **HbA1c of 52 mmol/mol** suggests the patient has good glycemic control and is not experiencing significant hypoglycaemia.- While dose adjustments might be considered to simplify the regimen, this does not present an acute safety risk comparable to **electrolyte imbalances**.*Bisoprolol should be reduced as it may be causing fatigue*- **Bisoprolol 10mg** is a standard target dose for the management of **heart failure (NYHA class II)** to improve long-term survival and reduce mortality.- Fatigue is a common side effect of **beta-blockers**, but dose reduction is not urgently required unless there is severe **bradycardia**, **hypotension**, or other significant adverse effects compromising the patient's stability.

Question 160: An 82-year-old man with heart failure, chronic kidney disease stage 3b, benign prostatic hyperplasia, and insomnia has been taking temazepam 10mg nocte for the past 8 years. He attends asking for a repeat prescription. His other medications include furosemide 40mg OD, ramipril 5mg OD, bisoprolol 2.5mg OD, and tamsulosin 400mcg OD. He reports that the temazepam 'works well' and he is reluctant to stop it. What is the most appropriate management approach regarding his benzodiazepine use?

A. Stop temazepam immediately and commence zopiclone as an alternative
B. Explain the risks and offer a gradual withdrawal plan with reduction of 2mg every 2 weeks (Correct Answer)
C. Continue temazepam but reduce the dose to 5mg to minimize harm
D. Prescribe 2 weeks only and advise he must see a psychiatrist for ongoing management
E. Continue temazepam as it is clearly effective and he has been stable on it for years

Explanation: ***Explain the risks and offer a gradual withdrawal plan with reduction of 2mg every 2 weeks*** - Long-term use of **benzodiazepines** in the elderly increases the risk of **falls**, **cognitive impairment**, and fractures; a **gradual taper** is essential to prevent severe withdrawal symptoms after 8 years of use. - **NICE guidelines** and **STOPP criteria** recommend a slow reduction (often 1/8 to 1/4 of the dose every 1-2 weeks) while providing patient education on the long-term benefits of cessation. *Stop temazepam immediately and commence zopiclone as an alternative* - **Abrupt cessation** of long-term benzodiazepines is dangerous and can precipitate **seizures**, **delirium**, or severe rebound insomnia. - **Zopiclone** is a 'Z-drug' with a similar safety profile and risk of **dependence** and **falls** as benzodiazepines, making it an inappropriate substitute in the elderly. *Continue temazepam but reduce the dose to 5mg to minimize harm* - While lower doses reduce some risks, a simple dose reduction without a structured **withdrawal protocol** does not address the underlying **physiological dependence**. - This approach lacks the necessary patient collaboration and **monitoring** required to successfully transition the patient off the medication permanently. *Prescribe 2 weeks only and advise he must see a psychiatrist for ongoing management* - Managing benzodiazepine withdrawal is a routine part of **primary care**; a referral to a **psychiatrist** is generally unnecessary unless there are complex co-morbid mental health issues. - Setting a rigid 2-week limit without an agreed **tapering plan** may damage the doctor-patient relationship and lead to patient distress or unsafe sourcing of medication. *Continue temazepam as it is clearly effective and he has been stable on it for years* - Stability does not equate to safety; the patient has multiple risk factors including **advanced age** and **polypharmacy** that heighten the risk of **adverse drug events**. - Physicians have a duty to periodically review and discuss the **deprescribing** of potentially inappropriate medications, even if the patient believes they are beneficial.

Question 161: A 66-year-old woman with rheumatoid arthritis, osteoporosis, gastro-oesophageal reflux disease, and hypertension attends for routine review. Her medications include methotrexate 15mg weekly, folic acid 5mg weekly, alendronic acid 70mg weekly, omeprazole 20mg OD, amlodipine 10mg OD, and she takes over-the-counter ibuprofen 400mg TDS for joint pain. Recent blood tests show Hb 98 g/L (normal 115-165), MCV 76 fL (normal 80-100), and eGFR 52 mL/min/1.73m² (previously 68). What is the most important prescribing issue to address?

A. The ibuprofen use is causing renal impairment and should be stopped (Correct Answer)
B. Omeprazole is causing iron deficiency anaemia and should be stopped
C. Alendronic acid should be stopped due to renal impairment
D. Folic acid timing needs adjusting to avoid interaction with methotrexate
E. Methotrexate dose should be reduced due to declining renal function

Explanation: ***The ibuprofen use is causing renal impairment and should be stopped*** - Regular **NSAID** use like **ibuprofen** is the most critical issue because it explains both the **declining eGFR** (via renal vasoconstriction) and the **microcytic anaemia** (via chronic gastrointestinal blood loss). - Additionally, combining **NSAIDs** with **methotrexate** is high-risk as it can reduce renal excretion of methotrexate, leading to potential **toxicity**. *Omeprazole is causing iron deficiency anaemia and should be stopped* - While **PPIs** like **omeprazole** can theoretically hinder iron absorption by increasing gastric pH, they are protective against **NSAID-induced gastropathy**. - In this patient, the **microcytic anaemia** is far more likely caused by **NSAID-induced GI bleeding** than by PPI-mediated malabsorption. *Alendronic acid should be stopped due to renal impairment* - **Alendronic acid** is generally considered safe to continue until the **eGFR** drops below **35 mL/min/1.73m²**. - With a current eGFR of **52 mL/min/1.73m²**, there is no immediate contraindication to its use based on renal function alone. *Folic acid timing needs adjusting to avoid interaction with methotrexate* - **Folic acid** is correctly prescribed to be taken weekly (usually at least 24 hours after the methotrexate dose) to mitigate **methotrexate side effects**. - While scheduling is important, it is a minor management detail compared to the active **renal damage** and **anaemia** caused by ibuprofen. *Methotrexate dose should be reduced due to declining renal function* - While **methotrexate dose** monitoring is necessary as renal function declines, the current **eGFR of 52** does not typically necessitate an immediate dose reduction. - The priority is to address the **nephrotoxic agent** (ibuprofen) first to see if renal function stabilizes before altering essential **RA treatment**.

Question 162: A 70-year-old man with heart failure, atrial fibrillation, hypertension, gout, and depression is taking multiple medications. During a medication review, you identify that he is taking warfarin, furosemide 80mg BD, ramipril 10mg OD, bisoprolol 10mg OD, allopurinol 300mg OD, and sertraline 100mg OD. His INR has been unstable over the past 3 months, ranging from 1.8 to 4.2 despite good reported compliance. Which of the following is the most appropriate strategy to address his unstable anticoagulation?

A. Increase frequency of INR monitoring to weekly
B. Switch from warfarin to a direct oral anticoagulant (DOAC) (Correct Answer)
C. Reduce sertraline dose as SSRIs increase INR
D. Add vitamin K supplementation to stabilize INR
E. Stop allopurinol as it interferes with warfarin metabolism

Explanation: ***Switch from warfarin to a direct oral anticoagulant (DOAC)*** - **DOACs** provide more predictable pharmacokinetics and have significantly fewer **drug-drug and drug-food interactions** than warfarin, making them ideal for complex patients with polypharmacy. - National guidelines (such as NICE) suggest switching to a **DOAC** if time in therapeutic range (TTR) is low or if there is **unstable INR** control despite compliance. *Increase frequency of INR monitoring to weekly* - Increased monitoring may identify deviations but fails to address the underlying physiological or pharmacological causes of **INR instability**. - This approach increases the **treatment burden** for the elderly patient without providing the superior stroke protection associated with stable anticoagulation. *Reduce sertraline dose as SSRIs increase INR* - While **SSRIs** like sertraline can increase bleeding risk by affecting **platelet function**, reducing the dose may destabilize the patient's **depression** management. - Adjusting the antidepressant dose does not solve the fundamental issue of warfarin's narrow **therapeutic index** in a polypharmacy context. *Add vitamin K supplementation to stabilize INR* - Regular low-dose **Vitamin K** is sometimes used for extreme instability, but it is complex to manage and can lead to **warfarin resistance**. - It is not a first-line strategy when a more reliable alternative like a **DOAC** is available and indicated for AF. *Stop allopurinol as it interferes with warfarin metabolism* - Stopping **allopurinol** unnecessarily risks a flare of **gout**, especially in a patient already taking a diuretic like furosemide. - While some interactions exist, removing essential chronic disease medications is inferior to switching to an anticoagulant that does not require **metabolic monitoring**.

Question 163: A 74-year-old woman with dementia, Parkinson's disease, type 2 diabetes, and recurrent urinary tract infections attends with her daughter. Her medications include co-careldopa 25/100mg TDS, donepezil 10mg OD, metformin 500mg BD, and she was recently prescribed prophylactic trimethoprim 100mg nocte by a locum GP for recurrent UTIs. The daughter reports that her mother has become increasingly confused and agitated over the past week, with worsening tremor and rigidity. What is the most likely medication-related cause of her deterioration?

A. Drug interaction between trimethoprim and metformin causing lactic acidosis
B. Trimethoprim-induced folate deficiency affecting neurological function (Correct Answer)
C. Donepezil toxicity due to accumulation
D. Drug interaction between trimethoprim and donepezil causing serotonin syndrome
E. Inadequate Parkinson's disease control requiring dose increase

Explanation: ***Trimethoprim-induced folate deficiency affecting neurological function*** - **Trimethoprim** is a **folate antagonist** that inhibits dihydrofolate reductase; even low-dose prophylactic use can lead to **folate deficiency**, particularly in elderly patients with pre-existing comorbidities and potential nutritional deficiencies. - **Folate deficiency** can manifest as neuropsychiatric symptoms like **confusion** and **agitation**, and can exacerbate existing neurological conditions such as **Parkinson's disease**, leading to worsening tremor and rigidity. *Drug interaction between trimethoprim and metformin causing lactic acidosis* - While **trimethoprim** can inhibit renal tubular secretion of **metformin**, increasing its plasma concentration, clinically significant **lactic acidosis** due to this interaction is rare without profound renal impairment. - **Lactic acidosis** typically presents with systemic symptoms like metabolic acidosis, tachypnea, and severe gastrointestinal upset, which are not the primary features described here. *Donepezil toxicity due to accumulation* - **Donepezil** is primarily metabolized by hepatic CYP enzymes, and there is no significant interaction with **trimethoprim** known to cause rapid accumulation or toxicity in this specific manner. - **Donepezil toxicity** (cholinergic crisis) would typically present with symptoms such as bradycardia, excessive salivation, miosis, diarrhea, and muscle weakness, rather than primarily increased rigidity and tremor. *Drug interaction between trimethoprim and donepezil causing serotonin syndrome* - Neither **trimethoprim** nor **donepezil** are potent serotonergic agents, and there is no established drug interaction between them that would lead to **serotonin syndrome**. - **Serotonin syndrome** is characterized by a distinct triad of cognitive, autonomic, and neuromuscular symptoms (e.g., hyperreflexia, clonus), which does not fully align with the described worsening of Parkinsonian rigidity and tremor. *Inadequate Parkinson's disease control requiring dose increase* - The acute onset of **confusion** and **agitation** alongside worsening motor symptoms, specifically following the introduction of a new medication (**trimethoprim**), strongly suggests a drug-induced cause rather than a sudden natural progression of **Parkinson's disease**. - While symptoms are worsening, the rapid and acute nature of the deterioration with neuropsychiatric features points towards an adverse drug reaction or interaction.

Question 164: A 68-year-old man with ischaemic heart disease, type 2 diabetes, hypertension, and hyperlipidaemia presents for his annual review. He takes aspirin 75mg OD, clopidogrel 75mg OD, bisoprolol 2.5mg OD, ramipril 10mg OD, atorvastatin 80mg OD, metformin 1g BD, and gliclazide 80mg BD. He had a drug-eluting stent inserted 18 months ago. He has no angina symptoms. His HbA1c is 64 mmol/mol and blood pressure is 128/76 mmHg. What is the most appropriate change to his antiplatelet therapy?

A. Continue both aspirin and clopidogrel indefinitely due to diabetes
B. Stop clopidogrel and continue aspirin alone (Correct Answer)
C. Stop aspirin and continue clopidogrel alone
D. Stop both antiplatelet agents and commence rivaroxaban
E. Continue both agents for a further 6 months then review

Explanation: ***Stop clopidogrel and continue aspirin alone***- After **drug-eluting stent (DES)** insertion, **dual antiplatelet therapy (DAPT)** with aspirin and clopidogrel is typically given for **12 months** to prevent **stent thrombosis**.- Given the patient is **18 months post-stent** and stable, **aspirin monotherapy** is the recommended long-term strategy for secondary cardiovascular prevention.*Continue both aspirin and clopidogrel indefinitely due to diabetes*- While **diabetes** is a risk factor, continuing **DAPT indefinitely** beyond 12 months for stable patients significantly increases the **risk of major bleeding** without clear additional benefit.- Current guidelines recommend transitioning to **antiplatelet monotherapy** after the initial DAPT period in patients with DES who are stable.*Stop aspirin and continue clopidogrel alone*- **Aspirin** is generally the preferred agent for **lifelong antiplatelet monotherapy** in secondary prevention of ischaemic heart disease due to its proven efficacy and cost-effectiveness.- **Clopidogrel monotherapy** is typically reserved for patients with a **contraindication or intolerance to aspirin**, which is not indicated in this patient's presentation.*Stop both antiplatelet agents and commence rivaroxaban*- **Rivaroxaban** is an anticoagulant, not an antiplatelet, and is generally used for conditions like **atrial fibrillation** or VTE prophylaxis, or in combination with aspirin in specific high-risk IHD patients (e.g., COMPASS trial).- Discontinuing all antiplatelet therapy in a patient with **ischaemic heart disease** and a **history of stent insertion** would expose him to a high risk of recurrent thrombotic events.*Continue both agents for a further 6 months then review*- The patient is already **18 months post-stent**, exceeding the standard **12-month DAPT duration** for DES.- Prolonging DAPT beyond the recommended period in stable patients increases the **bleeding risk** without a demonstrated reduction in ischaemic events.

Question 165: During a structured medication review, you are assessing a 72-year-old woman taking 12 different medications for multiple conditions. According to current UK guidance on medication reviews in primary care, which framework is recommended for conducting a comprehensive structured medication review to optimize prescribing and reduce polypharmacy-related harm?

A. The STOPP/START criteria (Correct Answer)
B. The Beers criteria
C. The Medication Appropriateness Index (MAI)
D. The Prescribing Observatory for Mental Health (POMH-UK) standards
E. The NICE Medicines Optimisation guidelines

Explanation: ***The STOPP/START criteria***- The **STOPP/START** (Screening Tool of Older Persons' Prescriptions/Screening Tool to Alert to Right Treatment) criteria are the evidence-based framework recommended in the **UK** for conducting clinical medication reviews in older patients.- It helps clinicians identify **Potentially Inappropriate Prescribing (PIP)** and potential omissions of beneficial drugs, effectively managing **polypharmacy** and reducing adverse drug reactions.*The Beers criteria*- The **Beers criteria** is a similar tool used to identify inappropriate medications in the elderly but is primarily used and developed in the **United States**.- While useful, it lacks the 'START' component for identifying omitted medications and is not the standard clinical framework cited in **UK primary care** guidance.*The Medication Appropriateness Index (MAI)*- The **MAI** is a scoring tool used to assess the appropriateness of individual prescriptions based on ten specific criteria such as efficacy and cost.- It is generally considered a **research tool** rather than a practical framework for performing a quick and systematic structured medication review in a busy **Primary Care** setting.*The Prescribing Observatory for Mental Health (POMH-UK) standards*- These standards are specifically designed for the audit and improvement of prescribing within **specialist mental health** services.- They do not provide a comprehensive framework for general **polypharmacy** or the multi-system comorbidities typically seen in structured medication reviews for elderly patients.*The NICE Medicines Optimisation guidelines*- **NICE guidelines** (NG5) provide overarching principles and professional standards for medicines management but do not offer a granular, drug-specific tool like **STOPP/START**.- While they mandate that reviews should be structured, they recommend using specific tools like **STOPP/START** to operationalize the clinical assessment of medication sets.

Question 166: A 65-year-old man with heart failure (NYHA class II), atrial fibrillation, and chronic obstructive pulmonary disease attends for annual review. His medications include bisoprolol 5mg OD, ramipril 5mg BD, furosemide 40mg OD, spironolactone 25mg OD, apixaban 5mg BD, tiotropium inhaler, and salbutamol inhaler PRN. He reports feeling generally well but has noticed increased breathlessness on exertion over the past 3 months. Examination reveals bilateral basal crackles and mild peripheral oedema. Which aspect of his multimorbidity management requires the most urgent review?

A. Increasing bisoprolol dose may worsen his COPD symptoms
B. The beta-blocker may be masking deteriorating heart failure (Correct Answer)
C. Spironolactone should be stopped due to his COPD
D. Apixaban dose may need adjustment for heart failure
E. Tiotropium is contraindicated in patients with atrial fibrillation

Explanation: ***The beta-blocker may be masking deteriorating heart failure*** - The patient's increased breathlessness, **bilateral basal crackles**, and **peripheral oedema** are clear signs of worsening **heart failure** and **fluid overload**. - **Beta-blockers** like bisoprolol suppress the heart's natural **compensatory tachycardia** in response to falling cardiac output, making it difficult to assess the severity of heart failure based on heart rate alone, thus masking the deterioration. *Increasing bisoprolol dose may worsen his COPD symptoms* - **Cardioselective beta-blockers** (like bisoprolol) are generally safe and beneficial in patients with **stable COPD** and are crucial for mortality reduction in **heart failure**. - While very high doses could theoretically exacerbate bronchospasm, the most urgent issue is the overt signs of **congestive heart failure**, not a hypothetical risk from a dose increase. *Spironolactone should be stopped due to his COPD* - **Spironolactone**, a **mineralocorticoid receptor antagonist (MRA)**, is a foundational therapy for **heart failure with reduced ejection fraction (HFrEF)** and is not contraindicated in **COPD**. - It helps manage **fluid retention** and improves outcomes in heart failure; stopping it would likely worsen his current symptoms of fluid overload. *Apixaban dose may need adjustment for heart failure* - **Apixaban** dosing is primarily determined by **renal function** (creatinine clearance), age, and body weight, not directly by the severity of **heart failure** or NYHA class. - While severe heart failure can affect renal function, there is no direct rule to adjust anticoagulation based solely on breathlessness or oedema without specific renal parameters. *Tiotropium is contraindicated in patients with atrial fibrillation* - **Tiotropium**, a **long-acting muscarinic antagonist (LAMA)**, is a standard treatment for **COPD** and is generally not contraindicated in **atrial fibrillation**. - While anticholinergics should be used with caution if arrhythmias are uncontrolled, the urgent priority here is the management of acute **fluid overload** from heart failure, not the LAMA.

Question 167: A 78-year-old woman with type 2 diabetes, hypertension, chronic kidney disease stage 3a, and osteoarthritis attends for a medication review. Her current medications include metformin 500mg BD, ramipril 10mg OD, amlodipine 5mg OD, atorvastatin 20mg OD, aspirin 75mg OD, paracetamol 1g QDS, and codeine 30mg QDS. Her eGFR has declined from 52 to 38 mL/min/1.73m² over the past year. Blood pressure is 142/84 mmHg. HbA1c is 58 mmol/mol. What is the most appropriate immediate medication change?

A. Stop metformin and commence gliclazide (Correct Answer)
B. Stop codeine and commence a selective COX-2 inhibitor
C. Stop aspirin due to increased bleeding risk with declining renal function
D. Increase ramipril to 15mg OD to improve renal protection
E. Stop amlodipine and increase ramipril dose

Explanation: ***Stop metformin and commence gliclazide***- **Metformin** is contraindicated with an eGFR generally below 30 mL/min/1.73m², but a significant decline to **38 mL/min/1.73m²** in a 78-year-old warrants immediate review due to increased risk of **lactic acidosis**.- **Gliclazide** is primarily metabolized by the liver, making it a safer and appropriate oral hypoglycemic alternative in patients with **moderate renal impairment** (CKD stage 3b) where metformin is a concern.*Stop codeine and commence a selective COX-2 inhibitor*- **Selective COX-2 inhibitors** (NSAIDs) can cause **acute kidney injury** by reducing renal blood flow and are generally contraindicated or used with extreme caution in patients with **chronic kidney disease**.- While **codeine** metabolites can accumulate, replacing it with an **NSAID** would pose a higher and more immediate risk of worsening renal function.*Stop aspirin due to increased bleeding risk with declining renal function*- **Low-dose aspirin (75mg)** is critical for **secondary cardiovascular prevention** in patients with multiple risk factors like diabetes, hypertension, and advanced age.- An eGFR of **38 mL/min/1.73m²** alone does not typically necessitate stopping low-dose aspirin, as the cardiovascular benefits generally outweigh the theoretical bleeding risk in this context.*Increase ramipril to 15mg OD to improve renal protection*- The maximum recommended and licensed dose for **ramipril** is typically **10mg OD**; a 15mg dose is not standard and exceeding the maximum increases adverse effects.- Increasing an **ACE inhibitor** dose in a patient with rapidly declining eGFR can precipitate **hyperkalemia** or further acute kidney injury and should be done with extreme caution and monitoring, not as an immediate change.*Stop amlodipine and increase ramipril dose*- **Ramipril** is already at its **maximum therapeutic dose of 10mg**, so increasing it further is not a clinically viable option.- **Amlodipine** is a safe and effective **antihypertensive** in chronic kidney disease and contributes to blood pressure control without adverse renal effects, so stopping it is not indicated.

Practice by Chapter

Medication reviews

Practice Questions

Multimorbidity

Practice Questions

Polypharmacy

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Chronic Disease Management — MCQs

Chronic Disease Management — MCQs

On this page